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ABSTRACT
This study evaluated the status of malaria transmission in
Serra do Navio region where a malaria control programme had
been carried out for more than 20 years, which included the
provision of a daily intake of chioroquinised salt.
Malaria endemicity in the study areas [target area: Serra
do Navio (SNV); control areas: Colonia Agua Branca (CAB),
Porto Terezinha (PT) and Arrependido (ARR)] was established
based on the spleen rate and prevalence of malaria
parasites among the 2-9 years age group. SNV was defined as
a non-endemic area for malaria since both rates were zero,
while CAB and ARR were concluded to be mesoendemic areas
since the rates were between 10 and 50%, and PT was
considered hypoendemic area because both rates were under
10%.
Antibody prevalence measured using IFAT with asexual form
antigens of Plasmodium .falciparum and Plasmodium vivax and
ELISA (asexual forms of P.falciparum, sporozoites of
P.falciparurn, P.vivax type 1, P.vivax type 2, P.vivax type
3 and P.malariae/P.brasilianum) was determined for
individuals from each study area. These results showed a
high frequency of P.falciparum antibodies in all areas.
The level of haptoglobin in 100 children from all these
areas demonstrated the close relationship between
hypohaptoglobinaemia and malaria in the control areas.
Haskin's method , a qualitative method, was applied for
testing chioroquine in urine. Therefore, chioroquine levels
were measured in serum and urine using the ELISA test and
the results were in agreement with the reports of the
intake of chioroquine salt.
The distribution and potentiality of the malaria vectors in
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all areas was determined. Fifteen anopheline species were
identified among 3053 mosquitoes collected by human biting
catches in the 4 study areas. 96.4% of the total mosquitoes
caught belonged to 4 species, namely, An.albitarsis,
An.braziliensis, An.nuñeztovari and An.triannulatus.
An.darlingi which is considered the main vector of malaria
in the Amazon region of Brazil was very scarce. Using ELISA
for the detection of Plasmodium spp sporozoites a
positivity rate of 0.799% (23/2876) was found covering six
species: 15 An. albitarsis, 4 An. nuñeztovari, and 1 of
each: An. braziliensis, An. triannulatus, An. oswaldoi and
An.rangeli. 9 out 23 positive mosquitoes were infected with
P. raalariae ; 9 with P. vivax- variant VK 247; 3 with P.
falciparum and 2 with the classical P.vivax.
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CHAPTER 1: Introduction
1.1 Malaria parasites
Malaria infection in man is used by protozoa that belong
to the Family Plasmodiidae wLthin the Order Coccidiidae.
The genus, Plasmodium, is characterized by exo-erythrocytic
schizogony, that is an asexual multiplication by division
occurring in the parenchymal cells of the liver of the
vertebrate host, and a further schizogony in the
erythrocytes. The four species of malaria parasites of man
are: Plasrnodium malariae (Laveran, 1881); Plasmodium vivax
(Grassi and Feletti, 1890); Plasiaodium falciparum Welch,
1897; and Plasrnodium ovale Stephen, 1922. P. falciparurn is
the most lethal.
1.2 Life cycle
The human malaria parasites hive, basically, the same life
cycle. The cycle has two phases: sporogony (exogenous
sexual phase) - with multiplication in Anopheles
mosquitoes; and schizogony (endogenous asexual phase) with
multiplication in the vertebrate host. The schizogony takes
place in the red blood cells (erythrocytic schizogony) and
in the parenchyma cells of the liver (exo-erythrocytic
schizogony). In exo-erythro:ytic schizogony, there is a
primary or pre-erythrocytic schizogony that follows the
development of the sporozoite and the delayed exo-
erythrocytic schizogony which is related to relapses in
Plasmodium vivax and P1asmodiurt ovale infections (Fig 1.2).
The infection in man is ini:Lated through the bite of an
infected female anopheline mosquito that inoculates
sporozoites into the blood stream. Sporozoites, then go to
the liver and invade hepatocytes where the exo-erythrocytic
schizogony takes place (asexual division). The infected
hepatocytes burst, releasing mero.oites into the blood
stream which invade the erythrocytes and begin the
erythrocytic schizogony. In this phase the merozoite
develops from the ring form through the trophozoite to the
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mature schizont, containing 8-24 daughter merozoites which,
after the erythrocyte ruptures, will initiate a subsequent
intraerythrocytic cycle.
After a period of asexual replication, some infected
merozoites differentiate into female and male gametocytes.
These forms, which are infective to the anopheline mosquito
during blood feeding, mate in the mosquitos' midgut and
produce zygotes that develop into ookinetes and then invade
the gut wall to form oocysts. Sporogony follows and as a
result thousands of sporozoites are produced, which are
released into the mosquito's haemocoel and invade the
salivary glands to await transmission to the vertebrate
host.
1.3 Morphology
The morphological differences among the four species of
human malaria parasites are shown in table 1.3 (Warhurst &
Williams, 1989). The differentiation is based on forms seen
on Giemsa-stained thin films of peripheral blood.
Plasmodium brasilianum, a monkey malaria parasite, was
discovered in a cacajao monkey (Calcajao calvus), from the
State of Amazonas in Brazil by Gonder et al., 1908 (vide
Garnham, 1966). Evidence has been found supporting its
morphological and genetical similarity to Plasmodium
malariae of man (Garnham, 1966 and Lal et al., 1988). Even
its quartian periodicity in erythrocytic schizogony is the
same as in P. malariae.
1.4 Clinical features of malaria infections
The clinical response to infection depends on the species
of Plasmodium and on the immunological status of the
patient.
The incubation period in malaria starts when an infected
mosquito inoculates sporozoites into the bloodstream of the
host, and ends when the first clinical signs appear, of
which fever is the most common. This period usually lasts
from 9 to 30 days and its length is correlated with the
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TABLE 1.3
MORPHOLOGICAL DIFFERENCES BETWEEN PlasmodLum SPECIES OF MAN.
SPECIES
P. FALCIPARUM	 P. vr.rAx	 P. 1M.LARLE	 p•
Trophozoites	 0.15-0.5 of	 0.3-0.5 of	 0.3-0.5 of	 0.3 diameter
a) ring forms diameter of RBC	 diameter of	 diameter of RBC	 of NBC which
which is normal	 RBC which is	 which is	 is unaltered
in size,	 unaltered in	 unaltered in
	 in size.
young rings:	 size,	 size.	 Cytoplasm:
cytoplasm very
	
Cytoplasm:	 Cytoplasm:	 circle,
fine;	 circle, thin,	 circle, thick,	 thicker.
old rings:
cytoplasm thick
irregular.
Marginal
(accolé) and 2
chromatin dots
forms and
multiple
infections
common.
Growing	 NBC unaltered,	 NBC enlarged,	 RBC unaltered.	 RBC unaltered
forms	 sometimes	 stippled.	 Parasite	 in size, or
stippled, pale.	 Parasite:	 compact, rounded slightly
Parasite	 amoeboid,	 or band-shape:	 enlarged; may
compact;	 vacuolate;	 Pigment: dark	 be oval &
Pigment dense	 Pigment fine and	 brown or black, 	 fimbriated.
brown or black	 scattered,	 often	 Parasite:
mass,	 golden brown	 concentrated in
	 compact,
a line along one rounded;
edge of band.
	 Pigment fine
brown grains.
Mature	 NBC unaltered,	 RBC much	 NBC unaltered.	 NBC frequently
schizont	 sometimes	 enlarged,	 Parasite fills
	 oval,
stippled, pale.	 stippled.	 RBC completely;	 fimbriated,
Parasites about 	 Parasite large,	 Nuclei or	 enlarged,
0.6 of NBC;	 filling enlarged	 merozoites: 6-
	 stippled.
Nuclei or
	
NBC;	 12, usually 8,
	 Parasite as
ynerozoites: 8-
	
Nuclei or	 sometimes	 for P.,nalariae
24;	 merozoites: 12-	 forming rosette;	 but does not
Pigment clumped,	 24;	 Pigment: brown	 entirely fill
black.	 Pigrent: a	 black central	 the slightly
golden brown	 clump	 enlarged NBC;
central loose	 Pigment; brown
mass,	 central clump
Gametocytes	 NBC distorted.	 NBC enlarged,	 NBC unaltered.	 RBC slightly
parasite	 stippled.	 Parasite small,
	 enlarged,
crescentic	 Parasite large,
	 round, filling	 stippled.
(banana shape).
	
rounded, filling
	 NBC.	 Parasite
_____________ _________________ enlarged NBC.	 _________________ round,
Stippling	 Maurer's clefts.	 Schuffner's	 None.	 Jane's dots.
dots.
R.BC - red blood cell
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species and strain of the parasite, with the intensity of
the infection, with the previous treatment, with the degree
of resistance of the host, and with previous exposure to
malaria.
The prepatent period in malaria lasts from the time of
infection to the first finding of malaria parasites in the
blood. This period also is correlated with the species of
Plasrnodiurn since the rate of growth of the preerythrocytic
stage and number of merozoites produced is variable among
the species.
The patent period in malaria refers to the time when
clinical manifestations coincide with detectable
parasitaemia in samples of peripheral blood.
1.4.1 Plasmodium falciparum
The incubation period of P.falciparum is variable and lasts
from 7 to 14 days.
Acute infection by falciparum malaria causes prolonged and
irregular high fever, intense headache, pains in the back
and legs, anorexia, prostration, nausea, vomiting and
occasional diarrhoea.
	 Where	 the parasitaemia is
successfully controlled by the immune response,
parasitaemia may persist for 6 months, or at most for 18
months.
Severe infection that is related to high parasitaemia,
commonly gives rise to hyperpyrexia, convulsions,stupor,
collapse, copious vomiting, diarrhoea, haemolytic anaemia
and jaundice.
In holoendemic and hyperendemic areas for falciparum
malaria, young children over the age of six months are in
the group in which most severe malaria occurs. Probably,
older children and adults are not so vulnerable due to the
acquisition of partial immunity.
Both children and adults can have severe malaria when they
live in areas of low endemicity for falciparum malaria
(Warrell et al., 1990).
Cerebral malaria, hypoglycaemia, pulmonary oedema, acute
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renal failure and massive haemolysis are the result of the
complications of falciparum malaria.
Splenomegaly and progressive anaemia are clinical signs of
chronic or repeated infections.
1.4.2 Plasmodium vivax
Vivax malaria has a period of incubation that varies
between 12 and 17 days, but it may last from 8 to 11
months.
P.vivax infection is characterized by its long-term
development, intermittent fever with paroxysms on alternate
days, and splenomegaly. Relapse (renewed occurrence of
clinical symptoms and/or parasitaemia after a time
considerably greater than the intervals between periodic
paroxysms of the primary infection, Bruce-Chwatt, 1985) may
occur after a variable period of latency.
The primary attack starts with headache, fever, pain in the
back, prostration and nausea. This symptoms are milder or
absent in relapses or in patients who have had previous
infections.
1.4.3 Plasmodiurn malariae
The incubation period in malaria caused by P.malariae is
not shorter than 18 days and can be longer, such as 40
days.
The clinical signs of this infection resemble that of vivax
malaria, but are less severe that the latter. The paroxysm
of P.malariae infection is regular (every 72 hours) and
usually occurs in the late afternoon. The anaemia is mild,
when present; splenomegaly is frequent. The infection
develops slowly and gradually.
Recrudescences in P.malariae are most frequent during the
first year, but the blood remains infective and
recrudescence may occur at long intervals (up to 52 years)
after the last exposure to infection (Bruce-Chwatt, 1985).
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1.4.4 Plasmodium brasilianum
Although this is a simian malaria parasite infective to
man, the transmission cycles of human and simian malaria
are independent (Deane, 1969).
The infectivity of this species to man was demonstrated
experimentally by Contacos & Coatney, (1963) when they used
A. freeborni heavily infected with sporozoites of P.
brasilianum for biting man. The period of incubation varied
from 24 to 64 days. Parasitaemia was always low (250
parasites per mm3).
Clinical signs were mainly the quartan periodicity as in P.
malariae infection, and splenomegaly was observed in some
infections.
1.5 Pathogenesis
The pathophysiological mechanisms that govern the clinical
manifestations caused by malaria are not completely
understood, although it is well known that those
manifestations result directly or indirectly from asexual
stage parasites. The remarkable feature of malaria is
fever, but anaemia, thrombocytopenia, splenoznegaly and
water and electrolyte disturbance are also present in
malaria caused by all four human malaria parasites.
Complications such as severe anaemia, renal and pulmonary
failure, and cerebral dysfunction can occur in falciparum
malaria. Nephrotic syndrome is related to chronic infection
with P. malariae.
Malaria has also been implicated as a cofactor in the
pathogenesis of African Burkitt's lymphoma and of tropical
splenomegaly syndrome (TSS) or h yper-reactive malarial
splenomegaly syndrome (HMS) (Bryceson et al., 1983).
Burkitt's lymphoma is mainly found in tropical areas where
malaria is highly prevalent. There are two hypothesis for
the role of malaria in its pathology: 1- malaria increases
B cell turnover promoting chromosomal translocation, thus
causing the transfer of the c-myc oncogene (in chromosome
8) to an area where it permits unrestrained growth of B
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cells (Klein, 1979) and; 2- malaria impairs the host's
ability to control the growth of EBV- infected immortalized
B cells once those have been formed (Greenwood, 1987)
In TSS the role of malaria in the aetiology is not clear,
since even though the patients develop massive splenomegaly
and a very high level of antimalarial and non-specific 1gM,
they do not have detectable parasitaemias and some cases do
not respond to antimalarial chemotherapy. However, there is
strong evidence that malaria has a dominant role, such as:
1- the HMS is found only in areas where malaria is endemic;
2- possession of the haemoglobin genotype AS provides
protection against HNS; 3- individuals with HMS have higher
levels of malaria AB than controls and; 4- level of
gammaglobulin and splenomegaly regress in many patients who
take malaria chemoprophylaxis (Greenwood & Whittle, 1981).
Repeated malaria infections stimulate further
imrnunoglobulin production and, serum levels of 1gM and
autoantibodies increase during life in residents of
malarious areas (Greenwood, 1987).
1.5.1 Fever
Although a correlation between schizont rupture and onset
of fever has been established and explains the periodicity
pattern of fever in synchronized infection, the mechanisms
of fever remain unclear. No exogenous pyrogen released from
infected cells has been identified. However, the
possibility that the ingestion of parasite debris released
at the time of schizont rupture may trigger release of an
endogenous pyrogen (specifically, interleukin 1) from
Kupffer cells and other macrophages has been proposed (see
section 1.6.3).
1.5.2 Anaemia
It is known that the red cell destruction caused by
parasitization with resulting haemolysis, does not entirely
account for the anaemia, since the degree of anaemia
exceeds the parasite density.
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P.falciparum can cause a severe, acute haemolytic anaemia
and in endemic areas the young children with this severe
condition have only a low parasite rate which, generally,
is preceded by recent and acute febrile illness. Thus,
their anaemia may be a result of previous severe and
untreated P. falciparum infection (Greenwood, 1987).
Mechanisms such as disturbed function of the bone marrow
and the increase of rbc turnover caused by repeated malaria
episodes which can lead to deficiencies in rbc production,
have been suggested as explanations for how low
parasitaemia could cause anaemia.
The role of iinrnuno factors in the pathogenesis of malaria
anaemia has been point out by Greenwood & Whittle, (1981),
who showed that sera from residents in malarious areas
contained heterophilic antibodies, cold agglutinins and
antibodies that reacted with altered human rbc, although
there was no proof of their haemolytic action in vivo.
An alternative explanation is that the nonimmunological
changes in uninfected erythrocytes (alterations in lipid
content of erythrocyte membranes) make these cells more
susceptible to splenic removal. Also, opsonization of
uninfected cells by antibody may take place (Sherman,1991).
1.5.3 Sequestration
In falciparum malaria the phenomenon of cytoadherence is
basic to the locally diminished tissue perfusion seen in
its more severe complications (see section 1.5).
Cytoadherence is the result of the expression on the
surface of the rbc containing later trophozoite or
schizonts of strain- and stage-specific parasite and,
probably host cell-derived ligands, which adhere to 2
specific receptors on the endothelial cells. Ockenhouse &
Chulay, (1988) identified some of the ligands, and White &
Dance, (1988) reported that the glycoprotein thrombospondin
may be involved in the specific receptor complex. Thus, the
small vessels become plugged by masses of parasitized rbc
and the consequent ischaemia produces symptoms that vary
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intense malaria transmission, acquire slowly and gradually
a partially protective immunity through constant boosting
by living parasites and protection is manifested by lower
peak parasitaemias and a relative tolerance to clinical
complications of infection (McGregor & Giles, 1960)
However, in P.vivax infection, the individual acquires a
potent immunity to an homologous strain of the parasite but
not to an heterologous one (Boyd, 1942). Thus, the
effective host immunity is strain-specific.
Experiments have demonstrated that immunoglobulins only
reduce the asexual parasitaemia and do not affect the
density of circulating gametocytes. This fact has focused
attention on the role of specific antibodies in mediating
antiplasmodial defence and has also established that this
humoral defence is stage-specific. The concept of antibody-
dependent defence in malaria infection has been the main
impetus for investigators who are trying to identify target
(vaccine) antigens.
Studies on immunity to sporozoites in humans have shown
that older children and adults residing in areas where
malaria is endemic develop antibodies to sporozoites which
are not detectable in younger children. Although there is
no evidence that these antibodies provide protection, the
belief that a sporozoite vaccine could be effective still
motivates further research (Titus et al., 1991).
Merozoite invasion of the erythrocyte stimulates the
production of antibodies, some of which will prevent
invasion. However, these invasion-blocking antibodies do
not uniformly correlate with the immune status. Merozoite
antigens have been isolated and they are targets for
vaccine production (see section 1.6.5).
The maturation of malaria parasites after entering
erythrocytes can be stopped by antibody and other soluble
factors. It is believed that antibodies binding to the
surface of infected erythrocytes might interfere with the
parasite's intracellular development and could also exert
a protective effect by facilitating removal of the cells
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from the circulation. The latter can be promoted by splenic
macrophages and Kupffer cells and may depend on antibody-
facilitated phagocytosis. Based on simian malaria studies,
the antibody that binds to appropriate antigens on P.
falciparum-infected erythrocytes can also interfere with
cytoadherence to endothelial cells. This antibody excludes
the mature forms from the sites of sequestration and
permits their removal from circulation by the spleen that
is capable of filtering out of circulation those plasmodia-
infected cells. Target antigens in this defence have been
considered as potential vaccine candidates.
A role for complement in defence against malaria infection
has not been established (Titus et al, 1991)
1.6.3 Cell mediated immunity
Basic cellular immunology has made remarkable progress
during recent years which has provided a better
understanding of cellular effector mechanisms. As a result,
it is now possible to consider that infected erythrocytes
might be targets of cytotoxic cells, including natural
killer (NK) cells or antibody-dependent or -independent
cytotoxic T lymphocytes. The NK can be involved in innate
immunity while the latter can be involved in acquired
immunity. The activated macrophage, theoretically, can also
be involved in malaria defence, perhaps by elaboration of
toxic oxygen radicals or soluble factors such as monokines.
Other T-cell products such as gamma-interferon can activate
the macrophages to exert antiparasitic effects.
Activated macrophages, as in almost all inflammatory
processes, induce the production of cytokines such as TNF,
IL-i and IL-6. They are products of different genes that
encode non-homologous proteins and bind distinct receptors.
However, their cellular source and their biological
activities overlap. TNF and IL-i can induce self
biosynthesis, biosynthesis of each other and of IL-6.
Therefore, all these three cytokines often act
synergistically ( Titus et al., 1991).
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with the organ involved and the degree of tissue anoxia.
In cerebral malaria, the cerebral and other vessels contain
infected erythrocytes, but in the brain the proportion of
parasitized rbc is much higher than in other organs due to
the sequestration (MacPherson et al., 1985). This
cytoadherence phenomenon is probably an adaptation to allow
the rbc containing later stage parasites to avoid passage
through the spleen and consequent destruction.
Evidence suggests that the mechanism of malaria
pathogenesis is more a result of proteins (cytokines)
secreted by the host's cells in response to the presence of
the parasite than due to the direct effect of the parasite
on the rbc. Tumour necrosis factor (TNF), a protein also
known as cachectin, and interleukins are involved in the
host response to infection (see section 1.6.3), since a
direct relationship between elevated TNF levels and
mortality from cerebral malaria was found by Grau et al.,
(1989). Grau, (1992) stated that in cerebral malaria,
pathogenesis appear to be a result of a cytokine cascade
mediated by the immune response and that TNF might be
involved in the pathogenesis of cerebral malaria.
The pathogenesis of nephrotic syndrome is probably a result
of immune complex deposition, since deposits of IgG, 1gM
and C3 in the glomeruli have been reported and electron-
dense deposits have been observed in the mesangium.
Chronic P. rnalariae infection can cause full-blown
nephrotic syndrome in children as a result of
membranoproliferative glomerulonephritis, which can evolve
into total glorneruloscierosis. The aetiological role played
by malaria in this syndrome is still in doubt because
antimalarial chemotherapy is not effective, although immune
complexes containing P. malariae antigens have been
identified in the glomeruli (Allison et al., 1969 and Ward
& Kibukamusoke, 1969).
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1.6 Immunology of malaria
1.6.1 Innate inimunity
Newborns are innately resistant to acute infection and it
is uncommon to become ill with malaria during the first 3
months of life, and when so, the manifestation is mild with
low parasitaemia. The mechanisms responsible for this
resistance to malaria at birth and early life is not
completely known. This resistance may be due to passive
immunity acquired from immune mothers and lasts for a few
months (Edozien et al., 1962).
Nonimmunological factors such as erythrocytes containing
large amounts of fetal haemoglobin (HbF) which was
demonstrated to retard the growth of parasites (Pasvol et
al., 1976, 1977), and the age of erythrocytes since old rbc
containing HbF do not support P. falciparum (Wilson et al.,
1977; Pasvol et al., 1980) must be taken in consideration.
Also, there are some indications that diet (PABA or iron
deficiency), and abnormal haemoglobins (such as sickle
haemoglobin) may mediate innate immunity (Wyler, 1990).
Gilles et al., (1967) has shown that children with sickle
cell trait (heterozygous haemoglobin - AS) in malarious
areas have lower parasitaemia than children with normal
haemoglobin (Ak). In addition, Colbourne & Edington, (1956)
and Edington, (1967) demonstrated that fatal malaria is
more frequent among normal children than those who are
heterozygous. It was observed by Adeloye et al., (1971) and
Luzzatto, (1974) that homozygous children [sickle cell
anaemia (SS)] were not protected against malaria since
malaria can be fatal within this group.
Thalassaemias are believed to protect against malaria,
since HbF persists in thalassaemic infants (Pasvol et al.,
1977) and parasitized thalassaemic erythrocytes bind
antimalarial IgG with more avidity than those from non-
thalassaemic ones. Thus, this fact may result in more
efficient splenic clearance of parasitized cells in
thalassaemia (Warrell et al., 1990). On the other hand, HIDE
and beta-thalassaeznia in Thailand do not confer changes in
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parasite rate, parasite density or mortality of falciparum
malaria in children (Kruatrachue et al., 1969).
Glucose-6-phosphate (G-6-PD) deficiency as a protection
against malaria remains under discussion since some
investigators have found a significant correlation between
this deficiency and lower parasitaemia and others have not
(Allison & Clyde, 1961; Gilles et al., 1967 and Martin et
al., 1979). However, Bienzle et al., (1972) found potential
protection against malaria in heterozygous females with
intermediate enzyme activity. Beside that, Luzzatto, (1979)
has demonstrated that when both G-6-PD normal and G-6-PD
deficient rbc are available in the circulation, p.
falciparurn infects preferentially the normal cells. The
mechanism of oxidant stress acting synergistically with G-
6-PD deficiency to confer resistance to malaria infection
has been suggested by Huheey & Martin, (1975) and Golenser
et al., (1983)
A distinctive type of hereditary ovalocytosis has been
found among Papua New Guinea and some areas of the South-
east Asian population (Axnato & Booth, 1977). The ovalocytic
erythrocytes were resistant to infection by P.falciparum
in culture suggesting their role in this innate resistance
to malaria infection (Kidson et al., 1981)
1.6.2 Humoral Immunity
Antibody (Ab) to erythrocytic asexual stages becomes
detectable a few days after the blood is invaded by the
parasite. High level Ab is found within the next two weeks
and can persist longer than the parasitological crisis. Ab
lasts for a variable period of time and depends on the
duration of infection.
In relapses or reinfection the Ab rises more rapidly and
reaches higher levels than in the initial infection
(Collins et al., 1964 a, b, C; Lupascu et al., 1966).
It is known that malaria infection only confers a partial
protective immunity in man. Individuals living in endemic
areas where they are exposed to repeated infections and
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Many effects of cytokines could enable the host to resist
the disease, but their overproduction can increase the
pathology as seen in cerebral malaria where TNF may be
largely responsible for pathology (Clark et al., 1987 and
1989, Grau et al., 1989 and 1992) . TNF as well as ILl may
also be responsible for the fever that follows schizont
rupture in patients with malaria (Titus et al., 1991).
Despite the contradictory reports available in the
literature, IL-i may also play an important role in malaria
immunity. As a clue, Curfs et al., (1990) demonstrated that
treatment with IL-]. prevents cerebral malaria and reduces
parasitaemia in mice infected with P. berghei.
The role of IL-6 in the pathogenesis of malaria is still
not understood. Kern et al., (1989) and Grau et al., (1989)
reported that the serum levels of IL-6 increase in mice
with P. berghei and in patients with P. falciparum,
respectively. However, Grau et al., (1990) have suggested
that IL-6 is not involved in the pathogenesis of cerebral
malaria since they failed to prevent cerebral malaria in
mice infected with P. berghei by treating them with an
anti-IL-6 antibody.
1.6.4 Malaria in Pregnancy
During pregnancy, acquired immunity to malaria can be
completely suppressed, which makes the pregnant woman
vulnerable to severe falciparum malaria. For unexplained
reasons, the primiparae are more susceptible. Semi immune
pregnant women, do not generally have the acute febrile
illness that is observed in children, but can develop
anaemia which in some cases may be severe anaemia (Fleming,
1981). As demonstrated by McGregor et al., (1983), low
level infections in pregnant women can cause parasitisation
of the placenta, which is important since lowering of the
birth weight can occur with a poor prognosis
The loss of immunity remains unexplained. Increased levels
of steroidal hormones are, however, believed to play a role
in the increased susceptibility of pregnant women to
38
certain nonparasitic infectious diseases and this may well
be involved (Wyler, 1990).
1.6.5 Vaccines
The types of vaccines that have been under investigation
are proteins from the sporozoite, asexual blood stage and
from the gamete, zygote or ookinete (transmission
blocking).
The development of sporozoite vaccines is based on the
target antigen of antisporozoite immunity which appears to
be the major surface coat protein of mature sporozoites
(circumsporozoite protein - CS). This protein contains
repetitive epitopes corresponding to oligopeptides tandemly
repeated and flanked by homologous sequences in all
Plasmodium species. From species to species, the number of
repeats, the composition and size of the oligopeptides that
establish the repetitive epitope, are variable.
Recombinant CS antigen produced from different Plasmodiurn
species and synthetic peptides of various lengths coupled
to carrier proteins can be tested as potential vaccines.
There are already indications of problems, however, with
all possible vaccines, since they apparently elicit low
antibody titers that are inconsistently boosted by repeated
inoculation (Wyler, 1990).
The vaccines using asexual parasite proteins from
merozoites and intraeythrocytic forms have as target those
antigens expressed on the surface of the merozoites, those
associated with surface membranes of infected erythrocytes
and rhoptry protein (table 1.6.5). Although they are
antigenically more complex and diverse than the CS, the
motivation to develop vaccines using these antigens is
based on two facts, 1- these stages are the targets of
defence in natural infections, and 2- since pathology is
associated only with the blood stages, morbidity and
mortality can be dramatically reduced even if only partial
protection can be achieved (Wyler, 1990).
The transmission-blocking vaccines are based on the
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possibility of inducing production of antibody against
sexual stages. These antibodies, which would act in the
blood meal of the mosquito, might interfere in the
development of the sporogonic cycle.
The immunodominant target epitopes are expressed on
macrogametes and are lost soon after fertilization. There
are also other antigens on the zygote and ookinete that are
targets for this type of vaccine (table 1.6.5)
The antigens shown in table 1.6.5 are the present targets
for vaccines, but they do not represent all of the
potential candidates since new antigens for both asexual
blood and sexual stages of P. talciparuni and P. vivax are
rapidly being discovered (Mendis, 1991)
Therefore, those antigens already used in human trials,
such as the sporozoite vaccine and asexual blood stage
vaccine, have raised questions about the immune response to
malaria antigens and the degree of protection they can
afford in a human malaria vaccine, respectively (Mendis,
1991)
The advantage of using vaccine antigens expressed only in
the mosquito is that they are not exposed to the immune
system and are therefore less likely to have variable
epitopes (Ya-Ping et al., 1992).
1.7 Diagnosis
1.7.1 Microscopy of blood films
Despite great advances in malariology since Laveran's
discovery of the malaria parasite in 1881, microscopy
remains the best method of diagnosis. It is a simple,
relatively inexpensive diagnostic technique that is based
on the morphological features showed in section 1.3.
Microscopy is sensitive; a well trained microscopist can
detect a very low parasitaemia such as one parasite per
microliter of blood (Dowling & Shute, 1966). From
examination of thick and thin blood film the species,
stage, and intensity of infection can be determined.
However, this technique has limitations since microscopy is
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TABLE 1.6.5
POTENTIAL MALARIA VACCINE CANDIDATES
TARGET ANTIGENS	 LOCATION	 TARGET PARASITE
SPECIES
(NAN?) 3	 sporozoite surface	 P. falciparuni
(Cs- protein)
1- PMMSA, P190, gp195,	 merozoite surface	 1- P. falciparum
P185, PSA, MSP-1 and	 (glycoprotein)
MSA-1	 2- P. falciparurn
2- MSA-2	 (Anders & Brown, 1990)
3- PV200	 3- P.vivax
4- NH-terrnina1 synthetic 	 (Del Portillo et al.,
peptide of the	 1991)
glycoprotein	 4- P. falclparum
5- NH2-terrninal synthetic	 5- P. falciparurn
peptide of the	 (Patarroyo et al.,
glycoprotein used in a	 1988)
multiple vaccine
6- rhoptry antigens	 merozoite	 6- P. falciparum
(Anders & Brown, 1990)
1- 230 Da protein,	 gamete	 1- P. falclparuni
48/45 Da protein
2- GAN-1	 2- P. vlvax
Pfs25	 zygote and ookinete	 P. falclparum
41
time consuming and tedious; routine examination of a thick
blood film takes 5-10 minutes or longer in the case of low-
level parasitaemia (WHO, 1986). It requires trained
personnel, a high-powered microscope and can be insensitive
if prior chemoprophylaxis has been taken (Warhurst, 1990).
Alternatively, there is the fluorescence microscopy by the
QBC (quantitative buffy coat-commercial capillary tubes
containing acridine orange dye). Its use as a method for
replacing the conventional microscopy of Giemsa-stained
thick blood films was tested and discussed by Baird et
al., (1992). They concluded that the lack of a public
electricity power source, the sensitivity of the tubes to
humidity, the failure to detect low-level parasitaemia and
the cost of the test are the limitations of this method for
diagnosis of malaria in field conditions.
1.7.2 Antibody detection
It is possible to detect the production of circulating
antibodies by the host in response to the parasite
infection. During the acute phase of malaria infection
there is a low concentration of antibodies in the
circulation which is a limitation for the application of
such tests in the diagnosis of acute malaria. However, this
is a very sensitive technique for measurement of the
intensity of exposure to malaria in population.
1.7.2.1 Indirect iniinunofluorescence test (IFAT)
In the indirect fluorescent antibody test (IFAT) the whole
parasite either from culture or infected blood is used as
antigen. Short term or continuous cultured parasites of P.
falciparum are the best source of antigen since mature
trophozoites or schizonts give the most sensitive test.
Fluorescein-labelled antihuman globulin is used to detect
the antiparasite antibody on the surface of parasites in
thick films.
This test detects antibody very soon after the blood is
invaded but can give negative results with sera from
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children. However, the number of false negative results in
this test are lower than in other tests, probably due to
the use of a crude antigen.
1.7.2.2 Enzyme-linked immunoassay (ELISA)
ELISA, the enzyme linked immunosorbent assay, is analogous
to IFAT, except that the antigen is coated onto a
microplate and the conjugate is an antiglobulin labelled
with an enzyme, which is then quantitated by means of a
chromogenic substrate.
This test had been widely applied to malaria with a wide
variety of specific antigens. There is general agreement
that there are more false negative results with this test
than with IFAT, probably because the antigen may not be
optimal.
1.7.3 Antigen detection
Detection of parasite antigen or nucleic acids can be used
both in epidemiology and diagnosis since current infection
is measured.
The techniques can either use monoclonal or polyclonal
antibodies for the detection of the parasites. ELISA can
also be used for the detection of antigens and the
principle and development of the technique is the same as
for antibody detection, except that the plate is coated
with a monoclonal or polyclonal antibody.
1.7.3.1 Monoclonal antibodies (MoAb)
The monoclonal antibodies are highly specific since they
only react with their corresponding antigen.
A large range of MoAb that are stage- and species-specific
for malaria parasites has been produced. They have been
used for clinical diagnosis, in which the infected blood is
tested against a range of MoAb by an IFAT. The antigenic
diversity of the different stages of malaria parasite has,
however, limited their application.
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1.7.3.2 DNA hybridization (probes)
Nucleic acid probes are based on the principle that there
are parasite-specific regions in the parasite DNA to which
short, specific, labelled oligonucleotides will bind or
hybridize. Most DNA probes used to detect P. falciparurn
are based on a repeated 21-base pair (bp) sequence of
genomic DNA (Hyde, 1990). Studies using DNA probes have
been able to detect small quantities of P. falciparum DNA
(Barker et al., 1989; Boonsaeng et al,. 1989; Franzen et
al., 1984; Holmberg et al., 1987; McLaughlin et al., 1987;
Sethabutr et al., 1988). DNA probes have also been used to
detect P. falciparum in mosquitoes (Holmberg et al., 1987)
and for species identification in the Anopheles gambiae
complex ( Gale & Crampton, 1987). The sensitivity of these
probes varies, but they may detect as few as 5-lOpg to ing
DNA per sample, which is equivalent to 100 to 10,000 ring
stage parasites (WHO, 1986; Goman et al. 1982). However in
general they are less sensitive than skilled microscopy in
detecting scanty parasitaemias. The advantage of DNA probes
over microscopy is that many samples can be examined
simultaneously. Thus DNA probes could be useful in large
epidemiological studies where great numbers of blood
samples are examined in a relatively short period of time,
for screening blood in blood banks, or in identification
and/or incrimination of Anopheles mosquitoes. A major
limitation of DNA probes is labelling with radioactive
isotopes. Although radioactive labelling confers a high
degree of sensitivity to the probes, the danger associated
with these short-life isotopes and the requirement for
special handling and repeated relabelling limits their
usage. Non-radioactive DNA probe techniques have been
developed based on enzyme-linked colorimetric or
chemiluminescent detection systems (McLaughlin et al.,
1987). Sethabutr et al., (1988) have shown study that non-
radioactive probes compare favourably with radioisotopes
which was confirmed by Wilson et al., (1992), while others
report at least a 10-fold reduction in sensitivity (Hughes
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et al., 1990). The sensitivity of probes is enhanced if the
target sequence is highly abundant. DNA probes to the 21-bp
repeat region take advantage of this principle. Recently,
ribosomal RNA (rRNA) has been suggested as an appropriate
target to increase sensitivity because there is 10-50 times
more RNA than DNA in malaria trophozoites (of which 90-95%
of the nucleic acid may be rRNA). Hence, probes to rRNA
might theoretically be at least 100-fold more sensitive
probes to DNA (Waters & McCutchan, 1990). However, the
stability of the rRNA in the sample is a limitation for the
use of its probe. Small ring stages, however, have a
relatively small content of rRNA compared with later forms,
so sensitivity and advantage over DNA-probes depend on the
stage circulating.
1.8 Cultivation in vitro
Attempts to cultivate malaria parasites in vitro date from
1912, when limited multiplication of human plasrnodia was
achieved. Further attempts were made by many research
workers until 1976 when an extremely simple method of in
vitro cultivation was discovered for Plasmodium falciparum
(Trager and Jensen, 1976). This method, with some
modifications and improvements, has also allowed the
cultivation of some plasmodia of monkeys (P.knowlesi,
P.cynomolgi, P.inui and P.fraqile) and partial success was
obtained for the cultivation of the human plasmodia,
P.malariae and P.vivax (Bruce-Chwatt, 1985).
1.9 Biochemistry and metabolism
1.9.1 Energy metabolism
The primary energy source for the intraerythrocytic stages
of malaria parasites is glucose from the blood. These
stages lack carbohydrate reserves. When compared with
normal erythrocytes the infected red blood cells (rbcs)
show 02 uptake stimulated by glucose. However, P. falciparum
does not oxidise glucose completely to carbon dioxide and
water; instead it is a microaerophilic homolactate
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fermenter, converting glucose mainly to lactate.
The enzymes of the Embden-Meyerhoff glycolytic pathway play
a major role in conversion of glucose to lactate with the
production of ATP, since all of them have been identified
in extracts of P. falciparum (Roth et al., 1988). p.
falciparurn also contains the non-glycolytic enzymes such as
glutamic dehydrogenase (GDH), isocitric dehydrogenase
(IDH), malic dehydrogenase and glutamic-oxaloacetic
transaminase.
Deslauriers et al., (1982) provided evidence that there
are different ways for regulating glycolysis in host cell
and parasite since the phosphofructokinase and lactic
dehydrogenase of Plasmodium are less sensitive to high
concentrations of substrate and low pH than those of the
rbcs.
1.9.2 Synthetic processes
The hexose monophosphate shunt pathway allows the infected
rbcs to produce ribose and NADPH which are important in
nucleic acid synthesis and thus in nuclear division due to
the requirement for purine, pyrimidine and ribose for
nucleic acid synthesis.
The malaria parasite is sensitive to active forms of
oxygen. However, it has been shown that P. falciparum and
P. berghei do not synthesize their own superoxide dismutase
(SOD) and so their lysosomes obtain SOD from host cells
(Sherman, 1991).
Like other malaria parasites P. falciparum is capable of
fixing carbon dioxide possibly producing isocitrate,
although the role of this pathway remains unclear in the
overall metabolism of the parasite.
Both, nicotinamide adenine dinucleotide (NAD) and NAD
phosphate (NADP) are involved in glycolysis and in the
hexose monophosphate shunt pathway for ribose synthesis.
Zerez et al., (1990) had shown an increase of NAD content
in P. falciparum infected cells. This increase could be due
to synthesis from both nicotinarnide and nicotinic acid
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since levels of nicotinic acid phosphoribosyltransferase
(NAPRT), nicotinamide phosphoribosyltransferase (NPRT) and
nicotinamicie dearnidase were also increased in P.
falciparurn infected cells.
Most malarias demonstrated the glycolytic enzyme lactate
dehydrogenase (LDH) and GDH activity. NADH can be oxidized
via LDH, and NADPH via GDH or IDH (Vander Jagt et al.,
1989). NADPH is possibly formed from NADH via an ATP-
requiring transhydrogenase.
The malaria parasite requires oxygen, but at a low level.
Oxygen is the final acceptor for electrons from the
cytochrome chain which have been transported via the
ubiquinones. The availability of oxidised ubiquinone in the
mitochondria allows the enzyme dihydroorotate dehydrogenase
to catalyse the conversion of dihydroorotate to orotate in
the de novo formation of pyrimidines (see later).
Sperrnine and spermidine, polyamines, are always found in
biological materials and increased levels are found in
rapidly growing cells. Both are involved in protein
synthesis and contribute to ribosome and possibly membrane
stability. They are synthesised from methionine and
ornithine.
The growing Plasmodi urn requires increased amounts of
material from the host cell and the extracellular
environment. Consequently, an increase in the flux across
the erythrocyte membrane may be essential for the survival
of the intracellular parasite. Changes in the permeability
of the membrane of the parasite-infected rbcs have been
observed, but a clear biochemical description of the
mechanism of such changes is not yet available (Sherman,
1991)
1.9.2.1 Pyrimidine synthesis
The mature mammalian erythrocyte loses its capacity to
synthesise pyrimidines de novo. Intraerythrocytic
Plasmodium contains a functional de novo pathway (Scheibel
& Sherman, 1988). In extracts of Plasmodiurn falciparurn 3
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of the 5 enzymes (dihydroorotate dehydrogenase, orotate
phosphoribosyltransferase and orotidine-5' -phosphate
decarboxylase) have been identified which catalyse the
conversion	 of	 carbamylaspartate	 to UMP	 (uridine
monophosphate).
Thymidylate synthetase, an enzyme converting uridylate to
thymidilate, is also found in Plasrnodiuin extracts, where
it exists as bifunctional protein in combination with the
enzyme of the	 pathway folate, dihydrofolate reductase
(DHFR)	 which	 produces	 its	 essential	 co-factor,
tetrahydrofolate (THF).
1.9.2.2 Purine salvage
Malaria parasites require a supply of preformed purines
since there is no functional de novo purine biosynthetic
pathway in these parasites.
Five enzymes (adenosine deaminase, adenosine kinase,
adenine phosphoribosyltransferase, hypoxanthine-guanine
phosphoribosyltransferase and purine nucleoside
phosphorylase) the purine salvage pathway have been found
in P. falciparum homogenates.
It has also been demonstrated that other species of
Plasmodi urn contain all enzymes necessary for purine salvage
(Sherman, 1991).
1.9.2.3Nucleic acids
The amount of DNA contained in the malaria parasite
increases 10-20 fold from merozoites to the mature forms
after schizogonic development. In P. falciparurn DNA
synthesis begins at the early trophozoite and increases
logarithmically until late schizogony.
The RNA of malaria parasites is mainly localized in
cytoplasmic ribosomes (rRNA). The amount of RNA in the
intraerythrocytic stage of malaria is aboit f:ve times
greater than the DNA (Sherman, 1991).
Shippen-Lentz et al., (1990) demonstrated tha. malaria
parasites possess at least five classes of rRNA
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transcription units, and McCutchan et al., (1988) has shown
that only one of the two small subscript rRNA genes is
expressed during erythrocytic development. The stability
and turnover of plasmodial ribosomes and the manner of
transcriptional regulation of the rRNA genes are unknown.
The molecular mechanism responsible for plasmodial
ribosomal protein synthesis in the cytoplasm is typically
eukaryotic.
1.9.3 Nutrition
The nutrient uptake of the intraeythrocytic stages of
Plasrnodium can be effected by pinocytosis, diffusion and/or
transport and bulk ingestion of host cell cytoplasm via the
cytosome (specialized organelle).
The early stages of malaria parasites contain a tiny food
vacuole bounded by a single membrane, and have small
granules of malaria pigment, haemozoin. The haemozoin is a
blackish brown pigment that is the end product of
haemoglobin degradation. The chemical composition of
haemozoin remains under discussion and was first believed
to be melanin, later haematin or haematin coupled to a
polypeptide. Afterwards, Yamada & Sherman (1979)
demonstrated that the pigment of P. lophurae consists of
insoluble	 monomers	 and	 dimers	 of	 haematin
[ferriprotoporphyrin (FP)] coupled to a plasmodial protein,
and methaemoglobin. For 	 P. falciparum, Fitch &
Kanjananggulpan, (1987) claimed that haemozoin was an
aggregate of insoluble haematin, while Ashong et al.,
(1989) claimed FP was coupled to a plasmodial protein.
Malaria parasites as well as their host cells are not able
to synthesize fatty acids or cholesterol de novo, but they
can form phosphatidyicholine and phosphatidyl ethanolamine
(PE) via de novo pathways, or by methylation of PE or
decarboxylation of phosphatidylserine (PS), respectively
(Vial et al., 1990).
The blood plasma serves as the primary source of the fatty
acids required for plasmodial membrane formation.
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1.9.4 Cal]. invasion
The sequence of the erythrocyte invasion by the malaria
parasite is: recognition and attachment by the merozoite
stage to specific receptors on the erythrocyte surface;
junction formation between the merozoite apical region and
the red cell membrane; discharge of the contents of the
apical organelles (micronemes and rhoptries); invagiriation
of the erythrocyte membrane to enclose the merozoite within
a vacuole; and resealing of the rbc membrane after parasite
entry is complete (Sherman, 1991).
The biochemistry of the recognition has been described for
several Plasmodium species. Barnwell et al., (1989);
Wertheimer & Barnwell., (1989) confirmed the Duffy
glycoprotein as the major receptor on human rbc for P.
knowlesi and P. vivax. For P. falciparurn, the sialic acid
rich glycophorins appear to be the principal receptor.
There is no biochemical knowledge for the understanding of
junction formation.
Rhoptries, micronemes and microspheres are the three
membrane-bound organelles which are found at the apical end
of the merozoite. It is believed that their chemical nature
is lipidic and Mikkelsen et al., (1988) claimed that the
apical organelles phospholipids were involved in invasion
and formation of the parasitophorous vacuolar membrane
(PVM).
The invaginated PVM is depleted of IMP (inosine
monophosphate). The PVM has not been isolated from any
species of Plasmodium and the knowledge that we have about
it, is that it enlarges with the intracellular growth of
the parasite, it differs in its IMP composition and in its
reactivity with cationized ferritin, and it is lacking in
the rbc membrane proteins, spectrin, glycophorin band 3 and
ankyrin (Sherman et al., 1988; Dluzewski et al., 1989).
1.10 Treatment
Cure of P.faiciparum and P.malariae infections can be
achieved through the use of blood schizontocides while for
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P.vivax and P.ovale infections, a hypnozoitocide has to be
added. Constraints on the treatment of malaria are mainly
drug toxicity and the spread and development of drug
resistance. In developing countries, in addition to
difficulty in obtaining recommended drugs through the
public health system, the indiscriminate use of available
drugs by the general population encourages the development
of resistance.
1.10.1 Plasmodiuni falciparum
Chioroquine is used for the treatment of the acute
infection but only against those strains which are
sensitive to this drug. Axnodiaquine is therapeutically
equivalent to chioroquine and cures some chioroquine
resistant strains (WHO, 1990)
Quinine is used in the treatment of complicated malaria
caused by P.falciparum, cerebral malaria, hyperpyrexia
and/or for the cure of P.falciparum infections due to
chioroquine resistant strains (Geary et al, 1986; WHO,
1990)
Looareesuwan et al., (1990) have reported the loss of
effectiveness of quinine in some endemic areas of malaria.
Where quinine alone has no effect against P.falciparum
malaria infection, either quinine + mefloquine or quinine
+ fansidar or quinine + tetracycline can be used (Mashaal,
1986)
Mefloquine may be used alone for the treatment of acute
malaria infection due to multiple-drug resistant strains of
P.falciparurn (WHO, 1990).
Fansidar is used for the treatment of acute P.falciparurn
infection, but only for the susceptible strains and where
chloroquine-resistant strains are known to occur.
Qinghaosu (artemisinin) and its derivatives have been used
in China for the treatment of P.falciparum chloroquine
resistant infections. Thaithong & Beale, (1985) had
demonstrated the highly efficacy in vitro of artemisinin
and artesunate on isolates of P. falciparurn from Thailand,
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independently of their susceptibility to chioroquine,
pyrimethamine or pyrimethamine/sulfadoxine. The efficacy of
artemisinin derivates was confirmed by Bunnag eL al.,
(1991) in a clinical trial carried out in adult males with
acute uncomplicated and acute complicated falciparum
malaria, where the cure rate was above 75%. on the other
hand White et al., (1992) in the Gambia compared the
efficacy of i.m. artemether against i.m. chioroquine in
children with moderate or severe falciparum malaria and
demonstrated that artemether treatment enhanced parasite
clearance in moderate malaria while in severe malaria there
was difference between the two treatments.
Halofantrine has been used for treatment of acute malaria
in adults from the Solomon Islands (Parkinson et al,
1989),in Pakistan (Rab et al, 1989), in children in Kenya
(Watkins et al, 1989), in Malawi (Wirima et al, 1989), in
children in Gabon (Richard-Lenoble et al, 1989), and has
been shown to be an effective blood schizontocide.
1.10.2 Plasmodium vivax
Chioroquine remains the drug of choice for the treatment of
naturally acquired P.vivax malaria aided by primaquine for
the elimination of dormant tissue forms (hypnozoites). When
the infection is acquired congenitally, from transfusions
or from contaminated injections, primaquine is not required
since the hypnozoite stages is not present. There have been
some reports of chloroquine resistance.
1.10.3 Plasmodium malariae
Chloroquine is still the drug of choice for this species of
Plasmodium. The other blood schizontocide drugs can also be
used.
1.11 Drug resistance
The antimalarial drugs are classified biologically taking
into account the varying degrees of susceptibility
exhibited by the various developmental stages in the life
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TABLE 1.11
CLASSIFICATION OF ANTIMALARIAL DRUGS ACCORDING TO THEIR
BIOLOGICAL ACTIVITY
(baeed on Bruce-chwatt et al, 1fl5)
CLASS	 ACTIVITY ON PARASITES 	 EFFECTS
Tissue	 inhibition of growing EE	 prevent clinical malaria
schizontocides	 stages in hepatocytes	 by stopping production
and release of EE
merozoites into the blood
Hypnozoitocides inhibition of latent LE stages 	 radical cure of P.v and
(Peters, 1983)
	 (hypnozoites) in hepatocytes 	 P.o imfections by
preventing relapse
Blood	 act on asexual blood stages of	 clinical cure of malaria
schizontocides	 all human malaria parasites and or suppression of blood
on their gametocytes. except on infection
mature P.f
gametocytes
Gametocytocides active against the sexual forms disrupts transmission by
of all human malaria parasites	 preventing development of
either in the human host or in
	
gametocytes in mosquitoes
the mosquito vector
SpOrontocidea	 iithit the d.v.laçeent of oOcyetI and	 interrupt. tbs cycl, in aeaquitoes.
•poto:oit.. in th. vector	 thu. preventing traneejecion
P.f. = P. falciparum; P.v.	 P. vivax; p .o. = P. ovale;
EE = exo-erythrocytic
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cycle of malaria parasites as shown in the table 1.11. Drug
resistance of Plasmodium species, mainly P. falciparum was
first reported in 1910 when inadequate responses to high
and regular doses of quinine were recorded in Brazil. In
the 60's resistance to chioroquine was also reported from
several areas of the world (Bruce-Chwatt, 1985; Wernsdorfer
& Payne, 1991). Resistance of P. falciparum to
pyrimethamine, was reported shortly after its introduction.
However, the combination of pyrimethamine with sulfadoxine
(Fansidar) has been used successfully for the treatment of
chioroquine resistant malaria for a long time and
resistance to this formulation has only been reported from
areas where it has been used on a large-scale. Thus, in the
1980s, 90% of all cases failed to respond to this treatment
on the Thai-Cambodia border. Resistance to Fansidar has
also been reported from other areas. Mefloquine, another
recently developed compound used for the treatment of
chioroquine resistant malaria, has been routinely used for
the treatment of P.falciparum malaria in Thailand and the
first observation of resistance to mefloquine was from that
country (Wernsdorfer & Payne, 1991).
Since the first report of drug resistant Plasmodium, it has
been the subject of intense study and discussion especially
the biological and molecular mechanisms that govern drug
resistance, since widespread resistance to antimalarial
drugs makes control of malaria increasingly difficult.
1.11.1 Pyrimethamine, fansidar and Proguani].
Pyrimethamine, a diaminopyrimidine, is very active against
growing exo-erythrocytic (EE) stages of P.falciparum with
limited effect against P.vivax. For the other two human
malaria parasites it also acts on EE stages but very
slowly. There is no evidence that it has any action on
the number or morphology of gametocytes, but it inhibits
sporogorly (Geary et al, 1986). It functions by inhibiting
the enzyme DHFR thus impeding the metabolism of folic acid.
Fansidar which is a combination of pyrimethamine and
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sulfadoxine, has the same activity as pyrimethamine alone,
but the sulfadoxine is synergic by inhibiting a second
enzyme dihydropteroate synthase (DHPS), which is required
for the metabolism of p-amino benzoic acid (PABA).
Proguanil belongs to the group of biguanides and has the
same role in the chemotherapy of malaria as the
diaminopyrimidines since they share a common mechanism of
action (Ferone, 1984).
The rapid development of resistance of Plasmodium
falciparum to proguanil and pyrimethamine is well
recognised. Cycloguanil, the active metabolite of
proguanil, and pyrimethamine are inhibitors of
dihydrofolate reductase (DHFR). Peterson et al., (1990) and
Foote et al., (1990) have shown that the resistance of
clones of Plasmodium falciparum to the antifolates involves
alternative mutations in the active site cavity of DHFR. In
a further study Peterson et al., (1991) have shown a high
incidence of the point mutation (Asn-108) responsible for
pyrimethamine resistance among isolates from the Amazon
region of Brazil. Most recently Gyang et al., (1992)
developed a rapid polymerase chain reaction (PCR) assay for
pyrimethamine and cycloguanil resistance based on the
invariance of the DHFR point mutations among resistant P.
falciparum parasites collected over large areas of South
America, Africa and Southeast Asia.
1.11.2 Quinine, Mefloquine and Halofantrine
Quinine and mefloquine belong to the group of 4-
quinolinemethanols and halofantrine to the group of 9-
phenanthrenemethanols (Bruce-Chwatt et al, 1981).
These three drugs are effective against the erythrocytic
stages of all malaria parasites but ineffective against
sporozoites and exoerythrocytic forms (Geary et al, 1986;
Schuster & Canfiel, 1989)
They have been shown not to cause clumping of malaria
pigment, but competitively inhibit chioroquine-induced
pigment clumping (CIPC). The studies of Peters, (1987)
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suggested that the mode of action of quinine, mefloquine
and halofantrine was similar and so explaining the cross
resistance seen among the three compounds in rodent malaria
and between halofantrine and mefloquine in humans (Gay et
al., 1990).
1.11.3 Artemisinin (Qinghaosu)
It is a sesquiterpene lactone which is isolated from the
Chinese wormwood plant Artemisia annua L. Qinghaosu and its
derivates (arthemether and sodium artesunate) are very
active against blood schizonts of all species of malaria
(blood schizontocide) and also against chioroquine-
resistant P.falciparum in man (Warhurst, 1987).
It is thought that artemisinin acts primarily on the
parasite membrane integrity and so the resistance developed
to this drug might involve alterations in the membrane
composition (Warhurst, 1987).
1.11.4 Primaquine
This is one of the 8-aminoquinoline drugs and is the least
toxic of this group. It is effective against the dormant
liver forms (hypnozoitocide), so it is a radical curative
drug for P.vivax and P.ovale. It is also active against
gametocytes of all four human Plasmodium species.
Primaquine also destroys pre-erythrocytic forms of
P.falciparum, but only in a toxic dose (Mashaal, 1986).
In addition to acting on parasite oxidation-reduction
balance, primaquine metabolites effects the oxidative state
of the erythrocyte which in turn has affects on the
intraerythrocytic malaria parasites (Warhurst, 1987).
Resistance to primaquine has been reported from in vitro
and clinical studies, which has shown some P.vivax strains
from South East Asia are less sensitive to primaquine than
those from other areas of the world (Warhurst, 1987).
1.11.5 Chioroquine and amodiaquine
Both are 4-aminoquinoline compounds and highly effective
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against asexual erythrocytic stages (blood schizontocide),
but also destroy gametocytes (gametocytocide) of P.vivax,
P.malariae and P.ovale (Bruce-Chwatt, 1985).
The mode of action of chioroquine is not yet clear but
proposed mechanisms include: DNA intercalation, lysosome
accumulation and binding to ferriprotoporphorin IX
(Meshnick, 1990)
The distribution of P. falciparum resistance to chloroquine
is worldwide (fig 1.11.5), throughout the malarious areas
where P.falciparum is found (WHO, 1992).
The nature of resistance of P. falciparurn to chioroquine is
still not clear, but is thought to involve a reduced
accumulation of the drug in the food vacuole of the
parasite (Krogstad et al., 1987) . It has been proposed that
this reduced accumulation is due to the efflux of the drug,
in a manner similar to that seen in multi-drug resistant
cancer cells, and in fact two genes have been identified in
P. falciparum that are homologous to the genes shown to be
responsible for this phenotype in cancer cells (Wilson et
al., 1989). One of these mdr homologous, pfmdrl, has been
sequenced (Foote et al., 1989) and the occurrence of a
pattern of point mutations was used to predict the correct
chioroquine sensitivity of 34 out 36 different isolates of
P. falciparum (Foote et al., 1990) . However, analysis of a
genetic cross between a chloroquine-sensitive and a
chioroquine-resistant strain suggested that the pfmdrl
sequence is not linked to chloroquine resistance (Wellems
et al., 1990). Further work by Wellems has identified a
region on chromosome 7 that segregates in the above
mentioned cross, in favour of the chioroquine-resistant
isolates (Wellems et al., 1991). More recently, Warhurst
and colleagues have shown that resistance may be mediated
by differential expression of the two pfmdr genes and in
field isolates was not related to point mutations in pfrndrl
(Ekong et al., 1993 and Awad el Kariem et al., 1992).
Evidence is also mounting that mefloquine resistance is
linked to a high degree of expression of pfrndrl (Barnes et
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al., 1992). Immunological detection methods have shown that
the protein product of the pfmdrl gene, the P-glycoprotein
(Pghl), is localised on the parasite digestive vacuole
during the trophozoite stage of the life-cycle, the stage
at which the parasite is normally most susceptible to
chioroquine (Cowman et al., 1991). It seems, therefore,
that there is a role for the pfmdr genes in multi-drug
resistance but there is no agreement on exactly what it is.
1.12 Epidemiology
1.12.1 Global malaria
Malaria is very widely distributed in the world and
estimates in 1990 (WHO, 1992) show that over 40% of the
world population spread among 99 tropical and subtropical
countries (Fig. 1.12.1) is at risk of catching malaria.
The global incidence of malaria is estimated to be about
120 million clinical cases per year and about 300 million
people are though to carry the parasites.
The four species of human Plasmodium are transmitted by
female anopheline mosquitoes. Congenital transmission and
transmission by blood transfusion or by the sharing of
contaminated syringes between drug addicts has also been
reported (Lo et al., 1991).
Only a small proportion of the 400 or so species of
Anopheles are efficient vectors of Plasmodium. About 15% of
the 400 species feed on man, and with sufficient regularity
to maintain endemic infection. There are several different
factors that influence the transmission, and temperature,
humidity and rainfall play an important role.
Environmental temperature lower than 16° C and higher than
32° C are lethal to the parasite, since at such temperatures
no human Plasmodium species can develop inside the vector.
The optimal temperature for rapid development of the sexual
cycle in the vectors is 27° C - this then takes 8 days for
P.vivax and 11 days for P.falciparum. The temperature also
affects the vector physioloqy because the higher the
temperature the shorter is the gonotrophic cycle (the
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World distribution of malaria
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period of the development of the female Anopheles following
the blood meal, which begins and ends with egg-laying).
Humidity is also important. A high relative humidity
increases the longevity and activity of the vector.
Rainfall also plays a role in malaria transmission due to
its direct effect on the temperature and humidity as well
in creating favourable breeding sites for the vectors
(Mashaal, 1986)
Malaria occurs from as far north as latitude 64°N and to
latitude 32°S, at altitudes from 400m below sea level (Dead
Sea) to 2800m above sea level (Cochabamba, Bolivia) (Bruce-
Chwatt, 1985).
Of the four human Plasmodiurn species, Plasrnodium vivax is
the most widely distributed and causes much debilitating
disease; Plasmodium falciparum is also widespread and is
responsible for the majority of malaria-related deaths
because it produces the most severe malaria; Plasmodium
rnalariae which also occurs commonly, causes the least
severe but most persistent malaria; Plasmodium ovale is the
least prevalent malaria of the four species and infection
is mainly confined to Africa (WHO, 1990). Plasmodium
falciparum is the predominant species of malaria in
tropical Africa, in three countries of Asia west of India,
in Bangladesh (middle south Asia), in eastern Asia and
Oceania, and in three countries of the Americas.
The malaria mortality in children has fallen in some areas
due to the widespread use of antimalarials and to
improvements in education and social development. However,
in the African region alone WHO registered 800,000 deaths
in 1991, but the figure is certainly greater than this
because of undereporting of cases. For example, in 1986 the
annual malaria mortality in Brazil was estimated at between
6,000 and 10,000 and the total reported period for the
Americas was only 1,428 deaths (WHO, 1992)
1.12.1.1 Malaria endemicity
Malaria endemicity can be measured either by the spleen
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rate or by the rate of positivity for human Plasmodiurn
infections . The enlarged spleen is detected by palpation
while the patient is lying down. The parasite rate for
human malaria infection is obtained by the reading of
individual blood films.
The criteria for endemicity which have been adopted by WHO
are measured in the age-group 2-9 years as follows (Bruce-
Chwatt, 1985):
Non endemic - no enlarged spleen or positive slides
Hypoendemic - less than 10% present enlarged spleen or
positive slides.
Mesoendemic - 11-50% have palpable spleen or positive
slides.
Hyperendemic- spleen or parasite rates constantly above
50%. High spleen rates in adults (over 25%).
Ho].oendemic - high spleen and/or parasite rates (over 75%).
Adults with low spleen rates.
The haptoglobin levels has been used as an indicator of
malaria transmission. Haptoglobins are alpha-2 globulins,
which are synthesised in the liver and whose specific
function is to bind free haemoglobin in the plasma.
The release of free haemoglobin into the plasma occurs
during haemolytic anaemia and results in rapid saturation
of the haptoglobin system and disappearance of free
haptoglobin.
Mainly in Africa, low or absent serum haptoglobin has been
found frequently and a close correlation between malaria
and ahaptoglobinemia has been suggested (Trape & Fribourg-
Blanc, 1988 and Sisay et al., 1992). Furthemore, Rougemont
et al., (1988); Boreham et al., (1981); Trape et al.,
(1985) have shown elimination of ahaptoglobinemia by the
administration of malaria chemoprophylaxis. As haemolysis
may occur in acute malaria an ahaptoglobinemia may be
expected during a malaria episode.
1.12.2 Prevalence of malaria in Brazil
According to estimates from WHO (1992) Brazil registered
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53% of the 1 057 000 cases recorded from the Americas in
1990. For falciparum malaria infection Brazil was
responsible for 75% of all falciparum infections reported
from the Americas. Plasmodium falciparum was resonsible for
45% of malaria infections in Brazil in 1990 (fig.1.12.2).
As shown in fig. 1.12.2a, in 1991 Brazil showed a small
decrease in the number of malaria cases recorded in
relation to 1990.
1.12.2.1 The distribution and severity of malaria in Brazil
Ninety seven percent of all cases reported in the country
in 1990, were from the Amazon region where the highest rate
of malaria transmission were found. Three states in this
region were responsible for most of the malaria cases:
Rondonia (45%), Pará (21%) and Mato Grosso (11%) (PAHO,
1991)
Since 1986 the epidemiological status of malaria in Brazil
has been similar to that described above because even in
1986, 96.3% of all cases recorded in the country were
concentrated in the Amazon region (PAHO, 1987). In 1986,
however, only two states (Pará and Rondonia) accounted for
70% of the all cases in the Amazon region.
Two major social processes are implicated in the increased
malarial incidence in the Amazon region: 1- the high and
disorderly migratory movement towards mining areas with
difficult access, precarious living and working conditions,
and the latter include production of stagnant water areas
causing increase transmission; 2- the population movements
towards areas of subsistence farming where settlements also
have very precarious conditions such as inaccessibility,
inadequate living conditions and poor health protection
(PAHO, 1991). These factors have provided conditions for
the continuing transmission and increased risk of
contracting malaria.
1.12.2.2 Malaria in Ainapá State (AP)
Amapá state in 1990 registered an Annual Parasite Incidence
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Figure 1.12.2
Comparison between the proportion of malaria caused by
Plasmodium falciparum or Plasmodium vivax
in the Americas.
(PAHO, 1992)
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Figure 1.12.2a
Distribution of malaria cases in Americas for 1991
(PAHO, 1992)
65
(API) of 43.2 per 1,000 (PAHO, 1991). From data kindly
provided by the Statistical Sector of the Fundacâo Nacional
de Saide (FNS) in AP, in 1989 11,156 cases of malaria were
registered (positive slides) of which 6,145 were from urban
areas and 5,011 from rural areas. For 1991, a total of
9,093 cases were recorded with 4,592 urban and 4,501 rural.
For the three first months of 1992 a total of 2,229 cases
were recorded with 1,002 urban and 1,227 rural. Throughout
these years two municipalities (Macapá and Santana) were
the locations where most of the cases were registered,
74.68% in 1989, 72.08% in 1990, 65.13% in 1991, and 70.21%
for the first three months of 1992.
1.13 Control of Malaria
Malaria control has been mainly based on the integrated use
of measures that target the interruption or reduction of
transmission; decreasing and/or stopping man-vector
contact, decreasing vector densities and the number of
mosquito breeding sites and also eliminating parasites from
infected individuals. These measures therefore target
towards the people, the vector and the parasite, and they
consist of: health education; individual protection (bed
nets, mosquito repellents, house screening); application of
insecticides and larvicides; use of biological agents such
as larvivorous fish (e.g. Gambusia) or bacteria pathogenic
to the mosquitoes	 (e.g.	 Bacillus thuringiensis);
environmental	 alterations;	 chemoprophylaxis	 and
chemotherapeutic treatment of clinical cases.
In 1985 the epidemiological stratification of malaria was
recognized as a tool for planning malaria prevention and
control activities, although it had emerged as a strategic
approach in 1979 (vide PAHO, 1992). This new strategy
provides the knowledge for the application of the correct
measures for malaria prevention and control, through
epidemiological studies of individuals and defined social
groups, of the risk factors that are responsible for the
incidence of malaria at the local level (PAlO, 1991).
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The control of malaria should be achievable with the
application of those measures, but there are so many
complicating factors such as the emergence and spread of
resistance to anti-malarial drugs and vector resistance to
insecticides, the toxicity of some anti-malarial drugs used
for prophylaxis and treatment, the lack of local
epidemiological knowledge and/or data, and economic
constraints on the application of control measures (high
cost, inadequate resource allocation related to the
priority endemic areas), that effective control of malaria
has not been possible (WHO, 1987). The use of the
epidemiological stratification strategy should, however,
modify this picture since it is a tool for providing the
best understanding of the epidemiological situation, for
identifying the factors involved in transmission, and for
determination of the most appropriate control measure(s)
(PAHO, 1991)
1.14 Conclusion
Malaria continues to be one of the most important parasitic
diseases in the world since its morbidity is high and
mortality affects mainly children.
Research progress from studies worldwide has given a better
understanding of this devastating illness.
Despite the knowledge during recent years, many important
problems remain. For example, microscopy is still the
method of choice for the diagnosis of malaria; efficient
continuous cultivation is only available for P. falciparurn;
the drug resistance continues to be an insoluble
difficulty; new drugs have been introduced but their use is
under evaluation; control measures have some effect but
need improvement to allow decrease in the morbidity of this
disease.
1.15 Aims
Based on the fact that Serra do Navio, AP is the only
remaining locality in Brazil where chioroquinised salt has
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been used for more than 20 years as a preventive measure
for malaria infection and this settlement is claimed to be
malaria free, this project had the following objective:
1- to obtain a better understanding of the epidemiological
status of malaria in the Serra do Navio area;
2- to evaluate the malaria antibody status of the
population of Serra do Navio and also of the population
of three small localities (control areas) surrounding
Serra do Navio;
3- to evaluate if the use of chioroquinised salt is a
effective preventive measure.
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CHAPTER 2: MATERIAL AND METHODS
2.1 STUDY AREAS
2.1.1 TARGET AREA: Serra do Navio (SNV)
Serra do Navio is a municipality of Nacapá city, the
Capital of Axnapá State. It is 146Km from Macapá (Fig.
2.1.1). The route for reaching Serra do Navio from Macapá
is by road (about 3 hours) or by rail (4-5 hours).
Serra do Navio was created in 1947, when the company ICOMI
- Indüstria e Comércio de Mineraçâo S.A. - received a
licence for the exploration of the mineral resource of this
area for a period of 50 years. From 1954 to 1957 the
company built the industrial project and from 1957-1960 the
residential village and the physical basis of the social
infra-structure (Gusmão, 1991). The administrative,
industrial, and residential areas are completely isolated
from one another. The overall structure was built for a
population of about 2 to 2.5 thousand inhabitants. This
village has the facilities for covering all population
needs, such as: roads, rail, hospital, houses, supermarket,
school, communication station, water purification plant,
sewage treatment plant, rain water drainage, rubbish
incinerator, post-office, bank, pharmacy, police station,
cinema, clubs, etc.
The water purification plant comprises the following
stages: Aeration, sedimentation, flocculation (using alum),
rapid sand filtration, chlorination and fluorination.
The sewage purification plant is a conventional sewage
treatment and has the following phases: Pretreatment and
primary sedimentation, trickling filters, secondary
sedimentation (humus tanks), and effluent discharge.
The residential area is divided up as shown below and
all houses are 3 bedroomed houses, very well ventilated to
allow for the conditions of climate in the Amazonian
region. They have chlorinated and fluorinated water and
screened windows and doors, but the size of each type
differs, decreasing from type WAif to type "D".
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	TYPE O
	
NAME or THE	 USERS' GROUP
	
ROUSE	 HOUSES
	
A	 Vhs CCM	Staff members
	
B	 Vhs DD"	 Highly specialized
workers
	
C	 Vila A"	 Medium-specialized
workers
	
D	 Vila "BC e	 Non-specialized
workers
Serra do Navio was chosen as the target area of the study
because of the dietary intake of chioroquinised salt by its
population for more than 20 years. The use of
chloroquinised salt was introduced in Serra do Navio in
1960 when the Federal Government through the CEM (Programme
of Malaria Eradication) started to produce and distribute
the salt as a control measure for malaria in all the Amazon
region (Gusmâo, 1990). The salt was not refined and had in
its composition 0.50g% of chioroquine diphosphate and was
packed in plastic bags of 30Kg. In April 1961 it was
decided to stop the obligation to use this salt in the
.Axnazonian region, but in spite of this the use of the salt
continued to finish the stock provided by government. Based
on the decrease of the monthly incidence of malaria during
the period - 1958 to 1963 - (Table 2.1.1) in October 1963
the company decided to produce and distribute the salt
for its two villages, one in Macapá and one in Serra do
Navio. The production, preparation, distribution and
quality control of the salt and the supervision of its use
is carried out by the company itself. The production takes
place in a small factory in Macapá and comprises the
following stages: trituration, drying, sieving, addition of
chioroquine to the refined salt to give a final
concentration of 0.40g%, homogenization by gyratory mixer,
sampling for testing the chioroquine dosage (Paulini method
- Pulini & Pereira, 1963), packing and distribution.
The salt is administered, orally, with the food, since this
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Figure 2.1.1
Map of Amapá State and the railway that links Serra do
Navio to Macapá.
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TABLE 2.1.1
MALARIA IN THE LOCALITIES OF SEPRA DO NAVIO AND PORTO SANTANA—AP
1958 - 1963
TRR MONTHS PROPRYLAXIS POPULATION I	 CASES OP INCIDENCE
k13.RIA
1958	 1-6	 none	 2.566	 252	 16.4
	
7-12	 pyr*	 140	 9.1
1959	 1-6	 pyr*	 3.189	 84	 4.4
	
7-12	 pyr*	 172	 9.0
1960	 1-6	 none	 3.476	 131	 4.7
	
7-12	 chs**	 24	 1.7
1961	 1-6	 chs**	 3.535	 19	 0.8
	
7-12	 none	 418	 23.7
1962	 1-6	 3.604	 316	 9.7
	
7-12	 none	 87	 8.1
1963	 1-6	 chs***	 3.819	 12	 0.5
	
7-12	 37	 1.6
# Population: 1958-1960 - estimate based on the data
obtained from the microscopical
survey.
1961-1963 - based on the data obtained from
the annual demographic census.
*Pyrimethamine: two tablets of 25mg per month
**Chloroquinised salt - without dosage control
## Camopri.m - 2 tablets of 150mg amodiaquine and 1 tablet
of 15mg of primaquine, each two weeks.
***Chloroquinised salt - with dosage control
DATA PROM GTJSMAO, 1990, pp. 135
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is the only available salt for cooking. The salt is sold
in the only supermarket in Serra do Navio and the control
of its use is carried out evry week in a random sample -
5% of the houses- by collecting samples of salt from the
kitchen of each house and testing them for the presence of
chioroquine (Paulini method - Paulini & Pereira, 1963). In
parallel, urine samples were collected from one or more
residents of each house selected (random sample) to confirm
the presence of chioroquine by Haskin's method (Haskin,
1958)
2.1.1.1 Geographical characteristics
Latitude	 -	 0 57' 00'' N
Longitude W.Gr. - 52 00' 49''
Altitude	 - 380 m (highest point)
145 m (houses type "A" and "B")
110 m (houses type "C", "D" and hospital)
Mean annual temperature: 26°C
Mean pluviometric rate: 293.6 mm (Jan-Jun 1990)
129.1 mm (Jul-Dec 1990)
The climate is that of a tropical rainforest usually with
a rainy season, during which 85% of the precipitation
registered during the year occurs, and a dry season.
The mean temperature does not vary much during the year
because of the position of Amapá State on the Equator (Fig.
2.1.1.1), while the daily temperature variation is marked
due to the number of hours of sun which is equivalent to
the duration of the nights C Arnapá State is localized at
very low latitudes). The rainfall is lower during the
hotter months.
The rainy season is characterised as follows: from December
to March - rain every day and several times a day with high
intensity but short duration; from April to June - heavy
and continuous rain; from July to November - scanty rain.
Serra do Navio itself according to Azevedo, (1967) is
classified as "Forest of firm soil" since it is comprised
by primary and secondary forest.
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Figure 2.1.1.1
Map of .Amapâ State with the localization of Serra do
Navio and its temperature and rainfall
variation.
74
2.1.1.2 Population characteristics
During the period that this study was carried out (1989-
1991), the population of Serra do Navio varied around 2000
inhabitants. They came from anywhere in Brazil and some of
them have lived in the area for more than 10 years. The
population is comprised of more adults than children and
teenagers because the young workers are generally single
and the teenagers usually go to other big cities for study.
2.1.1.3 Sample sizes
The size of the sample was established as 15% of the total
population of Serra do Navio, that is in 1989, about 250
persons. Random samples were collected by house for each
type of "vila". The population group selected was therefore
not precisely 15% of the total population because the
number of persons per house was variable.
All individuals included in this study had to sign an
agreement to allow themselves and their relatives to be
studied. For each person, an individual data form was
completed and blood and urine samples collected. The urine
sample was collected once only while blood samples were
taken 3 times during the study, that is once a year (1989-
1991)
2.1.2 CONTROL AREAS: Colonia Agua Branca (CAB), Porto
Terezinha (PT), Arrependido (ARR)
All three control areas C areas where no chioroquinised
salt has been used) are small villages, called localities,
and their populations have a standard of living contrasting
with that of the population of Serra do Navio (table
2.1.2), in the context of basic needs, such as: treated
water, sewage disposal, electricity (except PT),etc. Their
houses are made of wood and the roofs are made of zinc
panels and sometimes with strong plastic or dry palm tree
leaves (Fig. 2.1.2). The Amapari river is their main water
source that is used for drinking water, house cleaning,
bathing, etc. Rubbish is deposited everywhere, on the
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TABLE 21.2
BETWEEN THE TARGET AND CONTROL AREAS
DIFFERENT POINTS
	 TARGET AREA	 CONTROL AREAS
(SNV)	 (CAB, PT, APR)
Houses with screened
	 yes	 no
windows and doors
School	 yes	 yes
Supermarket	 yes	 no
Hospital	 yes	 no
Water purifictiort	 yes	 no
plant
Sewage treatment	 yes	 no
plant
Rain water drainage	 yes	 no
Rubbish incinerator	 yes	 no
DDT house spraying
	 yes	 yes
programme
Clearance of the	 yes	 no
small river borders
Residential areas,	 yes	 no
at least, 200 m from
the forest
Chioroquinised salt
	 yes	 no
programme
SNV - Serra do Navio
CAB - Colonia Agua Branca
PT - Porto Terezinha
APR - Arrependido
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Figure 2.1.2
The contrast of house type in the 4 study areas.
a. Serra do Navio, b. Colonia Agua Branca and/or
Arrependido, C. Porto Terezinha.
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river edges, beneath and/or behind the houses. There is no
proper disposal of human faeces since they use pit
latrines.
CAB and ARR cover a very large area but the house
distribution is mainly in patches. The patches in CAB are
formed by groups of about 10 houses while those in ARR are
of a maximum of 3 houses. PT covers the smallest area but
the housing is very concentrated as shown in Fig. 2.1.2.
2.1.2.1 Geographical characteristics
All these localities have the same geographical
characteristics as SNV, except for the altitude which is
lower, 85m (CAB) and 70m (PT and ARR).
2.1.2.2 Population characteristics
The population of these three localities surrounding Serra
do Navio is comprised of people mainly from the areas of
the Amazon region and northeast of Brazil. Their main
occupation is either free-lance mining (Garimpos) or
working for the ICOMI Company.
Population: (data from SUCAN -Ministry of Health, 1990)
CAB -	 611 inhabitants
PT - 459 inhabitants
ARR -
	 80 inhabitants
2.1.2.3 Sample sizes
This was determined as the greatest number of people that
it was possible to reach at the time of the sample
collections.
2.1.3 Indigenous group in Amapá State.
About 100Km away from the Serra do Navio area there is an
indigenous tribe (WAIAPI). Their houses are made of dry
palm trees and they have no sanitary facilities such as
treated water and sewage system. They have a very primitive
style of living but they are already civilized. The FJNAI
(Federal Government organisation for taking care of
78
indigenous groups) has a group of workers living with them,
comprising normally of a medical doctor and/or a nurse, a
dentist, a teacher and a manager who speaks their language
and is responsible for all subjects concerning their health
and well-being.
Their main health problem is malaria and because of this
the tribe is included in the DDT house-spraying programme
which is carried out by SUCAM (Anti-malaria programme)-
Ministry of Health. Malaria diagnosis and treatment are
carried out either by FUNAI and/or SUCAM. When the malaria
picture is complicated, however, and/or when malaria is
epidemic they generally go to the Serra do Navio hospital
for diagnosis and treatment.
2.1.3.1 Geographical characteristics
This area has the same characteristics of those described
above, except that the altitude is around 60m.
2.1.3.2 Population characteristics
They are native people and are distributed in 16
communities with a total of approximately 900 individuals
and a mean of 60 persons per community. Their main
occupation is fishing and hunting.
2.1.3.3 Sample size
In this study a small group was included consisting of 12
individuals from the "Aldeia ItaCissu" and 15 from the
"Aldeia Aramirà" which have populations of 51 and 73
inhabitants, respectively.
2.2 Microscopical examination of blood films
All the individuals included in this study were bled for a
10 ml sample of blood into an EDTA coated tube. Thick and
thin films were made from each sample. A drop of blood was
placed on the right side of a clean glass microscope slide
and a thick film was made by spreading a rectangle (2 cm2)
with the corner of another microscope slide. The thin smear
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was produced by touching on the drop with the edge of a
microscope slide held at about 45° to the other slide. The
blood cells were spread from the middle to the left edge
and across the width of the slide with a firm but smooth
movement.
The slides were air-dried, thin films were fixed with
methanol for 1-2 minutes, and thick films immersed in water
for about 10 seconds and immediately counter-stained with
methylene blue for 10". They were then placed face down on
a staining rack for staining with 10% Giemsa stain (1:9 in
buffered dH2O pH 7.2) for about 25-30 minutes. They were
subsequently rinsed gently and air-dried.
Slides were examined with a Zeiss light microscope using
oil immersion with a xlOO objective. The thick film was
observed first for the presence of Plasmodium parasites and
in this project counts and observations on morphology were
derived from thin smears. Parasitaemias were calculated as
the number of parasitised erythrocytes per the total number
of erythrocytes in 100 fields examined, expressed as a
percentage.
2.3 CULTIVATION IN VITRO
For the cultivation of Plasmodium, we used RPMI 1640
culture medium (CM) as follows:
STEP 1: Incomplete medium:
RPMI1640 . . .............	 10.40 g/l
HEPES. .................................5.94 gIl
Gentamicin . . . .......... 40 . 00 p.g/ml
Hypoxantine (50 mg/100 ml)...... ........50.00 ml
Two litres of medium were prepared by dissolving the RPMI
1640 in 1800 ml of distilled water (dH 2O) and adding the
other reagents. The pH of the medium was adjusted to 7.2
with 1OM NaOH after all the reagents were mixed well by
stirring on a magnetic stirrer. The final volume was
reached by adding dH2O up to a volume of 1920m1. The medium
was then sterilized on ll5ml filter units - 0.22 pm,
attached to a vacuum pump in a safety cabinet. Aliquots of
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90m1 were dispensed in flasks and stored at 37° C for 24h to
check their sterility, then stored at -20° C and thawed as
needed.
STEP 2:
When needed the number of flasks required were thawed and
human serum (A Rh+ or AB Rh+) added to give a final
concentration of 10% together with 2.1 ml of a 10% NaHCO3
solution for each 100 ml of CM.
The human serum was obtained either from the Blood Bank
(Health Secretary of Parã State-BR) or directly from donors
of the Malaria Programme - Evandro Chagas Institute. In
both cases their blood was collected in sterile bottles
and/or vacutainer tubes (20 ml each). Serum was removed
aseptically in the safety cabinet, dispensed in 10 ml
aliquots and stored at -20° C until required.
STEP 3:
A suspension of normal human erythrocytes (type 0 Fth+) was
prepared by washing them, twice, with incomplete CM. A 50%
suspension of the washed cells was then made in complete
CM.
2.3.1 Plasmodium falciparum
For culturing and maintenance of Plasmodium falciparum in
vitro the technique of Trager & Jensen (1976) and Trager
(1979) was applied. The initial step was to centrifuge the
infected whole blood of the patient for 10 minutes at l000g
and remove the supernatant (SN) and buffy coat. The red
blood cells (rbcs) were washed twice by adding an equal
volume of incomplete CM and centrifuging with the same
conditions described above. The washed cells were then
suspended to give a 50% haematocrit (HC). 0.5m1 of this
suspension was placed in a 60-mm culture dish (Falcon) and
4.5m1 of complete CM added to give a culture at 5% HC. To
set up a new culture from an existing one it was necessary
to calculate the dilution factor which is given by dividing
the estimated parasitemia in culture (%) by the required
parasitemia (%). This dilution factor was used for diluting
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the infected rbcs (50% HC) with the fresh rbcs (50% EC)
which were placed in a new culture dish, thus obtaining a
final HC of 5%.
The cultures were incubated at 370 C in a candle jar. For
this system a desiccator was used equipped with a stopcock
and a white candle. The candle was placed in the centre of
the desiccator and lit, the cover was put on with the
stopcock open, and when the candle went out the stopcock
was closed. This system produces a reduced concentration of
°2 and a raised concentration of CO2 . Medium was replaced
daily and fresh erythrocytes every third or fourth day.
2.4 Cryopreservation
In this study, glycerolyte 57 solution ( appendix -Fenwal
Laboratories, Canada) was used as cryopreservation
solution.
2.4.1 Cryopreservation of malaria parasites
Wilson et al., (1977) had demonstrated in their study that
ring stages of malaria parasites were the stage of choice
for the process of direct freezing at -196°C and thawing,
and that only cultures rich in rings had to be
cryopreserved.
Cultures with 5% or above of ring forms were centrifuged
and the SN discarded. Then, twice the cell volume of
glycerolyte, drop by drop and under agitation, was added to
the cells and each 1.0 ml of the mixture obtained was
dispensed into sterile 1.8 ml cryotubes (Nunc)
appropriately identified (ID code, date). The cryotubes
were then placed in ampoule canes inserted into cardboard
sleeves, then canisters, and immediately frozen at -196°C in
liquid nitrogen.
2.4.2 Recovery of parasites from liquid nitrogen
The ampoules with the parasites were quickly thawed at 37°C
with agitation. The cells, still cold, were transferred
into a sterile 10 ml tube and then centrifuged for 2
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minutes at 500 g and glycerolyte solution discarded.
Cells were suspended in an equal volume of sterile 3.5%
(w/v) NaC1 in RPMI 1640 and immediately recentrifuged. Two
washes (500 g for 5 mm) were carried out in CM, then cells
were transferred into a 60 mm culture plate containing 0.5
ml of washed rbcs (see section 2.3) and 4.5 ml of CM. The
plates were incubated and maintained as in section 2.3.1.
2.5 Drug resistance test
Pre drug-dosed plates, produced by the WHO Standard
Microtest Production Unit, NMCS, Manila, Philippines, were
used in this study.
The technique uses 96 well-microplates, in which the wells
of the columns identified by alpha codes (B...H) contain
increasing anti-malarial drug áoncentrations. The wells of
column A are control wells which have no drug. Those
identified by code number (l...12) are for the samples to
be tested (Fig. 2.5).
The samples were tested directly from the patient's blood.
Starting with a parasitemia of about 0.5-1% rings and early
trophozoites. Each blood sample was centrifuged, the SN and
buffy coat removed, the cells resuspended in an equal
volume of incomplete CM and washed twice at l000g for 10
minutes. Then the HC was brought up to 5% in complete CM
and 50 pi of the sample added to the wells of the same
numbered column from the control well to the highest drug
concentration. Plates were then rocked gently for about 5
minutes to obtain an homogeneous mixture of the sample with
the drugs. The plates were placed in a candle jar,
maintaining the humidity by pouring a small amount of water
or by placing a piece of wet cotton on the bottom of the
jar. They were incubated at 37°C for 24 hours.
For reading the plates were removed from the jar, the
medium aspirated from the control well and the remaining
red cells mixed and a thin smear made that was stained in
Giemsa 20% for 10 minutes. The slide was read as described
in section 2.2 and if there were no schizonts, the test
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_____	 1	 2	 3	 4	 5	 6	 7	 8	 9	 10	 11
A	 C	 C	 C	 C	 C	 C	 C	 C	 C	 C	 C	 C
R	 1	 1	 1	 1	 1	 1	 1	 1	 1	 1	 1	 1
C	 2	 2	 2	 2	 2	 2	 2	 2	 2	 2	 ___ 9
t
D	 4	 4	 4	 4	 4	 4	 4	 4	 4	 4	 414
F	 8	 8	 8	 8	 8	 8	 8	 8	 8	 8	 8	 8
P	 16	 16	 16	 16	 16	 16	 16	 16	 16	 16	 16	 16
0	 32	 32	 32	 32	 32	 32	 32	 32	 32	 32	 32	 37
H	 64	 64	 64	 64	 64	 64	 64	 64	 64	 64	 64	 64
Resistance
Figure 2.5
Example of pre-dosed chioroquine plate.
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returned back to the jar and incubated for several more
hours before repeating the procedure with another control.
If schizonts were seen in the control the test was
continued as follows: as many microscope slides as the
number of tested drugs were made and identified with the
date, the sample ID code and the drug name. All the plates
were removed from the jar and left resting at an angle of
45° in a safety cabinet until the rbcs had settled on the
bottom of the well. The CM was aspirated from each well and
a drop (20 ILl) of the cells spread on a slide, with the
same tip, as a small square. All squares for the same drug
were placed on a single slide in two lines of four squares
each (Fig. 2.5a). After air-drying for at least 48 hours,
the RBCs were stained with Giemsa 2% for 30 minutes.
The slide reading was carried out in the same way as for
thick films (see section 2.2) by counting 200 parasites and
noting how many were schizonts. Squares that showed no
schizonts were considered negative because the drug
concentration present in this well inhibited development of
the parasites. This concentration is the MIC (minimum
inhibitory concentration) and indicated if the sample was
sensitive or resistant to the drug(s).
2.5.1 Plasmodium falciparum
In this study 4 anti-malarial drugs, amodiaquine
(AMQ),quinine (QtJI), mefloquine (MQ) and chloroquine (CQ),
were tested.
Forty samples were tested but only 18 produced results.
For the limits of resistance and sensitivity see table
2.5.1.
2.6 Indirect immunofluorescence tests (IFATS)
To perform these tests the previously prepared antigen
slides (described below) were removed from the -70°C and
remained at RT for 30 minutes. Twenty tl of the patient
serum sample dilutions prepared in PBS Tween 20 and
positive and negative controls, were then applied to the
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WELL A	 WELL B	 WELL C	 UF.LI. I)
a______
i	 I	 I	 t	 I	 I	 II	
I	 I	 I	 I	 I
I,	 I	 I	 I	 J	 I
'I	 I	 I	 I	 I	 I	 I
I
I
___ [11111
WELL F.	 WELL F	 WELL C	 IELL H
Figure 2.5a
Layout of a microscope slide for reading of antimalarial
drug test.
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TABLE 2.5.1
CONCENTRATIONS LIMITS (junol/1 of blood) FOR ANTIMALARIAL DRUGS TESTED
IN VITRO.
(WHO, 1990)
	
TEST DRUG
	
SATISFACTORY	 INDICATION OF
RESPONSE	 RESISTANCE
COMPLETE SCHIZONT SCHIZONT GROWTH
INHIBITION AT	 AT
	
Anodiaquine	 0.4 or less	 0.8 or more
	
Quinine	 25.6 or less	 51.2 or more
	
tlefloquine	 (*)	 12.8 or more
	
Chioroquine	 0.8 or less	 1.6 or more
(*) Determination of critical concentration pending (on the
basis of comparative in vivo and in vitro tests).
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slides. Slides were incubated at 37°C for 30 minutes in a
moist chamber. Two washes with PBS (pH 7.2) were carried
out and the slides then covered with the optimum dilutions
(1/100) of goat anti-human conjugate (IgG-FITC). Following
incubation at 37°C for 30 minutes, two washes in PBS were
performed. Finally, they were stained with Evans blue 0.2%
in PBS for 5-10 minutes, mounted in 50% glycerol in PBS pH
7.2 and examined under an incident light fluorescent
microscope using a X40 objective.
All collected samples were tested by this technique.
2.6.1 Plasmodiurn falciparurn
A pool of Plasmodium falciparum isolates from the Brazilian
Amazon region was grown in vitro according to the technique
described in section 2.3 (Trager & Jensen, 1976).
Cultures with a 5% of schizontaemia were placed in 50 ml
centrifuge tubes and centrifuged at l000g for about 10
minutes. The SN was removed, the remaining cells washed
twice with incomplete CM and resuspended in complete CM
bringing up the HC up to 10%. Using a Haemobile, an
apparatus that allows the production of eight to twelve
drops of the same size and with homogeneous schizont
distribution, the slides were prepared. These slides were
air-dried, identified with a number for the batch and the
date of preparation. Then they were folded in paper
tissues, back to back and kept at -70°C.
In this study a screening test was performed with all serum
samples diluted at 1:20 in PBS-Tween 20. The positive ones
were retested in serial dilutions from 1:40 to 1:640.
2.6.2 Plasmodi urn vi vax
The inability to maintain P.vivax in long-term culture
required use of short-term culture (18-24 hours with 20%
human serum) for maturation of the parasite forms. The
antigens were therefore produced with a pool of the
following infected blood samples directly from the patient:
IEC-PV-184/92, IEC-PV-188/92 and IEC-PV-192/92. These
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samples originated from Para State, Brazilian Amazon
region.
A screening test was performed as for P.falciparum and the
positive samples were retested in serial dilutions.
2.7 Detection of antibodies against asexual forms of
Plasmodium falciparuzn by ELISA.
The antigen for this test was kindly provided by the
LaboratOrio de Soroepidemiologia do Instituto de Medicina
Tropical de São Paulo, tiniversidade de São Paulo -Drs.
Antonio Walter Ferreira and Sandra Avila.
The antigen was obtained from cultured Plasmodium
falciparurn (isolates from the Brazilian Amazon), ring forms
at about 10% parasitaemia, lysed with saponin and extracted
with zwitterionic detergent (ICN Flow).
The 96-well flat bottom microplates (NUNC) were coated with
the parasite antigen diluted in carbonate buffer O.06M pH
9.6 (5 pg/ml as recommended by the providers). The plates
were then incubated at 4°C for 18 hours and washed (X3) in
PBS 0.1M pH 7.2 and blocked with 5% non-fat powdered milk
in carbonate buffer at 37°C for 2 hours. The washes were
repeated and the diluted serum (PBS-Tween 20 and 1% non-fat
powdered milk, PBS-T-M) were placed in the appropriate
wells and the plate incubated at 37°C for 1 hour. The
dilution of conjugate at 1:5,000 in PBS-T-M (goat IgG anti-
human IgG-peroxidase - Jackson ImmunoResearch laboratories,
Inc.) was added and the plate placed at 37°C for another
hour. Washes were carried out as before and the chromogenic
substrate solution (10mg OPD + 25ml citrate buffer 0.1M
pH5.0 + 10 jLl H202
 30%) added. The plates were left at RT
for 30 minutes protected from the light and the reaction
was stopped with 2.5N sulphuric acid. OD was read at 492nm.
The Cut Off was determined for each plate by the mean of
negative controls plus 2 standard deviations (SD) of this
mean.
All samples were prescreened at a dilution of 1:20. The
positive sera were retested with serial dilutions from 1:20
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to 1:640.
2.8 Detection of antibodies against malaria sporozoite
species by ELISA
This ELISA protocol was described by Del Giudice, (1987),
and consists of antigen coated and uncoated plates for the
sample to be tested.
Coated plates were prepared by dispensing the antigen
(lp.g/ml in PBS pH 7.2 as recommended by the producer) on
each well of a 96-well flat-bottom plates (COSTAR -
E.I.A./R.I.A. plate, high binding) and incubating at 4°C
overnight. The uncoated plates were prepared by adding PBS
pH 7.2 to the plate wells and incubating as for coated
plates. The coated and uncoated plates, were blocked with
PBS-Tween 20 containing 5% non-fat powdered milk and
incubated at RT for 1 hour. They were then washed (X4) with
PBS-T and the horseradish peroxidase-conjugated goat IgG
anti-human IgG (Jackson ImmunoResearch laboratories, mc)
(1:1,000 in PBS-T-M) was added, and plates incubated at RT
for 1 hour. Finally, substrate solution (OPD, 0.4mg/mi in
citrate buffer 0.].M pH 5.0 containing 0.01% hydrogen
peroxide) was dispensed into the wells. Twenty minutes
after the latter step, the reaction was stopped by adding
2.5N H2SO4 . The OD was determined in a ELISA reader at
492 nm.
The final results were obtained from the difference between
the OD values of the coated and uncoated plates and the Cut
Of f was given by the mean of the negative controls plus 3
times the SD of this mean.
The serum samples were assayed in duplicate and first
examined at a 1:100 dilution as suggested by the provider
of the recombinant protein and/or synthetic peptides.
2.8.1 Plasmodium falciparum antigen for sporozoite ELISA
The antigen for P. falciparum was th recombinant protein
R32LR, was kindly provided by Dr. John Barnwell from
University of New York and Dr. Altaf Lal from CDC, Atlanta.
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The antigen is the recombinant peptide R32tet32 (consisting
of the sequence (NANP) 15-NVDP (NANP) 15NVDP, plus the first two
amino acids (leucine and arginine - LR) encoded by a
tetracycline-resistant gene read out-of-frame (tet32).
2.8.2 Plasmodium vivax antigen for sporozoite ELISA
A synthetic peptide (GDRADGQPA) 3 that is a nonpeptide
derived from the central regions of the prototype
Plasmodium vivax CS protein (Arnot et al., 1985 and
McCutchan et al., 1985) was used in this study as antigen.
Dr. Altaf Lal from CDC-Atlanta kindly provided the protein.
2.8.3 Plasmodium vivax - type 2 antigen for sporozoite
ELI SA
The 36-mer peptide (ANGAGNQPG) 3 was used as antigen for the
so-called Plasmodium vivax type 2 or variant VK 247.
The repeat unit of VK 247, as in Plasmodium vivax, was also
a nonapeptide, ANGAGNQPG, but differed from the reactive
repeat at six of nine amino acid (AA) positions, as
demonstrated by Rosenberg et al., 1989.
2.8.4 Plasmodium vivax - type 3 antigen for sporozoite
ELISA
Qari et al., (in press), have reported the occurrence of a
new malaria parasite in "P. vivax" infections in humans in
Papua New Guinea and Brazil. They also demonstrated that
this new "P. vivax-like" parasite is closely related to P.
simiovale.
The antigen used for this variant of Plasmodium vivax was
the peptide (APGANQEGGAA) 3 kindly provided by Dr. Altaf Lal.
2.8.5 Plasmodium malariae/ Plasmodium brasilianunz antigen
for sporozoite ELISA
A 16-mer peptide (NAAG) 4 representing the tetramer repeats
of P.malariae/P.brasilianum (Lal et al.,1988) was used as
antigen for these species of Plasmodium and it was kindly
synthesized by the peptide laboratory of the London School
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of Hygiene and tropical Medicine.
Lal et al.., (1988) had demonstrated a high degree of
similarity between the imxnunodominant region (IDR) of the
Cs gene of Plasmodium malariae and Plasmodium brasilianum,
and by comparison of the DNA sequence of both genes that
the Plasmodium brasilianum gene contains 58 and 6 copies of
the same major and minor repeats found in the Plasmodiurn
malariae gene.
2.9 Determination of haptoglobin levels in children
The haptoglobin assay was carried out with a Radial
Imxnunodiffusion (RID) kit (Serotec-England).
The 14-well plates contain an antiserum in agarose, which
had been adsorbed to the wells. The plates were taken out
from the fridge and left for 5-10 minutes at RT to allow
evaporation of any condensation on the gel. 5 p.1 of the
high, medium and low calibrators (the standards) were
applied into separate wells followed by the samples (neat
serum) into the remaining wells. After the sample
application, the plates were placed in separate lids which
were tightly closed and stored at RT for 72 hours, which is
the required diffusion time. As the ring diameter is
temperature-dependent incubation was at 22°C.
The precipitated ring was measured to the nearest 0.1mm
with standard scale provided by the maker.
To calculate the haptoglobin concentration of test samples,
a graph was constructed from the results of the standards
as follow: on the horizontal axis (abscissa) the antigen
concentration of the three standards were plotted and on
the vertical axis (ordinate) the squared diameter of their
precipitation rings produced by the three calibrators.
Then, a line of best fit to the three points was drawn and
the tested protein concentrations could be determined from
this reference line. This test was performed on one hundred
serum samples from children, who were resident in the study
areas.
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2.10 The Haskin method for detection of chi.oroquine in
urine
This qualitative assay was performed as described by
Haskin, (1958). l.5m1 of urine were mixed with 300 xl 10%
sodium chloride and l.5m1 chloroform. Then mixture was
vortexed and then centrifuged at 2000 rpm for 5 minutes.
The chloroform layer was removed and mixed by shaking with
150 11 of methyl orange solution. The presence of
chloroquine in the urine sample was detected by the
appearance of a definitive yellow colour in the chloroform
layer.
METHYL ORANGE SOLUTION consisted of: 100mg methyl orange,
5mg boric acid and lOOmi dH 2O, and was prepared by vigorous
shaking these reagents and leaving them to stand overnight
before filtering and storage at 4°C.
250 urine samples were tested, being 150 from residents in
Serra do Navio and 100 from residents in the control areas.
2.11 Quantification of chioroquine by ELISA
The ELISA assay for detection and quantification of
chioroquine in human urine and serum was described by
Shenton et al., (1988) and Witte et al., (1990). In this
study the ELISA developed by Witte et al., (1990) was
applied. It is based on the monoclonal antibody (MoAb which
recognises the 4-amino-7-chloroquinoline with specificity
for the chloroquine molecule (F149-12).
The kits were provided by Koninklijk Instituut Voor de
Tropen, Amsterdam, The Netherlands.
The assay consists of coating the microtest plate (COSTAR -
E.I.A./R.I.A. plate, high binding) wells with 100 ).Il of the
MoAb F149-12 (1:200 in PBS), and incubating at RT for 2
hours. One quick wash with PBS pH 7.2 with 0.05% Tween-20
followed by two 1 minute washes was performed. 50 gLl of
serum diluted 1:100 in PBS-T or urine in a serial dilution
of 1:10, 1:100 and 1:1,000 were added to each well and
mixed with 50 ILl of a dilution (1:100 in PBS-T-1% BSA) of
a peroxidase-labelled antichioroquine antibody (CQ-7), and
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the plate incubated at RT for 1 hour. Finally, the plates
were washed (1 quick wash and two 1 minute washes), 100 .tl
of substrate (0.5mg/mi OPD in phosphate/citrate buffer pH
5.0, 0.3% hydrogen peroxide) were added to each well and
the reading was carried out after 30 minutes in a
microtitre plate reader at 492nm.
A standard curve (Fig. 2.10) was produced for choosing the
best dilution for the conjugate. The procedure consisted of
coating the plate with the MoAb as described above. A
serial dilution of 11 concentrations of chloroquine
(0.156ng/mi to 160 ng/ml) was applied to the rows 2...12,
starting from the lowest concentration. Then 50 JLl of 4
dilutions (1:200, 1:100, 1:50 and 1:25) of the CQ-7
(conjugate) were added to the rows A...H (each dilution
into two rows) starting from the lowest concentration and
were then mixed with the chioroquine solutions. The plate
was incubated at RT for 1 hour, washed as described above.
100 ).t1 of the substrate were added to each well, the plate
incubated at RT, protected from the light, for 30 minutes
and read in a plate reader at 492 nm.
2.11.1 Urine
The urine samples were used in the follow dilutions: 1:10,
1:100, 1:1000 in PBS-T.
The urine samples were from the same individuals who had
serum samples tested.
2.11.2 Serum
The serum samples were used at 1:100 in PBS-T. All serum
samples collected from residents in the study areas were
tested.
2.12 Collection of adult and immature forms of mosquitoes
of Genus Anophelas
This was carried out 4 times, twice in 1990 and twice in
1991, in the wet and dry seasons for about 20 days on each
occasion. Different points (sampling places) were chosen
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within each study area (SNV, CAB, PT and ARR) and in the
forest adjacent to these areas.
2.12.1 Adult forms
All sampling places were visited for at least three days
each time that the work was carried out, by a group of 4
people. Catches were made at periodomestic sites (indoors
and outdoors) in the residential areas and with light traps
(Shannon and CDC) in the forest. Collection periods were
18-21 hours and at least once in each study area a 12 hour
collection was made (18-6). Mosquitoes were collected from
bare legs, using an aspirator and flashlight (fig. 2.12.1).
The group had a rotating catch timetable for preventing a
bias of data due to personal differences in attraction to
catchers and their skill. In the Serra do Navio area,
captures were only made in the adjacent forest. The
mosquitoes collected were separated at the time of their
collection into maximum groups of ten, per sampling
place/time/catch type, in glass tubes.
2.12.2 Immature forms
The collections of immature forms was carried out using
dippers (50m1 water) in all water collections (fig.
2.12.2): river edges, flooded forest (swamps), pools,
creeks, small rivers, ponds, arboreal and epiphytic plants
belonging to the Bromeliaceae family, around all study
areas. The collection period was: 6-10 am.
All specimens collected were placed into separate tubes
containing the breeding site water, split into different
stages.
2.13 Identification of adult mosquitoes and larvae
The identification of both forms of anophelines, adult and
larvae, was carried out by using the identification keys
for adult mosquitoes and anopheline larvae (Faran &
Linthicum, 1981).
The adult specimens were examined dead. The specimen can be
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Figure 2.12.1
Collection of mosquitoes on bare legs, using an aspirator
and flashlight
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Figur. 2.12.2
Examples of collection sites for immature forms of
Anopheles mosquitoes.
97
observed either placed on a microscope slide and moved up
and down, right and left using entomological forceps and/or
needles, or as a pinned specimen that allows it to be moved
by rotation, with up and down movements. In both cases the
specimen was observed under an entomological microscope.
For reaching the species identification the main
characteristics were observed and entered in the
identification key.
The anopheline larvae were identified alive or dead, and in
this study both types of identification were made. In both
cases, the specimen was placed on a microscope slide
containing a drop of water to prevent drying. With
entomological forceps and/or needles and under a light
microscope using X40 objective their main features were
observed and entered into the identification key to reach
the anopheline species.
2.14 Mounting of adult mosquitoes and larvae
2.14.1 Adult forms
In this study two methods were used for mounting adult
mosquitoes: in the first, the specimen was killed in a
killer-tube containing vapour of ethyl acetate and then
pinned with a special entomological pin (No.0) in the
region of the thorax with the head upright. Two labels were
prepared on card sheet as rectangles of 1.3 X 0.5 cm, one
containing information about the identification such as:
name of species, date and who identified it; the other
about the catch, where, when and by whom. Both rectangles
were also pinned by the same pin of the mosquito specimen
and then was placed in an entomological box for storage.
In the second, after the specimen was killed as described
above, it was fixed with nail varnish on the narrowest
point of a small triangle. It was fixed on the lateral
thorax with the head leftward of the triangle. The labels
were prepared as already described above and the mosquito
labelled and stored in an entomological box.
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2.14.2 Immature forms
The specimens were dropped into hot water for killing and
then transferred into a series of increasing dilutions of
alcohol for dehydration (70% alcohol for about 5 minutes,
90% alcohol for about 5 minutes and finally absolute
alcohol for 5 minutes). From the alcohol the specimens were
placed into xylene for at least 5 minutes. After that the
specimen was transferred to a microscope slide where it was
arranged with the head forward and the tail near to the
mounter and a covergiass of 20 mm with an appropriate
amount of Canada balsam was then put onto the larva. The
label on the right side of the slide contained the data for
the specimen and that on the left had the name of the
specimen. The slide was then placed in an oven for about
two weeks at 50°C to be dried.
2.15 Determination of the characteristics of breeding sites
The characteristics of the breeding sites in all study
areas were established by observing and/or measuring their
size, water pH, water temperature, ambient temperature mean
during the collection period, existence of vegetation on
the bed, surface and/or edge, type of water, exposure to
sunlight, type of stream (weak, strong, absent) and its
direction, connection with rivers or other water
collections, their distance from the nearest house(s).
2.16 Determination of sporozoite rates by salivary glands
detection
The determination of the sporozoite rates was performed on
anaesthetized mosquitoes with chloroform or precooled
specimens, under a Zeiss entomological microscope by the
dissection of their 3 salivary glands. The method applied
in this study was the same used by the SUCAN entomological
team, which consists of placing the specimen in a drop of
physiological solution (saline) on a microscope slide.
Using appropriate entomological forceps and/or straight and
curved needles, the mosquito head was separated from the
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body very carefully in order to allow the salivary glands
to come out in the saline without being destroyed or
damaged. If this was successful the salivary glands were
transferred to another microscope slide containing a drop
of a diluted methylene blue solution and a cover glass was
placed on the drop and pressed to rupture the glands. In
the ruptured glands it was possible to observe the movement
of the sporozoites and to count them (heavy or light
infection) under a light microscope using oil immersion
with X100 objective.
2.17 Determination of sporozoite species in Anopheles by
ELISA
The kits used to perform this test were obtained through
Dr. Robert A. Wirtz, Walter Reed Army Institute of Research
and they are produced by Kirkegard & Perry Laboratories.
The method was developed to detect Plasmodium species CSP
in malaria infected mosquitoes (Wirtz et al., 1987).
The assay is a "sandwich " ELISA and based on the
adsorption of the capture MoAb to the wells of "U" shaped
well flexible microplate. After the binding of the MoAb to
the plate by incubating at RT, the well contents were
aspirated and blocking was carried out by adding blocking
buffer (appendix 4). Aliquots of ground mosquito thorax
(in blocking buffer containing Nonidet-40 -NP-40) were
placed in the wells. At the same time positive and negative
controls were added to their specific wells. The incubation
required 2 hours, and then the contents were aspirated and
the wells washed. The appropriate peroxidase-labelled MoAb
was added to the wells and the plates were incubated for 1
hour at RT. Aspiration of contents and washes were carried
out again and the substrate solution (ABTS + hydrogen
peroxidase 3% v/v) was added. The reading of the plates was
carried out either visually or at 405-414 nm using an ELISA
reader 30 or 60 minutes after the substrate solution had
been added.
Preparation of the ground mosquitoes: the head-thorax of
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each specimen was separated from the body by cutting it out
with a special entomological scissor. The head-thorax was
placed in a labelled 1.5m1 microtube and ground with a
pestle in 50 ptl of blocking buffer containing NP-40. The
pestle was washed with the same buffer and the rinse
collected in the tube to reach a final volume of 250 JLl.
The positive mosquitoes for Plasmodium falciparum and
Plasmodium vivax were retested to confirm and estimate the
amount of Cs protein per mosquito.
Table 2.17 shows the material used in the development of
this technique.
As negative controls, male Anopheles or Culex were used.
The same batches of capture MoAb, peroxidase-labelled MoAb
and positive controls were used in all tests.
Not all mosquito specimens were tested for P. malariae.
The C.O. was selected as twice the mean of negative
control.
2.18 Studies in other localities
2.18.1 The prevalence of mutations associated with
pyrimethamine resistance
42 blood samples from individuals in the Amazonian region
with falciparum malaria infection were tested for the
presence of DHFR-mutations following the protocol described
by Peterson et al., (1990) which consists of the extraction
of DNA from 300 .tl of blood samples cryopreserved directly
without in vitro cultivation. The thawed samples were then
centrifuged and resuspended in lml of TSE(100 mM NaC1, 20
mM Tris, 50 m14 EDTA, pH 8.0), centrifuged again, and
resuspended in imi of TSE containing 0.15% saponin. The
samples were then incubated for 2-10 minutes at RT and
parasites were recovered by centrifugation, resuspended in
500 pi of TSE and lysed by addition of SDS and NaC1O 4 to
give a final concentration of 1% and 0.5 M, respectively.
The DNA extraction was performed with phenol:chloroform
(2X) and chloroform (1X), and the DNA precipitated with two
10].
TABLE 2.17
MATERIAL USED IN THE DETECTION OF SPOROZOITES IN ANOPHELES MOSQUITOES
BT ELISA
MATERIAL P. falciparum P. vivax P. malariae P.vivax type 2
(VK24 7)
MoAb of	 Pf	 Pv210	 Pm453	 Pv247-499
capture
conjugate	 Pf-PER	 Pv210	 Pm453-PER	 Pv247-PER
-PER
positive	 Pf	 Pv210	 Pm	 VK247
control
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volumes of ethanol.
The mutation-specific polymerase chain reaction (PCR) assay
was described by Peterson et al., (1991) and was performed
by the use of diagnostic primers DIA-3 (3'-specific for
Ser-108), DIA-9 (specific for Thr-108) and DIA-12 (specific
for Asn-l08) conjugated to the counterprimer SP1. For DNA
amplification, 45 cycles were used consisting of
denaturation for 30 sec(94°), renaturation for 45 sec(56°)
and extension for 45 sec(74°). Electrophoresis of the
amplified products was carried out in agarose gels
containing 1% standard agarose plus 2% NuSieve low melting-
point agarose (FNC Bioproducts, Rockland, ME). The PCR
products were stained with ethidium bromide and then
photographed.
In order to avoid any contamination 3 main measures were
adopted: 1- a sample of unparasitized blood was processed
in parallel with each sample of infected blood; 2- the
processing of blood samples and DNA preparations were
carried out in different parts of the laboratory from that
used to analyze the PCR reactions; and 3- separate sets of
pipettes were used for the analysis of the PCR products.
2.18.2 Paragominas and Jacunda cities, Para State
2.18.2.1 Polymorphism in the circumsporozoite protein of P.
falciparum and P. vivax.
In two trips to Paragominas (1990 and 1991) and one to
Jacundá. (1991), blood samples infected with malaria
parasites were collected.
From each individual epidemiological data and a blood
sample were collected. Blood films (thick and thin smears)
were made and the morphology of parasites and the
parasitaemia were recorded.
The blood samples were then cryopreserved either with
glycerolyte (see section 2.4) or without any
cryopreservation solution for further DNA studies.
The genomic DNA of the samples was isolated and amplified
by PCR, and the PCR products hybridized witth the CS
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protein gene probe and sequenced. The amplification was
carried with a polymerase chain reaction using specific
oligonucleotides as amplifying primers (AL 60 and AL 61 for
P. vivax, and AL 58 and AL 59 for P.falciparum - appendix
5). The amplified fragments were purified, digested with
EcoRI and BaniHI, cloned into the Bluescript plasmid, and
transformed into Escherichia coli. The hybridization
analysis used specific oligonucleotide primers (AL 114 and
116 for P. vivax, and AL 52, 53, 3, 9 and 164 for
P.falciparum - appendix 5). Cs gene-specific primers were
used to determine the nucleotide sequence of the CS gene by
the dideoxynucleotide method (Sanger et al., 1977).
2.18.2.2 Polymorphism in the ookinete vaccine antigen
(Pfs25) of Plasmodium falciparum
Fourteen blood samplesinfected with P. falciparura from
individuals from Paragominas were included in this study.
The Pfs25 antigen gene of the parasites was amplified from
the genomic DNA (Qari et al.,1991) using specific
oligonucleotide sequences as described above. The amplified
DNA fragment (654-bp) was isolated and cloned, and one
Pfs25 recombinant per isolate was sequenced.
2.19 Statistical analysis
The statiscal analysis was performed using the computer
programme Epi Info - STATCAL Epi calculator - for obtaining
the Chi-square and p-values with Yates correction.
For the comparison of the two means the t-test (Student test)
was applied.
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CRAPTER 3: RESULTS
3.1 Prevalence of infection
The prevalence of malaria infection and the grade of
endemicity for all study areas is shown on table 3.1.
3.1.1 Target area: SNV
The study carried out in SNV was longitudinal, where we
took 1 sample/year from each individual during 3 years,
1989-1991. The first sample comprised 260 individuals, the
second 229 and the third 217, 15.6%, 13.7% and 13.0% of the
total population (1667 in 1990), respectively.
The distribution of this population by age and sex is shown
in Fig. 3.1.1
In all three samples there were no records of positive
slides neither for falciparum malaria infection nor for
vivax malaria infection. As shown in table 3.1, the spleen
rate of the group aged 2-9 years as well as for adults was
zero. Based on these data Serra do Navio was classified as
a non-endemic area for malaria infections.
3.1.2 Control areas: CAB; PT; APR
As shown in table 3.1 the sample sizes for each control
area varied. Based on the populations of 1990, the samples
were: 41.1% of the population for CAB, 34.8% for PT and
61.2% for ARR.
There was little variation within the populations with
respect to standard of living, type of house or basic
health service.
The control areas were similar in many respects, except
that PT has electricity and a better standard of living
since the majority of the workers in this control area work
for the ICOMI Company.
The distribution of the population of all control areas by
age and sex is shown in Fig. 3.1.1. for comparison between
them.
The prevalence was calculated in relation to the population
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TABLE 3.1
PREVALENCE or )1ALARIA INTECTIONS IN THE STUDY AREAS.
	
STUDY	 POPULATION SAMPLE SIZE POSITIVITY	 PREVALENCE
	
AREAS	 (1990)	 (%)
sNv	 1667	 1- 260 (15.6%) 	 0	 -
2- 226 (13.6%)	 0	 -
3- 215 (12.9%)	 0	 -
CAB	 482	 198 (41.1%)	 58	 29.3
PT	 459	 160 (34.8%)	 10	 6.2
ARR	 80	 49 (61.2%)	 10	 20.4
IND	 124*	 27 (21.8%)	 11	 40.7
SNV - Serra do Navio (target area)
CAB - Colonia Agua Branca
PT - Porto Terezinha
APR - Arrependido
IND - Indigenous group
* Data from FUNAI
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SERRA DO NAVIO
Pigure 3.1.1
Distribution of the populations of all study areas by age
and sex.
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of 1990 by the number of positive slides for malaria
parasites at the time of the sample collection. The figures
were: CAB - 29.3%; PT - 6.2% and ARR - 20.4% (table 3.1).
In CAB and PT more infections were caused by P. falciparurn
than by P. vivax, whereas in ARR both had the same
prevalence (table 3.1.2).
The spleen rate of the 2-9 year old age group for the three
control areas were: CAB - 18.2% (12/66), PT - 6.9% (4/58)
and ARR 11.1% (2/18). The parasite rate determined for the
same age group was: CAB - 22.7% (15/66), PT - 1.7% (1/58)
and ARR 16.7% (3/18).
Both rates, in accordance with WHO classification for
endemicity (see section 1.12.1.1), classified the areas as
follows: mesoendemic (CAB and ABR) and hypoendemic (PT).
Table 3.1.2 shows the results for malaria parasites (P.
falciparum, P. vivax and mixed infection) and its
relationship with sex, age, spleen rate, malaria history
and use of chioroquinised salt and/or individual protection
such as bednets and domestic insecticide. The statistical
analysis of the figures shown in table 3.1.2 show no
correlation between malaria history and either sex or age
in the control areas (p > 0.05). There was a significant
correlation between malaria and spleen rate (p< 0.05) for
all areas, but this was strongest for ARR (p= 0.0004). No
correlation was demonstrated between prevalence of malaria
and use of chioroquinised salt in the two areas (p > 0.05
for both, CAB and PT) where 44.4% and 96.9% people had
claimed regular use of this salt. For the correlation
between prevalence of malaria and use of individual
protection (bednet and/or domestic insecticide), no
correlation was found in PT (p > 0.1), but in CAB a
siginificant correlation was demonstrated (X 2= 4.79 and p=
0.0285557).
The results shown in table 3.1 give a clear difference in
the prevalence of malaria infections in PT as compared to
the other control areas.
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3.1.3 Indigenous group in Amapá State
The sample which was 21.77% of the total population of the
two studied communities (aldeias) had a prevalence of
malaria infection of 40.7% (11/27) at the time of
collection (table 3.1). P. falciparum infection had higher
prevalence (90.9%) than P. vivax (9.1%) among this sample
(table 3.1.2). The distribution of the sample population by
age and sex is shown in Fig. 3.1.1.
The spleen rate was 60% among the group aged 2-9 years and
17.6% among the adults. The parasite rate for the same
groups was 66.7% and 29.4%, respectively. This area was
thus classified as an hyperendemic malaria area.
As for the three control areas a significant correlation
was found between malaria history and spleen rate (p =
0.010)
3.2 Cultivation in vitro
3.2.1 Plasmodium falciparuzn
18 (32.73%) out 55 falciparum infected blood samples were
grown with success, since they were maintained for several
cycles. The success of culturing samples from the field
depends on the level of technical skill as well as the
amount of anti-malarial drugs that the samples contain.
3.2.2 Plasmodiuzn vivax
All samples with high parasitemia and rich in trophozoite
forms (8) were grown for a short-time only to allow the
maturation of schizonts.
3.3 Drug tests
Of 17 falciparum malaria infected blood samples tested for
their sensitivity to antimalarial drugs, 16 were from the
control areas and 1 from the indigenous area. Of the 16, 12
were from CAB (75%), 2 from PT (12.5%) and the other 2 from
ARR (12.5%).
The amodiaquine resistance (AMQR) among the samples tested
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had a rate of 41.2% (7/17), while chloroquine resistance
(CQR) was 82.3% (14/17). There was no sample resistant to
either quinine or mefloquine. All AMQ-R samples were also
resistant to chioroquine.
No correlation was found between the ANQR and use of
chioroquinized salt in both cases tested: all samples (X2=
0.22 and p= 0.638) and CAB samples (X2= 0.02 and p= 0.897).
As for ANQ, there was no correlation between CQR and use of
chloroquinized salt either in the samples from CAB alone or
in all samples tested.
The 2 patients from ARR and the one from IND had not used
chloroquinized salt as a preventive measure and all three
samples were CQ-R, while the two samples from PT !had stated
regular use of this salt and their samples were also CQ-R.
All CQ-S samples were from CAB. Of the 9 CQ-R samples from
CAB, only 3 reported use of chioroquinized salt, while of
the 3 CQ-S only one reported its use.
Table 3.3 summarises these data.
We had also carried out some more drug tests with samples
from individuals living out of our study areas. They were
not included in this study, but we had found chioroquine
and amodiaquine resistance and also few quinine resistance
among their samples.
3.3.1 Plasmodiuzn falciparum
3.3.1.1 modiaquine
17 blood samples were tested for amodiaquine sensitivity:
10 were sensitive (58.83%) and 7 resistant (41.17%). These
results are shown in table 3.3 where the MIC for each
sample is expressed in J.Lmol/l blood.
Among the samples from CAB, 6 were amodiaquine resistant
(AMQ- R) and the remaining 6 were amodiaquine sensitive
(AMQ-S). Of those from PT (2) were ANQ-S; one of two from
ARR was ANQ-S and the other ANQ-R. The only sample from the
indigenous group was ANQ-S.
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TABLE 3.3
RESULTS OF THE DRUG TESTS OF THE SAMPLES FROM THE STUDY AREAS.
MIC - (imol/l of blood)
	
SAMPLE CODE	 STUDY CHS	 AI4Q	 QUI	 MQ	 CQ
AREA
	IEC-PF-07/89	 CAB	 no	 0.2 CS)	 1.6 CS)	 0.4 CS)	 3.2 (R)
	
IEC-PF-08/89	 CAB	 no	 0.2 (S)	 3.2 (S)	 0.4 (S)	 3.2 (R)
	
IEC-PF-12/89	 CAB	 no	 0.2 CS)	 1.6 (S)	 0.4 CS)	 0.4 (S)
	
IEC-PF-33/89	 CAB	 yes	 0.8 (R)	 6.4 CS)	 0.4 (S)	 6.4 (R)
	
IEC-PF-34/89	 CAB	 yes	 0.4 CS)	 6.4 CS)	 0.4 CS)	 6.4 (R)
	
IEC-PF-38/89	 CAB	 no	 0.4 CS)	 3.2 (S)	 0.4 (S)	 0.8 CS)
	
IEC-PF-45/90	 AER	 no	 0.4 (5)	 6.4 CS)	 0.4 CS)	 3.2 (R)
	
IEC-PF-49/90	 PT	 yes	 0.4 (5)	 6.4 CS)	 0.4 CS)	 3.2 CR)
	
IEC-PF-53/90	 ARR	 no	 3.2 (R)	 6.4 CS)	 0.4 CS)	 1.6 (R)
	
IEC-PF-54/90	 CAB	 no	 0.8 (R)	 1.6 (5)	 0.4 (S)	 1.6 (R)
	
IEC-PF-58/ go 	CAB	 yes	 0.8 CR)	 1.6 CS)	 0.8 CS)	 1.6 (R)
	
IEC-PF-59/90	 CAB	 no	 3.2 (R)	 6.4 CS)	 0.4 (S)	 1.6 (R)
	
IEC-PF-05/91	 CAB	 no	 1.6 (R)	 3.2 (S)	 0.4 CS)	 1.6 CR)
	
IEC-PF-06/91	 CAB	 no	 0.2 (5)	 3.2 CS)	 0.4 (5)	 0.8 (S)
	
IEC-PF-07/1	 CAB	 no	 0.8 (R)	 6.4 (S)	 0.4 CS)	 3.2 (R)
	
IEC-PF-15/91	 IND	 no	 0.2 (S)	 12.8 (S)	 3.2 (S)	 1.6 (R)
	
IEC-PF-48/2	 PT	 yes	 0.4 (S)	 6.4 (S)	 0.4 CS)	 3.2 CR)
TOTAL R	 -	 -	 7/17	 0/17	 0/17	 14/17
(41.2%)	 (82.3%)
MIC - minimal inhibitory concentration;
CHS - chioroquinised salt
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3.3.1.2 Quinine
All 17 samples tested were quinine sensitive (QUI-S).
Results are shown in table 3.3.
3.3.1.3 Mefloquine
As for quinine, 100% of the samples were mefloquine
sensitive (MQ-S). Table 3.3 shows the results.
3.3.1.4 Chioroquine
Among the 17 samples tested for chloroquine sensitivity 3
(17.6%) of them were chloroquine sensitive (CQ-S) and 14
(82.3%) were chioroquine resistant (CQ-R). 9 out of 12
samples (75%) from CAB were chloroquine resistant (CQ-R)
and both samples (100%) from PT and ARR were also CQ-R. The
only sample from the indigenous group was also CQ-R (100%).
3.4 Indirect iinmunofluorescence tests (IFATs)
3.4.1 Plasmodium falciparum
The seropositivity for this Plasmodium species was higher
than for Plasmodium vivax in all study areas.
3.4.1.1 Target area (SW)
In the target area (SNV) there was a seropositivity for
this species of Plasmodium of 12.3% (32/260) and 19
individuals were positive on one collected sample, 12 on
two and 1 on all three.
Table 3.4.1.1 shows the distribution of the titres of
positive samples among the population by age group. More
than 50% of the positive samples have a positive titre of
1:20, 19.3% of 1:40, 16.1% of 1:80 and 3.2% each of 1:160
and 1:640. There was no positive sample with a titre of
1:320.
71% of the positive samples were from individuals older
than 14 years.
There was significant correlation between malaria history
and antibody to P. falciparum detected by the IFAT (X2 =
4.20 and p< 0.05)
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TABLE 3.4.1.1
RESULTS OF THE SEROLOG! OF SNV
a.IFAT - P.falciparum / P.vivax
TESTED	 (-yE)	 RECIPROCAL TITP1S
	 (+VE)	 *GRTp
SA1LES	 PT/PV	 20 40 80 160 320 640	 (%)	 )IJI TITRE
Pr/Pv	 PT/Pv
	0-1	 3	 3/3	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 -/-
	
2-4	 32	 30/30	 2/0	 0/0	 0/0	 0/0	 0/0	 0/0	 6.2/0	 4.3/-
	
5-9	 39	 35/37	 2/2	 1/0	 0/0	 1/0	 0/0	 0/0	 10.2/5.1	 4.6/4.3
	
10-14	 41	 38/41	 2/0	 1/0	 0/0	 0/0	 0/0	 0/0	 7.3/0	 4.6/-
	
14	 145	 123/137	 12/2	 4/3	 5/3	 0/0	 0/0	 1/0	 15.2/5.5	 5.2/5.4
	
!o1.	 260	 229/250	 18/4	 6/3	 5/3	 1/0	 0/0	 1/0	 11.9/3.8	 -
- - - - -
b.ELISA - P.falciparum
	
AGE	 TESTED	 (-yE)	 RECIPROCAL TITRES	 (+VE)	 *39TP
	
GROUP	 SA1GLE3	 20	 40 80	 160 320 640	 (%)	 3KAN TITRE
	
0-1	 3	 2	 1	 0	 0	 0	 0	 0	 33.3	 4.3
	
2-4	 32	 19	 11	 1	 0	 1	 0	 0	 40.6	 4.6
	
5-9	 39	 20	 16	 3	 0	 0	 0	 0	 48.7	 4.4
	
10-14	 41	 28	 11	 2	 0	 0	 0	 0	 31.7	 4.5
	
> 14	 145	 112	 27	 5	 0	 0	 1	 0	 22.7	 4.6
	
TOTAL	 260	 181	 66	 11	 0	 1	 1	 0	 30.4	 4.5
- - - - - -
(-IrE) - negative;
(+VE) - positive
PF - P. falciparum;
PV	 - P. vivax
* log2
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3.4.1.2 Control areas (CAB, PT and APR)
For CAB the seropositivity for P. falciparum was 46.2%
(91/106). The distribution of positive samples by titres is
shown in table 3.4.1.2. 73.6% of the positive individuals
were adults (>14 years old). The correlation between
malaria history and positive IFAT for P. falciparum was
significant for all groups: children alone, adult alone and
all together. As shown in table 3.4.1.2a there was also
significant correlation between spleen rate and positivity
for IFAT for P.falciparuni for the group of children alone,
for all groups but no correlation was found within the
adult group. The correlation between IFAT for P. falciparum
and positive slides was significant for both groups,
children and all ages (table 3.4.1.2a)
Porto Terezinha area had a seropositivity rate for
falciparum malaria of 35% (56 positive samples). As for
CAB, the positivity is concentrated in the adult group
(67.8%)
Distribution of positivity by titres and age group is shown
in table 3.4.1.2b.
Table 3.4.1.2c sununarises the results of the statistical
analysis and shows the correlation between seropositivity
and malaria history, spleen rate and positive slide for the
group that includes all ages. When analyzed in isolation,
neither the children nor the adults show correlation
between any of the analyzed variables.
For ARR a seropositivity for P. falciparum by IFAT of 26.5%
was found. The positivity was higher among the adult group
where the rate was 76.9%.
The distribution of the positive samples by titres and age
groups is shown in table 3.4.1.2d.
As shown in table 3.4.1.2e only the correlation between
seropositivity, and history of malaria within the group of
all ages demonstrates significance.
As final analysis, the correlation between the
seropositivity with this test and all three variables (MH,
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TABLE 3.4.1.2
RESULTS OF THE SEROLOGY OF CAB
a.IFAT- P.falciparum X P.vivax
AE TESTED	 -VI	 RECIPROCAL TITERS	 +VE *E(gTpc
.0UP SAIa'LES PF/PV 20	 40	 80	 160	 320	 640	 (%)	 MEAN TITER
PF/PV	 PV/PV
0-1	 3	 1/2	 1/0	 0/0	 1/1	 0/0	 0/0	 0/0	 67/33	 5.3/6.3
2-4	 30	 24/23	 0/3	 0/0	 2/3	 1/0	 1/1	 2/0	 20/23	 7.8/5.7
5-9	 35	 26/27	 1/5	 1/2	 2/0	 3/0	 1/1	 1/0	 26/22	 6.8/5.1
10-14	 19	 12/16	 3/2	 0/0	 0/1	 3/0	 1/0	 0/0	 36/15	 6.2/5.0
> 14	 110	 43/68	 16/12	 3/7	 9/14	 10/6	 15/2	 14/1	 61/38	 7.0/5.5
T0	 197	 106/136	 21/22	 4/9	 14/19	 17/6	 18/4	 17/1	 46/31	 6.9/5.7
b. ELISA - P. falciparum
AGE TESTED	 -yE	 RECIPROCAL TITRES	 +VE *GEQ)4Tp,IC
GROUP SAMPLES	 20 40 80 160 320 640 (%) MEAN TITRE
3	 2	 1	 0	 0	 0	 0	 0	 33.3	 4.3
2-4	 30	 13	 15	 2	 0	 0	 0	 0	 56.7	 4.4
5-	 35	 26	 6	 1	 1	 1	 0	 0	 25.7	 4.9
10-14	 19	 6	 11	 0	 1	 0	 0	 1	 68.4	 4.8
> 14	 110	 51	 37	 3	 8	 6	 3	 2	 53.6	 5.3
TOTAL	 197	 98	 70	 6	 10	 7	 3	 3	 50.2	 5.1
__ __- = = = = =
—VE - negative;
+VE - positive
- P. falciparum;
PIT - P. vivax
* log2
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TABLE 3.4.1.2a
RESULT OF TEE STATISTICAL ANALYSIS OF TEE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. falciparum AND MALARIA HISTORI, SPLEEN RATE AND POSITIVE
SLIDE.
COLONIA AGUA BRANCA (CAB)
CORPELM!ION	 AGE GROUP	 CEI-3QUBE	 p VALUE	 SIGNIFICANCE
children	 14.45	 0.0001	 ye.
IFAT 31
	
adult	 5.40	 0.02	 ye.
	
all	 21.67	 0.0000
children	 12.46	 0.0004	 ye.
IFAT 31 SR
	
adult	 0.39	 0.53	 no
	
all	 7.00	 0.006	 ye'
children	 13.60	 0.0002	 yea
IFATXSL
	
adult	 2.74	 0.1	 no
	
.11	 14.23	 0.0002	 ye.
MH - malaria history
SR - spleen rate
SL - positive slide
children - (0 - 14 years)
adult - (<14 years)
Chi-square and p values used with Yates correction.
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TABLE 3.4.1.2b
RESULTS OF THE SEROLOGY OF PT
a.IFAT- P.falciparura / P.vivax
TESTED	 (-yE)	 RECIPROCAL TITRES	 (+VE) *GRTp,
ou	 SAMPLES PF/PV 20	 40	 80	 160	 320 640	 (%)	 MEAl TITER
PP/PV	 PF/Pv
0-1	 0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0
2-4	 19	 14/17	 0/0	 0/1	 2/1	 3/0	 0/0	 0/0	 26/10	 6.9/5.8
5-9	 37	 31/37	 5/0	 1/0	 0/0	 0/0	 0/0	 0/0	 16/0	 4.5/-
10-14	 30	 23/26	 1/2	 3/1	 1/1	 1/0	 1/0	 0/0	 23/13	 6.0/5.1
> 14	 66	 28/48	 5/3	 5/5	 6/6	 8/1	 4/1	 1/2	 58/27	 6.8/6.2
TO1.	 152	 96/128	 14/5	 9/7	 9/S	 12/1	 5/1	 7/2	 37/16	 6.6/6.0
- - -
b.ELISA - P.falciparum
AGE	 TESTED	 (-VE)	 RECIPROCAL TITERS	 (1-VE) *GETPC
	
GROUP	 20	 40	 80	 160 320	 640	 (%)	 MEAN TITRE
	
0-1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 -
	
2-4	 18	 11	 5	 0	 0	 2	 0	 0	 38.9	 5.2
	
5-9	 37	 22	 13	 0	 1	 0	 1	 0	 40.5	 4.7
	
10-14	 29	 16	 12	 0	 0	 0	 1	 0	 44.8	 4.6
	
> 14	 64	 26	 27	 2	 1	 3	 0	 5	 59.3	 5.3
TOTAL	 148	 75	 57	 2	 2	 5	 2	 5	 49.2	 5.0
(-yE) - negative;
(+VE) - positive
PF	 - P. falciparum;
PV	 - P. vivax
* log2
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TABLE 3.4.1.2c
RESULTS OF THE STASTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P.falciparum AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE
PORTO TEREZINHA (PT)
CORRELATION AGE GROUP	 CR1—SQUARE	 p VAWE SIGNIFICANCE
children	 2.07	 0.15	 no
IFAT X MH	 adult	 0.88	 0.35	 no
all	 9.32	 0.002	 yes
children	 0.01	 0.91	 no
IFAT X SR
	
adult	 0.80	 0.37	 no
	
all	 4.88	 0.03	 yes
children	 0.59	 0.44	 no
IFAT X SL
	
adult	 0.87.	 0.35	 no
	
all	 3.98	 0.04	 yes
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 C> 14 years)
Chi-square and p—value used with Yates correction.
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TABLE 3.4.1.2d
RESULTS OF THE SEROLOGY OF ARR
a.IFAT- P.falciparum / P.vivax
	
AGE	 TESTED	 (-yE)	 RECIPROCAL TITRES	 (+VK)
	
GROUP	 SA1LES PP/PV	 20 40
	
80	 160 320 640	 (+)	 )AN TITRA
PP/Tv	 PF/PV
- 1
	
0-1	 0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 -I-
	
2-4	 9	 8/7	 0/1	 0/0	 0/0	 1/0	 0/1	 0/0	 11/22	 7.3/6.3
	5-9	 9	 8/8	 1/1	 0/0	 0/0	 0/0	 0/0	 0/0	 11/11	 4.3/4.3
	
10-14	 12	 11/10	 0/2	 0/0	 0/0	 0/0	 0/0	 1/0	 8/11	 9.3/4.3
	
14	 19	 9/13	 6/3	 0/1	 1/2	 0/0	 2/0	 1/0	 47/32	 5.8/5.1
	
?OL	 49	 36/38	 7/7	 0/1	 1/2	 1/0	 2/1	 2/0	 26/22	 6.1/4.9
- - - -
b.ELISA - P.falciparum
	T28	 (-VZ)	 (+VZ)
U3WIZS	 20	 40	 SO	 160	 320	 640	 (5)	 1W TIm
0-1	 0	 0	 0	 0	 0	 0	 0	 0	 0	 -
2-4	 9	 9	 0	 0	 0	 0	 0	 0	 0	 -
5-9	 9	 9	 0	 0	 0	 0	 0	 0	 0	 -
10-14	 12	 12	 0	 0	 0	 0	 0	 0	 0	 -
> 14	 19	 16	 3	 0	 0	 0	 0	 0	 15.8	 4.3
	
49	 46	 3	 0	 3	 0	 0	 0	 6.1	 4.3
- - ______
(-yE) - negative; (+VE) - positive
PF	 - P. falciparum; PV	 - P. vivax
* log2
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TABLE 3.4.1.2e
RESULTS OF THE STASTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. falciparunz AND MPLARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
ARREPENDIDO (ARR)
	
CORRELATION AGE GROUP	 CHI-SQUARE	 p VALUE	 SIGNIFICANCE
	
children	 1.64	 0.2	 no
IFA X MH	
adult	 0.70	 0.4	 no
all	 7.64	 0.006	 yes
	
children	 2.25	 0.1	 no
IFA X SR
adult	 0.17	 0.7	 no
all	 2.45	 0.1	 no
	
children	 1.64	 0.2	 no
IFA X SL
adult	 0.11	 0.7	 no
all	 2.34	 0.1	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
121
SR and SL) was performed with the control areas samples
taken together due to their similaFity . Results are shown
in table 3.5.1.4 and the correlations were much more
significant mainly for the children and combined (all
samples) groups.
3.4.1.3 Indigenous group (IND)
The indigenous group had all samples positive for IFAT of
P.falciparum. The sample represents 59.2% of people (0-14)
and 40.7% of adults.
Thus, the statistical analysis used in this study was not
applicable in the case of children for the correlation
between seropositivity and MH because all children had
positive test and all had reported past malaria infection
that is there wasa constant association of the two.
In addition, no correlation was demonstrated, within the
age groups, between seropositivity and all variables tested
as all samples either with or without history of malaria,
enlarged spleen and positive slides had a positive test
(IFAT) for P. falciparum. Chi-square and p-values figures
are shown in table 3.4.1.3a.
3.4.2 Plasmodium vivax
3.4.2.1 Target area (SNV)
In SNV, the seropositivity for P. vivax was 3.8% (10/260).
8/10 (80%) of these positives were from adults.
Among the positive samples eight were positive in one
single collection, two for two collections and none for
all three collections.
Table 3.4.1 shows the seropositivity of this study area
distributed by titres and age groups. The positivity is
concentrated in the titres between 1:20 to 1:80.
Since 33 individuals from this area had reported past
malaria infection, the statistical analysis between these
data and seropositivity was performed. However, no
correlation was found.
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TABLE 3.4.1.3
RESULTS OF THE SEROLOGY OF IND
a.IFAT- P.falciparum / P.vivax
TBSTED	 (-Vi)	 RECIPROCAL ?IRES	 (+VK)	 *)(Tp,
	
GROUP	 SA1LE3 PP/PV
	
20 40 80 160 320 640
	 (%)	 MEAN TXtRZ
	
PP/Pv	 PF/PV
	0-1	 0	 0/0	 0/0	 0/0	 0/1	 0/0	 1/0	 0/0	 100/100	 8.3/6.3
	
2-4	 7	 0/1	 0/0	 0/2	 1/2	 1/1	 4/1	 1/0	 100/86	 8.0/6.5
	5-9	 2	 0/0	 0/0	 0/1	 0/0	 1/1	 1/0	 0/0	 100/100	 6.8/6.3
	
10-14	 6	 0/1	 0/0	 0/1	 0/2	 2/0	 4/2	 0/0	 100/84	 8.0/7.0
	
> 14	 11	 0/2	 0/1	 0/1	 0/2	 3/2	 4/2	 4/1	 100/82	 8.4/7.0
	
1.	 27	 0/4	 0/1	 0/5	 1/7	 7/4	 14/5	 5/1	 100/85	 8.1/6.7
— — — —
b.ELISA - P.falciparum
AiE	 TESTED	 (-VE)	 RECIPROCAL TITERS	 (+VE)	 *GR54TPJC
GROUP	 SA1GLES	 20 40 80	 160	 320	 640	 (+)	 NEAII TITRE
0-1	 1	 0	 0	 0	 0	 1	 0	 0	 100	 7.3
2-4	 7	 5	 0	 0	 1	 1	 0	 0	 28.6	 6.8
5-9	 2	 2	 0 0	 0	 0	 0	 0	 0	 -
10-14	 6	 4	 0	 0	 1	 0	 1	 0	 33.3	 7.3
> 14	 11	 7	 1	 0	 0	 1	 2	 0	 36.4	 7.0
TOTAL	 27	 18	 1 0	 2	 3	 3	 0	 33.3	 7.1
— —	 ____
(-yE) - negative;
(+VE) - positive
PF	 - P. falciparum;
PV	 - P. vivax
* log2
123
3.4.2.2 Control areas (CAB, PT and ARR)
The seropositivity (IFAT) for P. vivax in CAB was 31%. As
for P. falciparurn the higher positiwity was found among the
adult group (68.8% - 42/61).
The table 3.4.1.2 also shows the distribution of the
seropositivity for this malaria parasite species by titres
and age group.
The statistical analysis for the correlation of
seropositivity and variables such as malaria history,
spleen rate, positive slides were carried out for three age
groups, children, adult and all ages. The results are
expressed in table 3.4.2.2.
Significant correlation with a history of malaria was found
only in the children and combined groups, while with spleen
rate no correlation was demonstrated.. However, all groups
show significant correlation between seropositivity and
positive slides either with P. falciparum and/or P. vivax.
With respect to PT, the seropositivity was 15.8% and 70% of
the positive samples were from the adult group. In table
3.4.1.2b all results for serology for P. vivax are shown.
Siginificance was demonstrated in both correlations,
history of malaria and positive slides vs. seropositivity
in two groups: children and all ages. For spleen rate vs
seropositivity no correlation was found.
For ARR, where seropositivity was 22.4%, the adults also
showed a higher positivity rate (54.5% - 6/il) than
children.
Table 3.4.1.2d gives all results of the serology for P.
vivax by titres within the age groups.
All age groups demonstrated no correlation between their
seropositivity for this malaria parasite species and either
history of malaria, or spleen rate or positive slides.
Results for chi-square and p-values are shown in table
3.4.2.2b.
As for P. falciparurn, the statiscal analysis for IFAT for
P. vivax was performed for the control areas sample taken
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TABLE 3.4.2.2
RESULTS OF THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. vivax AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
COLONIA AGUA BRANCA (CAB)
CORRELATION AGE GROUP	 CR1-SQUARE	 p-VALUES SIGNIFICANCE
children	 4.10	 0.04	 yes
IFAT X MH
	
adult	 1.87	 0.2	 no
	
all	 8.27	 0.004	 yes
children	 0.94	 0.3	 no
IFAT X SR
	
adult	 0.12	 0.7	 no
	
all	 1.32	 0.2	 no
children	 4.00	 0.04	 yes
IFAT X SL
	
adult	 5.03	 0.02	 yes
	
all	 11.35	 0.0007	 yes
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
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TABLE 3.4.2.2*
RESULTS OF THE STATISTICAL ANALYSIS OF TIE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. vivax AND )(ALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
PORTO TEREZINHA (PT)
CORRELATION AGE GROUP	 CHI-SQUAPE	 p-VALUES SIGNIFICANCE
children	 5.45	 0.02	 yes
IFAT X MN	
adult	 0.07	 0.8	 no
	
all	 8.29	 0.004	 yes
children	 0.03	 0.8	 no
IFAT X SR
	
adult	 0.12	 0.7	 no
all	 3.74	 0.05	 no
children	 5.32	 0.02	 yes
IFAT X SL
	
adult	 3.18	 0.07	 no
	
all	 12.42	 0.0004	 yes
MI! - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
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TABLE 3.4.2.2b
RESULTS OF THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. vivax AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
AP.REPENDIDO (ARR)
CORRELATION AGE GROUP	 CHI-SQUARE	 p-VALUES SIGNIFICANCE
children	 0.21	 0.6	 no
IFAT X MH
	
adult	 1.06	 0.3	 no
	
all	 1.68	 0.2	 no
children	 0.09	 0.8	 no
IFAT X SR
	
adult	 0.12	 0.7	 no
	
all	 0.36	 0.5	 no
children	 0.36	 0.5	 no
IFAT X SL
	
adult	 1.71	 0.2	 no
	
all	 3.75	 0.05	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
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together and as shown in table 3.5.1.4, and the
significance of the positive correlations were stronger
that when the areas were analysed separately. Nevertheless,
the adult group continues showing no correlation for
seroporitivity vs. malaria history, but had demonstrate
correlation of seropositivity with spleen rate, which had
not been found for any of the areas separately.
3.4.2.3 Indigenous group (IND)
This group showed a lower seropositivity for P. vivax
(85.2%) than for P. falciparum (100%).
In contrast with all other study areas and in agreement
with the results for P. falciparum, this group had a higher
positivity among children (60.9% - 14/23).
As shown in table 3.4.1.3, where distribution by ititres and
age groups is given, the titres are distributed among those
higher than 1:20.
Table 3.4.2.3 shows the results obtained from statistical
analysis for the same variables tested in the other areas.
For all variables and all analyzed age groups no
correlation was demonstrated.
For the children, the correlation between seropositivity
and history of malaria was significant since all children
had past malaria infection and 87.5% (14/16) of them had
positive test for P. vivax ( X2= 4.90 and p-value= 0.027).
3.4.3 Infection rate
Draper et al., (1972) produced a mathematical model in
which it is possible to predict the probability of an
individual being infected during on year within a certain
area (appendix 4). The model is based on the fact that once
an individual is infected he remains serologically
positive, thus the pobability of an infected individual
being infected is constant in a small interval of time. He
drew standard lines of the probability being infected each
year (R) in a log 2 2 cycles graph paper which, from the
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TABLE 3.4.2.3
RESULTS OF THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(IFAT) FOR P. vivax AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
INDIGENOUS GROUP (IND)
	
CORRELATION AGE GROUP	 CHI-SQUARE	 p-VALUES SIGNIFICANCE
	
children	 4.90	 0.03	 yes
IFAT X HM	
adult	 0.36	 0.5	 no
all	 0.34	 0.6	 no
	
children	 0.11	 0.8	 no
IFAT X SR
adult	 0.13	 0.7	 no
ill	 0.02	 0.9	 no
	
children	 0.00	 1.0	 no
IFAT X SL
adult	 0.11	 0.7	 no
all	 0.03	 0.9	 no
ND - not done.
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
129
proportion of the population with antibodies at different
ages, can be used to predict approximately the transmission
in a population of an area.
The results of IFAT tests showed the probability of an
individual being infected in all study areas (fig. 3.4.3).
The transmission in SNV (R < 1%) is lower than the control
areas CR = 1 - 5%), but all areas have low transmission
levels.
3.5 ELISA with serum samples
3.5.1 Detection of antibodies against asexual forms of
Plasmodium falciparum
The study of antibodies against asexual forms of Plasrnodium
falciparum gave a rate of 43.35% (114/263) of positivity.
3.5.1.1 Target area (SNV)
The rate of positivity for P. falciparum by ELISA for this
study area was 30.4% (79/260). Of those, 44 were positive
in one single collection, 30 for two and 5 for all three.
Contrasting with the IFAT results for P. falciparum, this
test had a higher seropositivity among the children (57% -
45/79)
The distribution of titres shown in table 3.4.1
demonstrates that most titres were low; 83.5% were positive
for at a titre 1:20.
There was no correlation between seropositivity and malaria
history for any age group since the p-values were higher
than 0.05 (p= 0.92, 0.15 and 0.50 for children, adults and
all age groups respectively).
3.5.1.2 Control areas (CAB, PT and ARR)
The P. falciparum serology by ELISA in CAB had a positivity
of 50.2% (99/197) and as for SNV the group with the lowest
titre (1:20) was the largest.
As in the IFA test the adult group had higher positivity
than children (59.6% - 59/99).
Applying statistical methods it was demonstrated that there
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was no correlation between the ELISA seropositivity and any
of the variables tested in any of the age groups (table
3.5.1.2)
49.2% was the positive rate for P.falciparum in PT. Low
titres around 1:20 were most common (table 3.4.1.2b) and
there were more positives in the adult group (52% - 38/73).
In this study area no correlation between seropositivity
and the variables tested, malaria history, spleen rate and
positive slide was demontrated for all three age groups
(table 3.5.1.2a).
ARR was the study area where the positivity was the lowest
(6.1% - 3/49). The three positive samples were from adults
and had titres of 1:20. These results are shown in table
3.4.1.2d.
The statistical methods were not applicable to the analysis
among the children group because their tests were negative
whether or not they had had past malaria infection,
enlarged spleen or positive slides. As shown in table
3.5.1.2b, for the other age groups no correlation was
demonstrated between the seropositivity and all variables
tested.
However, in order to carry out the statistical analysis the
samples from all control areas were taken together, but
eventhough no correlation was found between positivity of
this test and all variables tested (table 3.5.1.4).
3.5.1.3 Indigenous group (IND)
33.3% of the samples were positive, and as for IFAT
children had higher positivity (55.5% - 5/9). In contrast
to the other areas the positive titres were above 1:80 (
table 3.4.1.3).
The table 3.5.1.3 summarises the results of the statistical
analysis and demonstrates no correlation between
seropositivity and the variables, malaria history, spleen
rate and positive slide.
Among the children, for the same reason as for ARR, the
correlation between seropositivity and malaria history was
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TABLE 3.5.1.2
RESULTS OF THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(ELISA) FOR P. fa.Lciparum AND MALARIA RISTOR, SPLEEN RATE AND POSITIVE
SLIDE.
COLONIA AGUA BRANCA (CAB)
CORRELATION AGE GROUP CHI—SQUARE p—VALUE SIGNIFICANCE
children	 0.76	 0.4	 no
EB X HM
	
adult	 0.03	 0.9	 no
	
all	 0.62	 0.4	 no
children	 0.39	 0.5	 no
EB X SR
	
adult	 0.52	 0.5	 no
	
all	 0.00	 1.0	 no
children	 0.39	 0.5	 no
EB X SL
	
adult	 0.08	 0.8	 no
	
all	 0.67	 0.4	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates corrected
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TABLE 3.5.1.2a
RESULTS OF THE STATISTICAII ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(ELISA) FOR P. falciparum AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
PORTO TEREZINHA (PT)
	
CORRELATION AGE GROUP 	 CHI-SQUABE	 p-VALUE	 SIGNIFICANCE
	
children	 0.04	 0.8	 no
EB X HM
	
adult	 0.33	 0.6	 no
	
all	 0.85	 0.3	 no
	
children	 0.06	 0.8	 no
EB X SR
	
adult	 0.02	 0.9	 no
	
all	 0.12	 0.8	 no
	
children	 0.24	 0.6	 no
EB X SL
	
adult	 0.11	 0.7	 no
	
all	 0.06	 0.8	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates corrected
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TABLE 3.5.1.2b
RESULTS OF THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN SEROLOGY
(ELISA) FOR P. falclparum AND MALARIA HISTORY, SPLEEN RATE AND POSITIVE
SLIDE.
ARREPENDIDO (ARR)
CORRELATION	 AGE GROUP	 CR1-SQUARE	 p-VALUE	 SIGNIFICANCE
children	 nd	 nd	 -
IFAT X MR	
adult	 0.20	 0.6	 no
all	 2.71	 0.1	 no
children	 nd	 nd	 -
IFAT X SR
adult	 0.01	 0.9	 no
all	 0.00	 0.9	 no
children	 nd	 nd	 -
IFAT X SL
adult	 0.53	 0.4	 no
all	 0.79	 0.4	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 C> l4years)
Chi-square and p-values used with Yates correction
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TABLE 3.5.1.3
RESULTS OF THE STATISTICAL PNALYSIS OF THE CORRELATION BETWEEN SEROLOG!
(ELISA) FOR P. falclparum AND )(ALARIA HISTORY, SPLEEN RATE AND
POSITIVE SLIDE.
INDIGENOUS GROUP (IND)
CORRELATION AGE GROUP	 CHI-SQUARE	 p-VALUE SIGNIFICANCE
children	 nd	 rid	 no
ES X MH
adult	 0.00	 0.9	 no
all	 0.00	 1.0	 no
children	 0.19	 0.7	 no
EB X SR
adult	 0.00	 0.9	 no
all	 0.02	 0.9	 no
children	 0.18	 0.7	 no
EB X SL
adult	 0.00	 0.9	 no
all	 0.04	 0.8	 no
MH - malaria history
SR - spleen rate
SL - positive slide
children (0-14 years)
adult	 (> l4years)
Chi-square and p-values used with Yates correction
136
not tested.
3.5.1.4 Correlation among the immunological tests
Finally, statistical analysis was carried for all three
immunological test for detection of antibodies against
blood forms (IFAT for either P. falciparum and P. vivax, or
ELISA) of the control areas samples taken togheter. The
results are shown in table 3.5.1.4, and demonstrate a
different result from those obtained from the analysis of
each area separately.
3.5.2 Detection of antibodies against malaria sporozoite
repetitive CS antigens
Table 3.5.2 shows the results of this ELISA test for each
study area and sample. Also is shown the positivity by
Plasmodium species and the number of different positive
species by sample.
SNV had a positive rate of 39.6% and as for the other
immunological tests the adults showed higher titres (24.6%
- 64/260) than children (15% - 39/260).
CAB was the study area where the highest positive rate was
obtained (60% - 117/195). Age was not correlated with the
seropositivity since the prevalence of anti-sporozoite
antibodies was similar in both groups ( 30.2% for adults
and 29.2% for children).
As for CAB, PT had similar seropositivity for both age
groups (18.7% for adults and 16.8% for children), while IND
had equal rate for the two age groups (18.5%) and ARR had
a higher rate for children (40.8%) than adults (10.2%).
In table 3.5.2 the positive rate for all areas is shown and
the range that was from 23.1 to 37.0%, excluding CAB.
The statistical analysis for correlating reported intake of
the chioroquinised salt with protection against malaria
infection was performed as follow: within the group of
individuals who had positive test for any of the tested CS
antigen it was taken two subgroups, one that had reported
the intake of the salt and one that not. From both
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TABLE 3.5.1.4
THE STATISTICAL ANALYSIS OF THE CORRELATION BETWEEN THE POSITIVITY OF
THE IMMUNOLOGICAL TESTS (IFAT AND ELISA FOR BLOOD FORMS) AND MALARIA
HISTORY, SPLEEN RATE AND POSITIVE SLIDE OF THE
CONTROL AREAS SAMPLES TAKEN TOGETHER.
CORREL&TION CHI-SQUABZ	 p-VALUE	 SIGNIPICAIICE
	
CR AD ALL	 CR	 AD	 ALL	 CII AD ALL
IF X ME	 16.8 4.0 30.2	 0.00004	 0.03	 0.00	 YES YES YES
IF X SR	 13.1 4.1 30.9	 0.0003	 0.04	 0.00	 YES YES YES
IF X SL	 27.1 3.1 29.1	 0.00	 0.07	 0.00	 YES	 NO YES
IV X ME	 7.9 1.0 20.9	 0.005	 0.3	 0.001	 YES	 NO YES
IV X SR	 18.8 5.4 22.6	 0.00	 0.02	 0.00	 YES YES YES
IV X SL	 6.4 4.7 4.9	 0.01	 0.03	 0.00	 YES YES YES
EB X ME	 0.3	 0.1 1.9	 0.6	 0.7	 0.2	 NO NO NO
EB X SR	 0.7	 0.0 0.4	 0.4	 0.9	 0.5	 NO	 NO NO
EB X SL	 0.6	 0.2 1.8	 0.4	 0.7	 0.2	 NO	 NO NO
IF - IFAT for P. falciparum
IV - IFAT for P. vivax
EB - ELISA for blood forms of P. falciparum
MH - malaria history; SR - spleen rate; SL - positive slide
Cl-I - children
AD - adult
Chi-square and p-values used with Yates correction
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subgroups it was taken the number of individuals who had or
not positive slides either for P. falciparum or/and for P.
vivax, see below. Thus, it was demonstrate non-significant
correlation for CAB alone, but when taken together with PT,
there was significant correlation between the intake of
chioroquinised salt and protection ( X2= 10.77 and p= 0.001).
CBS	 CS p08. test	 result of slide	 correlation
05	 neg
yes (243)	 94	 13	 81	 13/243
not (115)	 74	 21	 53	 21/115
As shown in table 3.5.2 antibodies against the Cs of P.
falciparum and P. malariae were the most and the least
prevalent among the total sample, respectively.
We tested our samples for other anti P. vivax, anti P.
vivax type 2 and anti P. vivax-like (type 3) CS. The
distribution of the samples that were positive for all
three types together or for eachof the two is shown in
table 3.5.2a. All study areas had positive samples for all
three types and only APR and IND areas had no positive
samples for type 1 and type 2 together.
It was observed that within SNV some whole families had
positive tests for the same species of malaria parasite
sporozoites which suggests that they had been exposed to
the same source of parasites.
The number of positive samples for the detection of
antibodies against the malaria parasites CS antigen and
those that were also positive for either IFAT for both P.
falciparum and P. vivax or for ELISA of the blood forms is
shown in table 3.5.2b.
In addition, statistical analysis of these correlation was
performed all samples taken together and no correlation was
demonstrated for the positivity of each two tests within
each type of CS antigen, except for the correlation between
the CS antigen of P. vivax type 1 and IFAT P. vivax and
ELISA for P. falciparum blood forms where significant
correlation was demonstrated (X2= 45.56 and p= 0.00; X2=
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TABLE 3.5.2
RESULTS OF THE ELISA TEST FOR THE DETECTION OF ANTI-MALARIA SPOROZOITES
ANTIBODIES BY STUDY AREA, BY SPECIES AND BY MULTIPLE ANTIBODIES.
AREAS TESTED	 (+VE)	 RESULTS	 No • OFINDIVIDUALS
S?JLE	 (%)	 PF	 PV1 PV3 PV, PlC	 POSITIVE FOR
1-5 CATEGORIES
1	 2	 3	 4	 5
	
sv1	 260	 73	 28	 23	 16	 26	 15	 53	 11	 5	 3	 1
(28.1)
	
SNV2 	 229	 53	 21	 23	 16	 23	 14	 24	 19	 6	 3	 1
(23.1)
	
SNV3 	 217	 53	 19	 14	 15	 20	 10	 33	 16	 3	 0	 1
(24.4)
	C?B	 195	 117	 69	 54	 47	 48	 5	 51	 33	 26	 7	 0
(60.0)
	
PT	 155	 56	 19	 19	 29	 23	 3	 34	 12	 5	 4	 1
(36.1)
	
ARR	 49	 17	 11	 4	 5	 10	 7	 8	 4	 0	 4	 1
(34.7)
	
IND	 27	 10	 5	 2	 6	 4	 2	 5	 2	 2	 1	 0
(37.0)
TOTAL	 1132	 379	 172 139 134 154	 56	 208	 97	 47	 22	 5
(33.4)
____ — — = — — — = = — —
(+VE) - positive
PF - P. falciparum, PV1 - P. vivax - type 1; PV2 - P. vivax
- type 2;
PV3 - P. vivax - type 3; PM - P. malariae/P.brasilianum
SNV1,2,3 - Serra do Navio samples 1, 2 and 3
CAB - Colonia Agua Branca; PT - Porto Terezinha
ARR - Arrependido; IND - Indigenous area
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TABLE 3.5.2a
DISTRIBUTION OF POSITIVE SAZ4PLES FOR 2 OR ALL TYPES OF P. vivax BY AREA
STUDYAREAS ALL3 TYPES TYPE+2 	 TYPE1+3 TYPE2+3
SNV1
	3	 4	 4	 3
SNVa	 5	 4	 4	 4
SNV3
	1	 2	 4	 2
15	 7	 10	 14
PT	 10	 4	 1	 3
ARR	 3	 0	 1	 2
IND	 1	 0	 1	 1
SNV1213 - Serra do Navio samples 1, 2 and 3
CAB - Colonia Agua Branca
PT - Porto Terezinha
ARR - Arrependido
IND - Indigenous area
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TABLE 3.5.2b
THE RELATIONSHIP OF THE RESULTS OBTAINED BY ELISA FOR MALARIA PARASITES
SPOROZOITES AND THOSE BY IFAT AND ELISA FOR BLOOD FORMS IN ALL STUDY
AREAS.
	
SPECIES RELATION STUDY AREAS	 TOTAL
	
SNV	 CAB	 PT	 APR	 lED
IF	 7	 30	 8	 4	 5	 54
CSF
IV	 1	 22	 4	 1	 4	 32
EB	 22	 18	 12	 1	 1	 54
IF	 8	 28	 11	 2	 2	 51
CSV
IV	 3	 19	 3	 1	 0	 26
EB	 28	 33	 9	 1	 1	 72
IF	 8	 19	 16	 1	 6	 46
CSK
IV	 2	 17	 5	 0	 5	 29
EB	 14	 19	 11	 0	 1	 45
IF	 8	 18	 14	 2	 4	 46
CSN
Iv	 4	 15	 4	 1	 2	 26
EB	 22	 23	 15	 1	 2	 63
IF	 6	 5	 0	 2	 2	 15
SCM
IV	 2	 2	 0	 1	 1	 5
EB	 5	 3	 2	 1	 1	 12
SNV - Serra do Navio; CAB - Colonia Agua Branca
PT - Porto Terezinha; ARR - Arrependido; IND - Indigenous
group
CSF, CSV, CSK, CSN and CSM - Cs antigen for P. falciparum,
P. vivax-type 1, P. vivax-type 2, P. vivax-type 3 and P.
malariae, respectively.
IF - IFAT for P. falciparum
IV - IFAT for P. vivax
EB - ELISA for P. falciaprum blood forms
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9.16 and p= 0.002, respectively). This results shown a very
strong correlation for the first relationship vs IFAT for
P. vivax.
3.6 Haptoglobin levels
A fresh calibration curve was prepared for each kit.
Fig. 3.6 shows one of the plates with precipitation rings
for the samples tested.
Table 3.6 shows the results of the tests in comparison with
past history of malaria and microscopy for Plasmodium
falciparum and Plasmodiuiu vivax at the time of blood
collection.
Figure 3.6a shows the distribution of the haptoglobin
levels found in the samples from the 5 study areas with the
mean and standard deviation for each area.
As shown in table 3.6, 49% of the samples had either hypo
or ahaptoglobinaemia. 11 out of the 49 positive samples had
no haptoglobin detectable at all and they were 6 from CAB
(20%), 4 from IND (26.7%) and 1 from ARR (7.1%) [percentage
of local samples].
Of those, 63.2% (31/49) had a history of past malaria and
44.9% (22/49) were microscopically positive for Plasrnodi urn
falciparurn and/or for Plasmodiurn vivax. Among those who had
normal level of haptoglobin, 31.4% (16/51) had a history of
past malaria, but only 5.9% (3/51) were microscopically
positive for Plasmodiuin. In hypo- and a-haptoglobinaemia a
highly significant correlation was found with those
children who had parasitaemia (X2 = 10.86 and p= 0.001)
while no correlation was found with malaria history.
Calculating separately the correlation for the two groups
hypo and ahaptoglobinaemia it was demonstrated correlation
only between hypohaptoglobinaemia and positivity for either
P. falciparum and/or P. vivax (X2= 3.86 and p= 0.05).
3.7 Haskin determination
Three areas had urine samples tested by the Haskin method
for the detection of chioroquine. SNV had 236 samples
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Figure 3.6
A plate of a radial immuno difusion (RID) showing the
precipitated rings.
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TABLE 3.6
RESULTS OF THE HAPTOGLOBIN LEVELS IN PPJ'T STUDY AREA IN CHILDREN AGED
2-14.
STUDY AREA SAMPLES TESTED	 HAPTO	 NH	 SL
	
L/N	 L/N	 L/N
sNv	 20	 3/17	 0/0	 0/0
CAB	 30	 17/13	 11/5	 11/0
PT	 21	 9/12	 6/6	 1/0
ARR	 14	 8/6	 2/2	 1/3
IND	 15	 12/3	 12/3	 9/0
TOTAL	 100	 49/51	 31/16	 22/3
L - Low level or absent
N - Normal level
PM - Past malaria history
PS - Positive slide either for P.falciparum or P.vivax
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DISRIBUTION OF HAPTOGL0BN LEVELS N 5 VILLAGES OF AMAPA STATE
SNV	 CAB	 PT	 ARR	 INO
VILLAGES
Figure 3.6a
Distribution of the haptoglobin levels of the samples
from all study areas with the mean and standard deviation
for each areas.
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tested of which only (55.1%) were positive even though all
individuals tested reported use of chioroquinised salt
daily. 59.4% (63/106) of the negative samples belonged to
children.
CAB had 57 samples tested and 35 (61.4%) were positive.
Among the individuals with a positive result, only 13 had
reported the daily intake of chioroquinised salt.
In PT where 96.9% of the sample population reported use of
chioroquinised salt, 108 samples were tested and 62 (57.4%)
were positive. All samples tested, positive and negative,
were from individuals who had reported the regular use of
chioroquinised salt.
The duration of the use of chioroquinised salt was from a
few days to about 30 years for all three areas from which
urine samples were tested and for all negative and positive
samples (see table 3.8)
3.8 ELISA for chioroquine
As shown in Table 3.8 a total of 372 urines from SNV, CAB
and PT and 626 sera from all study areas, were tested for
the quantification of chioroquine. Results are shown in
table 3.8.
3.8.1 Urine
370 out of 372 urine samples had a detectable amount of
chioroquine. From the positive samples, 213 were from SNV,
50 from CAB and 107 from PT with a range of chioroquine
concentrations of 150 to 5800 ng/ml, 23 to 7,664 ng/ml and
30 to 4,400 ng/ml for SNV, CAB and PT, respectively. All
positive samples from SNV and PT were from individuals who
had reported the daily intake of chioroquinised salt, while
only 13 (26%) out of 50 samples from CAB had reported the
same. There was no significant variation among the three
study areas for the range of positivity or presence of the
positive test and daily intake of chioroquiniseci salt. In
SNV there was one sample in which 10,000 ng/ml was
detected.
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TABLE 3.8
RESULTS OF THE QUANTIFICATION OF CHLOROQUINE IN URINE AND SERUM BY
ELISA AND COMPARISON WITh HASKIN'S METHOD.
STUDY	 RESULTS	 CHS	 MEAN OF
AREA	 (%)	 POSITIVITY
CQUR	 CQSE	 CQRU CQSE
ND N P	 ND N P ND N P	 ng/ml ng/ml
SNV	 24 106 130	 46 1 213 26 15 219	 260	 650	 3.8
(100)
CAB	 141 22 35 148 0 50 20 15 163	 88	 973*	 54
(44)
PT	 52 46 62	 52 1 107 16 .9 135	 155	 826	 1.7
(96)
AER	 49	 0	 0	 49 0	 0	 4	 5 40	 0	 ND	 2.9#
IND	 27	 0	 0 27 0	 0 2	 7 18	 0	 ND	 2.3
TOTAL 293 170 227 322 2 370 68 51 575	 -	 -	 -
CHS - use of chioroquinised salt
HK - Haskin's method
CQUR - ELISA for chioroquine detection in urine
CQSE - ELISA fro chioroquine detection in serum
ND - not done; N - negative; P - positive
SV - Serra do Navio; CAB - ColLonia Agua Branca;
PT - Porto Terezinha; ARR - Arrependido
IND - Indigenous group
* - except one 10,000 ng/ml
t - except one 180 ng/ml
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3.8.2 Serum
575 serum samples, 234 from SNV, 178 from CAB, 144 from PT,
45 from ARR and 25 from IND, were tested. As shown in table
3.8 there was some variation in the mean of serum
concentration of chioroquine between the areas. CAB had the
highest mean while PT had the lowest.
In SNV, the single negative sample was from a child, and
all those positive had reported the use of choroquinized
salt.
For CAB and PT, the areas where people had reported the in
take of the salt, no correlation was found with serum
positivity; CAB had a p> 0.1 and in PT had all negative and
positive values were seen in people reporting use of the
salt.
As ARR and IND areas had no report of intake of the salt,
the statistical analysis was applied to those who reported
the recent use of antimalarial drugs. No correlation was
found in both areas between this test positivity and recent
intake of antimalarials (p> 0.8 for ARR and p> 0.5 for
IND).
Fig. 3.8 shows the distribution of the concentration of
chloroquine detected in the urine and serum samples for
those who had positive or negative slides. The means and
standard deviation are also represented in the graph and no
much difference was shown for the chioroquine concentration
for both groups nor for urine and neither for serum
samples. The T test was applied for the comparison of the
means between the two groups, positive and negative slides,
in urine and serum samples tested. The results did not
shown significance; t = 0.76 and p> 0.1 (urine) and t= 1.01
and p> 0.1 (serum).
3.9 Distribution of mosquito species
95 daily mosquitoes captures were made during 4 trips (two
each in the dry and rainy seasons). The mean of the capture
time was 4 hours a day (from 6 to 10 pm). The range of
temperature during all collections was 23°C to 31°C. The
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Distribution of the concentration of chioroquine detected
in the urine and serum samples for individuals with
negative or positive slide
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relative humidity had a range of variation of 78 to 100% in
the wet season and 62 - 100% in the dry and the mean was
96% and 80.3% for wet and dry seasons, respectively.
However, just in a single ocasion, during the mosquitoes
collection in the dry season, a rate of humidity as low as
42% was registered.
Collections were carried out during all four phases of the
moon, on days with or without rain and wind. It was noted
that on the rainy days or moonlight nights or on windy days
the mosquito capture rate decreased.
The points for mosquitoes collection in SNV area, were
those used by the ICOMI team, which are in the forest
surrounding the SNV residential areas (fig. 3.9) and
carpintaria. This study had also carried out captures in
the forest areas along the roads (each 1 Kin) that links SNV
to CAB, to PT or to Macapá. The other collection points
were in the residential areas of CAB, PT and ARR, where
only indoors and/or outdoors captures were performed.
The number of bite/man/hour for each area during dry and
rainy seasons is shown in table 3.9, and the highest index
was obtained in the dry season.
Fifteen anopheline species were identified among 3053
mosquitoes collected during human biting catches in the 4
study areas. The most frequent species and their
distribution by study area are shown in table 3.9a and fig.
3.9a. 96.4% of the majority of mosquitoes caught consisted
of 4 species, namely, An. albitarsis, An. braziliensis, An.
nuneztovari and An. triannulatus. The remainder 11
species (An. oswaldoi, An. darlingi, An. peryassui, An.
minor, An. intermedius, An. mediopunctatus, Chagasia
bonneae, An. neivai, An. rangeli, An. noroestensis and An.
argyritarsis) were scarce.
77.2% of the total mosquitoes were collected during the dry
season and their distribution by season is shown in table
3.9.
Figure 3.9 shows the the distribution of the Anopheles
mosquitoes by places from where they were collected.
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TABLE 3.9
NUMBER 0? BITES/MAN/HOUR FOR THE AREAS IN WHICH
MOSQUITOES WERE COLLECTED, DURING THE DRY AND RAINY
SEASONS
(FEBRUARY & AUGUST 1990 AND APRIL SEPTEMBER 1991)
STUDY AREA	 DRY SEASON	 RAINY SEASON
SNV	 1.1	 1.4
CAB	 2.4	 2.5
PT	 4.7	 1.1
ARR	 14.6	 4.6
CARPINTARIA*	 6.5	 4.4
* a carpenter's workshop and the surrounding forest which
belongs to the ICOMI company and is situated at the base of
the hill, on the left bank of the Amapari river facing
(across the river) Porto Terezinha residential area
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TABLE 3.9a
DISTRIBUTION or Anopheles SPECIES COLLECTED IN STUDY AREAS
(SNV, CAB, PT and ARR)
	
Anophales	 SNV*	 CAB	 PT	 ARR	 TOTAL GRAND
SPECIES	 W/D	 W/D	 W/D	 WID	 W/D	 TOTAL
An. albitarsis	 91/91	 1/14	 71/90	 200/1407	 363/16	 1965
(43.7)	 (7.0)	 (48.6)	 (76.8)	 (64.4)
An. braziliensis	 30/27	 1/0	 33/37	 35/348	 98/412	 511
(13.7)	 (0.5)	 (21.1)	 (18.3)	 (16.7)
An. nuneztovari	 8/41	 61/79	 14/31	 6/50	 89/201	 290
(11.8)	 (65.1)	 (13.5)	 (2.7)	 (9.5)
An. triannulatus	 88/16	 7/20	 21/16	 7/3	 123/54	 177
(25.0)	 (12.5)	 (11.1)	 (0.5)	 (5.8)
	
An. oswaldoi	 4/10	 5/17	 2/1	 6/0	 17/28	 45
(3.4)	 (10.2)	 (0.9)	 (0.3)	 (1.5)
	
An. darlingi	 0/6	 0/4	 0/1	 1/4	 1/15	 16
(1.4)	 (1.8)	 (0.3)	 (0.2)	 (0.5)
	
An. peryassui	 0/1	 0/3	 1/1	 0/4	 1/9	 10
(0.2)	 (1.4)	 (0.6)	 (<0.2)	 (0.3)
	
An. minor	 0/0	 0/1	 0/8	 0/1	 0/10	 10
(0.5)	 (2.4)	 (<0.1)	 (0.3)
Other species**	 0/3	 0/2	 0/5	 4/15	 4/25	 29
(0.7)	 (1.0)	 (1.5)	 (0.9)	 (0.9)
TOTAL	 221/195	 75/140	 142/189	 259/1832	 697/2356	 3053
W- wet season; D - dry season
C ) percentages determined in relation to the total number
of mosquitoes collected by study area.
* includes mosquitoes collected in the "carpintaria"
locality.
** other Anopheles species collected in small numbers
included: An. interrnedius, An. mediopunctatus, An.
neivai, An. rangeli, An. noroestensis, An.
argirytarsis and Chaga.ia bonneae.
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Adult Mosquitoes
four main species
• other species
	 -
• M. darfingi	 -
• mosquitoes with P. malariae
mosquitoes with P. falcipanim
ci mosquitoes with P. vi type 1 • and/or 2. and/or 3.
Tigur. 3.9
Map of SNV region with the capture points of the Anopheles
adult mosquitoes and their distribution among the region
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Distribution of Mosquitoes in Serra do Navio region
Rainy season vs. Dry season
A
1,600
1.400
1,200
1,000
800
600
400
200
0
4,.. UJ4	 4,,..	 4,,. n,4v,i,i	 4,,.. Sa.niiaL,Li	 V6t,
Figure 3.9a
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The data from Serra do Navio Hospital on anopheline
mosquito collections during 1990 and 1991 is shown in table
3.9b. The mean number of mosquitoes collected by month is
also in agreement with our catches, and the mosquito
density was higher during the dry season. The species
identified by the ICOMI entomological team were essentially
the same as we had captured.
None new Anopheles species for these areas were found.
3.10 Breeding sites
Water sources and types of arboreal and epiphytic plant
species belonging to the family Bromeliaceae found within
all study areas were searched for the presence of immature
forms of anopheline mosquitoes.
Twenty one places were positive. Their type and the areas
where they were found is shown in table 3.10.
In SNV, no breeding site was found during our searches.
The water temperature and pH means for all positive
breeding sites were 24°C and 5.0.
15 out of the 20 breeding sites were exposed to the
sunlight and only 8 were of temporary origin formed by
rainy water and/or by the invasion of river water (flooded
areas). The small rivers and river edges had clear water
while the other breeding sites, ponds, pools, creeks,
flooded areas had not. Only the small and main rivers had
weak stream.
Only 4 breeding sites were far from the residential areas
(> 200m)
The vegetation is mainly on the edges of the breeding sites
but also there some breeding sites such as ponds where
there some small plants floating on the water.
The size of the breeding sites was variable and for ponds
it was about 200 m2 . The others were much smaller and the
range of size was about 20 - 50 m2.
The distribution of breeding sites per study area is shown
in fig. 3.10.
A total of 2571 immature forms of anophieline was collected
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TABLE 3. 9b
DATA FROM SERRA DO NAVIO HOSPITAL ON THE NUMBER OF Anophelea MOSQUITOES
COLLECTED DURING 1990 & 1991.
NUMBER 01
	 MEAN OF COLLECTED
	
NTUS	 TEAR	 MOSQUITOES	 MOSQUITOES
COLLECTED	 (MONTBLT)
JAN/FEB/MAR	 1990	 204	 68
APR/MAY/JUN	 146	 49
JUL/AUG/SEP	 359	 120
OCT/NOV/DEC	 550	 183
JAN/FEB/MAR	 1991	 108	 54
APR/MAY/JUN	 269	 90
JUL/AUG/SEP	 1263	 421
OCT/NOV/DEC	 2141	 714
	
TOTAL	 24 MONTHS	 5040	 212
* all are from forest adjacent to the SNV area, and were
collected by Shannon trap baited only with light.
obs: wet season generally from December to May.
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TABLE 3.10
DISTRIBUTION OF POSITIVE BREEDING SITES IN THE STUDY
AREAS
	
STUDY	 POSITIVE	 TYPE OF POSITIVE BREEDING SITES
	
BEA	 BREEDING	 RIVER POOLS CREEK
	 FLOODED	 SMALL	 POND
SITES	 EDGE	 AREAS	 RIVERS
c	 5	 0	 1	 0	 3	 0	 1
PT	 4	 1	 0	 1	 1	 0	 1
ARR	 6	 2	 0	 0	 0	 2	 2
	
ARRIPT*
	 4	 0	 0	 0	 1	 0	 3
	
CARP.**	 1	 0	 0	 0	 1	 0	 0
	
TOTAL	 20	 3	 1	 3.	 6	 2	 7
* road that divides Arrependido from Porto Terezinha
** carpintaria - area from SNV, but it is situated at the
foot of the hill facing Porto Terezinha
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Immature Forms
iii1*'!
+a pool
x river edge
• small river
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Tigure 3.10
Map of SNV region with the distribution of the different
types of breeding sites of the immature forms of Anopheles
mosquitoes.
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from the 20 positive breeding sites. 2013 out of the total
were larvae and 558 pupae. The larvae group had 1097
specimens of 1st and 2nd instars, and 916 of 3rd and 4th
instars.
The identification was carried out with 3rd and 4th instar
larvae and the species found were: An. albitarsis (24.2%),
An. triannulatus ( 38.1%), An.braziliensis (14.1%), An.
oswaldoi (10.2), An. nuneztovari (6.5%), and others
(including An. darlingi, An. rangeli, An. interrnedius and
Chagasia bonneae).
It was found only one specimen of An. darlingi and in a
breeding site which was not the classical, i.e., clear
water, shadow, small vegetation and some stream (Foratini,
1962). Rozendal, (1990) in his studies on the Guianas had
also found immature forms of An. darlingi in breeding
sites, which were not those normally described for this
species.
3.11 Sporozoite rate by salivary gland dissection
Few mosquito dissections were carried out since our main
objective was to know the distribution of the Anopheles
mosquito species and if they were infected by Plasmodiurn
parasites.
Mosquito dissection was a long and laborious task for our
small field team. Thus, only 88 dissections were carried
out. Of those 46 mosquitoes were parous, from which, 3 had
sporozoite in the salivary glands (1 each of: An.
albitarsis, An. braziliensis and An. nuneztovari), 4 had
oocysts on the stomach wall ( 2 were the same specimens
that had sporozoites - An. braziliensis, An. nuneztovari;
and 2 An. oswaldoi). The rate of positivity for the glands
was 3.4%, and for stomachs 4.5%.
3.12 ELISA with mosquitoes using anti-CS protein
The positivity rate of the total number of mosquitoes of 15
species tested by ELISA performed with CS antigen of P.
falciparum, P. vivax-type 1, P. vivax-type 2 (variant VK
160
247 isolated in Thailand) and P. malariae, was 0.799%
(23/2876) belonging to six species: 15 An. albitarsis, 4
An. nuneztovari, and 1 each of: An. braziliensis, An.
triannulatus, An. oswaldoi and An. rangeli.
This test was performed using only the head-thorax part of
the mosquitoes and individually.
9 out of 23 Anopheles specimens were positive for
Plasmodium malariae (5 An. albitarsis and one of each: An.
nuneztovari, An. braziliensis, An. triannulatus and An.
ran geli); 9 were positive for Plasmodium vivax - variant VK
247 (7 An. aibitarsis and 2 An. nuneztovari); 3 were
positive for Plasmodium falciparum (2 An. albitarsis and
1 An. oswaldoi) and 2 for the classical Plasmodium vivax
(1 An. albitarsis and 1 An. nuneztovari).
The positive mosquitoes either for P. falciparum or P.
vivax would be repeated for the quantification of
sporozoite, but as only 5 specimens (3 for P. falciparum
and 2 for P. vivax) were positives it was decided to not
carry out this test. However, all positive specimens had
also the abdomen tested and just one (Anopheles
triannulatus) out of the 23 mosquitoes was negative for
this second test.
All mosquitoes positivve for Plasrnodium malariae were
collected in the forest adjacent to the study areas (i.e
the parasites may be "Plasmodium brasilianum" from non
human primates).
3.13 Results of the studies in another localities
3.13.1 Prevalence of mutations associated with
pyrimethamine resistance
38 out of 42 (90%) of the samples studied contained the
Asn-108 codon AAC which in DHFR confers pyrimethamine
resistance and the remaining 4 (10%) contained only the
wild-type Ser-108 codon AGC. The Thr-108 codon ACC which is
linked with cycloguanil-resistant /pyrimethamine-sens it ive
strains, was not found within our sample.
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3.13.2 Polymorphism of the CS protein antigens of P. vivax
and P. falciparum in isolates from Paragominas and JacundA
cities, Pará State.
3.13.2.1 P. vivax
Variant forms of the human malaria parasite P. vivax were
found in individuals from Paragominas city, since
polymorphism in the repetitive and nonrepetitive regions of
its sporozoite CS protein was demonstrated.
P. vivax CS protein repeat sequences from this area were
the same as described from Thailand and Papua New Guinea
(PNG) - ANGA(G/D) (N/D)QPG -, which differs from those
described for South America, Central America and North
Korea - GDR(D/A)GQPA.
Polymorphism of P.vivax type 1 and type 2 CS proteins in
isolates from Paragominas (Brazil) and Papua New Guinea was
compared. P.vivax type 1 CS protein repeats were
GDRA(D/A)GQPA and type 2 were ANGA(G/D) (N/D)QPG.
A distinct variability in CS sequences of clones from 4
isolates from PNG was noted and the variation found ranged
from a change of a single AA residue to insertion of a
stretch of AAs. In both, Brazil and PNG, isolates were foun
that were a mixture of both type 1 and type 2.
Polymorphism in the nonrepeat region of P.vivax CS protein
was also found and was restricted to three domains: amino
to the conserved region in Region I, and amino and carboxyl
to the conserved region in Region II.
3.13.2.2 P. falciparum
The two study areas, Paragominas and Jacundá, showed
diversity in the immunodominant determinants of the CS
protein of P. falciparum. Comparison of the CS epitope
sequences of parasites from these two areas with Papua New
Guinea with CS epitopo sequences, already identified, of
parasites from Brazil and Gambia demonstrated that; 1-
polymorphism was found in the Th1R-Ni, Th2R and Th3R
regions: AA substitutions in the Th1R-Ni and Th2R showed a
conservative tendency and those found in the Th3R region
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did not, and 2- the polymorphism found in high malaria-
transimission areas (Papua New Guinea and Gambia) is higher
than in areas from Brazil where there is a relatively low
level of malaria-transmission.
3.13.2.3 P. falciparum ookinete vaccine antigen- Pfs25
The amino acid variation in the ookinete vaccine antigen
(Pfs25), showed no variation among 14 isolates from
Paragominas which had shown similar sequence to the
previously described 3DT clone of P. falciparum isolate
NF54 (Kaslow et al., 1988). For the 20 isolates from Papua
New Guinea one non-silent and two silent Al change were
observed.
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CHAPTER 4: DISCUSSION
4.1 Endemicity of malaria in the Serra do Navio region
As in Brazaville, Congo Republic (Trape, 1987), migratory
movement has played an important role in the spread of
malaria in Brazil (Cruz Marques, 1986), although in
contrast the exodus in Brazil has been from town to rural
areas and within the rural areas in the Amazon region. This
exodus was first a result of a Federal governmental
programme for populating and developing the Amazon region
and second a result of the belief that in the Amazon region
everybody would have land and it would be much easier to
become prosperous. As a result, an intense migration began
of farmers from the Central and Southern region, of people
from all regions of Brazil for working in the building of
hydroelectric plants and also the huge number of gold
prospecting sites (Alecrim, 1992). At this time,
deforestation and burning began in order to provide space
for the population settlements, which resulted in changes
in the eco-system of this region. Those changes and the
growth of population settlements without adequate
provision, either for basic living and/or for health-care,
are thought to have contributed to the spread of malaria
infection throughout the Amazon region by the formation of
new breeding sites for Anopheles mosquitoes. The intensity
of man-malaria vector contact increased which, together
with the migration of human beings, helped to spread the
malaria parasites from areas of transmission to areas
originally free from malaria.
At this time, in the 1960's, companies such as ICOMI
established their projects which created new residential
localities and also new jobs, which in turn attracted more
people to the area.
Even those companies that had made extensive preparation
and taken precautions, faced problems of morbidity and
mortality of tropical diseases, mainly malaria and
leishmaniasis. This was the stimulus for ICOMI to establish
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a programme for the control of malaria, the most important
disease in the area. They therefore introduced such a
programme which comprised measures described in section
2.1.
The migratory movement towards SNV is now not as intense
because of the emergence of new places for gold prospecting
attracting new migrants also exposed to malaria, where
malaria is consequently the most prevalent disease.
Considering the moderate prevalence of malaria infections
in the control areas and that malaria in the Amazon region
of Brazil is mainly linked to occupation and migratory
movement of the people (Cruz Marques, 1986 and 1987 and
Alecrim, 1992), the relatively low prevalence of this
disease can therefore be linked to the fact that the
majority of the people work for the ICOMI company and only
a small proportion of the population of these areas works
either as free-lance miners or fisherman and hunters.
Malaria infection in this study was due to two species of
Plasmodium (P. falciparum and P. vivax).
SUCAM (the governmental organization for malaria
programmes) had been reporting positive slides either for
Plasmodium falciparum and Plasmodium vivax or for mixed
infections every year in all the control areas. The
prevalence recorded in this study agreed with the limited
information available from SUCAN, since Amapá State is
shown as an area of low level positivity for malaria
parasites (WHO, 1992). Unfortunately, the SUCAN data are
compiled in groups of municipalities and/or localities and
generally are located under the name of the locality where
SUCAN has a notification post. As a result, SNV is shown as
a place of malaria transmission, but all cases reported as
being from SNV are in fact from the surrounding localities
which comprised the control areas of this study.
Data from the 1960s (Gusmão, 1990) show malaria infections
in SNV, but also show a sharp decrease in the rate
immediately after the establishment of the daily intake of
chioroquinised salt as part of the malaria transmission
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programme introduced first by the Federal Government and
afterwards continued by the ICOMI company until today.
In SNV, where chioroquinised salt has been used daily for
more than 20 years together with other methods of malaria
control, and where malaria prevalence had fallen with the
establishment of the programme of chloroquinised salt
(Gusmáo, 1990), it was not surprising to find negative
slides for malaria parasites and no clinical malaria. As
malaria infections had not been detected in SNV for several
years, the absence of palpable spleens was expected.
This absence of malaria is supported by the Serra do Navio
hospital records, where all clinical and parasitological
malaria cases registered there are from areas other than
SNV. During the three years of this study we did not
register a parasitological or clinical malaria infection
within the target area (SNV).
The endemicity levels established for the control areas
were based on the population sample with positive slides
and enlarged spleen. These data were collected once since
the study was designed for a single sample for each control
area. However, analysing the results it would have been
interesting to apply a longitudinal study to the control
areas to follow up the parasitaemia, the emergence of
enlarged spleen and especially the immunological status of
the population during different times of the year and for
more than one year.
It was noted that malaria infections (positive slides) were
not related to age and/or sex, and this suggests that the
transmission occurs in and/or outdoors, that is, close to
or within the houses.
4.2 Cultivation in vitro
Our inability to culture more field isolates of P.
falciparum has been to some extent a limiting factor for
this study. This is probably due to the conditions for
culturing in the area; we used the Hospital facilities and
laboratory, which did not provide all appropriate
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conditions such as a proper sterile cabinet for culturing
and an incubator with well controlled temperature.
Furthermore, infected blood from the field usually contains
antimalarial drugs, which interfere in the growth and
development of the parasite. To avoid this interference,
washing with incomplete culture medium at least twice was
used on the packed blood cells. However, all of the samples
were cryopreserved to provide a source of parasites from
this area for any further studies.
Past experiences with field isolation of P. falciparum gave
a similar level of failure and some measures such as
purchase of a portable sterile cabinet and a small
incubator with suitable temperature, were adopted in Belém
to improve the results. These facilities could not,
however, be taken to SNV.
Cryopreservation of blood infected samples and transfer to
the Belém laboratory for recovery and cultivation was
probably the most reliable method of making an
isolation.For P. vivax the culturing process is much more
complicated since it requires mainly young erythrocytes for
invasion (Mons, 1990), which is a limiting factor for its
continuous cultivation. Some techniques, however, such as
using hepatocyte feeder cells , or using blood sources of
young red blood cells (cord blood, placenta, etc.) improve
efficient cultivation, but the limitations are the
difficulty in obtaining these sources of blood and the cost
of using hepatocytes as a routine procedure. Therefore,
monkeys have also been used for the development and/or
multiplication of this parasite (Mons et al, 1988), but as
a routine procedure, it is limited due to the need for a
large number of animals, a suitable animal house, and the
cost of maintaining these facilities.
The discovery of new P.vivax variants and/or P.vivax-like
parasites, requires their cultivation to get relevant
information on their similarities (morphology of the blood
forms) and/or their patterns of sensitivity to antimalarial
drugs.
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4.3 Drug resistance
Drug resistance has spread throughout the Brazilian Amazon
region during recent years. The high level of resistance of
Plasmodium falciparum to chioroquine in the Amazon region
of Brazil (mainly Rondonia, Pará and Axnapá states) has been
extensively reported ( Rosário , 1983, Vasconcellos et al.,
1983, di Santi et al., 1987, Santos et al., 1987). The
observation of 82.5% of chioroquine resistant isolates
within our sample is in agreement with observations
elsewhere in the Amazon region. All chioroquine-resistant
P. falciparum isolates were found in the control areas. The
spread of chioroquine resistance is thought to be mainly
due to the extensive use of this antimalarial drug as the
first choice for treatment of falciparum malaria and also
because of its inappropriate use (Wernsdorfer & Payne,
1991). There is also a belief that the daily intake of
chioroquinised salt as a malaria transmission control
programme introduced in Brazil during the 1950's (Pinotti,
1953 and 1955) contributed to the spread of chioroquine
resistance (Payne, 1988). There is no proof, however, of
this hypothesis. The results here show no correlation
between the presence of chloroquine resistance and the
personal use of chioroquinised salt. Since it is now many
years since the introduction of protection using treated
salt, it is unlikely that such a comparison will tell us
whether salt was relevant to the appearance of resistance
in the late 1950s and 1960s, and the sample (17) is far too
small to detect anything but a very obvious correlation.
Amodiaquine resistance, which was less common than
chioroquine resistance in our sample has been reported
previously in Brazil. Some amodiaquine resistance in areas
of high level chioroquine resistance can be due to cross-
resistance between the 2 drugs and not only due directly to
use of amodiaquine. In Brazil and in our study area
amodiaquine has been used for the treatment of falciparum
malaria and thus this may be the reason for the level of
resistance to amodiaquine found among the samples.
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In the 1950's, quinine, though effective against falciparum
malaria was considered to be too toxic for routine
therapeutic use (Findlay, 1951) and its use was
discouraged: chioroquine, which was the newest and most
efficient antimalarial drug, became the drug of choice for
the treatment of falciparum malaria. The emergence of the
resistance of P. falciparum to chioroquine, and the
consequent need for alternative drugs for the treatment of
chlorquine resistant falciparum malaria, has led to the
reintroduction of quinine, alone or in association with
tetracycline.
Mefloquine, is a drug developed in the 1970s, which was
largely used in Thailand where P. falciparum is showing
resistance (Wernsdorfer et al., 1991). Based on these data
on the rapid emergence of resistance, the use of mefloquine
for treating malaria in Brazil was more carefully applied
and evaluated. In Brazil, mefloquine is used mainly in
those cases where the infection does not respond to any
other treatment or for very high parasitaemia which can
produce a more severe malaria. It is also well known that
there is an illegal market for mefloquine, mainly among the
miners (Souza, 1992). There are no clear reports, however,
of resistance of P. falciparum to this drug in Brazil.
Although Souza, (1992) comments on a possible few cases
reported as mefloquine resistant, he also stated that
better evaluation had to be carried out on similar cases in
order to determine if it was a true resistance or a matter
of inadequate cure due to early vomiting, diarrhoea or
intestinal malabsorption. In the experience of our team at
the Evandro Chagas Institute, where hundreds of falciparum
infected blood samples have been tested, no resistance to
mefloquine in vitro has been demonstrated.
Our results show that quinine and mefloquine should still
be effective in our study areas for treatment of falciparum
malaria.
Concerning P.vivax malaria there are no confirmed reports
about this parasite's resistance to antimalarial drugs in
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Brazil. The treatment adopted for vivax malaria, in Brazil,
is chloroquirie for the blood forms together with primaquine
for the tissue forms in order to avoid relapse. Garavelli
& Corti, (1992) reported a presumed case of chioroquine
resistant P. vivax in Brazil, but this was extensively
queried by other investigators (correpondence, Trans. Roy.
Soc. Trop. Med. Hyg., 86, 570-571).
Most samples tested for sensitivity to antimalarial drugs
were from CAB but this was due to chance, since we
collected blood samples from everyone coming to the SNV
hospital and/or SUCAM post who was positive for malaria
parasites.
We also carried out drug tests on samples from individuals
who did not live in the control areas. Although these were
not included in the results, it is relevant to note that
they were mainly from mining areas and that the majority of
their falciparum strains were chloroquine resistant.
Amodiaquine and a few cases of quinine resistance were also
detected.
Although this study did not investigate pyrimethamine
resistance in this area, a PCR study showed the wide spread
of this resistance throughout the Amazon region (Peterson
et al., 1991), and this drug has failed in the treatment of
malaria in Brazil (Almeida Netto et al., 1972).
Pyrimethamine resistance is probably widely distributed as
chloroquine resistance in the study area. This needs to be
confirmed by further studies.
4.4 Immunological status of the population
The results obtained from the immunological techniques, in
particular the IFAT tests show that the population has been
exposed to malaria infection. Seropositivity and prevalence
of high titres were age related, except for in the
indigenous area where all titres were represented in all
age groups. In SNV there was one individual (9 years old)
who had a titre of 1:160 for P. falciparum by IFAT (blood
stages) and no positivity either for IFAT with P. vivax or
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for ELISA with P. falciparum blood stages. No explanation
for this finding was found, since there was no history of
malaria and/or any other disease that could have produced
a cross reaction. In PT, there were 3 cases of children (2
of 3 years old and one of 4) with high titres by falciparum
IFAT of which 2 were seropositive by vivax IFAT. These 2
children had had malaria more than once. The other child
had no positive test by vivax IFAT, no history of malaria
and no present infection, which, as for the child from SNV,
could not be explained.
In SNV the correlation between IFAT positivity (blood
stages) and malaria history was demonstrated. Those with an
history malaria were reported to have had malaria more
than 10 years before. This suggests that their antibodies
persist for a long period of time. Despite correlation for
the control areas between IFAT seropositivity and past
malaria, it is not possible to determine the longevity of
their antibody reactivity because they had several past
malaria infections within different time periods.
Statistical analysis was applied to assess the correlation
between the positivity of the IFAT test and other variables
(MH, SR or SL). This analysis was carried out for each area
separately and all control areas taken together and the
highest correlation was obtained from the analysis of all
control areas together. The IFAT for either P. falciparum
or P. vivax demonstrated correlation with all three
variables in all age groups, except in the adult group for
P. falciparum IFAT and positive slide (SL) and for P. vivax
IFAT (IV) and history of malaria (MB). The lack of such
correlations could be due to, in the case of IFAT for P.
falciparum vs SL, the fact that these adults have already
been infected several times by P. falciparum so that a
fresh infection did not lead to a rise in rate of IFAT
positivity; and in the case of Iv vs MB, the fact that past
malaria in all areas is strongly linked to past falciparum
infection rather than to vivax infection.
In addition, the correlation among the combined children
171
was much stronger when the analysis was performed for
individual locations. These correlations demonstrate, that
it is best to examine children to understand the
immunological status and/or the pattern of malaria
transmission within a certain population, for example if
spleen rate and parasite rate in this group are to be used
to determine endemicity in an area.
The results from the ELISA tests are intriguing since for
SNV, CAB and PT the rate of positivity was much higher than
for IFA tests while in ARR it was very low. As the control
areas are similar and had given a similar pattern of
antibody response by IFAT the question of the sensitivity
and/or specificity of the ELISA arises, since if the test
was highly specific the results would not be so high in SNV
and in PT, but much higher in the APR and IND areas. If it
was highly sensitive, the results for at least the IND
areas would also be higher.
It is possible that this ELISA test using whole-parasite
antigen, is not yet completely standardised worldwide for
epidemiological studies or for diagnosis. To support this
hypothesis, the indigenous area, where malaria transmission
occurs frequently among all age groups of the population,
had a lower level of positivity with ELISA when compared to
IFAT (33.3% and 100% respectively).
Using the rate of infection obtained from IFA tests by age
group for all study areas and analysing them with the
method of Draper et al., (1972), it was demonstrated that
the risk of one person being infected within one year is
less than 1% for SNV and less than 5% for the control
areas. These findings are in agreement with the difference
in prevalence of malaria infection established in this
study for the SNV and PT study areas. CAB and APR were
classified as mesoendemic areas for malaria transmission
(parasite rate in children between 10 and 25%), on the
basis of IFAT results, but according to the ELISA data
alone these areas could not be classified satisfactorily.
Discussion on the most sensitive and/or specific
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immunological method for diagnosis with Dr. David Warhurst
(personal communication) led to the conclusion that IFAT is
still the best method for detecting antibody in malaria.
The low level of false positivity, which is nevertheless
always lower than with other methods.This study did not
examine innate immunity and related factors since the
number of young children sampled was in fact very low.
There were few pregnant women with malaria in all areas
(data from the Hospital - less than 5%) and there were no
data available concerning congenital factors such as G-6-PD
deficiency, thalassaemias or sickle cell disease for the
Amazon region, younger children were not necessarily
expected to show innate immunity.
Other studies on the immunological response to malaria
infection in Acre and Pará states of Brazil (Kremsner, 1992
and Arruda et al., 1989) found similar rates of
seropositivity within their target populations.
The studies on antibody to malaria CS indicate that in all
areas the population had experienced contact with malaria
sporozoites through the bite of infected Anopheles.
Antibody prevalence for P.falciparum, P.vivax type 1 and
P. malariae CS have already been reported from other areas
of Brazil (Arruda et al., 1986 and 1989, Kremsner et al.,
1992). The existence of the variants of P.vivax (type 2 and
type 3) in the study was not known, although type 2 had
been reported from areas in Acre State (Amazon region) by
Kremsner et al., (1992) using ELISA and by Qari et al., (in
press) by sequencing the CS protein gene. Type 3, the most
unexpected, has recently been discovered using PCR
amplification and sequencing of the CS gene ( repetitive
sequence: APGANQEGGAA) with human "P.vivax" infections from
PNG and Brazil (Qari et al., in press). This parasite is
closely related to P.sirniovale, which is a parasite of old
world monkeys (Garnham, 1966). However, anti- P.vivax type
2 and 3 sporozoite antibodies have been demonstrated here
in the populations of all areas. Both types are now
believed to be widespread in Brazil since there are reports
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of the existence of type 2 and 3 from Paragominas and
Jacundá cities in Pará State (Qari et al., in press), type
2 from Acre State and, reported here, type 2 and 3 from
Amapá State. Although all three states are in the Amazon
region they are very distant from each other. Malaria
infection caused by "P. ovale" has been registered in PNG,
but since PNG has no monkeys and Brazil has no Old World
monkeys, the origin of this P. simiovale -like parasite
malaria in Brazil and PNG needs further investigation.
The inability to demonstrate any correlation between the
positivity of ELISA using CS antigen and reported intake of
chloroquinised salt in CAB, is not entirely unexpected
since the majority of reported malaria infections and/or
positive slides for malaria parasites concern P.
falciparum, which in our study have shown a high level of
resistance to chioroquine (more than 80%). It is probably,
therefore, that the individuals with positivity for ELISA
using CS antigen who had recent malaria infection caused by
P. falciparum and reported the intake of chioroquinised
salt, were infected with a chioroquine resistant strain.
When the same correlation (positivity for ELISA using CS
antigens vs reported intake of chloroquinised salt) was
performed for CAB and PT together, a significant
correlation was demonstrated, i.e., there were
significantly more person with negative slides in the group
taking chioroquinised salt and showing positive CS
antibodies, than in the corresponding group not taken the
salt. This fact is mainly because in PT there were few
individuals with positive slides (prevalence 6.25%), all of
whom had reported the use of treated salt.
In SNV, where all the population sample reported the
regular use of chloroquinised salt and where no positive
slides for malaria parasites were detected during our
study, statistical analysis could not be carried out. A
proportion of this population had shown antibodies against
CS antigen, which implies that they had been bitten by an
infected Anopheles but did not develop the disease
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clinically and/or parasitologically because unlike some
antibodies CS antibodies are known be short lived. It is
possible to suggest then, that they had been protected by
the action of chloroquinised salt since this is the only
control measure which targets the parasite that is adopted
by those in SNV.
Considering that, at least, two whole SNV families
included in this study, were positive for one or more
malaria CS antigens tested and that no Anopheles mosquitoes
were detected inside their houses, the most likely
suggestion is that they were bitten in the forest area that
surrounds the SNV residential and industrial areas, where
they usually go for leisure and where, we know from this
study, that there are infected Anopheles.
4.5 Haptoglobin: an indicator of malaria infection?
For Brazil, there are no data available in the literature
available on haptoglobin levels in areas where malaria
transmission occurs, while for other countries in Africa
there are several reports showing that the hypo and/or
ahaptoglobinaemia are strongly linked with malaria
infection. Our results from areas of liqht and medium
level malaria transmission areas now clearly show a
significant correlation between low level and/or the
absence of haptoglobin and malaria. In SNV a non-endemic
area, the sample tested had displayed normal and high
levels of haptoglobin.
Surprisingly, a correlation between ahaptoglobinaemia
(absence of haptoglobin) and malaria was not seen whereas
it was seen for hypohaptoglobinaemia and malaria. It was
expected that the correlation with ahaptoglobinaemia would
be strongest, as has been shown in children from Africa.
The number of children without haptoglobin in their sera
(11 out of the 49 with abnormal levels of haptoglobin) was,
however, insufficient to show a correlation.. Nevertheless,
considering the analysis for the entire group of children
who had an abnormally low level of haptoglobin, it is
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possible to conclude that as in Africa, in Brazil
haptoglobin can be used as an indicator of malaria
infection.
4.6 Ch].oroquine in urine and serum
The results obtained from Haskin's method and ELISA for the
detection of chioroquine in urine and serum samples
confirmed the high sensitivity of the ELISA test in
comparison with the HK colorimetric test (Shenton et al.,
1988), and the difficulty of achieving a steady level of
chioroquine in human fluids sufficient to protect against
malaria infection. The sensitivity of the Haskin test
demonstrated by Shenton et al, 1988 was 3 Lg/ml and in the
comparison between this test and ELISA, showed that Haskin
failed to detect 30% of the urines positive detected in
ELISA. In our study the failure of Haskin test was about
50% and the ELISA test detected chioroquine concentrations
as low as 1 ng/ml. The negative results of the Haskin's
test for some urines with positive ELISA test is not
unexpected. The serum level of chloroquine recognised as
protective against malaria was established by WHO, (1973)
as an average level of 30 ng/ml. Salt intake varies from
individual to individual and is low in young children who
normally have more sweet and/or lightly salted meals, in
adults who have an unsalted diet due to medical advice, and
in those who use lightly salted food because they do not
enjoy the taste. In addition, the number of salted
meals/day and the excretion rate of chioroquine varies
individually (Paulini & Pereira, 1963), and can affect the
detection of chloroquine. Thus, the range of amounts of
chioroquine detected in both urine and/or serum samples can
be very variable individually and within a population. This
does not mean that the amount detected is or is not
protective.
The mean concentration of chioroquine detected in urine
showed variation between areas. For serum this variation
was also observed but was larger.
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Paulini & Pereira, (1963) carried out studies on the renal
excretion of chioroquine derivatives and found, that mean
rates of individual excretion differed statistically.
The results of high variability obtained in the individual
ELISA tests for chioroquine concentration in urine has
support in the study described above. A plot of
distribution of urine or serum chioroquine concentrations
versus the current malaria infection is shown in fig. 3.8
and no significant difference in levels between the two
groups was seen.
An analysis of the mean and standard deviations of the
concentration of chioroquine detected in both urine and
serum in individuals with either positive or negative
slides for malaria parasites was performed (t-test), no
significant difference was found between the mean values
either for urine and or for serum (p> 0.1 for both). There
was no evidence from this that chioroquine in the serum or
urine indicated any protection against infection.
4.7 Epidemiology of malaria transmission in the Serra do
Navio region
The previous data from SUCAN, shows only that malaria
infections in the SNV region are mainly caused by P.
falciparum and P. vivax and rarely by P.malariae.
As shown by the results of this study the P. vivax-type 2
(variant VK 247) is also widespread in this area since
within our sample populations antibodies against the
specific Cs antigen of this variant were detected and the
sporozoite of this variant was identified in mosquitoes.
Whether the clinical features, incubation and patent
period, relapses and the response to antimalarial drugs is
similar or not to those described for the classical and
well known P. vivax needs to be investigated.
The new "P. vivax-like" parasite (type 3), which was
detected in the population was not tested for Anopheles
mosquitoes. As it has been reported to be circulating
within two other populations of the Amazon region
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(Paragominas and Jacundá in Pará state), we believe that
like the other types of P. vivax, it is widespread in the
Brazilian Amazon. As for variant VK 247, nothing is known
about the clinical features, relapses, or sensitivity to
antimalarial drugs.
There were no previous published data about Anopheles
mosquitoes from this area and no study of transmission has
been carried out in this region by SUCAM. There are
records, however, of the Anopheles species distribution in
the SNV area obtained by the malaria control programme of
the ICOMI company. These reports show that in the 1960's
An. darling-i was found even in some places close to the SNV
residential areas. Due to the introduction of the control
programme, this species had disappeared from SNV and has
only been reported, occasionally, from the "carpintaria".
As An. darling-i is very anthropophilic (Deane et al.,
1948), the introduction of control measures against the
vector caused this species of Anopheles to lose its main
source of blood (man) and this probably led to the failure
of the population to survive in or close to SNV itself.
Our findings support the data from ICOMI since we captured
a small number of An. darling-i (16 specimens)only from the
carpintaria, CAB and ARR but none from SNV and PT. Its
distribution is basically in the areas localised at the
foot of the hill. On the top of the hill, where the SNV
residential and administrative areas are settled, the
Anopheles species captured during our study were species
known to be more zoophilic than anthropophilic. In the
forested areas along the roads the species captured were
the same as those captured on the top of the hill, with
only slight changes in the density and diversity of the
Anopheles mosquitoes when the collections were performed
close to the residential areas. Thus, those species
captured in the forest areas are mainly zoophilic and their
maintenance is supported by blood meals from animals other
than man.
Reports on malaria vectors in Brazil are few.. Based on
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studies carried out on the 1940's and 1950's by Prof.
Deane's team, it was established that along the coast,
malaria was transmitted with a low level of endemicity by
the salt-water breeder An. aguasalis and in all other areas
where malaria transmission occurred, An. darlingi was the
vector. They also demonstrated, however, that some other
species such as An. albitarsis and An. braziliensis could
be of secondary importance as malaria vectors.
Only in the 1980's Arruda et al., (1986) carried out
studies on the distribution of Anopheles species, and on
their role in malaria transmission in Pará state and found
other Anopheles species carrying malaria sporozoites by
ELISA and RIA (radioimmunoassay) and suggested they are
possible malaria vectors. The species are: An. darlingi,
An. albitarsis, An. oswaldoi, An. nuneztovari and An.
triannulatus. The last three had not been found infected in
Brazil. All species harboured P.vivax, but An. darlingi and
An. oswaldoi also harboured P. falciparum. Tadei et al.,
(1988), studied the distribution and the dynamics of
malaria transmission in Ariquemes in Rondonia State. They
demonstrated by positivity rate for sporozoites in the
salivary glands using traditional dissection that An.
darlingi is the main vector in this area, while by ELISA
they reported positivity in An. nuneztovari, An.
triannulatus, An. galvoi and An. peryassui for P. vivax,
and double positivity for, P.falciparum and P. vivax, in
An. darlingi. Klein et al., (1991) pointed out in their
study the role of An. albitarsis as a malaria vector in
Rondonia State. In the present study, in an area far from
all previously reported, we have found 15 different
species of Anopheles mosquitoes and also found other
Anopheles than An. darlingi carrying human malaria
sporozoites detectable by ELISA. The species were the same
as those found by Arruda and colleagues, plus	 An.
braziliensis and An. rangeli. The latter was positive only
for P. rnalariae.
Despite the apparently low rate of positivity of the
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Anopheles mosquitoes for malaria sporozoites, either
detected by salivary glands dissection or by ELISA, it is
well known that this low positivity is more than enough to
maintain continuity of malaria transmission, nevertheless
the finding of an Anopheles mosquito infected with a
malaria sporozoite does not mean that it is a vector (Wirtz
et al.,1988). To incriminate an Anopheles species as a
vector, studies on the behaviour and habits of the species
(anthropophilism, possible endophilism, time of biting,
life expectancy, life expectancy of infected females,
vectorial capacity, etc.) have to be carried out. The
positivity for the sporozoite, at least, demonstrates that
the species can be infected with malaria parasites, which
classifies it as a candidate vector.
Since all Anopheles species were collected with human bait,
they are obviously sufficiently anthropophilic to be
malaria vectors.
As An. albitarsis was caught only with human bait,
presented the highest density over all study areas, and was
positive by ELISA and by salivary gland dissection for
malaria sporozoites, it probably plays an important role in
the epidemiology of malaria in these area. Nonetheless, it
is worth noting the nuiriber of An. nuneztovari caught in
CAB, which as in Venezuela (Galbadon, 1981), in Suriname
(Rozendal, 1990) and in other areas of Brazil probably
plays a role in malaria transmission.All Anopheles
mosquitoes positive for P. malariae were collected in the
forested areas, where on several occasions during the catch
we saw small monkeys. As P. brasilianum (monkey malaria
parasite) is genetically and morphologically
indistinguishable, it is possible that a sylvatic cycle of
this parasite is taking place in such areas. Our records
did not show infection in man caused by P.malariae and the
Hospital records and SUCAN data shows a very low prevalence
of this parasite, and yet the highest positivity for
Plasrnodium in mosquitoes was for this species. The
maintenance of this Plasmodium could therefore be through
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the monkeys.
The positive breeding sites had the immature forms of those
Anopheles species that were also captured as adults,
demonstrating that these breeding sites are important in
the maintenance of all these species.
4.8 The role of chioroquinised salt as a preventive measure
for malaria in the study areas.
In all study areas, at least, one control measure for
preventing malaria has been applied, that is the house-
spraying of DDT every 6 months, which for the past years
has been applied irregularly by SUCAN. This is all that has
been done for ARR and IND, while in PT and CAB a certain
proportion of the population also use individual protection
such as bednets and/or domestic insecticide.
Resistance of the Anopheles mosquitoes to DDT has been
reported from different areas where malaria transmission
occurs. Suarez et al., (1990) reported resistance of An.
darlingi from an area of the pacific coast of Colombia, and
Tauil,	 (1992) refers to insecticide resistance in
mosquitoes from some areas of Brazil. Thus, the continuity
of malaria transmission in Brazil, where DDT has been
applied needs further investigation in order to determine
the spread and intensity of insecticide resistance.
In PT the majority use chloroquinised salt as a preventive
measure while in CAB a smaller proportion of the population
used this salt.
To establish some correlation between the habit of daily
intake of chloroquinised salt and protection against
malaria infection, we measured chloroquine in the urine and
serum, measured the positivity rate for Plasmodi urn
infection, and/or the level of anti-sporozoite antibodies.
Different factors may influence the results, such as other
measures for controlling malaria transmission.
Nevertheless, in SNV where other control measures were
applied, mainly to avoid the man-vector contact inside the
residential area, and where no malaria had been reported,
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measurement of the level of antibodies to sporozoites may
be a possible mechanism for examining correlation between
intake of the salt and protection against malaria
infection.
As is well known chioroquine, a blood schizontocide,
prevents the development and growth of malaria parasites in
the blood stream. Consequently, the release of merozoites
into the blood for the reinvasion of erythrocytes does not
occur and a new blood cycle does not take place.
Other control measures such as: treatment and/or
destruction of breeding sites, spraying of DDT, screened
windows and doors, good sanitation for all residential and
industrial areas, the existing cordon sanitaire separating
the populated areas from the forest areas, have been used
in SNV to decrease and/or stop man-vector contact. These
should not affect the relationship between positive blood
slide and anti-CS antibody.
Of course, the results obtained in SNV where a dramatic
decrease in malaria was reported in the 1960's and
thereafter no malaria infection has been reported within
the population of SNV, is due to the use of a combination
of control measures.
The results of this study show, however, that about 40% of
the sample of the SNV population studied have specific
antibodies against CS antigen but have not developed
infection, clinically and/or parasitologically despite
their contact with infected Anopheles mosquitoes. It is
arguable therefore that they have been protected by the
only control measure which targets the parasite,
chloroquinised salt.
The SNV population has been protected against P. faiciparurn
despite the high level of chloroquine-resistant P.
falciparuxn strains in the control areas. One expanation
would be that the strains of P. falciparum circulating in
the area of SNV are chioroquine sensitive.
The results do not demonstrate whether the ancpheline
population from Serra do Navio is isolated or r.:t from
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those found in the control areas. The probability of
interchange between the populations is high, since the
distance between SNV and the control areas, especially CAB
is not great (Eyles, 1944). Also the ability of mosquitoes
to fly long distances and be carried by wind (Eyles, 1944),
are factors that support the idea that the anopheline
populations are not separated. The lack of infected people
in SNV supports the idea that mosquitoes became infected by
blood meals taken from people in the surrounding areas
where it was known that chioroquine resistant P. falciparum
strains circulated. Why then was there no infection in SNV
if the residents were bitten by infected Anopheles as
demonstrated by the detection of anti-sporozoite
antibodies? P.vivax, P. malariae and probably the variants
of P.vivax are chioroquine sensitive, the intake of
chioroquinised salt probably protected against the
infection. In the case of P. falciparum, although the
number of people presenting anti-falciparum CS antibodies
was not high (about 10% of the population sample) and they
were detected in more adults than children (16 aged 5 to
13), it is still difficult to explain the complete lack of
infection by P. falciparurn. As suggested above it seems
that by chance the infected mosquitoes that had bitten
these individuals were infected only with the falciparum
chloroquine sensitive strains. A possible explanation is
that An. darlingi transmits the resistant strains and is
not found near SNV, whilst those mosquitoes in SNV only
transmit chloroquine sensitive P. falciparum (Sucharit et
al., 1977, Wilkinson et al.,1976) . The intake of other
antimalarial drugs could be an additional reason for
suppression of the infections, but there is no evidence of
this intake from the questionnaire in this study. Although
the absence of An. darlingi is suggestive, why P.
falciparum infection is not found in SNV remains a mystery.
4.9 An overview of malaria control in Brazil
The control measures adopted by the Brazilian government
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for malaria, based on WHO's malaria eradication programme
have been based on the assumption that: 1- transmission
occurs predominantly indoors, 2- there is no animal
reservoir of epidemiological importance and, 3 -
insecticide applied to surfaces provides contact and
residual effect (Tauil, 1992).
This programme has failed mainly in the Brazilian Amazon
where the increase of malaria was due to the migratory
movement, the emergence of drug resistance and the failure
of the effect of the control measures applied to target the
Anopheles mosquito.
Cruz Marques, (1986) and (1987) carrying out an analysis of
the spread of malaria in Brazil showed that such spread
started in the 1960's with the building of new roads
linking the south with north, continued in the 1970's with
the establishment of hydroelctric projects and in the
1980's with the emergence of the gold prospecting sites. He
classified the old transmission areas in the Amazon region
in Brazil as "stable malaria", and areas where transmission
had recently be introduced as "frontier malaria". The
latter, characterized by high vectorial density; exposure
to vectors and extradomiciliary transmission; low level of
immunity in the migrants; high morbidity but relatively low
mortality; a high proportion of cases of P.falciparum;
difficulty in the application of conventional control
measures and high population mobility.
Due to all the changes observed in malaria transmission
within the Amazon region summarised above, the Brazilian
governmental malaria control programme is redirecting
plans. The new strategies consider the characteristics of
malaria transmission one by one in the different
epidemiological zones, that is the new control strategy is
the identification of main local risk factors and the
subsequent adoption of appropriate measures. For example,
in the human settlements in gold prospecting areas the
houses have no wall, so, what is the objective in spraying
these "houses"?
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For areas such as gold prospecting sites it is very
difficult to establish which control measures will be
effective since house-spraying is useless, the antimalarial
drugs are ineffective due to the high level of resistance
and the miners are highly exposed due to the duties of the
job. So, the long term hope would be a vaccine that is not
usually influenced by the socio-economic status of the
population. The trials with vaccines have given rise only
to doubts due to the lack of proven efficacy.
A vaccine trial is being carried out in Rondonia State in
Brazil, using the blood-stage form vaccine (three fragments
of antigens from the inerozoite linked by a repeating
peptide of the CS protein) produced by Dr. Patarroyo but no
preliminary results have been reported. This vaccine is
also under evaluation in a double-blind randomized placebo-
controlled study that has started in Tanzania in January of
this year, since the data from the trial in Latin America
was inconclusive (TDR news, 1992). Other candidate antigens
for vaccines are being investigated and an effective new
tool for controlling malaria may result.
The Meeting of WHO held in Amsterdam last year resulted in
a global malaria control strategy which suggested that each
country based on its specific characteristics of malaria
transmission had to identify local problems and priorities
in order to apply appropriate interventions (WHO, 1992c).
The basic technical elements of the strategy have to be:
early diagnosis and prompt treatment, planning and
implementation of selective and consistent preventive
measures, early detection, containment or prevention of
epidemics and, to be up to date with the malaria situation
in the country, especially for the determination of
ecological, social and economical factors relevant to the
transmission of the disease.
Based on the suggestions described in the last paragraph
and considering the classification made by Cruz Marques,
(1986) and (1987), the control areas of our study, CAB, PT
and ABR have the characteristics of areas of "stable
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malaria". These characteristics together with the facts
that the houses are walled, the transmission is intra
and/or peridomiciliary and the prevalence of malaria
parasites is not so high, we believe that the
identification of the risk factors of these areas will
provide some useful tools for the design of an effective
plan for malaria control. Suggestions for appropriate
control strategies are listed in the section on
recommendations.
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CONCLUS IONS
The epidemiological picture of malaria infection in all
study areas has been well established:
1 - The malaria infections are mainly caused by Plasmodium
.falciparum and by Plasmodium vivax: "2 additional
variants" of P. vivax have been found circulating
within the populations;
2 - All study areas, except IND are areas of hypo to meso-
level of endemicity of malaria;
3 - Malaria infection in all areas other than SNV, is
not related to sex and/or age;
4 - In the control and IND areas, malaria is associated
with the presence of enlarged spleen;
5 - In CAB and PT, the intake of chloroquinised salt is not
related to the prevalence of the infection;
6 - Chloroquine and amodiaquine resistance occur in all
control areas.
7 - Quinine and mefloquine should still be effective as
antimalarial drugs for treating falciparuni malaria in
the control areas, according to in vitro results.
8 - Seropositivity agaisnt malaria parasites is seen to be
age-related in the population studied;
9 - In SNV, CAB and ARR, the IFAT-determined seropositivity
against P. falciparum is associated with history of
malaria and is seen mainly in the adults;
10- All individuals samples from IND show IFAT antibody
against P. falciparum;
11- In all studied areas, the antibody prevalence against
P. vivax is lower than that against P. .falciparum, but
for ARR this difference is very small;
12- In SNV and ARR, the presence of antibody against P.
vivax is not related to malaria history;
13- The presence of antibody against P. vivax in CAB and PT
is related to malaria history especially when the whole
group (children and adults) is taken together, but also
when children are considered separately;
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14- The risk of becoming infected with malaria parasites is
low (1-5% per year) for all control areas but lower
(< 1%) for SNV;
15- The ELISA test using asexual blood stages of malaria
parasites as carried oput in this study, has given
unsatisfactory results;
16- ELISA using malaria sporozoite repetitive CS antigens
has been valuable for demonstrating contact between
people and infected mosquitoes;
17- In all studied areas individuals were found who had
been challenged with more than one species or type of
malaria sporozoite;
18- The low level of haptoglobin in children is an
indicator of malaria infection in control areas
and IND areas;
19- Despite the low sensitivity shown by Haskin's method
when compared with the ELISA test for detecting
chioroquine, this method is applicable to the purpose
of monitoring the daily intake of chioroquinised salt;
20- ELISA for chioroquine detection is also a good tool for
monitoring the intake of chioroquine because it detects
very low concentrations (1 ng/ml);
21- Anopheles mosquitoes were not found inside the
residential area of SNV;
22- Transmission of malaria infection in the control
areas, is apparently both indoors and outdoors;
suitable mosquitoes were found in both locations;
23- Transmission can occur throughout the entire year but
is most likely after the rainy season when the density
of Anopheles mosquitoes becomes higher;
24- An. albitarsis, if not the main vector for these
areas, probably plays an important role in malaria
transmission in all control areas due to its density in
comparison to the other species found, its positivity
for malaria sporozoites aid its habit of feeding
indoors in the residential areas;
25- An. nuñeztovari may also play an important role in
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malaria transmission in CAB, where it was caught as
immature and adult forms: it was found positive
for P. vivax, P.vivax-variant VK247 (type 2) and P.
malariae;
26- There are other species of Anopheles mosquitoes such as
An. oswaldoi and An. braziliensis that also have a role
in malaria transmission, since the first was found
infected with P.falciparum and the second was the
second most frequent species in ARR and 'was found
positive for P. malariae.
27- An. darlingi, a very efective malaria vector was found
in collections with human bait, in the vicinity of ARR
and CAB, and not in SNV or adjacent forest;
28- The daily intake of chioroquinised salt th SNV has been
implicated, at least partially, in the prevention of
malaria infection in this area;
29- The lack of malaria infections in SNV although CS
antibody studies indicate exposure to infected
mosquitoes, suggests that there may be species in the
area which do not readily transmit chioroquine-
resistant P. falciparura strains. The absence of An.
darlingi from SNV may perhaps be responsible for the
apparent absence of chioroquine-resistarit malaria
there;
30- The programme for controlling malaria transmission in
SNV, proved to be very effective.
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7.1 Monitoring the presence and/or spread of
resistance of falciparum and vivax malaria to the
antimalarial drugs which have been or are used at
present;
7.2 Trials in the application of new antimalarial
drugs (halofantrine and artemisinin) recently
introduced into Brazil and the evaluation of their
efficacy and effects among these populations;
7.3 Studies of the diversity and polymorphism of the
malaria parasites and/or candidate antigens for
vaccines in order to assess the degree and
distribution of such diversity and polymorphism;
7.4 Studies on the distribution of P. vivax variants
to establish their clinical features, sensitivity
to antimalarial drugs and the occurrence of
relapses;
7.5 Nothing is known about innate susceptibility to
malaria in Brazil. It would therefore be important
to study the presence of the sickle cell gene,
thalassaemias and G-6-PD deficiency in the Amazon
region. An MHC study of association with malaria
infectivity or severity may be of interest;
7.6 Investigation of the protective impact of
chioroquinised salt within a selected population,
carrying out a trial where its effect alone and
together with other control measures could be
evaluated. The population diet would also have to
be surveyed in order to evaluate the real daily
intake of this salt;
7.7 Studies to study the behaviour of the Anopheles
species as vectors, and the capability of
harbouring chioroquine sensitive and resistant P.
fal ciparum;
7.8 Studies of the present levels of the sensitivity!
resistance of the Anopheles mosquitoes of these
areas to insecticides, not only to DDT that has
been used for many years, but also to others that
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RECOMMENDATIONS
1 - The use of antimalarial drugs such as chloroquine and
amodiaquine for treating falciparum malaria must be
avoided in this study region, unless a rapid
diagnostic test becomes available to determine if a
patient carries a resistant or sensitive strain;
2 - Areas such as ARR and CAB, in which the residential
area is too close to the forest, could try to
establish a ring of protection by forest clearing or
building houses about 20Cm away from the forest;
3 - For ARR, PT and CAB where breeding sites for the
immature stages of Anopheles mosquitoes were found,
a programme for their control could be established.
Those breeding sites that are permanent, such as
ponds, small rivers and the main river could be kept
free of vegetation on their edges, free of the rubbish
that is usually dropped into them, and be treated.
Those that are temporary such as pools, creeks,
flooded areas, could be removed and/or be kept clean;
3 - A sanitary education programme could be carried out in
the control areas in order to provide them with basic,
but important information about malaria transmission
and to demonstrate how and why malaria transmission is
prevented;
4 - The spraying of insecticides with residual effect
could be continued with monitoring for the possible
emergence of resistance of insecticides in the
vectors;
6 - Transference of the knowledge and experience of the
ICOMI programme for controlling malaria transmission
to other similar companies settled in the Amazon
region, would certainly contribute to the decrease of
the morbidity of malaria in Brazil;
7 - At least, the following further studies to understand
malaria in the areas where this study was carried out,
would be valuable:
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can be introduced into these areas in the future;
7.9 A study on the application of impregnated bednets
or hammocks, the usually bed for people in the
Amazon region and an evaluation of their efficacy;
Areas in this region of Amapã State would also be suitable,
following these further studies, for coordinated
intervention trials to establish a model for use in similar
localities throughout the Amazon region.
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APPENDIX 1
PERSONAL DATA
ID number: ..........
Name .
 ..........................
Sex.......Ages ......Place of birth......
Address:
How long have you been at the above address?
Past addresses (till 10 years ago):
1 - ...................period. ....
2 - ...................period. .
3 -	 ..................period:.
Do you use chioroquinized salt?
yes C ); no C )	 If yes, for how long' .......
Do you use personal protection?
yes ( ); no ( )	 If yes, which one?
Reported tropical diseases:
Malaria	 C )	 If yes, how many times? . .
Leishmaniasis
Filariasis
Chagas' disease	 ( )
Toxoplasmosis	 ( )
Past malaria infection:
Type	 Date (year)	 Probable area where infection
acquired
Are you using or have you used any medicine?
yes C ); no ( )	 If yes, which and for how long?
Splenic rate: 0 ( ); 1 C ); 2 C ); 3 ( ); 4 ( )
NOTES:
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APPENDIX 2
PAULINI'S METHOD
It is a spectrophotometric method for the dosage of
chloroquine, that is performed as:
0.5 g of chioroquinised salt containing approximately 0.2%
of chioroquine base, is dissolved in 100 ml of dH2O. After
vigorous agitation, if necessary, filtrate through dry
paper. Then, the CD is determined in a spectrophotometer
with 360 t.
For obtaining the percentage of chioroquine base in the
salt, the determined CD is multiplied by the factor 0.346.
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APPENDIX 3
Glycerolyte 57 solution
It is a sterile nonpyrogenic solution:
Glycerine USP ..................100 ml
Sodiumlactate ..................l.6g
Potassium chloride ...............30.0 mg
It is buffered with:
Monobasic sodium phosphate
Dibasic sodium phosphate
pH approx. 6.8
TENWAL LAEORATORIES
Division of Travenol Laboratories, Inc.
Deerfield, IL 600 15, USA
Distributed in Canada by
Travenol Canada Inc.
Mississauga, Ontario, Canada 14V 1J3.
1.6 mg
124.2 mg
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APPENDIX 4
Blocking buffer used in ELISA test for the detection of
malaria sporozoites in mosquitoes.
Casein (0.5%) . . . .	 ......	 .	 .	 . . 5.00 g
0 . iN NaOH . . . . . . . 	 .	 .	 .	 .	 .	 . 1 0 0 . 0 0 ml
PBS, pH 7.4 . . . . .	 ..... .	 .	 .	 . 900.00 ml
Thimerosal (0.1%) . . .	 ....... .	 . . 1.00 ml
Red phenol (0.1%) . . .	 .	 .	 ....... 200.00 Ll
1- Dissolve the casein in 0.1N NaOH solution by ebullition;
2 - Add the PBS to the solution of casein, but slowly;
3 - Adjust the pH to 7.4 b with HC1; and
4 - Add the timerosal and red phenol
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APPENDIX 5
METHOD OF ANALYSIS BY CARPENTER (DRAPER ET AL., 1972)
The risk of infection can be estimated in areaswhere
malaria is endemic by assuming that the inhabitants are at
fairly constant risk of infection.
Suppose t is a probability of a person being infected in a
short interval of time (a day), the probability of a person
never having been infected in n days (being serologically
negative at age n days) is:
Prob ( -ye) = (1 - t)	 e
If age is measured as usual in years and u = 365t, then
Prob (-ye at age A in years) = - uA and the
probability of a person livingin the area being infected in
a year is given by R,
R = probability of being infected in 1 year
= infection R
= 1 - • -u
Infection rate estimation of an area can be calculater by
producing the number of people tested, and the proportion
serologically positive in a sequence of age groups
(children under one year omitted, due to presence of
congenital antibodies).
According to the model in the ith group age A1
Proportion +ve = 1 - -uA
consequently,
-log (1-proportion =ve) = ua1
That is, if the proportiom of +ve is plotted on a reverse
log scale, the model predictsa linear relationship with age
apart from random sampling errors.
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APPENDIX 6
SEQUENCE OF PRIMERS FOR P. v.ivax AND P. falciparuzn
1 - P. vivax
AL 60 GTC GGA ATT CAT GAA GAA CTT CAT TCT C
AL 61 CAG CGG ATC CTT AAT TGA ATA ATG CTA GG
AL 114 ATC AAC CAG GAG CAA ATG
AL 116 GGT GAT AGA GCA GAT GGA
AL 54 CCA TGC AGT GTA ACC TGT GGA
2 - P. falciparum
AL 52 CAG GAA ACA GCT ATG AC
AL 53 GTA AAA CGA CGG CCA GT
AL 3 AAC ACA AGG GTT CTA AAT GAA. TTA
AL 9 AAT AAA AAC AAT CAA. GGT AAT
AL 164 CAT GGG GAG GAT TCA GTT G
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ABBREVIATIONS USED ON THE APPENDIX OF RESULTS
S
	 Sex
A	 Age
MH
	 Malaria history
SL	 slide
SR	 spleen rate
IF
	
IFAT for P. falciparum
Iv
	 IFAT for P. vivax
EB
	 ELISA for blood stages
CSF	 ELISA for sporozoite of P. falciaprum
cSv	 ELISA for sporozoite of P. vivax - type 1
CSK	 ELISA for sporozoite of P. vivax - type 2
CSN	 ELISA for sporozoite of P. vivax - type 3
CSM	 ELISA for sporozoite of P. malariae/P.brasilianum
CHS	 Chioroquinized salt
PF
	
P. falciparum
Pv	 P. vivax
MX
	 Mixed infection (P. falciparum + P. vivax)
ND	 Not done
N
	 Negative
P
	 Positive
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S	 A MH SR
F
F
M
F
M
F
M
F
F
F
F
F
M
M
M
F
M
F
F
F
F
N
F
M
F
F
F
F
F
F
F
F
M
M
M
F
F
M
M
M
M
M
M
F
F
F
M
F
F
F
25
5
3
6
9
5
37
11
11
33
26
5
4
3
1
34
47
9
33
17
35
26
4
ii
12
2
30
18
14
49
46
11
14
46
7
8
29
10
26
38
37
8
11
9
9
31
29
2
1
27
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y2
N
N
N
N
N
N
N
N
N
N
N
N
Yl
N
N
N
N
N
N
N
N
N
Yl
Y2
N
N
N
N
N
N
N
N
N
APPENDIX 7
TARGET AREA: SERBA DO NAVIO
HG BK CQUR CQSECODE
ICo-001
ICO-002
ICO-003
ICO-004
ICO-005
ICO-006
ICO-007
ICO-008
ICO-009
'Co-Olo
'Co-Oil
ICO-012
ICO-013
ICO-014
ICO-015
ICO-016
ICO-017
ICO-018
'Co-Olg
1C0-020
ICO-021
ICO-022
ICO-023
ICO-024
I Co -025
ICO-026
ICO-027
ICO-028
ICO-029
ICO-030
ICO-031
ICO-032
ICO-033
ICO-034
ICO-035
ICO-036
ICO-037
ICO-038
ICO-039
ICO-040
ICO-041
ICO-042
ICO-043
ICO-044
ICO-045
ICO-04 6
ICO-047
ICO-048
ICO-049
ICO-050
ND
ND
ND
ND
ND
1655
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
>250 0
ND
ND
ND
ND
ND
ND
1280
ND
ND
ND
ND
ND
ND
ND
p
	
ND
p
	
ND
N
	
ND
N
	
ND
N
	 600
N
	 1200
p 10000
N
	
ND
N
	
ND
N
	
ND
p
	 940
p
	 1200
p
	 990
p
	 490
N
	 990
p
	 1900
p
	 990
p
	 440
p
	 760
p
	 520
N
	 730
p
	
ND
N
	 990
N
	 1000
N
	 560
N
	 1000
p
	 1700
p
	 1600
p
	 900
N
	 450
N
	 760
N
	 950
N
	 880
N
	 700
p
	 1200
N
	 860
p
	 990
N
	 730
p
	 950
p
	 700
p
	 990
N
	 360
N
	 250
N
	 240
p
	 330
N
	 220
p
	 290
N
	 220
N
	 310
p
	 1600
12.5
ii
10.7
10.1
4.6
6.4
6.4
9
11.5
9.9
6.3
9
3.2
8.5
5.2
6.9
8.1
8.5
8.6
2
18
8.1
10.8
8
8.5
8.6
6.5
11.5
60
8.5
1
10
17
11.5
2.6
6
6.6
3.8
3.2
1.5
3.4
1.6
2.9
3.5
5.1
2.3
4.8
10
7.5
8.5
222
F
F
M
M
F
M
F
M
M
F
F
F
M
F
M
F
M
M
M
M
F
F
F
F
M
M
M
M
N
F
M
F
M
M
M
M
M
F
F
M
N
M
F
F
F
M
M
M
F
F
F
F
F
F
M
M
8
46
57
18
37
14
13
10
36
8
5
3
7
25
31
36
14
12
40
32
33
5
2
36
11
14
12
50
6
17
14
40
39
38
45
37
23
25
6
1
21
16
33
5
4
34
8
24
22
3
11
5
11
36
15
38
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Yb
N
N
Yb
N
N
N
N
Yl
N
N
N
Yl
N
N
N
Yl
N
N
Yb
Y4
Yb
N
N
N
N
N
N
N
N
N
N
Y4
N
N
N
N
N
Yb
Yb
N
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
250
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
P
N
P
N
N
P
P
P
N
N
N
N
N
P
P
N
N
N
N
N
P
N
N
P
N
N
N
P
P
P
P
N
P
N
P
P
P
N
P
N
P
P
P
P
P
P
P
N
P
N
P
N
N
P
P
P
ICO-051
ICO-052
I Co -053
ICO-054
ICO-055
ICO-05 6
I CO -057
ICO-058
ICO-059
ICO-060
ICO-0 61
ICO-062
ICO-063
ICO-0 64
ICO-0 65
ICO-066
ICO-0 67
ICO-068
ICO-069
ICO-070
ICO-071
ICO-072
ICO-073
ICO-074
ICO-075
ICO-076
ICO-077
ICO-078
ICO-079
ICO-080
ICO-081
ICO-082
ICO-083
ICO-084
ICO-085
ICO-086
ICO-087
ICO-088
ICO-089
ICO-0 90
ICO-091
ICO-092
ICO-0 93
ICO-094
ICO-0 95
ICO-096
ICO-097
ICO-098
ICO-099
ICo-100
'CO-b'
ICO-102
ICO-103
ICO-104
ICO-105
ICO-106
320
700
340
720
310
800
ND
700
420
210
360
990
410
780
250
8500
3911
1050
370
1900
4000
480
410
210
753
110
160
184
180
150
220
220
2349
160
230
190
200
260
220
190
230
280
260
180
210
290
310
360
410
230
250
200
220
1200
420
300
6.2
1
2.5
1
2.4
1
1.6
8
1
4.9
2.7
1
6.1
1.7
5.1
6.6
13
10
6.7
2
12
19
10
2.3
4
2.6
ND
5.6
1.8
1
4.4
2.5
4.9
1
2.4
1
6.4
8.2
8.5
12
9
2.1
1.9
2.6
5.1
1.2
1.3
1.5
1.3
1.2
1.1
1.1
1.2
1.2
1.2
1.3
223
M
F
F
F
M
F
F
F
M
M
F
M
M
F
M
F
M
F
F
M
F
M
F
F
M
M
F
F
F
M
M
F
M
F
M
M
F
M
M
M
N
F
F
M
F
M
F
M
F
F
M
M
M
F
F
F
31
30
5
13
3
7
10
31
42
31
28
9
7
4
2
19
23
3
25
24
8
7
6
33
30
48
42
3
22
13
20
21
51
46
6
43
36
12
10
3
29
24
13
5
31
35
43
53
3
10
26
26
35
26
11
3
N
Yl
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y2
N
N
N
N
N
Y3
Y4
Yl
N
N
Yl
N
N
Yl
Yl
N
N
N
N
N
N
N
N
N
N
N
Yl
N
Yl
N
N
N
N
N
N
N
N
ICO-107
ICO-108
ICO-109
'Co-lb
'Co-ill
ICO-112
1C0-l].3
ICO-114
ICO-115
ICO-116
ICO-117
ICO-118
ICO-119
ICO-120
ICO-121
ICO-122
ICO-123
ICO-124
I Co -125
ICO-12 6
ICO-127
ICO-128
ICO-12 9
ICO-130
ICO-131
ICO-132
ICO-133
ICO-134
ICO-135
ICO-136
ICO-137
ICO-138
ICO-139
ICO-140
ICO-141
ICO-171
ICO-172
ICO-173
ICO-174
ICO-175
ICO-176
ICO-177
ICO-178
ICO-202
ICO-203
ICO-204
ICO-205
ICO-206
ICO-207
ICO-208
ICO-209
ICO-210
ICO-211
ICO-212
ICO-213
ICO-214
ND
ND
ND
ND
1160
ND
1100
ND
ND
ND
ND
ND
1200
480
ND
ND
ND
2560
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
>250 0
ND
ND
ND
ND
1490
ND
ND
ND
ND
ND
ND
ND
ND
<250
ND
ND
ND
ND
1270
ND
ND
ND
ND
ND
ND
ND
p	 260
N	 212
N	 150
N	 155
N	 240
N	 ND
p	 155
N	 ND
N	 ND
N	 155
N	 230
N	 260
N	 180
ND	 ND
ND 540
p	 210
p	 170
N	 155
N	 155
N	 155
p	 180
N	 155
p	 ND
N	 130
N	 330
N	 220
p	 275
p	 260
N	 210
N	 180
N ND
N	 270
p	 850
N	 160
N	 ND
p	 180
p	 150
p	 180
p	 5195
p	 4268
N	 150
N	 150
N	 ND
N 1750
N 2100
p	 1460
N 1300
p	 6200
p 2100
N 6200
N 1450
N	 1100
p 1400
N 2100
N 1500
p	 1055
1.3
0
1.2
1.3
1.2
1.2
0
1.2
1.2
1.2
1.1
1.2
1.1
0
1.3
1.3
0
0
0
0
1.1
0
0
0
1.1
2.1
1
2.7
1
2.4
1
1.6
7.5
1
4.4
5
3.5
6.5
6.5
5.1
1.8
2.9
ND
6.8
8.2
7.5
6
4.2
1
10
8.5
2.8
1.6
1.55
4.2
1.3
224
M
F
F
M
F
F
F
F
F
F
M
M
M
F
M
F
F
M
F
F
F
M
F
M
F
M
F
F
F
F
F
F
F
M
F
F
F
F
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
M
M
F
8
5
29
33
14
7
5
10
12
39
41
33
37
31
9
6
4
33
25
2
32
3
16
58
26
7
45
24
13
59
24
2
25
4
2
29
3
27
3
31
3
12
32
50
28
4
15
25
25
12
29
20
41
48
36
33
N
N
N
Y2
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Yl
N
N
N
N
N
Y4
N
N
Yl
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ICO-215
ICO-216
ICO-217
ICO-218
ICO-219
ICO-220
ICO-221
ICO-222
ICO-223
ICO-224
ICO-225
ICO-245
ICO-246
ICO-247
ICO-248
ICO-24 9
ICO-250
SNV-001
SNV-002
SNV- 003
SNV-004
SNV-005
SNV-006
SNV-007
SNV-008
SNV-009
SNV-010
SNV-011
SNV-012
SNV-013
SNV-014
SNV-015
SNV-016
SNV-017
SNV-018
SNV-019
SNV-020
SNV-021
SNV-022
SNV-023
SNV-024
SNV- 025
SNV-02 6
SNV-027
SNV-028
SNV-02 9
SNV- 030
SNV-031
SNV-032
SNV-033
SNV-037
SNV-041
SNV-058
SNV-060
SNV-0 61
SNV-0 62
ND
1465
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1200
ND
ND
1430
ND
ND
1020
ND
2030
ND
ND
1900
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
p
	 5800
p
	 ND
p
	 1300
p
	
6000
p
	
980
p
	
1070
N
	
1080
p
	
5200
p
	 870
p
	
1850
N
	
8600
N	 1100
p
	
2245
p
	
2348
N
	
1148
N
	
880
P
	 ND
p
	
990
ND	 ND
ND	 ND
p
	 550
ND	 ND
P
	
280
p
	
1050
ND	 ND
P
	 580
p
	
1200
p
	
970
N
	
350
P
	
1180
ND	 ND
N
	
130
p
	
2100
N
	
150
N	 ND
ND	 ND
N
	
ND
p
	
ND
P
	
880
p
	
630
N
	
ND
ND	 ND
ND	 ND
ND	 ND
P
	
1250
N
	
145
N
	
130
P
	
775
p
	
710
P
	
1450
p
	
2100
P
	
1030
p
	
950
p
	
780
p
	
810
p
	
420
1.3
1.4
1.3
1.55
1.4
1.3
1.3
1.5
1.55
1.3
1.3
1.3
5
13
10
5
6
2.3
3.6
0
2.9
1.1
2.7
6.1
3.0
4.3
5.8
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1.1
1.2
ND
ND
1.7
18
21
1.3
1.2
3.1
1.5
225
F
F
M
M
M
F
F
F
F
M
F
F
F
M
F
M
F
F
F
F
F
F
F
F
F
F
N
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
14
12
9
11
7
37
10
4
32
29
22
20
28
44
39
48
31
19
28
51
22
43
36
4
36
29
4
16
24
36
12
31
21
13
63
15
28
15
46
13
20
34
N
N
N
N
N
N
N
N
Yl
N
N
N
N
Yl
N
N
N
N
N
Yl
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Yl
N
SNV-063
SNV-0 64
SNV-065
SNV-066
SNV-0 67
SNV-068
SNV-069
SNV-070
SNV-071
SNV-072
SNV-073
SNV-074
SNV-075
SNV-07 6
SNV-077
SNV-078
SNV- 079
SNV-080
SNV-081
SNV-082
SNV-083
SNV-084
SNV-085
SNV-086
SNV-087
SNV-088
SNV-089
SNV-090
SNV-09].
SNV-0 92
SNV-093
SNV-094
SNV-095
SNV-099
SNV-100
SNV-101
SNV-102
SNV-103
SNV-104
SNV-105
SNV-106
SNV-107
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1660
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
P
	
390
ND	 ND
ND
	 ND
P
	 150
ND
	 ND
P
	
2310
P
	
1740
N
	
290
P
	
230
N
	
120
N
	
0
P
	
370
P
	
280
P
	
1300
P
	
870
ND
	
ND
P
	
530
P
	
490
ND	 ND
P
	
270
P
	
315
P
	
80
ND	 ND
ND	 ND
P
	 ND
P
	
1540
N
	
320
P
	
1190
P
	
740
ND	 ND
ND	 ND
ND	 ND
ND	 ND
ND	 ND
ND	 ND
ND	 ND
ND
	 ND
P
	
975
P
	
850
P
	
1070
P
	
1350
P
	
2160
2.7
ND
2.1
1.1
0
10
2.6
1.3
1.5
1.1
0
1.2
2.3
3.0
1.8
1.7
1.6
1.3
ND
0
1.1
2.0
2.1
0
2.2
5.2
1.3
2.5
1.9
1.5
1.5
ND
ND
2.3
3.5
4.9
11
2.4
1.3
3.5
3.3
9.8
226
TARGET AREA: SERRA DO NAVIO - 1st sample
EB
20
20
20
N
20
20
N
N
20
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
20
N
N
N
N
20
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
CSN
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
P
N
N
N
N
N
N
P
CODE
ICO-col
ICO-002
ICO-003
ICO-004
ICO-005
ICO-006
ICO-007
ICO-008
ICO-009
'Co-olo
'Co-oil
ICO-012
ICO-013
ICO-014
ICO-015
ICO-016
ICO-017
ICO-018
ICO-Ol 9
ICO-020
ICO-021
I CO- 022
ICO-023
ICO-024
ICO-025
ICO-026
I Co -027
ICO-028
ICO-02 9
ICO-030
ICO-031
ICO-032
ICO-033
ICO-034
ICO-035
ICO-036
ICO-037
ICO-038
ICO-039
ICO-040
ICO-04 1
ICO-042
ICO-043
ICO-044
ICO-045
ICO-04 6
ICO-047
ICO-048
ICO-04 9
ICO-050
SL IF, IV
N	 N	 N
N	 N	 N
N	 N	 N
N	 N	 N
N	 N	 N
N
	 N	 N
N
	
N 80
N
	 N	 N
N N N
N
	 N	 N
N
	 N	 N
N	 N 20
N
	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N 80	 N
N	 N	 N
N	 N	 N
N
	 N	 N
N
	 N	 N
N 20	 N
N 20	 N
N
	 N	 N
N
	 N 40
N 20	 N
N 20	 N
N
	 N	 N
N	 N	 N
N	 N	 N
N	 N	 N
N	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N	 N
N 20	 N
N 40	 N
N
	 N	 N
N	 N	 N
N
	 N	 N
N
	 N	 N
N
	 N 40
N 80	 N
N
	 N	 N
N	 N	 N
N
	 N 40
CSF CSV CSM CSK
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 P	 N
N	 N	 P	 N
N	 N	 P	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 P	 N
N	 N	 P	 N
N	 N	 N	 P
N	 P	 P	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 P	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 P	 N
P	 N	 N	 N
P	 N	 N	 N
N	 N	 N	 N
N	 N	 P	 P
N	 N	 N	 P
P	 P	 N	 N
N	 N	 N	 N
N	 N	 P	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
N	 N	 N	 N
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ICO-051	 N	 N	 N	 N	 N	 N	 N	 N	 P
ICO-052	 N 40
	
N
	
N
	
N	 N	 N
	 N
	
N
ICO-053	 N 20
	
N
	
N
	
N	 N	 N
	 P
	 N
ICO-054	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-055	 N 20
	
N
	
N
	
N
	 N	 N	 N
	
N
ICO-056	 N	 N	 N	 N	 N	 N	 N	 N	 P
ICO-057	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-058	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-059	 N 20	 N	 N	 N	 P	 N	 N	 N
ICO-060	 N	 N	 N	 N	 p	 N	 N	 p	 p
ICO-061	 N	 N	 N	 N	 p	 N	 N	 N	 N
ICO-062	 N	 N	 N 160
	
p
	 N	 N
	 N	 N
ICO-063
	
N
	
N
	
N
	
N
	
N
	
N	 N
	
N
	
N
ICO-064	 N	 N	 N	 N	 N	 N	 N	 N	 p
ICO-065	 N 20	 N	 N	 N	 N	 N	 N	 N
ICO-066	 N	 N	 N	 N	 N	 N	 N	 P	 N
ICO-067	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-068	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-069	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-070
	
N
	
N
	
N
	
N	 N	 N	 N
	 N	 N
ICO-071	 N	 N	 N	 N	 N	 N	 P	 p	 P
ICO-072
	
N
	
N
	
N
	
20
	
N	 N	 N
	
N
	
N
ICO-073
	
N
	
N
	
N
	
N
	 N	 N	 N	 N	 N
ICO-074
	
N 20	 N	 N	 N	 N	 p	 N	 N
ICO-075	 N	 N	 N	 N	 N	 P	 N	 N	 N
ICO-076	 N	 N	 N	 N	 N	 p	 p	 P	 N
ICO-077	 N	 N
	
N
	
N
	
N
	
N	 N
	 N	 N
ICO-078	 N 80
	
N
	
20
	
N	 P	 N	 p
	
N
ICO-079	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-080	 N	 N	 N	 N	 N	 P	 P	 N	 p
ICO-081	 N	 N	 N	 N	 N	 N	 N	 N	 P
ICO-082
	
N
	
N
	
N	 N	 N	 N	 N	 N	 N
ICO-083
	
N	 N
	
N
	
N
	
N
	
N	 N
	
N
	
N
ICO-084	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-085	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-086	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-087
	
N
	
N
	
N
	
N
	
N	 p	 N	 N	 N
ICO-088
	
N
	
N
	
N	 N	 N
	
N	 N
	
N
	
N
ICO-089	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-090	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-091	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-092
	
N	 N
	
N	 N	 N	 N	 N	 N	 N
ICO-093
	
N	 N
	
N
	
N
	
N
	
N
	
N	 N	 N
ICO-0 94	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-095	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-096
	
N	 N
	
N	 N
	
N
	
N	 N
	
N
	
N
ICO-097
	
N	 N
	
N
	 N	 N
	
N	 N
	
N
	
N
ICO-098	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO- 099
	
N	 N
	
N
	 N	 N
	
N
	
N
	
N	 N
ICo-100	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-lO 1
	
N	 N	 N
	
N	 N	 N	 N	 N	 p
ICO-102	 N	 N	 N	 N	 p	 P	 N	 N	 N
ICO-103
	
N	 N	 N
	
N	 N	 N	 N	 N	 N
ICO-104
	
N	 N
	
N	 N	 N	 N	 N	 N
	
N
ICO-105	 N	 N	 N	 N	 P	 N	 N	 N	 N
ICO-106
	
N	 N
	
N	 N	 p	 N	 N	 N	 N
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ICO-107	 N	 N	 N	 N	 N
	 N	 N
	 N	 N
ICO-108
	
N	 N	 N	 N
	 p	 N	 N
	 N	 N
ICO-109
	
N	 N
	
N
	 N	 N	 N	 N
	
N	 N
'Co-lb
	
N	 N	 N	 N
	 N	 N	 N	 N	 N
'Co-ill
	
N
	
N	 N	 N
	 N	 N	 N
	 N	 N
ICO-112
	
N	 N	 N	 N	 N
	 N	 N	 N	 N
ICO-1i.3
	
N	 N	 N
	
20
	
N	 N	 N
	
N	 N
ICO-114	 N	 N	 N
	
20
	
N	 N	 N	 N	 N
ICO-115	 N	 N	 N	 N	 p	 p	 p	 p	 p
ICO-116
	
N	 N	 N
	
N
	
p
	 N	 N
	
N	 N
ICO-117
	
N	 N	 N
	
N
	
p
	 N	 N
	
N	 N
ICO-118
	
N	 N
	
N
	 N	 N
	 N	 N
	
N	 N
ICO-119
	
N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-120
	
N
	
N
	
N
	
20
	
N
	 N	 N	 N	 N
ICO-121
	
N	 N	 N
	 N	 N
	 N	 N	 N	 N
ICO-122
	
N 20
	
N
	
N
	
p
	
N
	
N
	
N	 N
ICO-123
	
N
	
N
	
N	 N	 N
	 N	 N	 N	 N
ICO-124
	
N	 N	 N	 N	 N
	 N	 N	 N	 N
ICO-125	 N	 N	 N
	
20
	
N
	
N
	
N	 N	 N
ICO-12 6
	
N
	
N
	
N
	
N
	
N
	
N
	 N	 N	 N
ICO-127
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
ICO-128
	
N	 N	 N	 N	 N
	
N
	
N	 N	 N
ICO-12 9
	
N
	 N	 N
	
N
	
N
	
N	 N	 N
	
N
ICO-130
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
	
N
ICO-131
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N	 N
ICO-132
	
N 640
	
N
	
N
	
N
	
p
	
N
	
N	 N
ICO-133
	
N	 N
	
N	 N	 N
	
N
	
N	 N	 N
ICO-134
	
N
	
N
	
N
	 N	 N
	
N
	
N
	
N
	
N
ICO-135	 N	 N	 N	 N	 N	 N	 N	 N	 p
ICO-136
	
N	 N	 N
	
20
	
p
	
N	 N	 N	 N
ICO-l37
	
N	 N	 N
	 N	 N
	
N
	
N	 N	 N
ICO-138
	
N	 N
	
N
	
N
	
N
	
N
	
N	 p	 N
ICO-139
	
N 80
	
N
	
40
	
p
	
N
	
N	 N	 N
ICO-140
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
ICO-141
	
N
	
N	 N
	
20
	
N
	
N
	 N	 N	 N
ICO-17].	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-172
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N	 N
ICO-173
	
N
	
N	 N
	
20
	
N	 N	 N
	
N	 N
ICO-174
	
N
	
N	 N
	
40
	
N	 p	 N	 N	 N
I Co -175	 N	 N	 N	 20	 N	 N	 N	 N	 N
ICO-176
	
N	 N	 N
	
20
	
N	 N	 N	 N	 N
ICO-177
	
N	 N
	
N
	
20
	
N	 N	 N	 N	 p
ICO-178
	
N	 N	 N	 N	 N
	
N
	 N	 N	 N
ICO-202
	
N
	
N	 N
	 N	 p
	
p
	 N	 p	 N
ICO-203
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N	 N
ICO-204
	
N
	
N	 N
	 N	 N
	
N
	
N	 N
	
N
ICO-205	 N	 N	 N	 N	 N	 p	 N	 p	 N
ICO-206	 N	 N	 N	 N	 N	 N	 N	 p	 N
ICO-207
	
N
	
N	 N
	
N
	
N	 N	 N	 N	 N
ICO-208
	
N	 N	 N	 N	 N
	 N	 N	 N
	
N
ICO-209
	
N
	
N	 N
	
20	 N	 p	 N	 N	 N
ICO-210
	
N
	
N	 N
	
20	 N	 p	 N	 N	 N
ICO-211
	
N
	
N	 N	 N	 p
	 N	 N	 N	 p
ICO-212
	
N
	
N	 N
	
20
	
p	 N	 N	 N	 N
ICO-213
	
N
	
N	 N
	
20	 N	 N	 N	 N	 N
ICO-214
	
N	 N
	
N
	
N	 N
	 N	 N
	
N	 N
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ICO-215
	
N
	
N
	
N
	
20
	
N
	
P
	
N
	
N
	
N
ICO-21 6
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-217
	
N
	
N
	
N
	
N
	
p
	
P
	
N
	
P
	
P
ICO-2].8	 N	 N	 N	 N	 p	 P	 N	 P	 P
ICO-219
	
N
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
ICO-220
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-221
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
P
ICO-222
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
P
ICO-223
	
N
	
N
	
N
	
40
	
N
	
N
	
N
	
N
	
P
ICO-224
	
N
	
N
	
N
	
40
	
p
	
N
	
N
	
N
	
P
ICO-225
	
N
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
P
ICO-245
	
N 40
	
N
	
20
	
N
	
N
	
N
	
N
	
P
ICO-24 6
	
N
	
N
	
N
	
20
	
p
	
P
	
N
	
N
	
P
ICO-247
	
N
	
N
	
N
	
20
	
N
	
P
	
N
	
N
	
P
ICO-248
	
N
	
N
	
N
	
40
	
N
	
N
	
N
	
N
	
N
ICO-24 9
	
N
	
N
	
N
	
40
	
N
	
N
	
N
	
N
	
P
ICO-250
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
P
SNV-001
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-002
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-003
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 004
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 005
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-006
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-007
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
SNV-008
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-009
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-010
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0].1	 N	 N	 N	 N	 P	 N	 N	 N	 N
SNV-012
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0].3	 N	 N	 N	 20	 N	 N	 N	 N	 N
SNV-014
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-015
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-016
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-017
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-018
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-019
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-020
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-021
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 022
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
SNV-023
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-024
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 025
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-026
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-027
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-028
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-029
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-030
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-031
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-032
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-033
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 037
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-041
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
SNV-058
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
SNV-0 60
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-061
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 62
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
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SNV-063
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-064
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-065
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-066
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-067
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-068
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-069
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-070
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-071
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV-072
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 073
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
SNV- 074
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-075
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-076
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-077
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-078
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-07 9
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-080
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-081
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-082
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-083
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-084
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-085
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-086
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-087
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-088
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-089
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-090
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-091
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 92
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-093
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-094
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-095
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-099
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
SNV-100
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
S NV- 101
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-102
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-103
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-104
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-105
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-106
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-107
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
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TARGET AREA: SERP.A DO NAVIO - 2nd sample
CODE	 SL IF IV EB CSF CSV CSM CSK CSN
'Co-aol
	
N
	
N
	
N 40
	
N
	
N
	
N
	
N
	
N
ICO-002
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-003
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-004
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-005
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-006
	
ND ND ND ND ND ND ND ND ND
ICO-007
	
ND ND ND ND ND ND ND ND ND
ICO-008
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-009
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-O 10
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
'co-oil
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
p
	
N
ICO-012
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-013
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-014
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-015
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-016
	
ND ND ND ND ND ND ND ND ND
ICO-017
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
I co-c 18
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-019
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
ICO-020
	
N
	
N
	
N
	
N
	
p
	
N
	
p
	
N
	
N
ICO-021
	
N 20
	
N
	
N
	
N
	
N
	
p
	
N
	
p
ICO-022
	
ND ND ND ND ND ND ND ND ND
ICO-023
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-024
	
ND ND ND ND ND ND ND ND ND
I Co -025
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-026
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-027
	
ND ND ND ND ND ND ND ND ND
ICO-028
	
ND ND ND ND ND ND ND ND ND
ICO-029
	
ND ND ND ND ND ND ND ND ND
ICO-030
	
ND ND ND ND ND ND ND ND ND
ICO-031
	
N 20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-032
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
IcO-033
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-034
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-035
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-036
	
N
	
N 20
	
N
	
N
	
p
	
N
	
N
	
N
ICO-037
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-038
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
ICO-039
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
ICO-040
	
N 20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-041
	
N 20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-042
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
p
	
N
ICO-043
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
p
ICO-044
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
I CO- 045
	
N
	
N
	
N
	
N
	
p
	
N
	
p
	
N
	
N
ICO-046
	
N
	
N 40
	
N
	
N
	
N
	
N
	
N
	
N
ICO-047
	
N 80
	
N
	
N
	
N
	
N
	
N
	
p
	
N
ICO-048
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-049
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-050
	
N
	
N 80
	
N
	
N
	
N
	
N
	
N
	
N
'co-os'
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
232
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
40
20
N
20
N
N
N
20
N
N
N
N
N
40
N
N
N
N
N
N
N
N
N
N
N
ND
40
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
p
N
p
ND
N
N
p
N
N
N
N
p
N
N
N
N
N
N
N
N
N
N
N
N
p
N
N
p
p
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
p
p
p
N
N
N
N
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
N
N
p
N
N
N
N
N
N
N
p
N
N
N
N
N
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
p
N
N
N
N
N
p
p
N
N
N
p
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
p
N
N
N
N
N
p
N
N
N
N
N
ND
N
N
N
N
p
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
p
N
N
N
N
N
ND
ICO-052
ICO-053
ICO-054
ICO-055
ICO-056
ICO-057
ICO-058
ICO-059
ICO-060
ICO-061
ICO-0 62
ICO-063
ICO-0 64
ICO-0 65
ICO-066
ICO-0 67
ICO-068
ICO-069
ICO-070
ICO-071
ICO-072
ICO-073
ICO-074
ICO-075
ICO-076
ICO-077
ICO-078
ICO-079
ICO-080
ICO-081
ICO-082
ICO-083
ICO-084
ICO-085
ICO-086
ICO-087
ICO-088
ICO-089
ICO-090
Ico-091
ICO-0 92
ICO-093
ICO-0 94
ICO-095
ICO-096
ICO-0 97
ICO-098
ICO-099
'co-lao
'co-la'
ICO-102
ICO-103
ICO-104
ICO-105
ICO-106
ICO-107
N
N
N
N
N
N
N
N
N
N
160
N
N
N
N
N
N
N
N
N
20
N
N
N
N
ND
20
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
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ICO-108
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-109
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
'co-lb
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
'co-ill
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-1l2	 N	 N	 N	 20	 N	 N	 N	 N	 N
ICO-l13	 N	 N	 N	 20	 N	 N	 N	 N	 N
ICO-114	 N	 N	 N	 20	 N	 N	 N	 N	 N
ICO-1l5
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
P
ICO-1l6
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-117
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-1l8
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
I CO-il 9
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-120
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-121
	
N
	
N
	
N
	
40
	
N
	
N
	
N
	
N
	
N
ICO-122
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
ICO-123
	
N
	
N
	
N
	
N
	
P
	
P
	
P
	
P
	
P
ICO-124
	
ND ND ND ND ND ND ND ND ND
ICO-125
	
ND ND ND ND ND ND ND ND ND
ICO-126
	
ND ND ND ND ND ND ND ND ND
ICO-127
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
ICO-128
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-129
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-130
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-131
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-132
	
N 80
	
80
	
20
	
N
	
P
	
N
	
N
	
N
ICO-133
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-134
	
N
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
ICO-135
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-136
	
N
	
N
	
N
	
N
	
P
	
P
	
N
	
P
	
N
ICO-137
	
ND ND ND ND ND ND ND ND ND
ICO-138
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-139
	
N
	
N
	
N
	
N
	
P
	
P
	
N
	
N
	
N
ICO-140
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
P
ICO-141
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
N
	
N
ICO-171
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-172
	
N
	
N
	
N
	
40
	
P
	
N
	
N
	
N
	
P
ICO-173
	
N
	
N
	
N
	
40
	
N
	
N
	
N
	
N
	
N
ICO-174
	
N
	
N
	
N
	
20
	
N
	
P
	
N
	
P
	
P
ICO-175
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-176
	
N
	
N
	
N
	
20
	
P
	
P
	
N
	
P
	
P
ICO-177
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-178
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-202
	
N
	
N
	
N
	
N
	
N
	
P
	
N
	
P
	
N
ICO-203
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-204
	
ND ND ND ND ND ND ND ND ND
ICO-205
	
N
	
N
	
N
	
N
	
P
	
P
	
N
	
N
	
N
ICO-206
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-207
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-208
	
ND ND ND ND ND ND ND ND ND
ICO-209
	
N
	
N
	
N
	
20
	
N
	
P
	
N
	
N
	
N
ICO-210
	
ND ND ND ND ND ND ND ND ND
ICO-211
	
N
	
N
	
N
	
20
	
P
	
N
	
N
	
P
	
P
ICO-212
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-213
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-214
	
N
	
N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
ICO-215
	
ND ND ND ND ND ND ND ND ND
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ICO-216
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-2 17
	
ND ND ND ND ND ND ND ND ND
ICO-218
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
ICO-219
	
ND ND ND ND ND ND ND ND ND
ICO-220
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-221
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
p
i Co -222
	
N
	
N
	
N 20
	
N	 L	 N
	
N
	
N
ICO-223
	
N
	
N
	
N 40
	
N
	
N
	
N
	
N
	
p
ICO-224
	
N
	
N
	
N 40
	
p
	
p
	
N
	
N
	
p
ICO-225
	
N
	
N
	
N 40
	
N
	
N
	
N
	
N
	
p
ICO-245
	
N 80 20
	
80
	
N
	
p
	
N
	
N
	
N
ICO-24 6
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
p
ICO-247
	
N
	
N
	
N 20
	
N
	
p
	
N
	
N
	
p
ICO-248
	
N
	
N
	
N 20
	
p
	
p
	
N
	
p
	
p
ICO-24 9
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
p
ICO-250
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
SNV-001
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-002
	
ND ND ND ND ND ND ND ND ND
SNV-003
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-004
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 005
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-006
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-007
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-008
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-009
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 010
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-01].	 N	 N	 N	 N	 N	 N	 N	 N	 N
SNV-012
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-013
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-014
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-015
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-016
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-017
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-01 8
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-019
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-020
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-021
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-022
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-023
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-024
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 025
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-02 6
	
ND ND ND ND ND ND ND ND ND
SNV- 027
	
ND ND ND ND ND ND ND ND ND
SNV-02 8
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-029
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-030
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-031
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-032
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-033
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-037
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-041
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-058
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-060
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-061
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-062
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-063
	
ND ND ND ND ND ND ND ND ND
235
SNV- 064
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-065
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-066
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-067
	
ND ND ND ND ND ND ND ND ND
SNV-068
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-069
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-070
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
SNV-071
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-072
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-073
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-074
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 075
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-07 6
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 077
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 078
	
ND ND ND ND ND ND ND ND ND
SNV-079
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-080
	
ND ND ND ND ND ND ND ND ND
SNV-081
	
ND ND ND ND ND ND ND ND ND
SNV-082
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-083
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-084
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-085
	
ND ND ND ND ND ND ND ND ND
SNV-086
	
ND ND ND ND ND ND ND ND ND
SNV-087
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-088
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-089
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-090
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-091
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 92
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-093
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 94
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 95
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-099
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
SNV-100
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-lOi.	 N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-102
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-103
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-104
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-105
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-106
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-107
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
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N
ND
ND
ND
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
ND
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
ND
ND
N
N
N
N
N
p
p
N
N
N
N
N
N
N
N
N
N
N
ND
ND
ND
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
ND
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
ND
ND
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
ND
ND
ND
N
N
N
N
p
N
p
N
N
ND
N
N
N
N
p
ND
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
ND
ND
N
N
p
N
N
N
P
N
N
N
N
N
N
N
N
N
N
N
ND
ND
ND
N
N
N
P
N
N
N
N
N
ND
N
N
N
N
p
ND
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
ND
ND
N
N
p
N
N
N
N
N
p
N
N
p
N
N
N
N
N
N
ND
ND
ND
N
N
N
N
N
N
N
N
N
ND
N
N
N
N
N
ND
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
ND
ND
N
N
N
N
N
N
N
N
p
N
N
N
N
N
N
N
N
TARGET AREA: SERRA DO NAVIO - 3rd sample
CODE	 SL IF IV EB CS? CSV CSM CSK CSN
Ico-001
ICO-002
ICO-003
ICO-004
ICO-005
ICO-006
ICO-007
ICO-008
ICO-009
Ico-olo
'co-oil
ICO-012
ICO-013
ICO-014
ICO-015
ICO-016
ICO-017
ICO-018
ICO-019
ICO-020
ICO-021
ICO-022
ICO-023
ICO-024
ICO-025
ICO-026
ICO- 027
ICO-028
ICO-02 9
ICO-030
I CO- 031
ICO-032
ICO-033
ICO-034
ICO-035
ICO-036
ICO-037
ICO-038
ICO-039
ICO-040
1C0-041
ICO-042
ICO-043
ICO-044
ICO-045
ICO-046
ICO-047
ICO-048
ICO-049
ICO-050
ICO-051
N N
ND ND
ND ND
ND ND
N 160
N 20
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
ND ND
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
ND ND
N
	
N
N N
N
	
N
N
	
N
N
	
N
N
	
N
N N
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
N
	
N
N 40
N
	
N
N
	
N
N
	
N
N
	
N
N N
N 20
N 20
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
N
	
40
N
	
N
N N
ND ND
ND ND
ND ND
N
	
N
N
	
20
N
	
N
N
	
N
N
	
N
N
	
N
N
	
N
N
	
40
N
	
N
ND ND
N
	
20
N 320
N
	
N
N
	
20
N
	
N
ND ND
N
	
N
N
	
N
N 20
N
	
N
N
	
20
N 20
N N
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
N 20
N
	
N
N
	
N
N
	
N
N 20
N 40
N
	
N
N N
N N
N 20
N
	
N
N N
N N
N N
N N
N N
N N
237
I Ca- 052
	
N
	
N
	 N 20
	
p	 N
	
N
	
N
	
N
ICO-053
	
N
	
N 20 20
	
N
	
N
	
N
	
N
	
N
ICO-054	 N 80
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-055
	
N	 N
	
N
	
N
	 N	 N	 N
	
N
	
N
ICO-056
	
N
	
N
	 N 20
	
N
	
N
	
N
	
p
	
N
ICO-057	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-058
	
N 40
	
N 20
	
N
	
N
	
N
	
N
	
N
ICo-05 9
	
N
	
N	 N 20
	
N
	
p	 N
	
N
	
N
ICO-060	 N	 N	 N	 N	 N	 N	 N	 p	 N
ICO-061	 N	 N	 N 20
	
N
	
N	 N	 N	 N
ICO-062
	
N
	
N	 N 20
	
N
	
N	 N	 N	 N
ICC-U 63
	
N
	
N
	
N 20
	
N
	
N	 N
	
N
	
N
ICO-064
	
N 20
	
80 20
	
N
	
N
	
N
	
N
	
N
ICC-U 65
	
N	 N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-066
	
N 20
	
N 20	 N	 N	 N	 p	 N
ICO-067
	
N
	
N
	
N
	
N
	
N
	
N	 p
	
N
	
p
ICO-068
	
N 20	 N 20
	
N	 p
	
p
	
N	 N
ICO-069
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-070
	
N
	
N
	
N
	 N	 N
	
N
	
N
	
N
	
N
ICO-071	 N	 N	 N	 N	 N	 N	 N	 N	 N
I CO- 072
	
N
	
N	 N 20
	
N	 N	 N	 p	 p
I CO- 073
	
N 20
	
N 20
	
N	 N
	
N	 N	 N
ICO-074
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N	 p
ICO-075
	
N
	
N
	 N	 N	 N
	
N
	
N	 N	 p
ICO-076
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
I CO- 077
	
ND ND ND ND ND ND ND ND ND
ICO-078
	
N 40
	
N 20
	
N
	
N
	
p
	
N
	
N
ICO-079
	
N
	
N	 N
	 N
	
N
	
N
	
N	 N	 N
I CO- 080
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 p
ICO-081
	
N	 N
	
N
	 N	 N
	
N
	
N
	
N	 N
ICO-082
	
N	 N	 N
	 N	 N	 N	 N	 N	 N
ICO-083
	
N
	
N
	
N
	
N
	
N	 N
	
N	 N	 N
ICO-084
	
N
	
N
	
N
	 N	 N
	
N
	
N	 N	 N
ICO-085
	
N
	
N
	
N
	
N
	
N
	
N	 N
	
N	 N
ICO-086
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
ICO-087
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-088
	
N
	
N
	
N
	
N
	
N
	
N	 N
	
N
	
N
ICO-089
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
N	 N
ICO-090
	
N
	
N	 N
	
N
	
N
	
N	 N
	
N
	
N
ICO-091
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N	 N
ICO-092
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N	 N
ICO-093	 N	 N	 N	 N	 N	 N	 N	 p	 N
ICO-0 94	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-095	 N	 N	 N	 N	 N	 N	 N	 N	 N
ICO-096
	
N	 N
	
N
	 N	 N
	
N	 N	 N	 N
ICO-097
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N	 N
ICO-098
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
ICO-099
	
N
	
N
	
N
	
N
	
N
	
N
	
N	 N
	
N
ICo-100
	
N
	
N	 N
	
N
	
N
	
N
	
N
	
N	 N
'CO-b'
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N	 N
ICO-102
	
ND ND ND ND ND ND ND ND ND
ICO-103
	
N	 N
	
N	 N
	
p	 N	 N	 N	 N
ICO-104
	
N	 N
	
N
	
N
	
N	 N	 N	 N	 p
ICO-105
	
N	 N
	
N
	
N
	
p	 N	 N	 N	 N
ICO-106
	
N
	
N
	
N
	
N	 p
	
N	 N	 N	 N
ICO-107
	
ND ND ND ND ND ND ND ND ND
238
ICO-108
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
ICO-109
	
ND ND ND ND ND ND ND ND ND
Ico-110
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
'Co-ill
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-112
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-113
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-114
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-115
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
p
ICO-116
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
ICO-117
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-i].8	 N	 N	 N	 N	 N	 N	 N	 N	 N
'Co-hg
	
N
	
N
	
N
	
N
	
p
	
p
	
p
	
p
	
p
ICO-120
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-121
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-122
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
ICO-123
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
I Co -124
	
ND ND ND ND ND ND ND ND ND
ICO-125
	
ND ND ND ND ND ND ND ND ND
ICO-126
	
ND ND ND ND ND ND ND ND ND
ICO-127
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-128
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-129
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-130
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-131
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-132
	
N
	
N
	
N
	
N
	
p
	
p
	
N
	
N
	
p
ICO-133
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-134
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-135
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-136
	
N
	
N
	
N
	
N
	
p
	
p
	
N
	
p
	
N
ICO-137
	
ND ND ND ND ND ND ND ND ND
ICO-138
	
ND ND ND ND ND ND ND ND ND
ICO-139
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-140
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-141
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
ICO-171
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-172
	
N
	
N
	
N
	
N
	
p
	
p
	
N
	
p
	
N
ICO-173
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
ICO-174
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-175
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-17 6
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
ICO-177
	
N
	
N
	
N 20
	
p
	
p
	
N
	
N
	
N
ICO-178
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-202
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-203
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
N
ICO-204
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-2 05
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-20 6
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-207
	
ND ND ND ND ND ND ND ND ND
ICO-208
	
ND ND ND ND ND ND ND ND ND
ICO-209
	
ND ND ND ND ND ND ND ND ND
ICO-210
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-211
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-212
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-213
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-214
	
ND ND ND ND ND ND ND ND ND
ICO-215
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
p
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ICO-216
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-217
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
P
	
N
ICO-218
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
ICO-219
	
ND ND ND ND ND ND ND ND ND
ICO-220
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
ICO-221
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-222
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
p
ICO-223
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
p
ICO-224
	
N
	
N
	
N 20
	
p
	
N
	
N
	
N
	
p
ICO-225
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-245
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
ICO-246
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
p
ICO-247
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
P
ICO-248
	
N
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
ICO-249
	
N
	
N
	
N
	
N
	
N
	
P
	
N
	
N
	
P
ICO-250
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-001
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-002
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-003
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-004
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-005
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-006
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-007
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
SNV- 008
	
ND ND ND ND ND ND ND ND ND
SNV-009
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-010
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-01].	 N	 N	 N	 N	 N	 N	 N	 N	 N
SNV-012
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-013
	
N
	
N
	
N 20
	
N
	
N
	
N
	
N
	
N
SNV-014
	
ND ND ND ND ND ND ND ND ND
SNV-015
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-016
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-017
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-018
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-019
	
ND ND ND ND ND ND ND ND ND
SNV-020
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-021
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-022
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-023
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-024
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 025
	
ND ND ND ND ND ND ND ND ND
SNV-02 6
	
ND ND ND ND ND ND ND ND ND
SNV-027
	
ND ND ND ND ND ND ND ND ND
SNV-028
	
ND ND ND ND ND ND ND ND ND
SNV-029
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
S NV- 030
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-031
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-032
	
ND ND ND ND ND ND ND ND ND
SNV-033
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-037
	
ND ND ND ND ND ND ND ND ND
SNV-041
	
ND ND ND ND ND ND ND ND ND
SNV-058
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-060
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 61
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-062
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-063
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
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SNV-0 64
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-065
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-066
	
ND ND ND ND ND ND ND ND ND
SNV-0 67
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 068
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-069
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-070
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 071
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 072
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 073
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-074
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-075
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 076
	
ND ND ND ND ND ND ND ND ND
SNV-077
	
ND ND ND ND ND ND ND ND ND
SNV- 078
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-079
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-080
	
ND ND ND ND ND ND ND ND ND
SNV-081
	
ND ND ND ND ND ND ND ND ND
SNV-0 82
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-083
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 084
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-085
	
ND ND ND ND ND ND ND ND ND
SNV-086
	
ND ND ND ND ND ND ND ND ND
SNV-087
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-088
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-089
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-090
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 91
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-092
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-093
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-094
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-0 95
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-099
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-100
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-101
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-102
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-103
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-104
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-1 05
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-106
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-107
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
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4
1
26
15
17
46
5
22
17
5
4
16
7
3
15
16
32
8
6
4
2
24
4
7
14
20
4
17
58
18
9
6
2
3
5
7
25
5
4
9
8
11
27
2
19
35
55
2
21
7
Y4
N
Y5
Y5
Ys
Ys
Y2
Yl
Yl
Ys
Y2
Ys
Yl
N
N
N
Y8
N
N
N
N
Yl
N
N
N
N
N
Y6
Yl
N
N
N
N
Y2
N
N
N
Yl
N
Yl
N
Yl
N
N
N
Y4
Yl
N
Y2
N
1
0
.7
.7
2
0
1
0
1
2
2
.7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
APPENDIX 8
CONTROL ABZA: COLONIA AGUA BRANCA
CODE	 S	 A ) SR SL HG BK CQUR CQSE CBS
1/91	 M
18/91	 M
2/91	 M
3/91	 M
32/92	 F
33/92	 M
34/92	 F
35/92	 F
4/91	 M
46/92	 F
47/92	 M
51/92 M
CAB-001 M
CAB-002 F
CAB-003 F
CAB-004 F
CAB-005 M
CAB-006 M
CAB-007 M
CAB-008 F
CAB-009 F
CAB-OlO F
CAB-Oil F
CAB-012 F
CAB-013 F
CAB-014 F
CAB-015 M
CAB-016 M
CAB-017 F
CAB-018 F
CAB-019 M
CAB-020 M
CAB-021 M
CAB-022 F
CAB-023 M
CAB-024 M
CAB-025 F
CAB-026 M
CAB-027 F
CAB-028 M
CAB-029 F
CAB-O30 F
CAB-031 F
CAB-032 M
CAB-033 F
CAB-034 M
CAB-035 F
CAB-036 F
CAB-O37 M
CAB-038 F
PV ND
PV ND
N ND
PV ND
N	 ND
N	 ND
N	 ND
N	 ND
PV ND
N	 ND
N 2500
N	 ND
N	 930
N 1610
N	 ND
N	 ND
N	 ND
N ND
N 1510
N 1840
N >2600
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N 520
N 980
N 1840
N 720
N 2140
N 375
N	 ND
Pv 980
N	 ND
Pv 1200
N	 ND
N >2500
N	 ND
N	 705
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
0
1.2
2.2
0
0
1.2
1.1
1.1
1.1
1.5
1.1
0
1.4
1.4
1.2
1.4
1.2
1.4
1.2
1.5
1.2
1.2
1.4
1.3
1.3
1.4
1.4
8.1
1.1
0
0
0
0
0
1.2
0
0
6.8
11
98
68
10
3.1
9
9.1
6.8
2.4
0
2.4
9.1
Y
N
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
Y
Y
N
242
F
F
M
F
F
M
M
F
F
F
M
F
F
F
F
F
M
M
F
M
M
M
F
F
M
M
M
F
M
M
F
M
M
F
F
M
F
M
F
M
F
F
M
F
F
F
F
M
M
M
M
N
F
F
F
F
11
17
19
65
13
16
21
20
20
4
14
16
27
25
4
8
28
14
4
32
49
23
18
19
36
8
14
43
3
2
29
2
24
22
19
9
40
9
5
4
31
12
4
1
4
7
9
11
17
72
74
37
70
67
43
14
Yl
N
Y3
N
N
Y3
Y4
N
N
N
Yl
Y2
Y2
Y3
N
Y4
Y4
Y3
Yl
Yl
Y2
Y4
Y4
Y4
Y3
Y4
Yl
N
N
Y4
Y2
N
Y4
Y4
Y4
Yl
Y2
Y3
N
Yl
Yl
Yl
Y3
Y2
Y5
Y3
Y2
Y5
Ys
Yl
Yl
N
Y
N
N
Yl
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
2
0
1
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
1
1
1
1
1
1
0
0
0
0
0
0
0
CAB- 039
CAB- 040
CAB -041
CAB -042
CAB-043
CAB -044
CAB -045
CAB -046
CAB -047
CAB- 048
CAB -049
CAB- 050
CAB-051
CAB- 052
CAB -053
CAB -054
CAB -055
CAB -056
CULPFO1
1CM 001
1CM 002
ICO-142
ICO-143
ICO-144
ICO-145
ICO-146
ICO-148
ICO-149
ICO-150
ICO-151
ICO-152
ICO-153
ICO-i54
I Co-i 55
ICO-156
I Co -157
ICO-158
ICO-159
ICO-160
ICO-161
ICO-i 62
ICO-1 63
ICO-1 64
ICO-1 65
ICO-166
ICO-1 67
ICO-168
ICO-169
ICO-170
ICO-179
ICO-180
ICO-181
ICO-182
ICO-183
ICO-184
ICO-185
N 1490
N
	
ND
PF ND
N
	
ND
N
	
ND
pv ND
N
	
ND
N
	
ND
N
	
ND
N 1910
N 1285
N
	
ND
N
	
ND
pv ND
N
	
ND
PF 980
PF ND
N ND
PF ND
pv ND
Pv ND
PF ND
PF ND
PF ND
N
	
ND
pv 1040
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
N
	
ND
pv 945
N
	
ND
N
	
ND
N ND
PF
	
0
PF
	
0
PF ND
PF
	
0
PF
	
0
PF
	
0
PF
PF ND
N ND
N
	
ND
N	 ND
N	 ND
N	 ND
N	 ND
N	 ND
243
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
p 7664
p
	 160
p
	 220
p
	 100
N
	 180
p
	 420
p
	 106
N
	 100
N
	 100
p
	 105
p
	 113
p
	 627
p
	 230
p
	 160
N
	 102
p
	 100
p
	 220
N
	 103
p
	 86
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
p
	 230
p
	 90
N
	 95
p	 ND
p	 ND
p	 ND
N
	
ND
82
68
4.2
4.2
2.2
3.3
2.1
1.5
1.5
2.2
1.6
8
2.6
1.3
1.5
1.5
1.8
1.2
ND
ND
ND
15
4
6.5
1.9
2.2
1.9
6
6.5
8.5
8
6
4.6
1.3
10.5
8.8
2.9
1.6
2.8
1.5
6
1.8
5
6.5
3.4
10
6.5
2
12.5
1
10
2.6
1.6
2.6
4.1
2
N
N
N
Y
Y
Y
Y
y
Y
Y
Y
N
N
N
N
N
N
N
N
N
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
F
F
F
F
F
M
F
M
F
M
M
F
M
M
F
M
F
F
F
F
F
F
M
F
F
F
F
M
M
F
M
F
F
M
M
F
M
F
F
F
M
F
M
M
M
M
M
F
M
M
M
F
M
M
F
N
11
66
33
8
12
7
4
3
14
9
5
10
12
2
14
44
41
6
18
4
24
16
2
4
26
31
9
26
7
5
4
2
23
36
10
42
21
16
5
15
35
21
8
19
22
3
62
17
31
17
30
29
46
30
3
39
N
N
N
N
N
N
Yl
Yl
N
N
N
N
N
N
Yl
N
Yl
N
N
N
N
N
Y4
N
Y4
N
N
Y2
N
N
N
N
N
Yl
Yl
Yl
Y3
Yl
Y3
Y3
Yl
N
Y2
Y2
Y2
Yl
Ys
Y8
Ys
Yl
Y3
Yl
Yl
Yl
Yl
N
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
2
0
0
2
0
0
1
0
0
0
2
1
1
0
2
1
3
1
1
0
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
PF
ICO-186
ICO-187
ICO-188
ICO-18 9
Ico-190
ICO-191
ICO-1 92
ICO-193
ICO-194
ICO-].95
ICO-196
ICO-197
ICO-198
ICO-199
ICO-200
ICO-201
ICO-22 6
ICO-227
ICO-228
ICO-22 9
ICO-230
ICO-231
ICO-232
I CO-2 33
ICO-234
ICO-235
ICO-236
ICO-237
ICO-238
ICO-239
ICO-240
ICO-241
I CO-2 42
ICO-243
ICO-244
PFO5/91
PFO6/91
PFO7/91
PFO8/91
PFO9/91
PF1O/91
PF11/91
PF12/91
PF13/91
PF14/91
PF3O/92
PF37/92
PF4O/92
PF42/92
PF52/89
PF54/90
PF56/90
PF57/90
PF58/90
PF59/90
PV2 6/92
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1690
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
p
	 700
N
	 850
p
	
ND
N
	
ND
N
	 150
N 180
ND 140
ND ND
p
	 23
N
	 460
p 1600
N 410
N 1050
ND 50
N 1070
p
	 400
p 4800
ND ND
N 49
p 2900
p 1300
N 5700
N 7500
N 2000
N 1200
p 150
p 1550
p 1700
p
	 850
N
	 390
p
	
ND
p
	 610
p
	
ND
N
	 920
p ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
1.3
4.2
2.5
3.0
1.4
2.4
1.5
6.5
1
8.5
12
2
2.1
1.9
2.6
3
9.1
10
8
8.2
8.5
6.5
18
6.2
8.2
1.5
10
18
11
2.7
5.9
6.5
3.5
3
6
0
0
1.4
1.6
1.2
1.2
1.4
1.4
1.3
1.1
3.3
ND
1.6
2.8
ND
ND
ND
ND
ND
ND
13
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
N
Y
Y
Y
N
Y
N
N
N
Y
N
N
N
N
N
Y
Y
N
N
N
244
M
M
M
M
M
M
M
F
M
M
M
M
M
F
F
F
F
F
F
M
M
F
M
F
M
M
M
F
M
F
F
F
M
M
M
M
19
38
38
30
17
41
1
28
15
21
31
37
25
23
14
35
30
9
8
63
26
22
51
49
19
24
18
10
7
27
7
63
71
36
46
19
Y6
Y4
Ys
Y2
Ys
Yl
Yl
Yl
Yl
Y3
Y2
Yl
Y3
Y2
Yl
Y2
Y
Y2
N
N
Y3
Yl
N
N
Y2
Y2
N
N
N
Yl
N
Yl
Yl
Yl
Yl
Y4
0
2
0
0
0
1
1
0
0
2
1
0
2
1
0
1
0
0
0
0
2
0
0
0
1
0
0
0
0
1
0
0
0
0
0
2
pv
pv
pv
pv
pv
N
N
N
N
PF
PF
N
pv
MX
N
N
N
N
N
N
N
N
N
N
N
N
PF
N
N
N
N
N
N
N
N
N
ND
ND
ND
ND
ND
I'JD
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
450
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ID
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
PV27/92
PV2 8/92
PV36/92
PV39/92
PV5O/92
SNV-113
SNV-118
SNV-119
SNV- 122
SNV-124
SNV-125
SNV-12 6
SNV- 127
SNV-34
SNV- 35
SNV-3 6
SNV-38
SNV-39
SNV-40
SNV- 42
SNV-43
SNV-44
SNV- 45
SNV-46
SNV-47
SNV-48
SNV-49
SNV-50
SNV-5].
SNV-52
SNV-53
SNV-54
SNV-55
SNV-56
SNV-57
SNV-59
3.5
ND
4.9
2.1
4.2
ND
ND
ND
1.1
ND
ND
ND
1.2
10
0
7.5
8.2
5.4
8.5
7
2.6
3
ND
ND
5.2
2.1
10.7
1.5
1.9
2.7
2.5
1.5
1.5
1.1
ND
1.5
N
N
N
Y
Y
N
N
N
N
Y
N
Y
Y
N
N
N
N
N
N
N
N
Y
Y
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
N
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CONTROL ABEA: COLONIA AGUA BR.ANCA
CODE	 IF IV	 EB CSF CSV CSM CSK CSN
1/91	 640
	
80
	 40	 N	 N	 N	 N	 N
18/91
	 20	 80	 N	 p	 N	 N	 N	 N
2/91	 80	 N	 N	 N	 N	 N	 N	 N
3/91
	
80
	
40
	
40
	
N
	
N
	
N
	
N
	
N
32/92
	 320
	
80	 N	 N	 N	 N	 N	 N
33/92	 320	 N 160	 N	 N	 N	 N	 N
34/92	 N	 N	 N	 p	 N	 N	 N	 N
35/92
	 320	 N	 20	 p	 N	 N	 N	 N
4/91	 160
	
80	 40	 N	 N	 N	 N	 N
4 6/92
	
80	 N	 N	 N	 N	 p	 N	 N
47/92	 160	 N	 N	 N	 N	 N	 N	 N
51/92
	 80	 N	 N	 N	 N	 N	 N	 N
CAB- 001
	
N
	
N
	
N
	
N
	
N
	
N
	
p
	
N
CAB -002	 N	 N	 N	 N	 N	 N	 p	 p
CAB -003	 N	 N	 N	 N	 N	 N	 p	 N
CAB -004	 N 20	 N	 N	 N	 N	 p	 N
CAB -005 640 160	 20	 N	 N	 N	 N	 N
CAB-006
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
CAB- 007	 N 20	 N	 N	 N	 N	 N	 N
CAB -008	 N 20	 N	 N	 p	 N	 p	 p
CAB- 009	 N	 N	 N	 N	 N	 N	 N	 N
CAB- 010
	
N N
	
N N N N p p
CAB-Oil
	
N
	
N
	
20
	
N
	
N
	
N
	
p
	
p
CAB -012 20	 N	 N	 N	 N	 N	 p	 p
CAB- 013	 N N	 N p	 N N	 p	 p
CAB -014	 N N	 N N N N p N
CAB- 015 N N	 N N p	 N p p
CAB- 016 640 320	 20	 p	 p	 N	 p	 p
CAB -017 640 320	 N	 N	 p	 N	 p	 p
CAB- 018	 N	 N	 20	 p	 p	 N	 p	 N
CAB -019	 N N	 N N N N	 p p
CAB -020	 N N	 N p	 N N p	 p
CAB -021	 N N	 N N N N N N
CAB -022	 N 20	 20	 p	 p	 N	 p	 p
CAB -023	 N 20	 N	 N	 N	 N	 p	 N
CAB -024	 N N	 N N N N p p
CAB -025	 N N	 N N p	 N p	 p
CAB -026	 N	 N	 N	 N	 N	 N	 p	 p
CAB -027	 N	 N	 N	 '4
	
N
	
N
	
p
	
p
CAB- 028 640 320	 N	 p	 p	 N	 p	 p
CAB -029	 N N	 N	 p	 p	 N	 p	 p
CAB -030	 N	 N	 20	 N	 N	 N	 p	 N
CAB -031	 N	 N	 20	 N	 p	 N	 p	 p
CAB- 032 N N	 N N N N N N
CAB- 033 20	 N	 20	 N	 N	 N	 N	 N
CAB- 034 640 80 640	 N	 p	 N	 p	 N
CAB- 035 20	 N	 20	 N	 N	 N	 p	 N
CAB- 036	 N N 20	 N N N N N
CAB -037 160 40	 20	 N	 N	 N	 p	 N
CAB -038	 N	 N	 N	 N	 p	 N	 p	 p
CAB- 039 N N	 N N N N p	 p
CAB -040 40 20	 N	 N	 p	 N	 p	 N
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CAB- 041 640
	
80
	 20	 p	 N	 N	 N	 N
CAB- 042
	
20 40
	 20	 N	 N	 N	 N	 N
CAB -043
	
N	 N	 N
	 N	 N	 N	 N
	 N
CAB -044 640 640
	
80
	
N	 N	 N	 N
	
N
CAB- 045 640
	
40
	
640
	
N
	
N
	
N
	
N
	
N
CAB-046
	
N
	
N
	
20
	
N	 N
	
N
	
N	 N
CAB- 047
	
N
	
N
	
20
	
N	 N
	 N	 N
	
N
CAB-048
	
N
	
N
	
20
	
N
	
N
	 N	 N	 N
CAB-049 20
	
N
	
80
	
N
	
N
	 N	 N	 N
CAB- 050 20
	
N
	
20
	
p
	
N
	 N	 N	 N
CAB- 051	 N	 N
	 20	 N	 N	 N	 N	 N
CAB -052
	
N 80
	
20
	
N	 p	 N	 N	 N
CAB- 053	 N	 N	 N	 N	 N	 N	 N	 N
CAB -054
	
80 20
	
N	 N	 N	 N	 N	 N
CAB -055 640
	
N 320
	
p	 N	 p	 N	 p
CAB -056 320
	
80
	
N	 N	 p	 N	 N	 N
CULTPFO1 ND ND	 ND ND ND ND ND ND
1CM 001 20 20
	
ND ND ND ND ND ND
1CM 002 20 20
	
ND ND ND ND ND ND
ICO-142 640
	
N
	
20
	
N
	
N
	
N
	
N	 N
ICO-143 640
	
20
	
20	 N	 N	 N	 N	 N
ICO-144
	
N	 N
	
80
	
p
	
p
	
N
	 N	 N
ICO-145 640
	
20	 80	 N	 N	 N	 N	 N
ICO-146	 N	 N	 40	 N	 N	 N	 N	 P
ICO-148
	
N
	
N
	 20	 N	 N	 N	 N	 N
ICO-14 9
	
N	 N	 N	 N	 N
	 N	 N	 N
ICO-150
	
N	 N
	 N	 p	 N	 N	 N	 N
ICO-151
	
N	 N
	 20	 p	 N	 N	 N	 N
ICO-152
	
20	 N	 20	 N	 p	 N	 N	 N
ICO-153
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
ICO-154 160
	
N
	 20	 N	 N	 N	 N	 N
ICO-155 640
	
20	 20	 N	 N	 N	 N	 N
ICO-156 640
	
80
	
20	 N	 N	 N	 N	 N
ICO-157	 N 20	 N	 N	 N	 N	 N	 N
ICO-158	 N 40
	
N
	 p	 N	 N
	 N	 N
ICO-159
	
N 40
	
N	 N	 N	 N	 N	 N
ICO-160
	
N	 N 160
	
N	 N	 N	 N	 N
ICO-161
	
N 80
	
N	 p	 N	 N
	
N	 P
ICO-162 160
	
40
	
20	 p	 p	 p	 N	 P
ICO-163 160
	
N
	
640
	
p
	
p
	
N
	
N
	
P
ICO-164
	
80
	
N
	 20	 N	 p	 N	 N	 N
ICO-165
	
80
	
N
	
20
	
p
	
p
	
N
	
N
	
P
ICO-166
	
80
	
N
	
40
	
p
	 p	 N
	 p	 N
ICc-i 67 160
	
N
	
20
	
p
	
N
	
N
	
N	 P
ICO-168 160
	
20	 20	 p	 N	 N	 N	 N
ICO-169 160
	
N
	
20
	
N
	
N
	
N
	
N	 N
ICO-170
	
80 160
	
320
	
p
	
N
	
N
	
N	 p
ICO-179 20	 N	 20	 p	 p	 N	 N	 N
ICO-].80	 20	 N	 20	 p	 p	 p	 N	 N
ICO-181
	
N	 N	 N
	 p	 N	 N
	
N	 p
ICO-182
	
N
	
N
	
20
	
N	 N	 N
	
N	 N
ICO-183
	
20
	
N
	 20	 p	 N	 N	 N	 N
ICO-184
	
20
	
N
	 20	 N	 p	 N	 N	 N
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ICO-185 20	 N	 20	 p	 N	 N	 N	 N
ICO-186	 N	 N	 20	 p	 N	 N	 N	 N
ICO-187	 N	 N	 20	 p	 N	 N	 N	 N
ICO-188	 N	 N	 20	 N	 N	 N	 N	 N
ICO-189	 N	 N	 20	 p	 N	 N	 N	 N
ICO-190	 N	 N	 20	 p	 N	 N	 N	 N
ICO-191	 N	 N	 20	 p	 N	 N	 N	 N
ICO-192	 N	 N	 20	 N	 N	 N	 N	 N
ICO-193	 N	 N	 20	 N	 N	 N	 N	 N
ICO-1 94	 N	 N	 20	 N	 N	 N	 N	 N
ICO-195	 N	 N	 N	 N	 p	 N	 N	 P
ICO-196	 N	 N	 N	 p	 p	 N	 N	 N
ICO-197	 N	 N	 20	 N	 P	 N	 N	 N
ICO-198	 N	 N	 20	 p	 p	 N	 P	 P
ICO-199	 N 20
	 20	 N	 N	 N	 N	 P
ICO-200 160	 20	 20	 p	 N	 N	 N	 P
ICO-201 20	 N	 20	 N	 P	 N	 N	 P
ICO-226	 N	 N	 N	 p	 N	 N	 N	 N
ICO-227	 N	 N	 N	 N	 N	 N	 P	 P
ICO-228	 N	 N	 20	 N	 N	 N	 N	 N
ICO-22 9	 N	 N	 20	 p	 P	 N	 N	 P
ICO-230	 N	 N	 N	 p	 P	 N	 N	 P
ICO-231	 N	 N	 20	 p	 N	 N	 N	 N
ICO-232	 N	 N	 20	 N	 N	 N	 N	 N
ICO-233	 N	 N	 20	 N	 N	 N	 N	 N
ICO-234	 N	 N	 N	 N	 N	 N	 N	 N
ICO-235	 N	 N	 N	 p	 P	 N	 N	 P
ICO-23 6	 N	 N	 N	 N	 N	 N	 N	 N
ICO-237 20	 N	 20	 N	 p	 N	 N	 N
ICO-238	 N	 N	 20	 N	 p	 N	 N	 N
ICO-239	 N	 N	 20	 N	 N	 N	 N	 N
ICO-240	 N	 N	 20	 N	 p	 N	 N	 P
ICO-241	 N	 N	 20	 p	 P	 N	 N	 P
ICO-242	 N	 N	 20	 p	 P	 N	 N	 N
ICO-243 320
	
20
	
20	 N	 N	 N	 IN	 P
ICO-244	 N 20
	
20	 p	 N	 N	 N	 N
PF 05/91 160 160
	
80	 N	 N	 N	 P	 P
PB' 06/91 80	 N	 N	 N	 N	 N	 N	 N
PB' 07/91 320 160	 N	 N	 P	 N	 P	 P
PF 08/91 320	 N	 N	 p	 N	 N	 P	 N
PF 09/91 320
	
20	 160	 p	 P	 N	 P	 N
PB' 10/91 320	 N	 320	 N	 N	 N	 P	 N
PB' 11/91 160	 80	 80	 N	 P	 N	 P	 P
PB' 12/91 160	 40
	
80	 N	 P	 N	 P	 P
PF 13/91 320
	
20	 160	 p	 P	 N	 P	 N
PB' 14/91 80	 N	 160	 p	 P	 N	 P	 P
PF 30/92 320 320	 N	 p	 N	 N	 N	 N
PF 37/92 160
	
80	 80	 N	 N	 N	 N	 N
PF 40/92 80	 N	 N	 N	 N	 N	 N	 N
PF 42/92 320	 N	 N	 p	 N	 N	 N	 N
PF 52/89 N 20	 N	 N	 N	 N	 N	 N
PF 54/90 N	 N	 N	 N	 N	 N	 N	 N
PF 56/90 320	 40	 40	 N	 N	 N	 N	 N
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PF 57/90 640
	
N
	
N
	
N
	
N
	
N
	
N
	
N
PF 58/90 320
	
80
	
N
	
N
	
N
	
N
	
N
	
N
PF 59/90 640
	
80
	
20
	
N
	
N
	
N
	
N
	
N
PV 26/92 N
	
160
	
N
	
p
	
p
	
N
	
N
	
N
Pv 27/92 320
	
80
	
N
	
p
	
p
	
N
	
N
	
N
Pv 28/92 N
	
N
	
20
	
N
	
N
	
N
	
N
	
N
Pv 36/92 160
	
80
	
20
	
N
	
N
	
N
	
N
	
N
PV 39/92 80
	
80
	
160
	
p
	
N
	
N
	
N
	
N
PV 50/92 80
	
80
	
N
	
p
	
p
	
p
	
N
	
N
SNV-113 40
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-118
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-119
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 122
	
N
	
N
	
N
	
p
	
N
	
N
	
p
	
N
SNV-124 320
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-125 160
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-126 40
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-127 20
	
80
	
N
	
N
	
N
	
N
	
N
	
N
SNV-34 320
	
N
	
80
	
p
	
p
	
N
	
N
	
N
SNV-35
	
20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-36 320
	
160
	
160
	
p
	
p
	
N
	
p
	
N
SNV-38
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV-39
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-40
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV- 42
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV-43
	
N
	
N
	
N
	
p
	
p
	
N
	
N
	
N
SNV-44
	
20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-45
	
N
	
20
	
N
	
N
	
N
	
N
	
N
	
N
SNV-46
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-47
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
SNV-48
	
N
	
N
	
N
	
N
	
p
	
N
	
N
	
N
SNV-49 160
	
N
	
80
	
p
	
p
	
N
	
N
	
N
SNV-50
	
N
	
N
	
N
	
p
	
p
	
N
	
N
	
N
SNV-51
	
40
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV- 52
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV-53
	
N
	
N
	
N
	
p
	
N
	
N
	
N
	
N
SNV-54
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-55
	
20
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-56
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-57
	
N
	
N
	
N
	
N
	
N
	
N
	
N
	
N
SNV-59
	
N
	
N
	
N
	
p
	
N
	
N
	
p
	
p
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M
F
F
F
M
M
F
M
N
F
F
F
F
F
M
F
N
F
N
M
F
N
F
M
M
F
F
F
F
M
M
M
F
F
F
F
N
F
M
F
M
F
M
M
M
M
M
F
F
F
61
3
18
17
30
25
23
4
4
2
7
23
11
59
20
19
3
23
19
12
6
8
40
46
52
13
12
25
31
9
13
7
6
38
8
2
5
24
9
28
23
21
14
24
48
32
20
12
57
49
Y2
Yl
Y2
Y4
Y2
Yl
Y3
Y2
N
N
N
Yl
N
N
Y6
N
N
Y2
Y5
Yl
N
Yl
Yl
Yl
Y6
N
N
Yl
N
N
Yl
N
N
Yl
N
N
N
N
Yl
Y6
Y4
N
N
Y4
Y4
Y2
Y4
N
Yl
Y2
0
0
0
3
2
0
2
2
0
0
0
0
0
0
3
0
0
1
1
0
0
0
0
C
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
1
0
0
2
1
0
3
0
0
0
N
N
N
PF
PF
PF
PF
PF
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
pv
N
N
N
N
N
N
N
N
N
PF
N
N
N
N
N
N
N
N
N
1.3
1.4
1.2
1.5
1.5
0
2.8
ND
9.6
1.7
2
1.1
2.2
4.2
5.1
2.3
1.5
2
ND
1.4
1.5
6.2
2.8
1.5
1.5
1.2
1.7
2.4
2.2
1.5
6
1.7
2.2
ND
6.7
2.8
1.4
1.5
1.2
1.4
1.6
1.5
1.5
ND
2.1
2.4
ND
2
ND
1.9
Y
Y
Y
Y
Y
Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
APPENDIX 9
CONTROL AREA: PORTO TEREZINHA
CODE
	
S A MB SR SL HG HE CQUR CQSE CBS
31/92
38 / 92
44/92
PF16/91
PF29/92
PF48/92
PF5O/89
PF5 1/89
PT-001
PT-002
PT-003
PT-004
PT-005
PT-C 06
PT-007
PT-008
PT-009
PT-Oil
PT-012
PT-013
PT-014
PT-015
PT-016
PT-017
PT-018
PT-019
PT-020
PT-021
PT-022
PT-023
PT-024
PT-025
PT-026
PT-027
PT-028
PT-029
PT-030
PT-031
PT-032
PT-033
PT-034
PT-035
PT-036
PT-037
PT-038
PT-039
PT-040
PT-041
PT-042
PT-043
ND
1885
ND
ND
ND
ND
ND
ND
2310
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1575
ND
2240
ND
ND
ND
ND
ND
ND
ND
ND
<250
ND
ND
ND
ND
ND
ND
ND
2500
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
P
	 980
ND ND
P
	 780
P
	 750
N
	 230
P
	 900
P
	 680
N
	 610
P 1200
P
	
740
N
	 800
P 1000
P
	 580
N
	 880
P
	 800
N
	 850
P
	 490
N 750
P
	 850
P
	 550
P
	 490
N 1000
ND ND
N 310
P 1000
N 270
N 540
P 620
N 1150
N 1000
P 1300
P
	
750
p 740
P 1200
N 1350
P 1000
p 700
p 3900
P 1100
ND ND
p
	 750
P
	 460
P 4400
I:)	 750
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F
F
M
F
F
M
F
M
M
F
M
M
F
F
F
F
F
F
F
M
F
N
M
M
F
F
F
M
M
F
M
F
F
M
M
F
M
M
F
F
M
M
M
F
F
F
F
M
F
M
F
M
M
M
M
F
7
25
4
27
11
10
28
4
2
6
4
45
25
9
20
9
14
27
12
5
7
13
5
2
5
3
23
8
11
9
20
59
20
43
17
6
13
4
43
17
60
17
17
28
9
7
3
5
32
32
12
14
8
14
4
6
N
N
N
Y4
N
N
N
N
N
N
N
Yl
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Yl
Y5
N
Y6
Yl
N
Ys
Y4
N
N
N
N
N
Yl
Y3
Yl
N
N
N
N
N
N
Yl
Yl
N
N
Y4
Y4
N
C
0
0
2
C
0
0
0
0
0
0
0
C
0
0
0
0
0
C
0
C
C
0
0
0
C
C
0
2
C
2
0
0
1
1
0
C
0
0
0
0
1
C
0
C
0
0
0
0
0
0
0
C
2
2
0
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
1.5
1.8
1.3
1.4
1.4
1.5
1.5
1.3
1.5
1.5
1.3
2.4
ND
1.5
1.3
1.2
1.2
ND
1.5
1.8
1.2
1.3
1.3
1.5
1.2
1.5
1.5
ND
1.3
1.3
1.2
1.5
1.2
1.3
1.3
1.3
1.6
ND
1.2
1.5
1.4
1.2
1.2
0
1.2
1.4
0
1.3
1.5
1.5
1.1
1.5
1.2
ND
2.4
1.2
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
PT-044
PT-C 45
PT-046
PT-047
PT-048
PT-049
PT-050
PT-051
PT-052
PT-053
PT-C 54
PT-055
PT-056
PT-057
PT-058
PT-059
PT-U 60
PT-061
PT-C 62
PT-063
PT-064
PT-U 65
PT-C 66
PT-067
PT-C 68
PT-C 69
PT-070
PT-071
PT-072
PT-073
PT-074
PT-075
PT-076
PT-077
PT-078
PT-079
PT-C 80
PT-081
PT-082
PT-083
PT-084
PT-085
PT-086
PT-087
PT-C 88
PT-C89
PT-U 90
PT-C 91
PT-C 92
PT-093
PT-094
PT-C 95
PT-C 96
PT-C 97
PT-C 98
PT-099
ND
ND
ND
ND
ND
ND
ND
2600
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
2600
ND
ND
ND
ND
1425
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
1360
ND
ND
ND
2500
ND
P
	 390
P
	 380
P
	 470
P
	 880
P
	 700
P
	 690
N
	 460
P 1200
ND ND
ND ND
P 1000
P
	 810
P
	 480
P 1200
P
	 980
P
	 720
P
	 850
P 2000
P
	 750
P
	 900
P 1400
P
	 990
N
	 860
ND ND
ND ND
ND ND
N 650
P 2900
N 1200
N 3500
N
	 360
ND ND
N
	 500
P 1200
P
	 690
N
	 630
N
	 450
P
	 890
N
	 490
N 750
N
	 680
P 1100
P 920
P 1000
N 2100
N 210
N
	 660
N 410
P 1300
ND ND
N
	 460
N
	 600
P
	 750
P
	 570
ND ND
N	 790
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M
F
F
F
F
M
F
F
F
M
F
F
M
M
F
M
F
F
F
F
M
F
F
M
F
M
M
F
M
M
F
M
F
F
F
M
M
M
F
M
F
M
M
F
M
F
M
F
F
F
F
M
M
M
11
11
12
6
14
11
8
23
10
46
9
7
27
5
28
4
3
44
30
20
2
37
19
49
45
50
7
13
12
7
11
6
30
14
12
9
9
50
36
18
12
9
7
2
25
12
7
12
7
25
20
25
23
43
Yl
N
N
Yl
N
N
N
Y4
N
N
N
N
Yl
N
N
N
Yl
Y2
N
Y4
N
N
Yl
Y4
Y4
Yl
N
Yl
N
N
N
N
Yl
N
N
N
N
Y4
Yl
Y4
N
N
N
N
Y4
Y2
Yl
N
N
Y3
N
Y3
Y4
Yl
0
0
0
1
0
0
0
2
0
0
0
0
0
0
0
0
1
0
0
2
0
0
0
2
3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
2
0
0
0
0
0
1
1
2
0
N
N
N
N
N
N
N
PF
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Pv
Pv
N
N
N
0
1.5
1.5
ND
1.3
1.4
1.3
2.8
1.3
1.3
2.4
1.6
1.5
1.8
1.2
1.5
1.3
1.2
2.3
0
0
1.5
1.5
1.5
1.3
1.3
1.3
0
1.2
1.5
1.3
1.5
1.6
1.4
1.5
1.3
1.3
1.1
1.5
1.3
1.4
1.2
1.5
1.5
0
1.1
1.5
1.1
1.3
ND
ND
ND
0
ND
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
Y
N
PT-100
PT-l01
PT-102
PT-103
PT-104
PT-105
PT-106
PT-107
PT-lOB
PT-109
PT-lb
PT-ill
PT-112
PT-113
PT-i14
PT-1l5
PT-116
PT-l17
PT-118
PT-119
PT-120
PT-121
PT-122
PT-123
PT-124
PT-125
PT-126
PT-i 27
PT-i28
PT-129
PT-130
PT-131
PT-132
PT-133
PT-134
PT-135
PT-136
PT-137
PT-138
PT-139
PT-140
PT-l41
PT-142
PT-l43
PT-144
PT-145
PT-146
PT-147
PT-148
PV2 5/92
PV49/92
SNV- 123
SNVO2/91
SNVO7/89
ND
ND
880
ND
670
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
980
ND
ND
ND
ND
ND
ND
ND
ND
ND
1530
<250
ND
2500
ND
ND
ND
ND
660
890
ND
ND
ND
ND
ND
ND
ND
ND
ND
680
250
ND
ND
ND
ND
ND
ND
ND
N 820
N 700
N 850
ND ND
N 850
N 900
N 820
P
	 980
N
	 810
P
	 600
N 460
P
	 620
P 1200
N
	 0
N 820
N 660
N 900
N 900
P
	 650
N
	 600
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
ND ND
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CODE	 IF	 Iv	 EB CSF CSV CSM CSK CSN
31/92	 160	 640	 20	 N	 P	 N	 N	 P
38/92	 160	 80	 160	 N	 N	 N	 N	 P
44/92	 320	 80	 N	 N	 N	 N	 N	 N
PF16/91 640	 80	 ND	 P	 P	 N	 P	 P
PF29/92 320	 80	 N	 N	 N	 N	 P	 P
PF48/92 640	 80	 N	 N	 P	 N	 P	 N
PF5O/89	 40	 40	 80	 N	 N	 N	 N	 N
PF51/89 160	 40	 N	 N	 N	 N	 N	 N
PT-C 01	 N	 N	 N	 N	 N	 N	 N	 N
PT-002	 N	 N	 N	 N	 N	 N	 N	 N
PT-003	 N	 N	 320	 N	 N	 N	 N	 N
PT-004	 N	 N	 640	 N	 N	 N	 N	 N
PT-005	 N	 20	 20	 N	 N	 N	 N	 N
PT-006	 20	 N	 160	 N	 N	 N	 N	 N
PT-007	 160	 N	 20	 N	 N	 N	 N	 N
PT-008	 N	 N	 20	 N	 N	 N	 N	 P
PT-009	 ND	 ND	 ND	 ND ND ND ND ND
PT-Oil	 80	 N	 640	 P	 N	 N	 N	 P
PT-012	 N	 N	 20	 N	 N	 N	 N	 N
PT-013	 N	 N	 N	 P	 N	 N	 N	 N
PT-014	 20	 N	 N	 N	 N	 N	 N	 P
PT-015	 N	 N	 N	 N	 N	 N	 N	 N
PT-016	 20	 N	 40	 P	 N	 N	 N	 N
PT-017	 N	 20	 20	 P	 N	 N	 N	 N
PT-018	 80	 N	 160	 N	 N	 N	 N	 N
PT-019	 N	 N	 20	 N	 N	 N	 N	 N
PT-020	 N	 N	 20	 N	 N	 N	 N	 N
PT-021	 N	 N	 20
	
N
	
N
	
N
	
N
	
N
PT-022	 N	 N	 N	 N	 N	 N	 N	 N
PT-O23	 N	 N	 N	 N	 N	 N	 N	 N
PT-024	 20	 80
	
20	 N	 N	 N	 N	 N
PT-025	 N	 N	 20	 N	 N	 N	 N	 N
PT-026	 20	 N	 20	 N	 N	 N	 N	 N
PT-027	 N	 N	 ND	 N	 N	 N	 N	 N
PT-028	 N	 N	 20	 N	 N	 N	 N	 N
PT-029	 N	 N	 20	 N	 N	 P	 N	 P
PT-030	 N	 N	 20	 N	 N	 N	 N	 N
PT-031	 80	 40	 20	 N	 N	 N	 N	 N
PT-032	 N	 N	 20	 N	 N	 N	 N	 N
PT-033	 N	 N	 20	 P	 N	 N	 N	 N
PT-034	 640	 N	 640	 P	 N	 N	 N	 N
PT-035	 N	 N	 N	 N	 N	 N	 N	 N
PT-036	 N	 N	 20	 N	 N	 N	 N	 N
PT-037	 ND	 ND	 ND	 N	 N	 N	 N	 N
PT-O38	 80	 N	 N	 N	 N	 N	 N	 N
PT-039	 40	 N	 20	 N	 N	 N	 N	 N
PT-040	 ND	 ND	 ND	 N	 N	 N	 N	 N
PT-041	 N	 N	 N	 P	 N	 N	 N	 N
PT-042	 ND	 ND	 ND	 N	 N	 N	 N	 N
PT-043	 N	 N	 20	 P	 P	 N	 N	 N
PT-044	 N	 N	 20	 N	 N	 N	 N	 N
PT-045	 N	 N	 20	 N	 N	 N	 N	 N
PT-046 160	 N	 N	 N	 N	 N	 N	 N
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PT-047	 N	 N
	
20	 N	 N	 N	 N	 N
PT-C 48	 N	 N
	
20
	
N	 N
	
N
	
N
	 N
PT-049	 N	 N	 N	 N	 N	 N	 N	 N
PT-050	 N	 N	 N	 N	 N	 N	 N	 N
PT-051	 N	 N	 20	 N	 N	 N	 N	 N
PT-052	 80	 N	 20	 N	 N	 N	 N	 N
PT-053	 N	 N	 N	 N	 N	 N	 N	 N
PT-054	 N	 N	 20	 N	 N	 N	 N	 N
PT-055	 20	 N	 20	 N	 N	 N	 N	 N
PT-056	 ND	 ND	 20	 N	 N	 N	 N	 N
PT-057	 N	 N	 N	 N	 N	 N	 N	 N
PT-058	 N	 20
	
20	 N	 N	 N	 N	 N
PT-059	 N	 N	 20	 N	 N	 N	 N	 N
PT-060	 N	 N
	
20	 N	 N	 N	 N	 N
PT-061	 ND	 ND	 ND	 ND ND ND ND ND
PT-C 62	 N	 N	 N	 N	 N	 N	 N	 N
PT-063	 N	 N	 20	 N	 N	 N	 N	 N
PT-C 64	 N	 N	 N	 N	 N	 N	 N	 N
PT-C 65	 N	 N	 N	 P	 N	 N	 N	 N
PT-C 66	 N	 N	 N	 N	 N	 N	 N	 N
PT-C 67	 N	 N	 N	 P	 N	 N	 N	 N
PT-C 68	 N	 N	 N	 N	 N	 N	 N	 N
PT-C 69	 N	 N	 N	 N	 N	 N	 N	 N
PT-C70
	
N	 N
	
N	 N	 N
	
N
	
N
	
N
PT-C71	 ND	 ND	 ND	 ND ND ND ND ND
PT-C72	 N	 N
	
ND
	
ND ND ND ND ND
PT-C73	 N	 N
	
20
	
N	 N	 N
	
N
	
N
PT-074	 N	 N	 N	 N	 N	 N	 N	 N
PT-075
	
20	 N
	
20	 N	 N	 N	 N	 N
PT-C76
	
20	 N	 N	 N	 N	 N	 N	 N
PT-077
	
640	 160
	
20	 P	 N	 N	 N	 N
PT-078
	
160
	
N
	
2C	 N	 P	 N	 N	 N
PT-079
	
40	 N
	
80
	
N	 N	 N
	
N	 N
PT-C80
	
N	 N
	
20
	
N	 N	 N
	
N	 N
PT-081
	
N	 N	 N	 N	 N
	
N	 N	 N
PT-C 82
	
160
	
N
	
20
	
N	 N	 N
	
N	 N
PT-C83
	
N	 N
	
20
	
N	 N	 N
	
N	 N
PT-084
	
20
	
N	 N	 N	 N
	
N
	
N	 N
PT-C85	 N	 N	 N	 N	 N	 N	 P	 N
PT-C86	 N	 N	 N	 N	 N	 N	 N	 N
PT-087
	
20	 N	 N	 N	 N	 N	 N	 N
PT-088	 N	 N	 20
	
N	 N	 N	 N	 N
PT-089	 N	 N	 N	 N	 N	 N	 N	 N
PT-09C	 N	 N	 N	 N	 N	 N	 N	 N
PT-C 91	 N	 N	 N	 N	 N	 N	 N	 N
PT-092
	
N
	
N
	
N	 N	 N	 N
	
P	 N
PT-093	 N	 40
	
20
	
N	 N	 N	 N	 N
PT-094
	
320
	
20
	
N	 N	 N	 N
	
N	 N
PT-095	 N	 N	 20
	
P
	
P
	
P
	
P	 P
PT-096
	
N	 N
	
20	 P	 P	 N	 P	 P
PT-C 97	 ND	 ND	 N	 N	 N	 N	 N	 N
PT-098
	
80	 N	 20	 N	 N	 N	 N	 N
PT-C 99	 N	 N	 N	 N	 N	 N	 P	 N
PT-1OC	 N	 N	 N	 N	 N	 N	 N	 N
PT-1O1	 N	 N	 N	 N	 N	 N	 N	 N
PT-102
	
80
	
40	 N	 N	 N	 N	 N	 N
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PT-103	 N	 N	 N	 N	 N	 N	 N	 N
PT-104	 40	 N	 20	 N	 N	 N	 N	 P
PT-105	 N	 N	 N	 N	 N	 P	 N	 N
PT-106	 N	 N	 20	 N	 N	 N	 N	 N
PT-107	 160	 N	 20	 N	 N	 N	 P	 N
PT-108	 N	 N	 N	 N	 N	 N	 N	 N
PT-l09	 640	 40	 640	 N	 N	 N	 N	 N
PT-lb	 N	 N	 N	 N	 N	 N	 N	 N
PT-ill	 20	 N	 N	 N	 N	 N	 P	 N
PT-112	 N	 N	 N	 N	 N	 N	 N
	 N
PT-113	 N	 N	 N	 N	 N	 N	 P	 P
PT-li 4	 N	 N	 N	 P	 N	 N	 N	 N
PT-115	 N	 N	 160	 N	 N	 N	 N	 N
PT-116	 N	 N	 N	 N	 N	 N	 N	 N
PT-117	 40	 N	 40	 N	 N	 N	 P	 N
PT-118	 N	 N	 ND	 P	 N	 N	 N	 N
PT-119	 80	 N	 20	 N	 N	 N	 N	 P
PT-120	 N	 N	 N	 N	 N	 N	 N	 N
PT-121	 N	 N	 N	 N	 N	 N
	 N	 N
PT-122	 N	 N	 N	 N	 P	 N	 P
	 N
PT-123
	 640	 N	 640	 P	 P	 N	 P	 P
PT-124	 80	 N	 20	 P	 P	 N	 P	 P
PT-125	 160	 N	 20	 N	 P	 N	 P	 P
PT-126	 N	 N	 N	 N	 P	 N	 N	 N
PT-127	 N	 N	 20	 N	 N	 N	 N	 P
PT-128	 160	 N	 320	 N	 P	 N	 P	 P
PT-129	 N	 N	 N	 N	 N	 N	 P	 N
PT-130	 N	 N	 20	 N	 N	 N	 N	 P
PT-13l	 N	 N	 N	 N	 P	 N	 P	 P
PT-132	 N	 N	 N	 N	 P	 N	 P	 N
PT-133	 N	 N	 N	 N	 N	 N	 P	 N
PT-134	 N	 N	 N	 N	 N	 N	 P	 P
PT-135	 20	 N	 N	 N	 P	 N	 P	 N
PT-136	 ND	 ND	 ND	 ND ND ND ND	 ND
PT-137	 40	 N	 20	 N	 N	 N	 P	 N
PT-138	 40	 N	 20	 N	 N	 N	 N	 N
PT-139	 320	 40	 160	 P	 N	 N	 P	 N
PT-140	 40	 N	 N	 N	 N	 N	 N	 N
PT-141	 N	 N	 N	 N	 N	 N	 N	 N
PT-142	 N	 N	 N	 N	 N	 N	 N	 N
PT-143	 N	 N	 N	 N	 N	 N	 N	 N
PT-144	 N	 N	 N	 N	 P	 N	 N	 N
PT-145	 40	 N	 N	 N	 P	 N	 P	 P
PT-146	 20	 N	 N	 N	 P	 N	 P	 P
PT-147	 N	 N	 ND	 N	 N	 N	 N	 N
PT-148	 N	 N	 20	 N	 N	 N	 P	 N
PV-25/92 320	 320	 N	 N	 N	 N	 N	 N
PV4 9/92 160	 640	 N	 N	 N	 N	 N	 N
SNV-123 160	 80	 N	 N	 N	 N	 N	 N
SNVO2/91 640
	
80	 N	 N	 N	 N	 P	 N
SNVO7/89 20
	
20	 N	 N	 N	 N	 N	 N
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SM
F
F
F
F
M
M
F
M
M
F
F
M
F
M
F
F
M
M
F
M
M
M
M
M
M
F
F
F
F
F
N
F
M
M
F
F
F
F
F
M
F
F
M
M
M
M
M
M
A
10
8
5
3
37
4
11
39
4
7
22
21
29
15
17
15
2
11
14
34
45
4
10
7
5
4
18
6
10
6
13
13
10
7
5
70
54
12
11
22
36
3
2
61
2
29
29
36
12
MB
Yl
N
N
N
Y2
N
N
N
N
N
N
N
N
Yl
Yl
N
N
N
N
N
Y2
N
Y2
N
N
N
Yl
N
N
N
N
N
N
N
N
Yl
Yl
N
N
Yl
Ys
Yl
N
Ys
Y
Yl
Y4
Y3
Ys
SR
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
1
N
2
N
1
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
1
N
N
N
1
2
N
N
2
SL
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
pv
Pv
pv
N
Pv
N
N
N
N
N
N
N
N
N
N
N
N
N
Pv
N
N
N
PF
PF
PF
PF
PF
APPENDIX 10:
CONTROL AREA: ARREPENDIDO
CODE
ARR- 001
ARR- 002
ARR- 003
ARR-004
ARR- 005
ARR- 006
ARR-007
ARR- 008
ARR- 009
ARR- 010
ARR- 011
ARR-012
ARR-013
ARR- 014
ARR- 015
ARR- 016
ARR-017
ARR- 018
ARR- 019
ARR-020
A.RR- 021
ARR- 022
ARR- 023
ARR-024
ARR- 025
ARR- 026
ARR- 027
ARR- 028
ARR- 029
ARR- 030
ARR-031
ARR- 032
ARR- 033
.ARR-034
ARR-035
ARR- 036
ARR- 037
ARR- 038
ARR- 039
ARR- 040
ARR- 041
ARR-042
ARR- 043
ARR- 044
PFO4/91
PF45/90
PF53/89
PF53190
PF54192
HG
0
750
450
ND
ND
310
1160
ND
730
ND
ND
ND
ND
ND
ND
ND
1210
ND
ND
ND
ND
1850
>2 600
1465
1235
ND
ND
ND
ND
ND
ND
ND
1000
ND
ND
ND
ND
ND
ND
ND
ND
2560
ND
ND
ND
ND
ND
ND
<250
CQSE
0
0
0
0
0
2.2
1.8
6.5
10.5
2
1.5
9.2
1.5
2.8
1.5
2
1.6
1.3
3.6
1.5
1.5
4
1.5
1.5
2.1
1.6
2.4
2.1
2.4
6.5
1.5
4.2
9
180
7
1.5
1.3
1.3
1.7
2.3
1.5
1.3
1.6
4.2
ND
ND
ND
ND
1.8
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CODE	 IF IV EB CSF CSV CSM CSK CSN
ARR- 001	 N	 N
	 N
	 N	 N
	
N
	 N
	
N
ARR- 002
	
N
	 N
	 N
	
N
	
N
	
N
	 N
	 N
ARR- 003	 N	 N
	 N
	 N
	 N	 N	 N
	 N
ARR-004
	
N	 N
	 N
	 N
	
N
	
N
	
N
	
N
ARR-005 20
	
N
	 N
	 N	 N
	
N
	
N
	
N
ARR- 006	 N	 N
	
N
	 N	 N
	
N
	
N
	
N
ARR-007
	
N 20
	
N
	 N	 N
	
N
	 N	 N
ARR- 008 20
	
N
	
N
	 p	 N
	
N
	 N	 N
ARR- 009	 N	 N	 N
	 p	 p	 p
	 p	 p
ARR-010
	
N	 N
	
N
	
N
	
N
	 N	 p	 p
ARR- 011
	
N
	
N
	
N
	
p
	 N	 N
	
N
	
N
ARR- 012
	
N
	 N
	
N
	
N
	 N	 N
	
N
	 N
ARR-013
	
N	 N
	
N
	 N
	
N
	
N
	 N
	 N
ARR-014
	
N 20
	
N
	
N
	 N
	
N
	 N
	
N
ABP-015	 N	 N
	
N
	
N
	 N
	
N
	 N
	
N
ARR- 016	 N	 N
	
N
	 N
	
N
	
N
	 N
	 N
ARR- 017	 N 20
	
N
	 N
	
N
	
N
	 N
	 N
ARR- 018
	
N	 N	 N
	 N	 N	 N	 N
	 p
ARR- 019
	
N
	 N
	
N
	 N
	 N	 N	 N
	 N
ARR- 020
	
N	 N
	
N
	 p	 N
	
p
	 p	 p
ARR-021 20
	
N	 N
	 p	 p
	
N
	 p	 p
ARR- 022
	
N
	 N
	
N
	 N
	 N	 p
	
N
	 N
ARR- 023
	
N
	
N
	
N
	 N
	
N
	
p
	 N
	
p
ARR- 024
	 N 20
	
N
	 N
	 N
	
N
	 N	 N
ARR- 025	 N	 N	 N	 N
	 N
	
N
	 N
	
N
ARR- 026
	
N
	
N
	 N
	 N	 N
	
N
	 N	 N
ARR- 027	 N 20
	
N
	 N	 N
	
N
	 N
	 N
ARR- 028
	
N
	 N
	
N
	 p
	
N
	
N
	 N
	 N
ARR-029
	
N
	 N	 N	 N
	
N
	
N
	 N	 N
ARR- 030
	
N
	 N	 N
	 N	 N
	 N	 N
	 N
ARR- 031	 N	 N	 N	 N
	 N	 N	 N
	 p
ARR- 032
	
N 20
	
N
	 N	 N
	 N	 N	 N
ARR- 033	 N	 N
	
N
	 p	 N
	
N
	 N	 p
ARR-034
	
N	 N
	
N
	 p
	
p
	
N
	
p
	 p
ARR-035 20
	
N
	
N
	
N
	
N
	
p
	
N
	 N
APR- 036 20
	
N
	 N
	 N
	
N
	
N
	
N
	 N
ARR-037 20
	
N
	 N
	 N	 N
	
N
	 N	 N
ARR- 038
	
N
	
N
	 N
	
N
	 N
	
N
	
N
	 N
APR- 039 N N N N N N N N
ARR- 040
	
N	 N	 N
	 N	 N
	
N
	 N
	
N
ARR- 041 20 20
	
N
	 N
	
N
	
N
	 N
	
N
ARR- 042
	
N
	
N
	 N
	 p	 N
	
N
	
N
	 N
ARR- 043
	
N
	
N
	
N
	 N
	 N	 N
	 N
	
N
ARR- 044 320
	
40
	
20
	
p	 p	 p	 N
	
p
PFO4/91 160 320
	
N
	
N
	
N
	
N
	
N
	
N
PF45/90
	
80
	
80
	
20
	
N
	
N
	 N	 N
	
N
PF53/89 320	 N	 20	 N	 N	 N	 N	 N
PF53/90 640
	
80
	
N
	 N	 N	 N
	
N
	
N
PF54192 640	 N	 N	 p	 N	 p	 N	 N
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APPENDIX 11
CONTROL AREA: INDIGENOUS AREA
CODE	 S A )' SR SL	 HG
03/91	 M	 3	 Yl	 2 PF	 0
04/91	 M 48	 Y	 0	 N	 ND
05/91	 M 41	 Y 1 PF	 ND
06/91	 M 28	 Y	 0	 N	 ND
07/91	 M 5	 Y	 0	 N 2540
08/91	 M 10	 Y	 0	 N 1290
09/91	 F 13	 Y	 0	 N	 715
10/91	 F 34	 Y 0	 N	 ND
11/91	 M 4	 Y	 0	 N >2600
12/91	 M 14	 Y	 0	 N	 920
13/91 M 21	 Y 0	 N	 ND
14/91	 F 31	 Y	 0	 N	 ND
15/91 M 32 YS	 1	 N	 ND
16/91 M 34	 N 0	 N	 ND
17/91	 M 11	 Y	 1 PF <250
18/91	 F 12	 Y	 0 PF	 0
19/91	 M 4	 Y 2 PF <250
20/91	 M 4	 Y	 1 PF <250
21/91 M 2	 Y 1 PF <250
22/91	 F 11	 Y 2 PV	 380
23/91	 M 7	 Y	 0	 N	 770
24/91 F 1	 Y 0	 N	 ND
26/91 M 21	 Y 0	 N	 ND
27/91 M 21	 Y 0	 N	 ND
PF15/91	 M 4	 Y	 4 PF	 0
PF17/91	 F	 2	 Y 3 PF	 0
PF45/92 F 32 Y4	 0 PF	 ND
CQSE
1.5
2.1
2.6
1.5
0
2.8
4.9
4.1
3.9
4.1
1.3
0
0
0
1.5
2.1
1.3
1.7
2.2
1.2
1.3
1.5
0
0
ND
ND
0
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CODE	 EB CSF CSV CSK CSN CSM IF	 Iv
03191	 N P	 N	 P	 P	 N	 640	 320
04/91	 N P	 p	 p	 p	 N	 160	 N
05/91	 N	 P	 N	 N	 N	 P	 640	 130
06/91	 N N	 N	 N	 N	 N	 320	 640
07/91	 N N	 N	 N	 N	 N	 320	 160
08/91	 N N	 N	 P	 N	 N	 320	 80
09/91	 N N	 N	 N	 N	 N	 320	 320
10/91	 N N	 N	 N	 N	 N	 320	 40
11/91	 N N	 N	 N	 N	 N	 320	 80
12/91	 N N	 N	 N	 N	 N	 160	 320
13/91	 N N	 N	 N	 N	 N	 640	 160
14/91 160	 N	 P	 N	 P	 P	 320	 N
15/91	 N N	 N	 P	 N	 N 320	 320
16/91	 20	 N	 N	 N	 N	 N	 160	 20
17/91	 80	 N	 N	 N	 N	 N	 160	 40
18/91	 N N	 N	 N	 N	 N 320	 N
19/91	 N P	 N	 P	 N	 N	 80	 80
20/91	 N N	 N	 N	 N	 N 320	 N
21/91	 N N	 N	 N	 N	 N	 160	 40
22/91 320	 P	 N	 N	 N	 N	 320	 80
23/91	 N N	 N	 N	 N	 N 160	 40
24/91 160	 N	 N	 P	 N	 N	 320	 80
26/91 320	 N	 N	 N	 P	 N	 640	 80
27/91 320	 N	 N	 N	 N	 N	 640	 160
PF15/91	 80 N	 N	 N	 N	 N	 320	 40
	
PF17/91 160	 N	 N	 N	 N	 N	 320	 160
PF45/92	 N N	 N	 N	 N	 N 160	 80
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PREVALENCE OF THE DIHYDROFOLATE REDUCTASE ASN-108
MUTATION AS THE BASIS FOR PYRIMETHAMINE-RESISTANT
FALCIPARUM MALARIA IN THE BRAZILIAN AMAZON
DAVID S. PETERSON, SILVIA M. Dl SANTI, MARINETE POVOA, VANJA S.
CALVOSA, VIRGIUO E. DO ROSARIO, Aim THOMAS E. WELLEMS
Laboratory of Parasitic Diseases, Naional instil we ofAllergy and infectious Diseases.
National Insulates of Health. Bethesda Marylamt SUCEN. Sao Paulo, SP. Brazil; Inst auto
Eva ndro Chagas. Belem. Brazil; Inst itwo de Higiene e Medicina Tropical, Lisbon, Ponugoi
Abstract. Pyrimethamine resistance in cultivated laboratory isolates of Plasinodium
fakiparum is linked to the dihydrofolate reductase mutation Asn-108, a mutation that acts
by interrupting drug binding within the active site of the enzyme. To determine the prev-
alence of this mutation in endemic regions harboring pyrimethamine-resistant malaria, we
used a mutation-specific polymerase chain reaction assay to survey P. falcipanim strains
from a wide section of the Brazilian Amazon. Mutations were identified directly from blood
samples without intervening steps of in vitro cultivation. Of 42 samples collected from
four states in Brazil. 38 (90%) contained the Asn-108 codon AAC that confers pynme-
thamine resistance, four samples contained only the wild-type Ser-108 codon AGC, and
none contained the Thr-108 codon ACC found in cycloguanil-resistant pyrimethamine-
sensitive strains. These findings indicate that a very high incidence of the Asn-108 DHFR
mutation is responsible for pyrimethamine resistance in the Amazon, and they are con-
sistent with recent failure rates reported for Fansidar (pyrimethamine-sulfadoxine). We
suggest that limited use of proguanil be evaluated as an alternative to pyrimethamine.
Pyrimethamine and proguanil are antimalar-
ial drugs that selectively inhibit Plasmodium
dihydrofolate reductase (DHFR; EC 1.5.1.3,
present in Plasmodium as a bifunctional en-
zyme with thymidylate synthase EEC 2.1.1.45]).'
Since the introduction of pyrimethamine and
proguanil nearly 40 years ago, drugs have
been widely used in malaria prophylaxis and
treatment. Unfortunately, drug-resistant P/as-
inodiuin has become widespread, and the use
of pyrimethamine or proguanil (or cycloguanil,
the active metabolite of proguanil) is no longer
effective in many regions endemic for malaria.
Specific point mutations in DHFR confer dif-
ferential resistance to pyrimethamine and cy-
cloguanil in naturally resistant laboratory iso-
lates of P. fakiparum. 4 ' All pyrimethamine-
resistant strains have been found to have a Ser-
108 - Asn-108 mutation that produces only a
small decrease in susceptibility to cycloguanil.
In contrast, parasites with paired Ser-lOS - Thr-
108 and Ala-16 - Val-16 mutations have been
found to be resistant to c)cloguanil, but not to
pyrimethamine. Mutations causing cross-resis-
tance to both drugs have been reported for only
two isolates from southeast Asia; both isolates
exhibited the Ser-108 - .Asn-108 mutation, a
second lie- 164 -. Leu-1 64 mutation, and a third
Cys-59 — Arg-59 mutation.'3
Since all pyrimethamine and cycloguanil-re-
sistant isolates examined to date have point mu-
tations in DHFR, resistance to these drugs may
be predicted by assays that detect point muta-
tions in the DHFR gene. Some methods of de-
termining point mutations, such as restriction
fragment length polymorphism analysis, clon-
ing and sequencing, or hybridization with se-
quence-specific oligonucleotides are time con-
suming and labor intensive. Recently, however,
methods have been described that use the poly-
merase chain reaction (PCR) for rapid and ef-
ficient detection of point mutations.'-' These
methods are based on the observation that oil-
gonucleotides having a single base mismatch at
the 3' end are much less efficiently extended
during PCR than are perfectly matched primers.
To detect point mutations responsible for pyr-
imethamine and cycloguanil resistance, we have
developed a mutation-specific PCR assay that
can be applied to a few drops of P. fa/ciparurn-
infected blood. We report herein the results of
a field study in which this assay was used to
examine the incidence ofDHFR Asn-1 08 among
P. falciparum strains collected in the Brazilian
Amazon.
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Fiouaa 1. Strategy for PCR amplification of Plas-
modiumfalcipanm DHFR sequemes in the mutation-
specific assay. Pontionso(codon 108 and of sequences
recognized by the PCR primers are indicated.
MATERIALS AND METhODS
Mutvion-specuzc PCR assay
Three P. fakiparum clones with known drug
profiles were used to establish the ntutation-spe-
ciflc PCR assay. Drug responses and DHFR Se-
quences for each clone have been reported 4.10
the pyr'-cyc' 3D7 clone encodes Ser-108 (AGC),
the pyrcycr ItG2F6 clone encodes Thr-108
(ACC), and the pyi'-cyc' 11B3 clone encodes Mn-
108 (AAC). Parasite cultivation and DNA ex-
traction were performed as previously de-
scnbed
Point mutations were detected by a mutation-
specific PCR assay similar to that reported by
Zoig and others" (Figure 1). Diagnostic primers
DIA-3 5'-GAATGCITTCCCAGC-3' (specific
for Ser-108), DIA-9 5'-GAATGCTTTCCCA-
GG-3' (specific forThr-108), and DIA-125'-GG-
AATGCITFCCCAGT-3' (specific for Mn- 108)
were purchased from Synthecell Corporation
(Rockville, MD). All diagnostic primers were used
in conjunction with countcrpnmer SPI5'-ATG-
ATGGAACAAGTCTGCGAC-3'. PCR reac-
tions were performed in standard reaction buffer'°
with 500 ng ofa diagnostic primer and SPI. For-
ty-five cycles of amplification were completed,
each consisting ofdenaturation for 30 sec (94°C),
renaturation for 45 sec (56°C), and extension for
45 sec (74°C). Amplified products were stained
with ethidiwn bromide and photographed after
electrophoresis in agarose gels containing 1%
standard agarose plus 2% NuSieve low melting-
point agarose (FMC Bioproducts, Rockland, ME).
Blood samples and DNA preparation
Blood samples were collected before treatment
from individuals who had not been under prior
medical care for their malaria. Samples were di-
rectly cryopreserved without in vitro cultiva-
tion. For DNA extraction, cells from 300 gil of
eadi thawed sample were pelleted in a micro-
DIA-3 DIA .9 D!A42
M3 11131113 IH
Fiouar 2. Mutation-specific amplification with diagnostic primers. DIA-3 detects the Ser-108 codon o(the
p'.r-cyc 3D7 clone (lane 3), DIA-9 detects the Thr-108 codon of the cyc-pyl' ltG2F6 clone (lane I), and DIA-
12 detects the Mn-108 codon of the pyr-cyc H83 done (lane H). Each amplification was performed with
munterprimer SPI on 100 ng of genornic DNA for 32 PCR cycles. The sorow indicates she position of the 337-
bssepair PCR products detected by ethidium bromide staining after agarose gel electrophoresis.
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M12345 678M
Fouaa 3. Sensitivity of the mutation-specific PCR assay. Lanes 1,2,4,5, and 7 show ampLification from
samples containing 1.0%, 0.1%, 0.01%, 0.001%, and 0.0001% parasite-infected erythrocytes, respectively. Lanes
3. 6, and 8 show that no amplified product was obtained from samples of unparasitized blood processed in
parallel with parasitized samples. Lane M contains DNA size markers (X I 74-HaeIfl plus A-HindlJI).
centrifuge, resuspended in 1,000 MI of TSE (100
mM NaCI, 20mM Ths, 50mM EDTA, pH 8.0),
pelleted again, and resuspended in 1,000 Ml of
TSE containing 0.15% saponin. After incubation
at room temperature for 2— 10 miii, parasites were
recovered by centrifugation, resuspended in 500
gil of TSE and tysed by the addition of SDS and
NaCIO4
 to give final concentrations of 1% and
0.5 M, respectively. Samples were extracted twice
with phenol:chloroform, once with chloroform,
and precipitated with two volumes of ethanol.
To monitor for cross contamination, a sample
of unparasitized blood was processed in parallel
with each sample of infected blood. Other pre-
cautions against contamination included pro-
TABta I
Occurrence by stale of Asn-108 and Ser-!08 in the
DJIFR of Plasmodium falciparum isolate?
M,ard
?.o	 Ser-	 The-	 ksn- Mn-lOS +
Siale	 mplea	 10*	 10$	 10$	 Set-SOS
Rondonia	 21	 2	 0	 18	 I
Pain	 14	 2	 0	 Il	 I
MazoGrosso	 6	 0	 0	 5	 1
imazonas	 1	 0	 0	 I	 0
Total	 42	 4	 0	 35	 3
The ,ample poinis and sean o(colkcuon wete Costa Marques Ron-
.ioiva(l987. 598$ and 5989)- nquemesRondonsaiI87 198$ and
9*9p Puno Velbo. Rondouna 11911 198$ 59*9 and 19901- Redençao.
Pan (598$)- Iuauub.. Pan (5987 I 98$ 1989 and 59905- Maraba. Pam
• 1989) clen,. Pam (1990t Guuarana do 7-one Maio Grosso (198k
ita Flartita. Maso Grosoo 1 l9885 Pessoio & Azesedo Mate Orosto
I SU) ipucas. Mate Grosso (I 9$9)- Camarus. Asnazonat (198$)
cessing of the blood samples and DNA prepa-
rations in a different part of the laboratory from
that used to analyze the PCR reactions. Separate
sets of pipettes were used for the analysis of the
PCR products.
RESULTS
The mutation-specific PCR assay is based on
the observation that efficient amplification under
stringent PCR conditions occurs only when there
is a perfect match between the target DNA and
the 3' terminus of the diagnostic pruner.'-' A
single nucleotide change can thus be rapidly de-
tected by a PCR primer having a 3' terminal
nucleotide complementary to the mutation. De-
tection of mutations at position 108 in P. fakip-
arum DHFR is readily performed, since in all
cases, Asn-l08 has been found to be encoded by
AAC, Ser-108 by AGC, and Thr-108 by
ACC.4 i. (0.I3-I Figure 2 shows that diagnostic
primers having a 3' terminus complementary to
the second base of codon 108 produced clear
discrimination of the Ser-108 (p-cyc'), Thr-
108 (cyct-pyr), and Asn-108 (pvr-cyc') muta-
tions. A reannealing temperature of 55-56C in
the PCR cycle provided effective discrimination
between mutations while providing high yields
of amplified product. These findings are com-
parable to those of Zoig and others," although
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the assays differ in the primers used and the seg-
ments of the DHFR gene amplified.
The sensitivity of the mutation-specific PCR
assay was assessed by combining known nuxn-
bers of parasitized erythrocytes with 300 p1 of
uninfected whole blood. One-tenth of the DNA
extracted from these samples was subjected to
mutation-specific PCR amplification. Figure 3
shows that the limit of detection in these studies
was better than 0.0001% parasitemia. Because
of the extreme sensitivity of this technique, cross-
contamination of samples was carefully avoided.
In addition to standard measures to prevent con-
tamination of the DNA extractions and PCR re-
actions, samples of unparasitized blood were in.
cluded with the infected samples and processed
in parallel during the assays. These precautions
against contamination were effective, in all as-
says described, only a single instance of ampli-
fication was seen in a control reaction. In this
case, analysis of the control and adjacent samples
was repeated without reoccurrence of contami-
nation.
Table 1 shows results from 42 samples col-
lected during the years 1987-1990 from the states
of Rondorna, Para, Mazo Grosso, and Amazo-
nas. Thirty-eight of the 42 isolates were found
to have the DHFR Asn. 108 mutation diagnostic
of pyrimethamine resistanor, three of these sam-
pies showed evidence of both Asn-108 and Ser-
108. Since the erythrocyte stage of the P. falcip-
arum parasite is haploid," these three samples
probably comprised mixed infections of pyri-
methamine-resistant and pyrimeshamine-sensi-
tive parasites. The remaining four samples con-
tained only the Ser-108 residue that is found in
pyrunethamine-sensitive parasites. No sample
showed evidence of the Thr-l08 mutation that
occurs in cycloguanil-resistani, pyrimethamine-
sensitive P. fakiparuni."5
DSSCUSS1ON
Previous studies have demonstrated that the
Asn.l08 mutation in DHFR produces pyrime-
thasnine resistance in P. falciparum. Patient iso-
lates from pyriznethamine failures exhibit in vitro
50% inhibitory concentration (lC, ( values) that
are 500 to 1,500-fold greater than IC values
of susceptible isolates; these IC, 0 values have been
linked to DHFR Asn-l08 in a genetic cross.41°
Biochemical studies have shown that this mu-
lation interferes with the action of pyrimetham-
inc by interrupting binding of the drug within
the DHFR active site, an effect that is enhanced
by the ancillary mutations lie-Si and Arg-
59IO. II. 14. To date, parasite isolates from pa-
tients who have failed Fansidar treatment have
all contained the DHFR Asn-108 mutation'0
(unpublished data). Other codons or alternative
mechanisms of natural pyrimethamine resis-
tance have not been reported.
In this study, we examined the incidence of
the P. foiciparum DHFR Asn-108 mutation
across four states that span Brazil from the Bo-
livian border to the mouth of the Amazon River.
Of these samples, 90% were found to harbor
DHFR Asn-l08, indicating that this mutation is
the principal factor responsible for pyrimetham-
inc-resistant malaria in endemic regions of South
America.
The incidence of the Asn- 108 mutation is
comparable with recent failure rates reported for
Fansidar (pyrimethamine-sulfadoxine). In vitro
and in vivo drug response studies from the early
1 980s documented 16-63% Fansidar failure rates
from various regions of the Amazon."- 2 ' More
recently, with continued wide availability and
use of the drug, 92% of samples collected from
Acre state in 1987 were found to be Fansidar
resistant. This correlation between resistance
and the incidence of Asn-1 08 suggests that po-
tential augmentative effects of sulfadoxine in the
Fansidar combination are inactive against the
present strains ofpyrimethamine.resistant P.fal-
ciparum.
Additional studies are needed to determine the
cycloguanil responses and survey other DHFR
mutations in the P. falciparum strains of South
America. Clinical and field studies from other
continents have found that proguanil (or the
closely related analog chiorproguanil) can be ef-
fective against some strains of pyrimethamine-
resistant falciparum malaria. 2 These findings
can be explained by the different point mutations
in DHFR that govern cycloguanil resistance.'3
Proguanil has been little used in South Amer-
ica.2' Since Fansidar is now virtually ineffective
on this continent, the use of proguanil on a lim-
ited basis may be of value. It is clear, however,
that its wide use will lead to the spread of ad-
ditional DHFR mutations and of proguanil-re-
sistant malaria.
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We have found polymorphism in the repetitive and
nonrepetitive regions of the sporozoite vaccine anti-
gen, the circumsporozoite (CS) protein, in Plasmodium
vivax malaria parasites from two geographically dis-
tant malaria endemic regions of the world. Like the
recently described variant repeat sequence of P. vivax
from Thailand, the CS protein repeat sequence of the
variant P. vivax parasites from Papua New Guinea
and Brazil is ANGA(G/D)(NID)QPG, which differs
from the previously identified CS repeat sequence,
GDRA(D/A)GQPA, of P. vivax parasites from South
America, Central America, and NoithKorea. Compar-
ison of the P. vivax CS protein outside the repeat
region revealed restricted polymorphism in regions
that have exhibited T-cell immune function and se-
quence heterogeneity in the CS protein of Plasmodium
(akiparum. Our results show that P. vivax malaria
parasites with the variant CS repeat sequences are
widespread in nature and that the polymorphism in the
CS protein of P. vivax is also present in the nonrepeat
region.
effectively prevented by neutralizing the sporozoites (1). The
CS' protein, which covers the surface of the sporozoite, is a
candidate target for the production of a sporozoite-based
malaria vaccine (1, 2). The gene encoding the CS antigen has
been cloned from three of the four human malaria parasites
(3-7). Immunologic experiments and sequence determination
of the CS protein genes have revealed species-specific repeti-
tive sequences (B-cell determinants) that make up the central
one-third of the molecule and T-cell epitopes that reside in
the nonrepeat part of the protein (8-10).
The nature and extent of variation in the vaccine-target
immunodominant determinants of the CS protein of field-
derived malaria parasites must be considered in the develop-
ment of a subunit vaccine. Prior analyses of the CS proteins
of Plas,nodium fakiparum parasites have revealed that poly-
morphism is restricted to the nonrepeat T-cell immunodom-
inant regions of the molecule (11-13). Relatively less is
known, however, about CS protein polymorphism in Plasmo-
dium vivax parasites at the geographic leveL In Thailand
Rosenberg and his co-workers (14) recently fed mosquitoes
on humans infected with P. vivax. These investigators isolated
sporozoites from the infected mosquitoes and found that
sporozoites from nearly 14% of the infected individuals had
CS proteins with a variant repeat sequence, ANGAGNQPG.
This repeat sequence, obtained from a clone designated as
VK247, is different from the previously identified CS repeat
sequence, GDRA(D/A)GQPA, of parasites from South Amer-
ica (Belem), El Salvador ( Sal-i), and North Korea (NK) (5,
6, 15). Because the presence of variant forms of malaria
parasite has implications for the efficacy of vaccine formula-
tion, we have undertaken a study of polymorphism in the
plasmodial vaccine candidate antigen from biologically rep-
resentative field isolates of malaria parasites. The results
presented here show widespread variant CS repeat- and non-
repeat-bearing P. vivax parasites in nature.
EXPERIMENTAL PROCEDURES
The objective in the development of a vaccine against
malaria, a disease that affects nearly half a billion people
worldwide, is to intervene immunologically in the develop.
ment of the parasite in the human host or Anopheles vector.
Because malarial infections are initiated by sporozoites that
are inoculated into a human by the bite of an infected mos-
quito, it has been proposed that the infection can be most
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International Development PASA Grant BST-0453-P-HC.2086-07,
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ance with 18 U.S.C. section 1734 solely to indicate this fact.
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Isolation of Parasites—Field isolates of P. uwax employed in this
study were from Paragaminos, Brazil and Madang, Papua New
Guinea. Blood that had been microscopically confirmed as having P.
vivax blood stage infection was collected for the isolation of genomic
DNA.
Purification of the Parasite Genomic DNA and Amplification, Hy-
bridization, and Sequencing of the CS Protein Gene—After the ge-
nomic DNA from field-derived parasites was isolated, 100 ng of the
DNA was used in a polymerase chain re%,ct,on amplification of the
CS gene using oligonucleotides AL 60 (GTCGGAATTCATGAA-
GAACTI'CATT'CTC) and AL 61 (CAGCGGATCCTTAATFGAA-
TAATGCTAGG) as amphf ing primers. These oligonucleotides,
which correspond to the terminal regions of the CS gene, were
designed to contain an EcoRl (AL 60) and a BamHl (AL 61) site.
Following 25 cycles of amplification, the amplified DNA was tested
on gel, purified, and ligated Into Bluescript plasmid DNA.. The
plasmid DNA was isolated from recombinant clones for hybridization
and sequencing procedures. In preparation for hybridization experi-
ments. oligonucleotides AL 114 (ATC AAC CAG GAG CAA ATG,
complementary to a portion of the repeat sequence ANGAGNQPG),
AL 116 IGGT GAT AGA GCA CAT GGA., complementary to a
portion of the repeat sequence GDRAAGQPA). and AL .54 (CCA
TGC ACT GTA ACC TGT GGA. complementary to the conserved
region. Region II) were kina ..ed. Three nitrocellulose slot blots con-
The abbreviations used are: CS. ctrcumsporozolte; SDS. sodium
dodecvl sulfate.
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taming samples of the purified plasmid DNAs (10 per amplified DNA)
were prepared. These blots were denatured, renatured, and baked
before being prehybridized in 4 x SSC, 0.2% polyvinylpyrrolidone,
0.2% FicoIl, 0.1% SDS. and 0.4% bovine serum albumin at 42 C for
30 mm. The blots were hybndized at 42 C overnight in the same
buffer supplemented with tRNA. Posthybndization washes were car-
ned out for 15 mm in 6 x SSC, 0.1% SDS at room temperature
followed by 5 miii a wash in 6 X SSC, 0.1% SDS at 5 C below the
melting temperature of the oligonucleotides. The nucleotide sequence
was determined using plasmid and CS gene-specific primers.
RESULTS AND DISCUSSION
Polymerase chain reaction-mediated amplification of P.
vivax CS protein gene using genomic DNA from field isolates
and P. viuo.x CS-specific primers produced a DNA fragment
of about 1.2 kilobases. In a Southern blot experiment, these
amplified fragments hybridized to oligonucleotides comple-
mentary to the conserved region, Region II of the CS protein
gene (data not shown). The amplified CS DNA fragments
from P. vivax parasites (14 from Madang and 30 from Pars-
gaminos) were cloned into the plasmid vectors in preparation
for hybridization and DNA sequencing. At least 10 recombi-
nant clones from each transformation were analyzed by hy-
bridization and/or nucleotide sequence analyses.
CS Repeat Sequence Polymorphism—In a hybridization cx-
perünent using oligonucleotides complementary to Region II
and to both types of the CS repeats, we found that the CS
gene clones from all P. vivax parasites hybridized to the
Region II probe, but the hybridization was specific for either
the ANGAGNQPG or the GDRAAGQPA repeat oligonucle-
otide probe (data not shown). Using this hybridization pro-
cedure with the 14 P. vivax isolates from Papua New Guinea,
we found that one patient had parasites with a GDRAAGQPA
CS repeat sequence, one had mixed infections with AN-
GAGNQPG and GDRAAGQPA repeat-bearing parasites, and
the remainder of the patients were infected with parasites
whose CS protein had the ANGAGNQPG repeat sequence.
These findings differ from a previous serologic study that
showed anti-GDRAAGQPA reactivity in a large number of
serum samples from Madang (16). However, at the time the
earlier study was conducted, the Thai type of the P. vivax CS
repeat (ANGAGNQPG) had not been identified. Therefore,
it would be useful to reevaluate the reactivity of those serum
antibodies with the ANGAGNQP repeat peptides.
In the case of parasites from Brazil, however, a very differ-
ent profile emerged from that found in Papua New Guinea.
Of the 30 isolates analyzed, two had P. uivax with mixtures
of ANGAGNQPG and GDRAAGQPA repeat-bearing para-
sites, and the remaining 28 isolates had parasites of the
GDRA(D/A)GQPA CS repeat sequence. This within-isolate
CS protein diversity underscores the need to analyze multiple
recombinants from an individual transformation when char-
acterizing parasite antigen genes. To determine the presence
of parasite polysnorpha within a patient, we sequenced 13 and
9 CS recombinants from isolates of P 19 and P 4 P. vivax
parasites, respectively. Complete nucleotide and deduced
amino acid sequences of four CS genes (P 19/D and P 4/B
from Papua New Guinea, and B 7-4 and B 19-2 from Brazil)
are presented in Fig. 1. Among the 13 CS clones sequenced
from the P19 isolate 11 recombinants contained CS genes
with the ANGAGNQPG repeat sequence, and two had the
GDRAAGQPA CS repeat sequence. On the other hand, all
nine CS clones sequenced from the P4 isolate had the AN-
GAGNQPG CS repeat sequence. These results were in agree-
ment with the hybridization data.
Ve found 19 copies of the nonapeptide repeat sequence,
ANGA (GfD)(N/D )QPG, in the CS gene of each of the para-
sites analyzed from Papua New Guinea and Brazil, compared
with 18 units of repeats in the isolate from Thailand (VK247)
(Fig. 1) (16). The repeat region sequence is polymorphic in
the 5th (Asp/Gly) and 6th (Asp/Mn) residues. Even though
glycine is present at positions 3, 5, and 9, and asparagine is
present at positions 2 and 6 of the repeating unit, it is
intriguing that the variation is oniy restricted to the 5th and
6th positions. This within-repeat polymorphism was not seen
in the CS protein gene from Thailand. However, nonrandom
third-base silent changes in the repeat region are shared by
the CS gene of parasites from Brazil, Papua New Guinea, and
Thailand, which probably indicates common origin and/or
pressures (recombinational events) that maintain these repeat
sequences.
Nonrepeat-based Polymorphism—Comparison of the nu-
cleotide and deduced amino acid sequences outside the repeat
region shows deletion/insertion and nonsynonymous changes
(Figs. 1 and 2). Amino to the repeat region is a 24-nucleotide
deletion in the P 4/B, B 7-4, and B 19-2 CS genes (Fig. 1).
Like P. fakiparum CS protein which has nonrepeat based
variability, the CS protein of P. vivax is also polymorphic in
regions outside the repeat domain. The three variable regions
identified by our sequence comparison are amino to the repeat
region, and amino and carboxyl to the conserved region,
Region II. Amino to the conserved region, Region I, there is
a nonsynonymous change from glycine to asparagine at the
38th amino acid position (Fig. 1). Another variable amino
acid is post-Region H in a recently identified proliferative T-
cell site, VTCGVGVRVRRRVNA(AIr)NKKP, of the CS
protein in P. vivax (17) (Fig. 1). The third and the most
variable region is amino to Region II. In this region, the amino
acid residues that are polymorphic are 294, 295, 298, 310, 311,
and 316 (Fig. 2). Also in this region, one CS clone, P 19/M,
from isolate P 19 from Papua New Guinea had a deletion of
16 amino acids; the repeat sequences in this gene extend up
to the polymorphic G/A position at amino acid 298. The CS
gene of the previously identified North Korean P. vivax and
a clone (P 19L) of the P 19 isolate from Papua New Guinea
have an insertion of seven amino acids at position GNAG-
GNA, identified by an asterisk in Fig. 2. Sequence analyses of
multiple clones of the CS protein gene from two isolates (P
19 and P 4) from Papua New Guinea revealed the presence
of variants with polymorphic repeat and nonrepeat sequences
(Fig. 2). Comparison of the CS protein gene sequences of six
field isolates of P. vivax from distant geographic regions
revealed that the variant amino acids in the nonrepeat region
are shared.
Like the P. falciparum CS protein, the T-cell immunodom-
inance of the P. vivax CS protein has not been extensively
studied. Although more extensive studies to characterize the
polymorphism in the CS protein gene of field isoLates of P.
vivax are needed to fully understand the nature and extent of
antigenic variability, at least three facts seem to emerge from
this study. First, the repeat-sequence polymorphism in P.
vivax is similar to the already identified repeat-sequence
variability in PLasmodium cynomo(gi and Plasmodwin know-
lesi CS proteins (18, 19), which has not been seen in the P.
fakiparwn CS protein. This difference in the nature of poly-
morphism between the sporozoite proteins of P. foiciparum
and P. vivax, P. knowLesi and P. cvnomoLgi is probably because
the latter three parasites have evolved longer in response to
host immune pressures compared with the recently evolved
P. fakiparum (20). However, this explanation may not hold
true for blood-stage antigens, since mutations leading to se-
lective advantages for the parasites are likely to be fixed
rapidly in the blood forms. which are present in much greater
numbers and exposed to the host immune system for a longer
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FIG. 1. Nucleotide and deduced
amino acid sequences of the CS pro-
tein of variant P. vivax parasites
from Papua New Guinea and Brazil.
P 19fD and P 4/8 are CS genes from
parasites that originated from patients
in Madang, Papun New Guinea. B 7-4
and B 19-2 are two CS genes from par-
asites isolated from patients in Paraga-
rninos, Brazil. The CS gene sequence is
compared with the published CS gene
sequence of P. vwax (North Korean) in
the nonrepeat region and with the CS
gene of P. vivax (Thai, VK247) in the
repeat region. A period indicates se-
quence similarity to the P 19fD se-
quence; a dash indicates deletions. Silent
and nonsilent changes are shown by
lower and upper case letters. Amino acid
changes resulting from nonsilent nucleo-
tide changes are shown.
::':
SI C P INCA CCC C = $ S
Pill) SAC TTC 7CC CC 4CC 4*4 TM Ste w An CIA CA? CC ?CC SM
ntiS CC ETC CAT CC CAT CCC CIA CCC VT? ACT AG? CIA ALA CCC ACT
ill ICC CIT CCC CCC ALA CM CIA GAL CA ACT CC? AlL CA CCC CAL
Glee PP.5)! SpACE
PIlfl CCC CT? CT CIA ALA CCC CAT SAC CCC CAL CCC CT CAT CCC SM
• C5CP I AC P C C P S C P
PITIC SM flAIL? CA AC MA ALA CM CC AC SAT SM CC CAL LAX
ff7
P415 ....0 .A..C C........................ C ......
C... ........................... C ......
...	 CAICA
flit) CA CCC AC LAX (CL CM CC? CAT MA CC CAL AC ALT CCC CC?
P415 ........... C .... . CA.................C...
.15-s ............I .... . C A.. ... ............
CAL ..............cd ........................
:	 . .	 . • * •,• PC A
pit,, CAL CL? CA AC CAL AC CAT CC CC CT at CAL CCL CCL CPA
PAlS .A C	 .. ...C...	 C
...t..CA .............
CC ASP I P C £151 C N I
PlAIN ACT AC CT CC CAT CCC CC SM CC MACCOt? CCC AS? CA
Pa,. ..................................C..' ......
PC CCC & •COP C C ICC
PIN!) CA CAL SPA ALl CCC CAT 5CC ACT CC AC (CA CC CA? CCC CC
CQPC&5 C & CCC PAL
PC,,: CC? LAX CA CA CAL CC AL? AC CC CCC ACT CM CCL CCC CC
IC.AS	 .CCA...................... C ................
SC AC) C PC £ P CL C P 5
PACtS CLI CCC Ca CCC MT CM CA NSA CCC MT AC CC ALT AC? CA
PC C N CA COO PC £0 C *
Pin) CCC CA CCL CAT CAL CCC CAT CAT MA CA CA COLA? CAC CC?
pCl) ........... ...
Cl 9 PCACC*CC C PA A
P1)10 CCC CAT CCC CCL GAL CCL CAT CAL CCL CC? CA? CM CA ALA CCC
C C * C CC PC £ C C AC it
PATtI CAT CCC CCC CCC CAT CC (MCCC AM CAT AL WIlTST CA
C PC P	 CCC A C C CA CC
::: : CCA S CAL CCC CC? CL CCC CC CL
PCTI$ WALT lit CA AC MA CIA CCC CC CLAW CCL - -
PA,. .......................
-	 .CCCAQCC N C C N
PAIl) __.CC ALA CAL CA CA ACT CC? CAL ALt C ALT
P
. 15 --- - - - . .................
TALL-	 ..................................
SC	 ALL CL CCO .0..............................
. ,..	 ,	 . . . .
CIlIA CC AC CAT CM ACt Ii? CT) AM CCC ICC CS SAT MACC? CAL
C.........................................
£ T I C S N A S P IC	 V T c CT
Pitt, CC CC CT? CCC CC SM ICC ACT CS tiC ACT dTC ACT ICC .CA
TCTP TO. S V C C £ C 9 5
PA:it CS CT SIC ICC CII CAL AM ALA CT? SIT CC C? CM SM
P C I STIP Pt N T C C C?
PCTIP CC CLI it? CT? CC? VT) Ut CT? CCC IC? AC CCC CC ICC
• All ........................................
C NC C A C! PS V TI CC &
PCl/C CI) SC? C It? ACT CCC CTC TI? CCC CT? Cit SC? CC CL fTC
P I,) ......................................
CC. Till? IC ICC
Pill) ICC CCC CC ACt TIC fTC Cit tIC CC fit fit AL? CC	 IllS
• 4/5 ...............................
22	 C	 II	 A
C A C A A C A C A C Q I P I C
LAG CCL CCL GAG CCL CGA CCL CCL CAG CCL CAL SAT SAT CIA ACT P iIIAF.I.X.I
P1,/C
........................... P 11/3:, 4/A
................................. p 4is-i p 19-1:1 7-4
A. A........ s.0.........................	 11/i.
--.c......................... P11/N
......C.G......................... PCTALi
I.
P 1	 I	 318
A P & S P 1 1 1 V I C V
CCC SAT CCC ACA ALT GSA SAC TCT CTC 5*5 GAL TAG P it/S-F,8.1.A
PLIG
C.......................... P 1I/J:P I/A
P 4/1-1.1 D2;I 7-4
C.......................... P1)/I
Cr......................... P Il/N
C.......................... PP
C.......................... TAIL
FIG. 2. Comparison of the polymorphic pre-Region II CS
protein sequence of P. vivax. Amino acid residues in the poly-
morphic site (amino acids 292-318) are shown. The nonsilent nucleo-
tide changes are shown by upper case letters underneath the nucleotide
and deduced amino acid sequence of the representative sequence of
P 19/A-F, H, I, and K. Previously characterized CS sequences of P.
twax CS proteins from North Korean (NK) and from Thailand
VK247) are also shown. The dash indicates a deletion in the CS
protein gene in P 19/M. An asterisk in the NK and P 19/L sequence
points to the insertion site of the seven-amino acid sequence GNAG-
GSA.
time than the sporozoite stage of the parasite. The obvious
issues that emerge from this study are: 1) whether the CS
repeat sequences exist as coding or noncoding cassettes in
plasmodial genome, and whether genomic rearrangement re-
suits in generation of a variant repeat-bearing CS protein
gene: and 2) whether more than two types of CS repeat-
bearing P. vivax sporozoites are present in natural parasite
populations. While further field studies are required to ad-
dress the second issue, we have begun testing the first issue
experimentally, employing parasites that are known to con-
tain either ANGAGNPG or GDRAAGQPA repeat-bearing
CS proteins.
Second, the pattern of nonrepeat-based polymorphism is
similar to the previously identified polymorphism in the CS
protein of P. falciparum. Since analogous regions around the
conserved region, Region II, are also immunogenic in the CS
protein of rodent malaria parasites P. berghei and P. elii (9,
21, 22), we speculate that the immunodominant epitopes of
the P. vivax CS protein may reside in these polymorphic
regions. Selective changes in the parasite protein sequences
that interface with the host immune system can enable the
parasites to evolve around host immune pressures, as has been
suggested previously (23). In view of the above, one or more
immunodominant determinants of the P. uivax CS protein
are likely to reside in amino acids 292-318. Since the amino
end of this polymorphic region (amino acids 292-318) is
affected by insertion and deletion, unlike the rest of the region
in this sequence, this part of the sequence may not contain
immunologically and/or biologically relevant domains. How-
ever, this possibility needs to be tested experimentally.
Third, amino acid residues in the pol ymorphic positions are
shared by CS proteins from distant geographic locations. This
observation is similar to the finding for the P. falcipc.rum CS
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protein and reflects the extent of biologic and/or immunologic
constraints on these regions and the independent origin of
these changes. For vaccine considerations the development of
'vaccine resistance" may be far less likely against a vaccine
capable of inducing protective immunity with limited types
of polymorphic components.
In summary, we have found that the variant form of P.
vivux originally detected in Thailand is also prevalent in other
malaria-endemic regions of Papua New Guinea and Brazil,
though in different proportions. More importantly, we find
that the repeat and nonrepeat polymorphic sequences of the
P. viuo.x CS protein are shared by parasites from geographi-
cally distant regions of the world, thus indicating that a
limited number of polymorphic parasites may have universal
distribution. This limited universal polymorphism implies
that a CS-based vaccine, alone or in combination with other
antigens from sporozoite or other parasite stages, covering
variant epitopes may be universally effective.
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Short Communication
Single amino acid variation in the ookinete vaccine antigen from field
isolates of Plasinodium falciparum
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Pfs25. a 25-kDa protein expressed on the
zygotes and ookinetes of Plasmodiuni
kilciparuin. is a candidate vaccine antigen in
the development of a transmission-blocking
vaccine [I]. Monoclonal antibodies directed
against the Pfs25 antigen inhibit parasite
development in the mosquito midgut [2]. The
gene encoding this protein has been cloned and
sequenced from the human malaria parasite.
Plasmodiu,n /alc:parum; the avian malaria
parasite. Plasinodiu,n gallinaceurn: and the
chimpanzee malaria parasite, Plasinodiun:
reiclienowi [3-5]. Mouse antibodies against
Pfs2S vaccinia virus recombinant vaccine have
been recently shown to inhibit P. frilciparuni
development in Anopheles freeborni mosqui-
toes [6].
In view of the polymorphic nature of other
malaria parasite antigens, the sequence of the
Pfs25 antigen from 8 laboratory cultured
strains clones of P. lalciparun: was determined
[7].The Pfs25 antigen of one parasite (clone
Dd2) from Indochina has one non-silent
substitution that leads to a conservative
amino acid change (Ala to Gly) at the l32rd
amino acid of the protein [7]. No silent
nucleotide substitutions ere seen in the 25-
kDa antigen genes in that study. However.
because the culture-derived parasites employed
('nrrt.panclite uddre'.i Altjf A. Lal. 1alana Branch. 1aiI
Stop l--12. (DC. I(i4K) (,Iifton Road. Atlanta. GA 3OS.
L S A Tel 41,4.4's-40 q l-.i: 4O4-4-4427
in the above study poorly infect mosquitoes.
and because in vitro culture induces phenoty-
pic and genotypic changes in parasites, we
undertook a stud of Pfs25 antigen variation
employing field-derived P.faiciparunz parasites
from Madang, Papua New Guinea (PNG), a
holoendemic, high malaria transmission area,
and Paragaminos. Brazil, a relatively low
malaria-transmission area. Malaria parasites
from 20 patients from Madang. PNG. and
from 14 patients from Paragaminos, Brazil.
were used in this study. The Pfs25 antigen gene
of the parasites was amplified from the
genomic DNA [8] using the_oligonudeotide
sequences GTCGGAATTCTT 11 AAAAAT-
GAATAAACTTTAC (AL8O) and CAGCG-
GATCCTTACATrATAAAAAAGCATAC
(AL8I). which correspond to the two ends of
the gene. The oligonucleotides ere designed
to carry the EcoR! (AL8O) and Ba,nHI (AL8I)
restriction sites to facilitate cloning of the
amplified fragments. Amplification of the
genomic DNA yielded a 654-bp DNA frag-
ment from all of the parasite DNA used in the
study (data not shown). The DNA fragment
as isolated and cloned, and one Pfs2S
recombinant per isolate was sequenced.
We found that the Pfs25 antigen genes from
all 14 isolates of P. fidciparuns from Braml were
identical to the preiouslv described sequence
from the 3D7 clone of the NF54 P.Jàk Iparun:
isolate [I]. On the other hand. sequence
analses of 20 isolates from PNG reeaIed
I 1(t)
129	 147
IC	 7	 C	 V	 C	 S	 C	 ii	 I	 G	 L	 V	 P	 ii	 V	 Q	 D	 Q	 W
AAA AC? GGA C?? 7CC ?CA TG? AAT ATA CCC AAA C?? CCC AAT GTA CA?. GA? CAA A?.? 3D1, BRAe, PPIGØ
A
Dd2
A
PNG1
fig I. The nuckotide and the deduced amino acid sequence of the Pfs2S anti gen gene is shots n from amino acid 129 to 14
The scqucnces arc presented in groups: 3D7. BRAO (parasite numbers 4. 5. 6. 8. 9. 12. 15. (6. 17. 21. 22. 23. 24. and 26). PNG(I
(parasite numbers 21. 27. 28. 41. 47. 52. 61. 65. and 72). and PTGl (22. 31. 34. 38. 42. 45. 58. 68. 90. 92. and 98).
on non-silent and two silent changes in the
Pfs25 antigen gene (Fig. 1). Six isolates had a
silent nucleotide change at position 117 (T to
C), and one isolate showed a silent nucleotide
change at position 297 (T to C). The non-silent
mutation at amino acid position 143 (GTA to
GCA), found in 11 of the 20 isolates analyzed
from PNG. resulted in a change from valine to
alanine. This variable position is 12 amino
acids carboxyl to the previously identified
variable amino acid of this gene in the Dd2
strain of P.jalciparum from Indochina [7]. This
non-silent amino acid change. like the one
observed previously, results in conservative
amino acid substitution and is resident in a
putative T-cell determinant of the molecule
(Quakyi, I. A.. personal communication). This
limited and restricted nature of polymorphism
in the Pfs25 antigen suggests that the antigen
may not be expressed during the gametocyte
stage in the human host, as was speculated
earlier [1]. In such a case this antigen ould not
be exposed to host immune pressure, unlike the
sporozoite and blood-stage antigens of malaria
parasites. However, the vaccine-related rele-
vance of the polymorphic amino acids needs to
be determined in order to understand any
vaccine-related implications of using P25 in a
transmission- blocking vaccine.
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The circumsporozoite (CS) protein that coers the surface of infectious sporozoites S 4 candidate amigen in malaria
vaccine deelopment. To determine the extent of B- and T-epitope polymorphism and to understand the mechanisms of
antigenhi ariabiluy. se have characterized the CS protein gene of Plasmodium rirax from field isolates representing
geographicall distant regions of Papua Ne Guinea (PNG) and Brazil. In the central repeat region of the CS protein, in
addition to variation in the number of repeats. an
 array of mutations 'has observed which suggests that point mutations have
led to the emergence of the anant CS repeat sequence ANGA(G DMN D)QPG from GDRA(DA)GQPA. Outside the
repeat reaion of the protein, the nonsiknt nucleozide substitutions of independent origin are localized in three domains of the
protein that either harbor kno n T-cell determinants or are analogous to the Plasmodium falciparwn immunodominant
determinants. Th2R and Th3R. We have found that. ih the exception of one CS clone sequence that as shared b one P.
viia.v isolate each from PNG and Brazil. the P. rivax CS protein types can be grouped into Papuan and Brazilian types. These
results .uggest that an in-depth study of parasite population dynamics is required before field trials for saccine formulations
based on polymorphic immunodominant determinants are conducted.
Ke ords: Plasmodiuni rivax: Circumsporozoite protein: Clonal typing: Epitope polymorphism
Introduction
In contrast to the progress towards vaccine
development against P. falciparwn malaria
parasite. for hich several stage-specific vac-
cine antigens have been characterized, studies
of D parasite antigens have been limited.
partl because of the lack of in vitro culture cap-
abilit) - Only to vaccine candidate antigens of
P. thav hae been characterized: the circum-
sporozoite (CS) protein and the blood-stage an-
tigen. PV 200 [1-71. Immune responses against
the CS protein have been studied. and accine
ndtu,, jjjrecc AlijI A Lii MaLina Brandt. \LjiI
Stop I- 12. Centers for Diseaie Control. AtLinu. GA M13.
LS T,i 404i 4" 4079 Fa (4041 48' 44r
formulations have been produced [8-16].
Vaccination with specific antigens or epi-
topes offers the possibility of inducing immu-
nity against causative organisms of infectious
diseases. However, natural polymorphism in
the target determinants of the parasite proteins
ma compromise the efficacy of a subunit
vaccine. Whether a vaccine is based on a
critically important antigen present only in a
single stage of the parasite or on a combination
of important antigens present in several
different stages, failure to deal with antigenic
pol morphism could result in a accine that is
unable to protect individuals exposed to a
parasite with an antigenic variation. Therefore.
whether the vaccine is targeted against single
or multistage proteins, if a portion of a
106
parasite population can escape the effects of a
vaccine because of heritable polymorphism in
vaccine target antigens. the natural population
could rapidly evolve vaccine resistanc& in a
manner analogous to the development of drug
resistance in malaria parasites. To ensure the
efficacy of subunit vaccines based on poly-
morphic determinants. antigenic polymorph-
ism of malaria parasites must be studied at the
population level.
Polymorphism in the CS protein of P.
falciparwn has been shown to be restricted to
the T-cell determinants [17-19]. However.
polymorphism in the CS protein of P. rivax.
which was originally observed in the repetitive
B-cell determinant of the protein, has also been
recently found outside the repeat region [5].
Variant P. i'ivax parasites from Thailand.
Papua Ne Guinea (PNG) and Brazil have
the repeat sequence ANGAGNQPG. which
differs from the repetitive sequence
GDRADGQPA of P. vivax CS proteins of
parasites analyzed earlier [4,5]. We and others
have subsequently shown that P. irax para-
sites with the variant B-epitope repeat se-
quence have a wide geographic distribution
[5,20]. In continuation of our earlier studies of
the prevalence of CS proteins with the variant
repeat sequence ANGAGNQPG in P. ivax
field isolates from PNG and Brazil. we
investigated: (I) nonsynonymous changes in
the repeat region of P. vivax that result in the
emergence of variant repeat sequences: (2)
types of CS protein-bearing P. vivax parasites
that predominate in PNG and Brazil: and (3)
polymorphism outside the repeat region, in the
T-cell determinants, of the P. i-irax CS protein.
Materials and Methods
Origin 01 P. rirax parasites. Microscopicall)
confirmed P. vu ax-infected blood as collec-
ted directly from indiiduals living in a high
malaria-endemic region of PNG (Madang) in
March 1990 and from persons in relatRelv lo
malaria-endemic regions of Brazil (Paragami-
nos and around São Paulo) between 1986 and
1990.
Isolation and cliaracier,:aiio,i of the cirewn-
sporo:oite protein genes. As described earlier
[5]. blood collected from patients infected with
P. ii'ax was passed through a two-layer
column of acid-ashed glass beads and CF
II cellulose to remove leukocytes. Parasite
genomic DNA was isolated from infected
erythrocytes, and 100 ng was used in a
polymerase chain reaction (PCR -mediated
CS protein gene amplification. Oligonucleo-
tides AL6O (GTCGGAATTCATGAAGAA-
CTTCATTCTC) and AL6I (CAGCGGA-
TCCTTAATTGAATAATGCTAGG) corre-
sponding to he terminal ends of the CS
protein were vised as amplification primers.
The PCR-generated fragments were digested
with EcoR! and Ba,nHl. cloned in Bluescript
plasmid. and transformed into Escherichia co/i.
The repeat sequence of the recombinant CS
clones was identified by DNA:oligonucleotide
duplex hybridization analysis using oligonu-
cleotide probes ALl 14 (ATCAACCAGGAG-
CAAATG), and ALl 16 (GGTGATAGA-
GCAGATGGA) complementary to a portion
of the repeat sequences ANGAGNQPG and
GD RAAGQPA respectively. AL54 CCATG-
CAGTGTAA OCTGTGGA) complementary
to the genus conserved CS region. R II was
also used. CS gene-specific primers vere used
to determine the nucleotide sequence of the CS
gene by the dideoxynucleotide method [21].
Results
On PCR-mediated amplification of the P.
CS protem gene amplification. genomic
DNA extracted from blood samples of the
patients from ?NG and Brazil yielded DNA
fragments approximately 1.2 kb in length. We
sequenced the CS protein genes of a total of
115 CS clones representing 15 isolates from
PNG and 24 fr m Brazil. The entire sequence
of a total of 13 CS clones representing 8 P.
iiiav isolates from Brazil and 3 clones
representing 2 isolates from PNG as deter-
mined. The CS genes of the remaining 102 P.
ihax clones were sequenced to reeal sequen-
ces outside the cepeat regions and portions of
I0
the central repeat sequences. Of the 115 CS
clones, we have previously described the
complete sequence of 4 CS genes (P19 D. P4
B, B7 4, and B 19/2) and the partial sequence of
another 20 CS clones [5]. For the purpose of
presentation. we are designating the
GDRA(D/A)GQPA and ANGA(G D)(N
D)QPG CS protein repeats as type I and type
2 repeats, respectively.
Within-isolate pohinorphism of tile circum-
sporo:oile proteins. To determine the pre-
sence of parasite polymorphs among patients
from PNG. we sequenced 13 clones from the
P19 isolate, 10 clones from the P4 isolate, and
2 clones from each of the isolates P6. P7. P9.
P10. P18. P25. P26. P72. and P73. A distinct
variability in sequences as noted among the
clones of P19. P4, P6, and PlO isolates; these
variations ranged from a change of a single
amino acid residue to insertion of a stretch of
amino acids (Fig. 1). The isolate P19 was a
mixture of both type I andtype 2 CS repeat-
bearing parasites: two clones, P19,L and P19
M. had type I repeat sequences. while the
remaining 11 clones had type 2 repeat
sequences, indicating that the variants coexist
within a single isolate.
Similarly, polymorphism was noted in the
repeat and nonrepeat regions of the P. vivax
CS protein from Brazil (Fig. 1). We sequenced
8 clones from the B19 isolate, seven from the
B37. 6 each from the B5 and BlO isolates, 5
from the B7, 3 each from the BI 1.. B15, B21.
B31. B34. B40, and B43, and 2 clones from the
B14. B20, B26, B30. B38, and B39. Like the
mixed infection observed in the P19 isolate
from PNG, isolates B7 and B19 had both type
I and type 2 repeat sequence bearing parasites.
However, no amino acid variation was noted
among 2-7 clones sequenced from each of the
11 isolates from Brazil.
Evolution of the repeat region of the circuni-
sporo:oite protein. Based on the nature of the
non-synonymous changes, we have grouped
the repeat domain of the CS genes of P. i'ivax
into four categories (Fig. 2). The repeat
sequences in rows 1-3 encode the type I CS
repeat sequences, and the sequence in the
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fourth row encodes the type 2 CS repeat
sequence. Analysis of the nucleotide sequences
of the diverging repeats reveals evolutionary
relatedness between these sequences at both
the nucleotide and amino acid level (Fig. 3).
The CS protein repeat sequence from the
parasites B7 5. B3 1, and B30 2, shown in the
first row (Fig. 2), is similar to the previously
identified sequence of parasites from Brazil [I].
El Salvador [2], and North Korea [3]. in that
the 5th (D A) and 8th (P'A) amino acid
residues in the repeating unit are polymorph-
ic. One clone. B13 1, had no variation in the
8th residue. The CS protein repeat sequences
of the B5 I. B5/6, and B26, I clones, shown in
the second row, differ from the above
described set of sequences in that no polv-
morphism was found in the 5th or 8th residue
in the repeat unit, except in the degenerative
last repeat unit. However, polymorphism was
noted in the 2nd amino acid position of the
repeat (D N) in this group. The D/N transition
was also found in the previous characterization
of the CS gene from the North Korean isolate
of P. vii'ax. but in the repeat units 4, 13. 14 and
20 [3]. The third group of the representative CS
repeat sequences was seen in clones B38 2.
Bl9 3, B19 8. and B19 5. which had no
polymorphism except in the last degenerative
repeat. In one clone, B38 2, there was a
transversion from 0 to A at the 6th triplet
codon of the 8th repeat.
The fourth category of repeat domain
consists of the variant repeats identified in P.
G/R 0/N R G
	
A DIAIG G/R Q
	
P/A	 A
GGA GAC 4GA GCA OAT GGA CAG CCA GCA
A,' At 0	 C	 A i	 a 0
GCA AAT GGA OCT GGC AAT CAA CCA GGA
a	 AL GGa	 g 6	 C
A	 N	 G	 A G/D NIDG Q	 PA GA
Fig. AcumuLuioa of siknt (Itmer case) and nonsiknt
(upper case) mut.uions Ifi a population of tpe-1 (top) .*nd
type-i (bottom) repeat bearing clones. The deduced amino
acid residues are shown in bold. A erucal line indicates the
sinek point mutanon chat appears distinct in the
diflcrcniuiion ot these to repeal i pes at the prtM'in k'cl
iitax parasites from PNG and Brazil. All
clones from PNG (P19/D, P19/B, and P4 B)
and from Brazil (B7 4 and B 19/2) are poly-
morphic at the 5th and 6th amino acid
residues, whereas the last degenerative repeat
is polymorphic at the 8th and 9th positions as
flell. No polymorphism was noted in the
repeat sequences reported from Thailand
isolate [4].
Pofrrnorphisrn in the nonrepea region of CS
protein. The comparison of the CS protein
sequences outside the repeat region revealed
that sequence polymorphism is restricted to
three domains: amino to the conserved region.
Region I (RI), and amino and carboxyl to the
conserved region, Region II (Ru) (Fig. 4). A
24-nucleotide insertion amino to the repeat
region coding for EDGAGNQP was observed
in II ofthe l3clonesin Pl9andoneofthe 10
clones of P4 isolates from PNG. A similar
insertion was originally seen in the CS gene of
the VK247 P. vivax parasite [.4].
Amino to the conserved region, RI, poly-
morphism is restricted to amino acid positions
11, 13. 38, 49. 52 and 82. We have found that
CS proteins that bear type I CS repeats exhibit
greater polymorphism in this domain. Among
73 type I CS clones analyzed. polymorphism
was identified in 5 of 6 amino acid positions. In
contrast, only one of 42 CS clones bearing type
2 repeats exhibited amino acid L instead of V
at position 52.
The second and the most anab1e region is
amino to Ru. In this region, amino acid
residues 294 (0 E). 295 (D N), 298 (A/G).
310 (1 P L), 311 (N S), and 316 (K 1) are
polymorphic in both type I and type 2 CS
repeat-bearing parasites. The CS protein genes
from PNG (clones P19 M and P22 C). which
are similar to.the CS protein gene from the
North Korean (NK) strain [3], have a 16-
amino-acid deletion 3' to the repeat sequence.
This deletion is seen in all isolates from Brazil
with type I repeats. The CS gene of PNG
clones P19 L and P28 3 and the previously
identified N K strain of P. i'ira t have a 7-amino
acid insertion (GNAGGNAi at amino acid
number 297 (Fig. 4). The P. irax CS protein
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(9) I clone (P6 C): (10) I clone (P28 C); (II) I clone (P19 L); (12) I clone (P19 M): (13) I clone (Bl3 I): (14) I clone (B3 I
(15) 1 clone (B15 3): (16) I clone(B10 3); (Ii) I clone (BI 1/2); (18)1 clone (BlO 2): (19)61 clones from 23 isolates (P22 C. B4
1, B5 1-6. B7 2.3.5.6. BlO 1.4-6. 811 1.3. B14 1.2. Bl5,1,2. Bill. Bl9 1.4-9. B20 1.2. B21 2. B26 1.2. B28 I. B30 1.2. B3I I.
3. B34'l-3. B37 1 .7. B38 1.2. 839 1.2. 840 2.3.842 1.843/2,4); (20) 1 clone (B21 I): (21)1 clone (B21 3): (22) I clone (840 h.
sequence in this region, (TIP,' LXN/S)EKSV(KI
I)EYLDKVRATVG, analogous to the T-
helper site. Th2R, sequence of the P.
falciparun: CS protein, is also polymorphic.
However, the inimunogenic nature of this
region in P. i'irax needs to be established.
The third variaL'e region is located carboxyl
to the conserved :gion Rh. In this region,
polymorphism is restricted to amino acids 341
(V to A), 350 (A to T), 355 (E to G), 359 (L to
S). 364 (T to A). 374 (0 to S). and 388 (L to S).
This polymorphic region contains the known
T-celI determinants VTCG(VIA)GV RVRR R-
VNA(A/T)NKKP. DLE(T A)DVA-TNDKA,
and DKAA(G'S)IFNVVSN and a cell adhe-
sion site VTCG(V A)GVRVR of the CS
protein of P. vivax [9-11. 22]. In this region
the P. ;'isax CS protein sequence (RVNA(A/
T)NKKP(E G)DLT(L S)NDLE(T A), which
is analogous to the CTL containing determi-
nant. Th3R. in P. fakiparum. is also poly-
morphic.
Clonal diversity of the circunisporo:oize protein
bearing parasites. To determine the propor-
tional prevalence of parasites with polymorph-
ic CS epitopes in two geographically distant
malaria-endemic regions of the world, PNG
and Brazil. we have grouped the CS protein
sequences of 115 clones anal yzed here, based
on both the repeat region type and outside
repeat region polymorphism. Our comparison
identified 22 different clonal types of CS
proteins and revealed that with one exception
in each PNG and Brazil. the CS clonal types of
P. vivax parasites from PNG were distinct
from those from Brazil. For instance. CS
clonal type 5 as found predominantly in
Madang. PNG: 24 CS clones representing 11
of 15 P. vivax isolates from Madang. PNG
ere clonal type 5. In contrast. clonal type 19
was most prevalent in P. riva parasites from
Paragarninos. Brazil: 61 clones representing 23
of the 24 isolates from Brazil contained this
form of pobmorphic CS protein.
I''
Discussion
We have undertaken a longitudinal, popula-
tion level study of the CS protein of P. 'i;'ax
from two distant malaria-endemic regions,
PNG and Brazil, to elucidate the nature and
extent of epitope variability in this vaccine
candidate antigen. We have found that both
repeat and nonrepeat regions of the P. vivax
CS protein are polymorphic. Sequence com-
parison of the repeat of the CS proteins,
aligned in groups of type I and type 2 CS
repeats, shows a pattern of both silent and
nonsynonymous mutations and indicates that
point mutations have led to the emergence of
variant repeat sequences (Figs. 2 and 3). A
single point mutation. G to C (second
nucleotide of first triplet) in the common
genetic pooi of the CS clones anal yzed here,
representing type 1 and type 2 CS repeats,
makes these two repeat types different at the
protein level (Fig. 3). The array of mutations
and amino acid substitutions present in the
population of type I repeats suggests that this
type of CS repeat sequence may have mutated
to type 2 variant repeats: however, the reverse
cannot be ruled out. Examination of repeat
diversity in the CS proteins of other human
malaria parasites showed a similar point
mutation based diversity in the repeat se-
quence. For example. the change of the repeat
sequence from NAAG to NDAG in Plasmo-
diun, malariae [231 and from NANP to NVDP
in P.fa!ciparurn [24] can be explained by point
mutations and subsequent expansion of the
repeating unit.
Genetic recombiriation between homolo-
gous single-copy CS alleles during meiosis
would not result in progeny with variant
repeat types in the event of a single or even
double crossover. However, mutations that
contribute to the polymorphic nature of the
regions outside the repeat region can be
redistributed between the progeny. A new
repeat type can only emerge if there is
crossover inside the repeat region between
alleles with different repeat types. in which
case the progeny will have a part of each type
of repeat with a distinct junction to predict the
exact position of genetic exchanges. Such a
genetic event, which has been seen in the P.
falciparum merozoite surface antigen gene [25].
has not been observed in CS protein genes.
However, this does not rule out the existence of
P. vivax parasites with CS repeat sequences
distinct from the known type I and type 2
sequences.
In the nonrepeat regions of the CS protein,
nonsilent nucleotide substitutions are localized
in the identified T-cell epitope and in regions
analogous to the immunodominant Th2R and
Th3R regions of the P. falciparwn CS protein.
We propose that these two polymorphic
regions may harbor immuriodominant deter-
minants of the protein; the underlying ratio-
nale is that mutations in the parasite's proteins
that interface with host immunity, and which
are advantageous to the parasite, would be
positively selected rapidly [26]. This school of
thought is contrary to the other opinion that
favours DNA based selection and maintai-
nance of polymorphism in the CS protein of
human malaria parasites [27,28]. However,
irrespective of the origin and the mechanism
that maintains polymorphic sequence bearing
parasites studies of antigenic polymorphism of
parasite candidate vaccine antigens Constitutes
a step towards identifying vaccine-essential
immunodominant determinants of parasite
proteins. It remains to be determined experi-
mentally whether Th2R and Th3R analogous
regions in the P. i'i;'ax CS protein are
immunogenic in nature. Information on the
sequence variation of these regions would
allow us and others to test the vaccine related
effects of polymorphism.
Comparison of the CS protein gene sequen-
ces of field isolates of P. i-it ax from distant
geographic regions. Brazil and PNG, revealed
that each of these regions had distinct types of
polymorphic CS protein-bearing parasites.
However, we also found that certain types of
polymorphic CS proteins were present in both
PNG and Brazil. Moreover, mutations leading
to individual amino acid changes were shared
by Papuan and Brazilian parasites, indicating,
as has been suggested before. a common but
independent origin of sequence polymorphism
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[29]. Our results suggest that both immunolo-
gic and genetic events are operational in the
selection and expansion of the repeat sequence.
To summarize, we have shown that poly-
morphism in the CS protein of P. vivax is
resident in both repeat and nonrepeat regions,
that point mutations cause repeat sequence-
based antigenic diversity in the CS protein, and
that different clonal types of P. tivax pre-
dominate in the malaria-endemic regions of
PNG and Brazil investigated here. Similar
cross-sectional and longitudinal studies of
vaccine antigen diversity are essential before
malaria vaccine programs can be implemented
in malaria-endemic regions. While a cross-
sectional geographic level study would reveal
the extent and proportional prevalence of
polymorphic epitope-bearing malaria para-
sites, a longitudinal study at the population
level would help clarify the dynamics of
parasite populations as they relate to parasite
infectivity and disease.
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DIVERSITY IN THE IMMUNODOMINANT DETERMINANTS
OF THE CIRCUMSPOROZOITE PROTEIN OF
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PAPUA NEW GUINEA AND BRAZIL
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Abstract. To determine the nature and extent of variation in the T cell sites of the
Plasmodium falciparum circunisporozoite (CS) protein, a candidate antigen in the devel-
opment of a malaria vaccine, we cloned and sequenced 69 recombinant clones of the CS
protein gene representing 18 and 17 P. fakiparum isolates from infected individuals from
Madang, Papua New Guinea (PNG), a holoendemic malaria region, and Paragaminos
and Jacunda, Brazil, relatively low endemic regions, respectively. As previously known,
the amino acid sequence polymorphism was restricted to the three immunodominant
regions of the protein, ThIR-Ni, Th2R, and Th3R. While some of the observed nonsilent
mutations in the T cell determinants of the CS protein were similar to those previously
identified, we have found new amino acid changes in each of the polymorphic sequenccs
in parasites from PNG and Brazil. A comparison of the CS epitope sequences of parasites
from PNG and Brazil with the previously known CS epitope sequences of parasites from
Brazil and The Gambia showed the following 1) polymorphism was found in the ThlR-
Ni, Th2R, and Th3R region; however, while amino acid substitutions in the Th1R-NI
and Th2R region tended to be conservative, the substitutions found in the Th3R region
were not, suggesting that the Th3R epitope may be rapidly evolving to allow parasites to
escape host antiparasite cytotoxic T cell-enforced immune responses, and 2) the CS proteins
of P. faiciparum from high malaria-transmission regions (PNG and The Gambia) appear
more polymorphic than the CS proteins of parasites from relatively low malaria-endemic
regions in Brazil, where P. falciparum infection has been recently established.
The worldwide spread of malaria and the num-
ber of people affected by this disease is growing
at an alarming rate due to limited effectiveness
of dnigs and insecticides. In view of the failures
of conventional malaria control measures, there
is an urgent need for a malaria vaccine to help
combat the disease. Several stage- and species-
specific vaccine antigens of malaria parasite have
been identified and are presently being evaluated
for vaccine efficacy.' The circumsporozoite (CS)
protein, which covers the surface of the infective
sporozoite, is one of the candidate vaccine an-
tigens.2
The immunodominant B cell epilope (repeat
region) and T cell determinants of the CS protein
of the human malaria parasite Plasmodiumfal-
crparum have been identified. 3-' The T cell sites
of the CS protein, ThIR-Nl, Th2R. and Th3R,
reside outside the repeat region of the protein.'
Present efforts in sporozoite malaria vaccine de-
velopment are directed towards inducing in vivo
protective antibody and cytotoxic responses
against the infecting parasite. For vaccine con-
siderations, however, polymorphism in the im-
munodominant determinants in parasite popu-
lations can rapidly result in the selection of
vaccine-resistant malaria parasites. In view of
these considerations, several investigators have
characterized the CS protein epitope sequences
from laboratory and field P. fakzparum para-
sites.'°-' 4
 Sequence determination and hybrid-
ization analyses of the CS protein from labora-
tory-cultured isolates and sequence determination
of the CS protein from field-derived parasites
have shown various degrees of sequence poly-
morphism outside the repeat regions of the pro-
844
CS PROTEIN EPITOPE DIVERSITY
	 845
tein.'° "Immunologic experiments have shown
that while some variant amino acids nullified the
immune reactivity of the determinants, others
did not effect the immune functions.'7
We have undertaken a study of parasite surface
protein variability in field isolates of parasites
from low and high malaria-endemic regions. Our
long-term goals are to identi1r the proportional
prevalence of polymorphic determinant-bearing
parasites in clinically nonimmune children and
clinically immune adults in low and high ma-
laria-endemic regions of the world. In the present
study, we have characterized the CS protein genes
of parasites from Madang, Papua New Guinea
(PNG), a holoendemic P. falciparum malarious
region, and Paragaminos and Jacunda, Brazil,
relatively low malaria-endemic regions, and
compared the polymorphic imniunodominant
sequences with available data on the CS epitope
sequences ofparasites from Brazil and The Gam-
bia.
MATERIALS AND METHODS
Parasite origin and extraction of genomic DNA
Field isolates of P.faiciparum used in this study
were from two locations in Madang Province
(Alexishafen and the town clinic), PNG and from
Paragaminos and Jacunda Provinces in Brazil
Plosmodiumfakiparum-infected blood was ob-
tained from persons with an age range of 2-36
years who lived either within a 40-km radius of
Maclang in PNG or in Paragaminos and Jacunda
in Brazil Diagnosis of the malaria parasite was
done on site by microscopy. The majority of cases
were pure P. falciparuni or P. vivax infections,
however, we found low-level infections of I) P.
malariae and P. ovale in PNG, 2) P. malanae in
Brazil. and 3) dual P. falciparum and P. vivax
infections in both Brazil and PNG. Following
microscopic detection of P. falciparum infection,
infected blood was collected by venipuncture into
hepannized tubes and centrifuged. The plasma
was separated and the bufl coat containing white
blood cells was discarded. The parasitized red
blood cells were frozen at -80°C until further
use. Genomic DNA from 100 ,d of infected blood
was extracted in 0.5 ml of lysis buffer (50 mM
Tns HCI, pH 7.5,100mM NaC1; 50mM EDTA,
pH 8.0. 1.0% sodium dodecyl sulfate) supple-
mented with 50 pg/mI of proteinase K. The ex-
traction was carried out by incubation at 42°C
for up to 1 hr. The genomic DNA was isolated
from this lysis solution by consecutive extrac-
tions with phenol, phenol:chloroform. and chlo-
roform. Following this organic extraction, the
genomic DNA was precipitated in the presence
of salt and ethanol and reconstituted in 200 p1
of sterile water.
Amplification and sequencing of the CS protein
gene
The CS protein gene was amplified from the
genomic DNA (100-200 ng) using oligonucleo-
tides AL 58 (GTCGGAATTCATGATGAG
AAAATTAGCAT1) and AL 59 (CAGCG
GATCCTAATTAAGGAACAAGAAGG),
which are complementary and specific to the ter-
minal ends (N and C terminals, respectively) of
the CS gene of P. falciparuni.". These oligonu-
cleotides were designed to contain an Eco RI (AL
58) and a Barn HI (AL59) irestriction endonu-
clease cleavage site to facilitate cloning of the
amplified DNA fragments into Bluescript (Stra-
tagene, La Jolla, CA) cloning vectors. Following
25 cycles of amplification, Ihe amplified DNA
was analyzed on a 1.0% agarose gel The anipli-
fled fragments (1.2-1.3 kb) were purified, di-
gested with Barn HI and Eco RI, and ligated into
appropriately digested Bluescript plasmid DNA.
The recombinants were usedi to transform com-
petent Escherichia ccli (XL blue). Bacterial col-
onies containing the recombinant CS genes were
identified, and plasmid DNA was isolated in
preparation for nucleotide sequencing using plas-
mid and CS gene-specific primers.' 9 An average
of two clones per transformation were se-
quenced. The sequences of the primers used are
AL 52, CAG GAA ACA OCT ATG AC; AL 53,
GTA AAA CGA COG CCA GT; AL 3, AAC
ACA AGO GT CTA AAT GAA rrA AL 9,
AAT AAA AAC AAT CAA GOT AAT; and AL
164. CAT 0<3<3 GAG OAT TCA orr G.
RESULTS
The field-derived parasitized red blood cells
were used in genomic DNA extraction to avoid
any culture-induced artifacts. The amplification
of the genomic DNA using CS gene-specific
primers yielded 1.2-1.3-kb DNA fragments that
hybridized to the conserved region, region II, and
the repeat (NANP) sequence-specific oligonu-
cleotide probe. We used the CS gene and plasmid
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Fiouaz 1. Variation in the three immunodominant determinants ThIR-NI, Th2R, and Th3R in the cir-
cumsporozoitc (CS) protein gene of Flasnwdzum foJc:parum from Madang, Papua New Guinea (PNG), and
Paragaminos and Jacunda, Brazil (BRA). Nucleotide and deduced amino acid sequences of the CS protein
immunodominant determinants are compared with the sequences of a laboratory-cultured strain. 708, shown
at the top. The sequences are grouped as PNGO-PNG4 for Papua New Guinea and BRAO-BRA2 for Brazil.
The number represents the patient blood sample, and the letter denotes recombinant clones from an isolate.
Th1R-Ni region: PNGO (33 clovs/l6 isolates), 6B, 61), and 6E; 20A, 20C, 20E, and 20H; 22B; 23E, 23B, and
23G; 24H; 27E; 31A and 31C; ..80; 45B and 45H; 52E and 52F; 56B, 56E, 56G. and 56H; 58E; 70E; 92A.
928, 92C, 92F, and 92H; 93B; 132G. PNGI (4 clon&3 isolates), 28E 631; 93G and 93H. PNG2 (1 clone/i
isolate), 58B. PNG3 (I clone/i isIate) 6F. BRAO (19 clones/Il isolates), 1E 21)-, 5A: 7B and 7D 8A and 8B;
9Aand9B; l3Band 13F; i4Aanc l4F; l6Dand 16H; 2lCand 2lE 26B and 26G. BRAI (II clones/7 isolates).
IA; 4A and 4B; 6A 12A; iSA an 15C; hA and I 7B; 25A and 25B. Th2R region: PNGO (3 clones/I isolate).
238, 23E and 236. PNGI (2 clones/2 isolates) 28E 631. PNG2 (34 clones/IS isolates), 6B, 6D. 6E, and 6F;
20A, 20C, 20E, and 20 H: 22B; 24H; 27E 31A and 31C: 380; 45B and 45H; 52E and 52F; 56B, 56E, 560
and 56H; 58B and 58E; 70E 92A, 92B, 92C, 92F and 92H; 93B, 930 and 93H; 102G. BRAO (19 clon&I I
isolates), 1E21Y,5A;lBand7D8Aand8B;9Aand9B: l3Band 13F; l4Aand l4F: l6Dand 16H;2lCand
2lB; 26B and 260. BRAI (5 clones/4 isolates), IA: 4A and 4B: 6A; 12A. BRA2 (6 cloncs/3 isolates), ISA and
15C; hA and 17B; 25A and 25B. Th3R region: PNGO (11 clon&5 isolates), 23E, 23B. and 23G: 45B and 45H:
56B, 56E, 560, and 56H; 58E; 92C. PNGI (21 clones/Il isolates) 6B, 6D, 6E, and 6F; 20A, 20C, 20E, and
20H 22B; 24H; 380; 52E and 52F; 588: 70E; 92A, 92B, 92F, and 92H; 93B; 102G. PNG2 (2 clones/2 isolates)
28E 631. PNG3 (I clone/I isolate) 27E. PNG4 (4 clones 2 isolates) 3lA and 31C: 930 and 93H. BRAO (25
clones/l4isolates), 1E2D5A;7Band7D:8Aand8B;9Aand9B; l3Band 13F; I4Aand 14F: lSAand 15C:
16D and 16H; hA and 17B; 2lC and 21E; 25A and 25B: 26B and 26G. BRAI (5 clones/4 isolates), IA; 4A
and4B;6A; 12k
DNA—sequence specific primers to determine the the entire outside repeat region and the ends of
nucleotide sequence of69 CS clones representing the repeal domain were sequenced. Figure I
18 and 17 isolates of F. fakiparum from PNG shows the nucleotide and the deduced amino acid
and Brazil, respectively. The primers for se- sequences of the three polymorphic regions.
quencing of the CS gene were designed such that ThlR-Nl, Th2R, and Th3R. Based on the na-
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ture of polymorphic sequences of the immuno-
dominant determinants, we have categorized the
sequences in groups PNGO to PNG4 for parasites
from PNG, and BRAO to BRA2 for parasites
from Brazil. The amino acid sequences of the
polymorphic determinants are presented along
with a comparison with the previously identified
polymorphic sequences from The Gambia and
Brazil in Figure 2.
In the region of the CS protein that contains
the putative hepatocyte binding site and the pro-
liferative T cell determinant composed of amino
acids 103-123 (ThIR-NI), prior information on
polymorphism is based only on the analyses of
laboratory-derived parae'° Of 18 isolates of
P. falciparum from PNG and 17 isolates from
Brazil used in the present study, the CS protein
gene sequence of 33 clones representing 16 iso-
lates in the PNGO group and 19 clones repre-
senting 11 isolates in the BRAG group was sim-
ilar to the 7G8, We!, and T9-1O1 CS genes.' i 20
The CS protein gene sequence of four clones rep-
resenting three isolates in the PNG 1 group and
11 clones representing seven isolates in the BRA!
group in the ThIR-Nl region was similar to the
NF54, LE5, and T9-98 strains of P. falcipa-
ruin.'0' ' Each remaining isolate from PNG
had substitutions leading to amino acid changes
not seen previously (PNG2 and PNG3). An over-
all comparison of the sequences shows that ami-
no acid 117 (G/AIV) is most polymorphic in this
domain of the CS protein.
Carboxyl to this variable region, in the alter-
nating minor (NVDP) and major (NANP) re-
petitive sequence region, we found only one
change: clone 230 of a PNG-derived isolate had
NANS instead of NANP as the first repeating
unit sequence, resulting from an initial base
change of C toT. Two other CS clones (23E and
23B) from the same transformation had the
NANP sequence as the first repeating unit. We
do not know whether this observation represents
a new repeat sequence of the CS protein in the
process of emerging, such as the repeat sequence
variation observed in P. max. P. cvnoino!gi. and
P. knowles, CS repeat sequences, or a degenerate
repeat, as seen in P. rivax CS protein.2 Fur-
ther studies of field isolates are required to de-
termine any repeat sequence—based polymor-
phism in the CS protein of P. falciparum.
Carboxyl to the repeat region, where the T cell
immunodominant determinants (Th2R and
Th3R) of the CS protein reside, we have found
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FIGURE 2. Ilydrophilic and hydrophobic balance
of the immunodoininant epitopes of the circumspo-
rozoite protein of field- and laboratorv-de,ived Plas-
,nod,umfalc,parum parasites. ATHIR-NI. B,Th2R.
C TH3R. The solid, open. and hatched boxes represent
hydrophilic (usually on the protein surfice), hydro-
phobic (usually Internal), and neutral (both internal
and external) amino acids, respectively. The geograph-
ic origin of the laborator-culturrd and field-derived
P. falciparum isolates/strains are laboratory derived.
7(38 (Brazil).' LE5 (Labena),'° WEL (West Africa),20
NF54 (The Netherlands; parasites were recovered from
a traveler),' 3 T4, 19-98, and 19-101 (Thailand);' 2 field-
derived, GAMO-GAM6 (The Gambia)." and BRAO-
BRA2 (Brazil). 2' The description of the underlmed par-
astir sequences from Papua New Guinea (PNG) and
Brazil (BRA) is given in Figure 1.
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a varying degree of polymorphism within the F.
foiciparum populations in Madang, PNG and in
Paragaminos and Jacunda, Brazil. From 69 CS
clones analyzed representing 18 isolates in PNG
and 17 isolates in Brazil, variation in the Th2R
could be grouped into four categories (Figure 1).
Of 39 clones from PNG and 30 clones from Bra-
zil, 34 from PNG (PNG2) and five from Brazil
(BRA1) had sequences similar to the CS protein
gene of Wel, T4, and T9-101 strains of P. fal-
ciparum. Nineteen CS clones representing II iso-
lates from Brazil (BRAO) and three of the re-
maining five CS clones from PNG (PNGO) had
Th2R sequences similar to the 7G8 CS sequence.
Each of the remaining two clones (two isolates)
of PNG had a sequence unlike any previously
observed (PNGL). Six clones representing three
isolates from Brazil (BRA2) had previously iden-
tified sequences."
In the Th3R region of the CS protein, which
contains a cytotoxic T cell determinant, we ob-
served greater diversity than in the other two
variable regions of the protein, Thi R-Nl and
Th2R (Figure 1). In the Th3R region, the 39
clones from PNG can be grouped as follows: 21
(PNG1) were of the WEL type, 11 (PNGO) were
of the 7G8 type, and the remaining seven (PNG2-
4) represented five isolates that contained pre-
viously unknown sequences. Of the 30 CS clones
from Brazil analyzed, only two types of variants
were identified: 25 (BRAO) were of the 708 type,
and the remaining five (BRA I) had sequences
similar to PNG4.
Since a change in conformation due to amino
acid changes can influence the immunogenicity
of a dei'rminant, we analyzed the changes in the
hydroph lic amino acids (putative T cell receptor
binding site [epitopic)) and in the hydrophobic
amino acids (putative Ia binding site [agretopic])
of these polymorphic determinants.' In the Thl R-
NI and the Th2R regions, the observed poly-
morphism does not alter the hydrophobic and
hydrophilic balance of the region (Figure 2A and
B). In the case of Th2R, variation in all except
one amino acid is resident in the putative T cell
receptor domain of the amphiphilic complex,
suggesting that the parasite is evolving in an ep-
ilopic rather than an agretopic fashion (Figure
2B).A very different picture emerged, however,
hen a similar comparison was made of the poly-
morphic sequences of the Th3R region (Figure
2C). Not only is this the most polymorphic re-
gion in parasite proteins from PNG and The
Gambia, but the polymorphism in this region
distinctly alters the amphiphilic balance of the
determinant. Of the eight variable positions in
this determinant, changes in four amino acids
result in a change from a hydrophobic to a hy-
drophilic or a neutral amino acid, suggesting that
this determinant, unlike Th2R, is evolving both
in epitopic and agretopic fashions. Even though
epitopic variation alone would aid parasites in
evading immune surveillance, a combination of
the epitopic and agretopic variation, as seen in
the case of cytotoxic T lymphocyte (CTL)-con-
taming TH3R, would increase the chances of the
parasite to escape host immune surveillance. It
is also possible that even a conservatively altered
sequence may no longer be recognized in an in-
dividual primed with the original sequence.
To determine the nature and extent of the CS
protein polymorphism in parasites from PNG.
The Gambia, and Brazil, we compared the se-
quence of polymorphic determinants of the CS
proteins (Figure 3). The results are presented as
the percentage of variants bearing a polymorphic
sequence in three malaria-endemic areas. In the
ThIR-NI region of parasites analyzed in this
study, we found four polymorphic sequences in
parasites from PNG and two polymorphic se-
quences in parasites from Brazil. Of the poly-
morphic sequences, the 708 type sequence was
the most prevalent sequence in parasites from
PNG (84.6%) and Brazil (63%). In the Th2R
region, only four types of variants were found in
P. falciparum parasites from PNG and Brazil
(Figure 3) when compared with seven types of
polymorphic sequences in parasites analyzed
from The Gambia. Among these four types of
variant Th2R sequences, the 7G8 t ype sequence
was present in 71% of parasites from Brazil.
whereas the variant type 3 Th2R sequence was
present in 87% of parasites from PNG. When
the polymorphism in the CTL-containing Th3R
region was compared among three malaria-en-
demic areas, the results were different: only two
types of variants were found in parasites ana-
lyzed from Brazil compared with five and si
polymorphic Th3R epitopes. respectively, in
parasites from PNG and The Gambia.
DISCUSSION
The polymorphic nature of malaria vaccine
candidate antigens is of concern to viccine de-
'velopers. The CS protein gene sequence deter-
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8.quenc.	 GAX(%)	 PNG(%)	 BRA(%)
Th1R-1J1:
1) EXLRKPXRICXLKQPODGNPDP	 $4 • 6	 63 • 3
2) ..............A
	10.2	 36.7
3) ..............V 	 2.6
4) •...R	 2.6
Th2R:
1) P8DKHIEQThAIXNSI8	 7.7	 71.7
2) ...........T.Q..L.	 5.1
3) .............Q..L.	 87.2	 9.4
4) ...Q...K...R.Q..L.	 1.8.9
5) ..... . XE..N..Q..L.	 18
6) . . .Q...K.. .T.Q..L.
	 2
7) .. .Q...K...T....L.	 42
.Q . . .K..Q. .Q . .L.	 4
9) ...Q...R..Q..... L. 	 20
10)......... . )1T.Q. .L.
	 2
12
Th3R:
1) IKPGSANIPKDELDYENDIE 	 6	 28.3	 90.5
2) ......D....Q	 53.8
3) ........... Q 	 5.1
4) ......D... .Q..C.S	 2.6
5) ......G.8	 10.3	 9.4
6) ...............A... •	 28
7) ........... Q. . .A	 308) ........... Q.N 	 30
9) .........R..... A 	 2
10)............... AD 	 4
Fioup.e 3. Proportional prevalence rates of variants in the three immunodorninant regions of the circum-
sporozoite (CS) protein from field isolates of Plasmodzumfciciparum. Variants ofdeterminants in the CS protein
of parasites from The Gambia (GAM) (50 clon&5 isolates)," Papua New Guinea (PNG) (39 clones/IS isolates),
and Brazil (BRA) (53 clon&40 isolates; clones previously known2s and our data combined) are compared.
PoI morphic sequences of the CS protein of parasites are shown as percentages. The top sequence in each
immunodominant region represents the laboratory strain 7G8. In the ml R-Nl region, only variants from Papua
New Guinea and Brazil are shown, since this region of the parasite proteins from The Gambia was no! analyzed.
mination of a few laboratory-adapted P. fakip-
arum clones and strains revealed that
nonsynonymous nucleotide changes were local-
ized in three T cell-recognizing regions.'° Sub-
sequent studies using field isolates have shown
various degrees of polymorphism in the immu-
nodominant determinants of the CS protein.""
There is a continuous debate on the origin, se-
lection, and maintenance of polymorphism in
the T cell immunodominant regions of the CS
protein. 26.27 One hypothesis is that the human
immune response is important in selection of
variation, and another denies the existence of
selectively maintained polymorphism in the
regions of the protein that interface with host T
cells. This is an important issue that needs to be
explored to further our understanding of the ge-
netic variability of malaria parasite antigens and
the evolution of antiparasite host immune re-
sponses. From the perspective of vaccine devel-
opers, however, information about the nature
and extent of epitope variation is crucial, re-
gardless of how polymorphism in T cell sites
arose.
Our comparison of polymorphic CS protein
determinants from three distant malaria-endem-
ic regions lends support to the hypothesis of host
pressure-induced selection of polymorphic pro-
tein-bearing parasites. It appears that the pri-
mary
 function of the surface protein determi-
nant(s) is to ensure successful host-parasite
interaction. Nonsilent mutations in the regions
of the CS protein that nullify parasite interaction
with host cellular receptors will be rapidly se-
lected against, and the representative parasites
would disappear from the population of pare-
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sites. This would imply that the nonpolymorphic
regions of the CS protein or a blood-stage antigen
involved in host-parasite interaction may harbor
the biologically sensitive targets of the protein.2'
From an immunologic perspective, parasite
protein sequences andlor conformations predi-
cate the immune dominance or immunogenicity
of a region, and the epitopes that interface with
the host immune system would preferentially ac-
cumulate changes to escape the pressures of im-
munity. In situations in which biologically and
immunologically sensitive regions of the protein
coexist, accumulation of any nonsilent muta-
tions would have to first pass through the bio-
logic filter before being tested at the immunologic
level. In the case of purely irnmunodominant
determinants, however, nonsilent changes can be
positively selected, particularly if the mutation
results in an amino acid change that helps the
parasite evade host immune pressures. In view
of these considerations, the CTL-containing
Th3R region would fit the definition of a true
immunogenic site. his only in this region that
accumulated mutations result in altering of am-
phiphilic balance, as if the parasite is in the pro-
cess of eliminating or changing the conformation
of the CTL determinant.
Parasite protein polymorphism also needs to
be examined from epidemiologic and entomo-
logic perspectives. Our comparison of the prev-
alence of polymorphic amino acid sequences of
the T cell epitopes shows that parasites in low
malaria-endemic regions of Brazil are less poly-
morphic than parasites in high-malaria endemic
regions of The Gambia and PNG. It remains to
be determined whether the low-malaria endem-
icity of a region is due to presence of fewer poly-
morphic parasites, or to other human host and
vector-associated factors. A longitudinal study
of parasite protein polymorphism in low and high
malaria-endemic regions would increase our
ability to make intelligent guesses in this matter.
The maintenance of parasite polymorphs is a
function of the evolution of a population of par-
asites within a host and of a population of par-
asites within a population of hosts. We are con-
tinuing these studies of proportional prevalence
of parasite polymorphs in dilterent age groups in
a longitudinal study in regions with both low-
and high-endemic malaria to increaseourknowl-
edge of parasite mobility in diflërent malaria-
endemic regions of the world.
In conclusion, e have shown that the three
T cell determinants of the CS protein of P. fal-
ciparum from PNG and Brazil contain new as
well as previously identified polymorphic amino
acid sequences. Our results suggest that the CTL-
containing Th3R domain is evolving rapidly, as
is evident from the nonconservative nature of its
polymorphism compared with the conservative
nature of polymorphism in the other two T cell
determinants. We also found that the immuno-
dominant determinants of the parasite are more
conserved in a low malaria-endemic region than
in two high malaria-endemic regions. These re-
sults and similar studies in the case of other vac-
cine antigens are essential in the development of
malaria vaccines, and would help understand the
complex immunologic, entomologic, and epi-
demiologic facets of malaria.
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